

Evidence Synthesis

Number 105

Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. HHSA-290-2007-10057-I-EPC3, Task Order No. 13

Prepared by:

Pacific Northwest Evidence-based Practice Center
Oregon Health & Science University
Mail Code: BICC
3181 SW Sam Jackson Park Road
Portland, OR 97239
www.ohsu.edu/epc

Investigators:

Linda Humphrey, MD, MPH
Mark Deffebach, MD
Miranda Pappas, MA
Christina Baumann, MD, MPH
Katie Artis, MD, MPH
Jennifer Priest Mitchell, BA
Bernadette Zakher, MBBS
Rongwei Fu, PhD
Christopher Slatore, MD, MS

AHRQ Publication No. 13-05188-EF-1
July 2013

This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0024). The investigators involved have declared no conflicts of interest with objectively conducting this research. The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

The report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

Suggested Citation

Humphrey L, Deffebach M, Pappas M, Baumann C, Artis K, Priest Mitchell J, Zakher B, Fu R, Slatore C. Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 105. AHRQ Publication No. 13-05188-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013.

Acknowledgements

The authors acknowledge Andrew Hamilton, MLS, MS, for assistance with literature searches and Amanda Brunton, BS, for assistance with preparing this report. We also thank AHRQ Officers Jennifer Croswell, MD, MPH, Mary Barton, MD, MPP, Tracy Wolff, MD, MPH, and Tess Miller, DrPH, and USPSTF leads Sue Curry, PhD, Mike LeFevre, MD, MSPH, Virginia Moyer, MD, MPH, and Doug Owens, MD, MS, for their contributions to this report.

Structured Abstract

Background: Lung cancer is the leading cause of cancer-related death in the United States. However, persons with early lung cancer have lower lung cancer–related mortality than those with extensive disease, suggesting early detection and treatment of lung cancer might be beneficial. Low-dose computed tomography (LDCT) and chest x-ray (CXR) have been studied for early screening, with several new studies reporting results since the last review.

Purpose: To update the 2004 review of screening for lung cancer for the U.S. Preventive Services Task Force.

Data Sources: MEDLINE (2000 to 2012), Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through fourth quarter 2012), Scopus, and reference lists.

Study Selection: English-language randomized, controlled trials or cohort studies that evaluated screening or treatment interventions for lung cancer and reported health outcomes.

Data Extraction: Details about participants, study design, analysis, followup, and results were abstracted; study quality was rated using established criteria, where applicable.

Data Synthesis (Results): Four trials reported the effectiveness of screening with LDCT for lung cancer in patients with personal smoking exposure: one large good-quality trial reported screening was associated with reduced lung cancer and all-cause mortality reductions of 20 percent (95% CI, 6.8 to 27.6) and 6.7 percent (95% CI, 1.2 to 13.6), respectively. Three small European trials (two fair- and one poor-quality) showed no benefit of screening. When the three good- or fair-quality trials were combined in random effects meta-analysis, the relative risk of lung cancer mortality was 0.81 (95% CI, 0.72 to 0.91). One trial evaluated CXR screening in over 150,000 participants from the general population and reported no benefit of screening in this group or in a subset with personal tobacco smoke exposure. The reported sensitivity of LDCT for detecting lung cancer ranged from 80 to 100 percent and specificity from 28 to 100 percent in six studies; each study varied in its reporting method. The harms associated with LDCT screening included radiation exposure ranging from 0.61 to 1.5 mSv per scan, some degree of overdiagnosis of lung cancer that varied by study, and a high rate of false-positive examinations, which were typically resolved with further imaging. Most patients with positive results who underwent an invasive procedure were diagnosed with lung cancer. Smoking cessation was not significantly impacted by screening, although individuals with positive or indeterminate screens showed a trend toward reduced smoking or sustained abstinence. Patients with positive or indeterminate scans had some evidence of short-term increases in anxiety and distress but not long-term in the five studies evaluating this; patients with negative scans had a reduction in distress. Finally, no trials comparing treatment of stage I non-small cell lung cancer (NSCLC) with no treatment have been conducted. However, survival associated with surgical resection was evaluated in 11 studies of mostly symptomatic and unselected patients that have shown 5-year survival rates in the 71 to 90 percent range for stage IA NSCLC and 42 to 75 percent for stage IB NSCLC and that surgical resection is the U.S. standard of care. Harms of treatment of stage I NSCLC were poorly reported and ranged among the studies that reported

them.

Limitations: Three trials were underpowered and of too short of duration to reach conclusions on effectiveness of screening. Overdiagnosis is an important harm of screening but its magnitude is uncertain. No studies of LDCT have reported results in women or minority populations.

Conclusions: Good evidence shows LDCT can significantly reduce mortality from lung cancer. However, there are significant harms associated with screening that must be balanced with the benefits. More efforts to reduce false-positive examinations are of paramount importance and smoking cessation remains the most important approach to reducing lung cancer mortality.

Table of Contents

Chapter 1. Introduction.....	1
Purpose of Review and Prior USPSTF Recommendation.....	1
Condition Definitions	1
Prevalence and Burden of Disease	2
Risk Factors	2
Natural History.....	3
Rationale for Screening.....	4
Interventions/Treatment.....	4
Current Clinical Practice.....	4
Recommendations of Other Groups.....	4
Chapter 2. Methods.....	6
Key Questions and Analytic Framework.....	6
Key Questions	6
Search Strategies.....	6
Study Selection	7
Data Abstraction and Quality Rating.....	7
Data Synthesis.....	7
External Review.....	8
Chapter 3. Results.....	9
Description of Randomized, Controlled Trials.....	9
Randomized Trials of Low-Dose Computed Tomography Compared With Chest X-Ray	9
Randomized Trials of Low-Dose Computed Tomography Compared With No Low-Dose Computed Tomography	10
Randomized Trials of Chest X-Ray Compared With Usual Care	14
Key Question 1. How Effective Is Screening for Lung Cancer in Reducing Mortality and Morbidity?.....	14
Summary	14
Evidence.....	15
Key Question 2. What Are the Test Characteristics of Screening Tests for Lung Cancer?	18
Summary	18
Evidence.....	18
Key Question 3. What Are the Harms Associated With Lung Cancer Screening and Are There Ways to Modify Harms?.....	20
Summary	20
Evidence.....	21
Key Question 4. How Effective Is the Treatment of Surgical Resection of Early (Stage IA) Non- Small Cell Lung Cancer?.....	27
Summary	27
Evidence.....	27
Key Question 5. What Are the Harms Associated With Surgical Resection of Early (Stage IA) Non-Small Cell Lung Cancer?.....	29
Summary	29

Evidence.....	29
Chapter 4. Discussion.....	31
Summary of Review Findings	31
Limitations	36
Emerging Issues and Future Research	37
Conclusions.....	39
References.....	40

Figures

- Figure 1. Analytic Framework
- Figure 2. Meta-Analysis of Lung Cancer Incidence
- Figure 3. Meta-Analysis of Lung Cancer Mortality
- Figure 4. Meta-Analysis of All-Cause Mortality

Tables

- Table 1. Recommendations of Professional Organizations
- Table 2. Summary of Included Randomized, Controlled Trials
- Table 3. Incidence Rates of Lung Cancer Outcomes
- Table 4. Computed Tomography Parameters
- Table 5. Results of Screening Rounds in Randomized, Controlled Trials
- Table 6. Results of Screening Rounds in Cohort Studies
- Table 7. Smoking Rates
- Table 8. Survival Benefit and Adverse Events After Treatment of Stage I Lung Cancer
- Table 9. Summary of Evidence

Appendixes

Appendix A. Detailed Methods

- Appendix A1. Search Strategies
- Appendix A2. Inclusion and Exclusion Criteria
- Appendix A3. U.S. Preventive Services Task Force Quality Rating Criteria for Randomized, Controlled Trials
- Appendix A4. List of Reviewers
- Appendix A5. Literature Flow Diagram
- Appendix A6. List of Excluded Full-Text Papers

Appendix B. Evidence Tables and Quality Tables

- Appendix B1. Evidence Table of Included Randomized, Controlled Trials
- Appendix B2. Quality Rating Table of Includes Studies
- Appendix B3. Evidence Table of Included Cohort Studies

CHAPTER 1. INTRODUCTION

Purpose of Review and Prior U.S. Preventive Services Task Force Recommendation

The purpose of this report is to update a previous evidence review¹ commissioned by the U.S. Preventive Services Task Force (USPSTF) on screening for lung cancer. In 2004, based on the previous evidence review, the USPSTF found there was insufficient evidence to either recommend for or against routinely screening asymptomatic persons for lung cancer with either low-dose computed tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests (I statement).²

The previous evidence review assessed six randomized, controlled trials (RCTs) of poor- or fair-quality of CXR screening with or without sputum cytology examination conducted in the 1960s and 1970s among men at high risk for lung cancer because of exposure to tobacco smoking. No studies showed reduced lung cancer mortality among any of the screened participants.¹ However, participants in all studies received some level of screening, limiting conclusions about screening compared with no screening.

The previous evidence review also included five fair-quality case-control studies from Japan of high-risk men and low- or unknown-risk women.¹ All studies found lower odds of dying of lung cancer among those screened periodically with CXR, with odds ratios (ORs) ranging from 0.4 to 0.7. One poor-quality case-control study did not show benefit.³ Focusing specifically on the efficacy of lung cancer screening in women, the previous evidence review identified a suggestion of benefit from Japanese case-control studies of CXR screening, but found no RCTs evaluating CXR screening in women.

Screening for lung cancer with LDCT was evaluated in six cohort studies included in the previous evidence review. These studies screened both high- and low-risk individuals and found LDCT identified more early-stage lung cancer than CXR or than is typically identified in clinical practice. The previous evidence review identified no RCTs on the use of LDCT screening for lung cancer.

The current evidence review will be used by the USPSTF to update its 2004 recommendation on screening for lung cancer. This update focuses on evidence that has been published since the previous evidence review on the effectiveness of screening asymptomatic men and women for lung cancer, as well as the risks and harms associated with screening. The report will emphasize evidence applicable to typical practice in the United States.

Condition Definitions

Lung cancer is a proliferation of malignant cells arising in the airways or tissues of the lung. Ninety-five percent of lung malignancies are either non-small cell lung cancer (NSCLC) or small

cell carcinoma, with small cell carcinoma accounting for 16 percent of cases. The remaining 5 percent of primary pulmonary malignancies include rare entities such as carcinoid tumor. NSCLC is a heterogeneous designation with subsets including squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and undifferentiated carcinoma. Individual tumors can show features of several of these subtypes. Adenocarcinoma is the most common subtype, encompassing 36 percent of all lung cancers, with squamous cell carcinoma making up 20 percent of cases in a large survey of U.S. lung cancer from 1998 to 2001.⁴ The World Health Organization has recently revised the histology classifications for lung cancer, including several new preinvasive lesions within the adenocarcinoma classification.⁵

Lung cancer is staged according to the American Joint Committee by the TNM system. The TNM and stage designations have been recently revised and a new breakdown of early-stage primary cancers into T1a (<2 cm) or T1b (2 to 3 cm) has been added.⁶ Stage IA NSCLC is less than or equal to 3 cm in its greatest dimension, does not invade the visceral pleura or bronchus within 3 cm of the main carina, and has no evidence of lymph node or metastatic spread.⁷

Prevalence and Burden of Disease

Lung cancer is the second most commonly occurring cancer in the United States among men and women and the leading cause of cancer-related death.⁸ The American Cancer Society (ACS) predicted there would be approximately 226,160 new cases and 160,340 lung cancer-related deaths in the United States in 2012.⁴ Notably, lung cancer is expected to account for almost 28 percent of all cancer-related deaths in 2012. Current estimates suggest that almost 7 percent of men and women born today will be diagnosed with lung cancer during their lifetime and almost 6 percent will die from it.^{4,9,10} Lung cancer and lung cancer-related deaths have been increasing in epidemic proportions throughout the world, with differences between countries largely explained by differences in smoking rates.¹¹ Worldwide, it is estimated there were 1.6 million new cases and 1.4 million deaths from lung cancer in 2008.¹¹ Rates of lung cancer vary by smoking status. In one very large population-based cohort study of approximately 50,000 people ages 40 to 70 years, lung cancer death rates among women and men smoking 20 or more cigarettes per day were 41 and 43 per 1,000 or 16 and 11 percent of all deaths, respectively. Among never smokers, lung cancer mortality was 1.0 and 1.3 per 1,000 for women and men, respectively.¹² As a measure of the burden of lung cancer in the population, lung cancer is the leading cause of years of life lost to cancer in the United States, with an estimate of 15 years of life lost on average per person dying of lung cancer.¹³

Risk Factors

The biggest single risk factor for lung cancer is smoking,¹⁴ causing approximately 85 percent of lung cancers in the United States.¹⁵ Worldwide, smoking accounts for 75 to 80 percent of cases in men and at least 50 percent in women.^{11,16} Smoking has been associated most strongly with squamous cell and small cell carcinoma¹⁷ and to a lesser degree with adenocarcinoma, including the bronchioloalveolar subtype.¹⁸

Utilizing data from 2006 through 2007, the Tobacco Use Supplement Survey from the National Cancer Institute reported 37 percent of adults in the United States as current or former smokers.¹⁹ Although the prevalence of current smoking has declined slowly in recent years, in 2010 it was estimated that 19 percent of U.S. adults were current smokers²⁰ and that 17 percent of adults will still be current smokers in 2020.²¹ Furthermore, it was estimated that in 2008, there were 7 million people in the United States ages 55 to 75 years with at least a 30 pack-year smoking history,²² the approximate target group for lung cancer screening in most trials published to date. In the United States, a high percentage of lung cancer occurs in former smokers because of the large group of former smokers in the population and because lung cancer risk does not decrease until many years after smoking stops.²³⁻²⁵ In recent years, the incidence of lung cancer in the United States has been slowly declining, but given these estimates of both current and former cigarette smoking, it is unlikely to decline significantly for many years, and lung cancer will remain a major public health problem in this country and an increasing problem worldwide.

The incidence of lung cancer also significantly increases with age. Other risk factors for lung cancer include family history,^{14,15,17} chronic obstructive pulmonary disease,^{15,18,26} pulmonary fibrosis,¹⁴ exposure to passive tobacco smoke,²⁷⁻²⁹ indoor cooking fumes,¹¹ environmental radon, and occupational exposures such as asbestos, arsenic, chromium, and coal tar.^{15,26} Some studies suggest women are at higher risk for lung cancer than comparably exposed men.^{14,28,30,31} In addition to these risk factors, blacks are nearly twice as likely as their white counterparts to have a tobacco-related cancer,³² suggesting that race/ethnicity may also be a risk factor for lung cancer. There is also some evidence suggesting that the incidence of lung cancer is higher among people of disadvantaged socioeconomic status, although this may be due to unmeasured confounding from smoking.^{33,34}

If lung cancer among nonsmokers is considered alone, it would be the seventh leading cause of cancer-related death in the world,¹⁶ and as smoking rates decrease, will represent a larger fraction of lung cancer than is currently the case. Notably, there are major sex, clinicopathologic, and molecular differences in lung cancers arising in nonsmokers and smokers.¹⁶

Natural History

The rate of progression of lung cancer varies by cell type as well as molecular biology, but generally has a poor prognosis and is the cause of death in more than 90 percent of affected individuals.³⁵ The 5-year survival rate for all stages combined is approximately 16 percent.⁹ Stage at diagnosis is a strong predictor of lung cancer mortality.⁷ Unfortunately, 75 percent of patients with lung cancer present with symptoms due to advanced local or metastatic disease that is not amenable to cure.³⁵

For patients diagnosed with localized disease (defined as cancer limited to the lung without spread to other organs or lymph nodes), 5-year relative survival is 52 percent compared with 25 and 4 percent for regional (spread to regional lymph nodes) and distant (metastatic) disease, respectively. For the earliest-stage tumors, median 5-year survival is estimated at 77 percent.⁷ Currently, however, only 15 percent of lung cancers are diagnosed at an early stage.⁴ Accordingly, there is considerable interest in the early detection and treatment of lung cancer in

order to give patients the highest chance for cure.

Rationale for Screening

Lung cancer has many attributes that make it appropriate to consider screening for, including high morbidity and mortality and a relatively high prevalence in high-risk populations. Lung cancer mortality and survival are related to the initial stage of diagnosis, suggesting that treating early may be beneficial; therefore, an effective screening program for the early detection and treatment of lung cancer could have a significant impact on its high mortality rate.

A good screening test for lung cancer should be sensitive, specific, acceptable to patients and providers, and relatively cost-effective. In this regard, LDCT has emerged from observational studies as a promising new technology for diagnosing early lung cancer. In the early 1990s, LDCT was introduced as a screening test with hope that improved sensitivity might improve lung cancer screening outcomes, and several observational studies and RCTs began to evaluate this modality. Thus, with data now being reported from several ongoing trials, it is appropriate to reexamine the literature to date on the outcomes of screening for lung cancer. Current screening efforts are directed toward the early detection of NSCLC, since small cell lung cancer is less common and often grows and spreads too quickly to be reliably detected by intermittent screening.

Interventions/Treatment

Small cell lung cancer and NSCLC are managed differently. While small cell lung cancer is treated as a systemic disease, except in rare instances, the current standard of care for the treatment of localized NSCLC is surgical resection,^{27,29,36} whereas advanced NSCLC is often treated with radiation and/or chemotherapy, in addition to surgical resection when possible. For patients with poor performance status, supportive care may be the only appropriate therapy. Detecting and treating early-stage NSCLC is the focus of most screening programs for lung cancer since early treatment can lead to cure of NSCLC.

Current Clinical Practice

Until recently, few patients in the United States were being screened for lung cancer and no professional organizations, including the USPSTF, the ACS, the American College of Chest Physicians (ACCP), and the American Academy of Family Physicians, recommended routine screening. However, since the early 2000s, LDCT for the detection of early lung cancer has been broadly available, and there is evidence that patients and clinicians are already engaging in lung cancer screening.³⁷⁻³⁹

Recommendations of Other Groups

In May 2012, based primarily on results from the National Lung Screening Trial (NLST), several

organizations, including the ACCP, the American Society of Clinical Oncology, and the American Thoracic Society,⁴⁰ as well as the National Comprehensive Cancer Network (NCCN)²² and the American Lung Association⁴¹ recommended lung cancer screening, modeled closely on the NLST, using a LDCT program for individuals ages 55 to 74 years with a 30 pack-year history of cigarette smoking and the ability to partake in organized programs of screening (**Table 1**). The American Association for Thoracic Surgeons recommends screening select groups from ages 50 to 79 years in its recently developed guidelines, which differ slightly from the NLST study population of 54- to 74-year-olds.⁴² In January 2013, the ACS also began recommending screening for lung cancer with LDCT.⁴³ In addition, several patient organizations, such as the Lung Cancer Alliance⁴⁴ and the National Lung Cancer Partnership, are currently advocating screening.⁴⁵⁻⁴⁷

CHAPTER 2. METHODS

Key Questions and Analytic Framework

Using the methods developed by the USPSTF,⁴⁸ the USPSTF and the Agency for Healthcare Research and Quality (AHRQ) determined the scope and key questions for this review. Investigators created an analytic framework with the key questions and the patient populations, interventions, and outcomes reviewed (**Figure 1**). The target population for lung cancer screening was asymptomatic men and women at average risk or current and former smokers at high risk.

Key Questions

1. How effective is screening for lung cancer in reducing mortality and morbidity?
 - a. How effective is screening in persons at average risk?
 - b. How effective is screening in persons at higher risk for lung cancer (e.g., current or former smokers)?
 - c. Does effectiveness differ by subgroups (e.g., sex, age, race, presence of comorbid conditions, other lung cancer risk factors)?
2. What are the test characteristics (sensitivity, specificity, predictive value) of screening tests for lung cancer?
 - a. How do these test characteristics vary by lung cancer risk?
 - b. How are test characteristics different by subgroups (e.g., sex, age, race)?
3. What are the harms associated with lung cancer screening and are there ways to modify harms (e.g., unnecessary biopsy, radiation exposure, overdiagnosis, and psychosocial harms)?
4. How effective is surgical resection for the treatment of early (stage IA) NSCLC?
5. What are the harms associated with surgical resection of early (stage IA) NSCLC?

Key question 1 focuses on direct evidence that screening for lung cancer improves important health outcomes compared with no screening. The remainder of the analytic framework (key questions 2 through 5) evaluates the chain of indirect evidence needed to link screening for lung cancer with improvement in important health outcomes. Links in the chain of indirect evidence include the performance, yield, and acceptability of the screening test for lung cancer; the effectiveness of interventions for reducing morbidity and mortality; and any harms associated with screening and subsequent interventions.

Search Strategies

In conjunction with a research librarian, investigators searched the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the fourth Quarter 2012), MEDLINE (2000 through December 2012), reference lists of papers, and Scopus for relevant English-language studies and systematic reviews. Search strategies are described in

Appendix A1.

Study Selection

At least two reviewers independently evaluated each study to determine eligibility for inclusion. Investigators selected studies on the basis of inclusion and exclusion criteria developed for each key question (**Appendix A2**). Papers were selected for full-text review if they were about lung cancer screening, were relevant to a key question, and met the predefined inclusion criteria. We restricted inclusion to English-language articles and excluded studies only published as abstracts. Studies of nonhuman subjects were also excluded, and studies had to include original data.

For key questions 1, 2, and 3, we included large ($n \geq 1,000$) screening trials and/or studies of adult (age ≥ 18 years) men and women without signs of lung cancer. The screening interventions were LDCT, CXR, sputum cytology, or a combination of these screening interventions. For key questions 4 and 5, we focused on surgical resection of early (stage I) NSCLC. Outcomes were mortality, morbidity, impact on smoking cessation, quality of life, incidental findings, and harms from screening (such as false-positives, radiation, and overdiagnosis) and treatment. For key questions 4 and 5, we limited our review of treatments to studies involving 500 or more people and those published in the last 12 years, as our interest was in treatment outcomes that are relevant to current practice. Given differences in stage classification, diagnostic procedures used to define stage, and surgical techniques, we determined studies published before those dates would be unlikely to be generalizable to current clinical practice.

Data Abstraction and Quality Rating

For each included study, an investigator abstracted details about the patient population, study design, screening procedure, imaging assessment, analysis, followup, and results. A second investigator reviewed data abstraction for accuracy. Investigators used criteria developed by the USPSTF⁴⁸ to rate the quality of each RCT as good, fair, or poor (**Appendix A3**) if they reported results for both comparison groups. Two investigators independently rated the quality of studies and resolved discrepancies by consensus. Several studies reported their findings in more than one paper. When this occurred, the data reported in this review are from the most recent publication unless unique data were presented in an older publication.

Data Synthesis

We assessed the aggregate internal validity (quality) of the body of evidence for each key question (“good,” “fair,” “poor”) using methods developed by the USPSTF, based on the number, quality and size of studies, consistency of results between studies, and directness of evidence.⁴⁸

Meta-analyses were conducted to summarize data and obtain more precise estimates on outcomes for trials that were homogeneous enough to provide a meaningful combined estimate.

In order to determine whether meta-analysis could be meaningfully performed, we considered the quality of the studies and the heterogeneity among studies in design, patient population, interventions, and outcomes. When meta-analysis could not be performed, the data were summarized qualitatively.

Only dichotomous outcomes (cancer incidence and mortality and all-cause mortality) were included in meta-analysis and relative risk (RR) was used as the effect measure. All combined effects were estimated using random-effects models.⁴⁹ The Q statistic and the I^2 statistic (the proportion of variation in study estimates due to heterogeneity) were calculated to assess heterogeneity in effects between studies.⁵⁰ Because of the small number of studies, it was not feasible to conduct subgroup analysis and meta-regression to explore heterogeneity. We conducted sensitivity analyses to check the impact of quality on the results. All analyses were performed using Stata/IC 12.0 (StataCorp, College Station, TX).

External Review

The draft report was reviewed by content experts, USPSTF members, AHRQ Project Officers, and collaborative partners (**Appendix A4**). Revisions have been made in response to reviewers' and USPSTF members' comments.

CHAPTER 3. RESULTS

We reviewed 8,149 references from electronic searches, reference list review, and manual searches of recently published studies. After applying inclusion and exclusion criteria, 1,734 full-text papers were reviewed. Of the full-text papers, 63 provided data to answer one or more of the key questions and were included in this evidence review. **Appendix A5** shows the results of our literature search and selection process and **Appendix A6** shows the list of excluded full-text papers.

Description of Randomized, Controlled Trials

We identified seven RCTs that reported results of screening with LDCT⁵¹⁻⁵⁷ and two of screening with CXR (**Table 2** and **Appendix B1**).^{58,59}

Randomized Trials of Low-Dose Computed Tomography Compared With Chest X-Ray

National Lung Screening Trial

The NLST was a good-quality trial of lung cancer screening comparing LDCT with single-view posterior-anterior (PA) CXR.⁵⁴ The NLST enrolled participants from August 2002 through April 2004 at 33 sites in the United States. Asymptomatic men and women ages 55 to 74 years who had at least 30 pack-years of smoking history and were current or former (>15 years since quitting) smokers were eligible. Of the 53,454 subjects enrolled, 26,722 were randomized to LDCT and 26,732 to CXR. Subjects were followed for a median of 6.5 years from randomization (maximum 7.4 years) for the outcomes of lung cancer incidence and all-cause mortality and 5.5 years for lung cancer mortality. Screening was conducted from 2002 to 2006 and participants followed in the trial from 2002 to 2009, when the trial was stopped early; participants are still being followed, however.

Subjects received a baseline evaluation (LDCT or CXR) with annual evaluations at 1 and 2 years. Screening radiology procedures were performed in accordance with a standard protocol. Results and recommendations of interpreting radiologists were reported to the participant and their health care provider within 4 weeks of a positive study; followup of abnormal scans was determined by the subject's individual health care provider. A positive ("suspicious for lung cancer") LDCT scan was one that showed any noncalcified nodule or mass 4 mm or greater in any diameter. A positive CXR image was one showing any noncalcified nodule or mass. Abnormalities such as adenopathy or pleural effusions were also classified as positive findings. Radiology findings suggesting other clinically significant processes were noted but not categorized in the publications to date. Abnormalities that were suspicious for lung cancer were classified as minor if they remained stable after the third round of screening.

The LDCT and CXR groups were both comprised of 59 percent men and 73 percent were ages 55 to 64 years, with a mean age of 61.4 years.⁶⁰ At baseline, 48 percent in both groups were current smokers and 52 percent were former smokers, with a mean smoking history of 56 pack-

years.⁶⁰

Overall, adherence to the screening protocol was high: 95 percent in the LDCT group and 93 percent in the CXR group. Contamination was also relatively small; among a subgroup of 500 subjects, 4.3 percent of the participants in the CXR group self-reported that they received a screening CT outside of the study.

Lung Screening Study

The Lung Screening Study (LSS) was a trial of lung cancer screening comparing LDCT with PA CXR designed as a feasibility study in preparation for the NLST.⁵⁵ The trial was conducted at six sites in the United States from September 2000 through November 2001 and followup continued into 2002. Men and women ages 55 to 74 years who were current (≥ 30 pack-years) or former (quit < 10 years ago) smokers were enrolled. Of the 3,318 subjects enrolled, 1,660 were randomized to LDCT and 1,658 to CXR. Subjects received a baseline (LDCT or CXR) and one annual evaluation, which were evaluated by 32 different radiologists; abnormalities were evaluated by community providers.

The definition of a positive screen changed between the baseline and annual screens. At baseline, noncalcified nodules 4 mm or greater, as well as several other specific findings (even with nodules < 4 mm), were described as positive. At the 1 year examination, any noncalcified nodule 4 mm or greater was considered a positive screen, and other abnormalities could be considered suspicious for lung cancer at the discretion of the radiologist. Thus, the incidence screen involved more radiologist discretion than the baseline screen. Although more participants were randomized, only 1,586 (96% of 1,660) received a baseline LDCT and 1,550 (93% of 1,658) received a baseline CXR.

The overall population was 59 percent male and 68 percent were ages 55 to 64 years, though no mean or median age was reported. At baseline, 58 and 57 percent in the LDCT and CXR groups, respectively, were current smokers and 42 and 43 percent, respectively, were former smokers, with a median smoking history of 54 pack-years.

Randomized Trials of Low-Dose Computed Tomography Compared With No Low-Dose Computed Tomography

Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays Trial

The Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays (DANTE) Trial^{51,61} was a fair-quality trial of lung cancer screening comparing the addition of LDCT with a usual care protocol that involved baseline CXR (type not specified) and sputum cytology for all participants. The trial was conducted in Italy from March 2001 through February 2006. Male current or former smokers (≥ 20 pack-years) ages 60 to 74 years were eligible. Men were excluded if they did not meet eligibility criteria or if they had severe comorbidity or a life expectancy less than 5 years. Participants could have had cancer if treated more than 10 years previously or prior “early” squamous cell cancer of the oral cavity or larynx if treated more than 5 years prior to enrollment.

Of the 2,472 subjects enrolled, 1,276 were randomized to LDCT and 1,196 to usual care. LDCT results were considered positive if they showed noncalcified pulmonary nodules or nonnodular lesions suggestive of malignancy. Generally, abnormalities were followed with interval LDCT or high resolution CT over several months; patients with lesions greater than 6 mm often underwent a trial of antibiotics with followup CT. Other LDCT abnormalities, such as noncalcified nodules 10 mm or greater in diameter or smaller nodules with spiculated margins, or nonnodular lesions that were suggestive of malignancy were also reported.⁶¹ Abnormalities found on screening LDCT were evaluated within the study by a diagnostic algorithm based on the abnormality's size, growth, descriptive characteristics, and response to a trial of antibiotics.

All subjects received a baseline clinical interview and examination, CXR, and 3-day sputum cytology; those in the LDCT group also received LDCT. All subjects were followed annually for approximately 4 years with clinical interviews and physical examinations focused on detecting lung cancer; participants randomized to LDCT also underwent annual LDCT.

This trial included only men; the LDCT group had a mean age of 64 years and the usual care group of 65 years. At baseline, 56 and 57 percent in the LDCT and usual care groups, respectively, were current smokers, with a mean smoking history of 47 pack-years in both groups. The LDCT group had significantly more subjects with respiratory comorbidities at baseline compared with the CXR group (35% vs. 31%; $p=0.04$).

The final results of this trial have not yet been reported, but preliminary findings with median followup of 34 months were reported in 2009.⁵¹ As of January 2008, 3,612 LDCT scans had been performed,⁵¹ 95 percent of participants had completed baseline questionnaires, and 68 percent had provided baseline sputum samples.⁶¹ At 3 years, equivalent numbers of patients in each group had received an extra CT scan (6.0% and 6.1%) and an extra CXR (19%).

Danish Lung Cancer Screening Trial

The Danish Lung Cancer Screening Trial (DLCST)⁶² was a fair-quality trial comparing LDCT with usual care (no lung cancer screening). The DLCST enrolled participants between June 2000 and June 2001 and was conducted from October 2004 through March 2006 in a single center in Denmark. The study was planned to last 5 years, with a baseline LDCT followed by four annual LDCT scans. It was also designed to study predictors of smoking cessation and the effect of LDCT participation on smoking behaviors. The study population involved healthy men and women ages 50 to 70 years who were current or former smokers (≥ 20 pack-years smoking history). Former smokers must have quit after age 50 years and less than 10 years prior to enrollment in the study. Eligibility required the ability to walk up 36 steps without stopping; exclusions included prior treatment for breast or lung cancer, any cancer within the last 4 years, and any illness that would be expected to shorten life expectancy to less than 10 years. All study participants underwent baseline pulmonary function testing (PFT) and, to confirm smoking status, carbon monoxide level in exhaled air. In addition, all participants had an annual visit with PFTs and health questionnaires.

Nodules 5 mm or greater in diameter were considered positive or indeterminate unless they had benign characteristics. Nodules 5 to 15 mm in size were considered indeterminate and rescanned after 3 months; individuals with nonbenign appearing nodules greater than 15 mm were referred

to chest physicians in two lung cancer diagnostic centers for evaluation. Nodules were considered benign if they appeared benign or were less than 5 mm. Nodules greater than 14 mm and any growing nodules were referred for diagnostic evaluation, as well as “suspicious” nodules. Growth was defined as an increase in volume of at least 25 percent. Volume doubling time (VDT) was used to measure growth rate and supplemented decisionmaking. Rapid VDT increased the suspicion that a nodule might be cancer. Participants needing further evaluation were referred to chest physicians in two specialized centers. Lung cancers in the usual care group were diagnosed and treated by the subject’s personal clinician, independent of the study, but this mostly involved the same lung cancer diagnostic centers used in the LDCT group.

Of the 4,104 subjects enrolled, 2,052 were randomized to LDCT and 2,052 to usual care. There were no significant baseline differences between the study groups in mean age (58 years), sex (56% male in LDCT and 55% male in usual care), mean smoking history (36 pack-years), or PFT results (mean forced expiratory volume in 1 second [FEV1], 2.9 in both groups; mean FEV1 % predicted, 93% in LDCT group and 94% in usual care group). Current smokers comprised 75 percent of the LDCT group and former smokers 25 percent. The usual care group included 77 percent current smokers and 23 percent former smokers. The authors noted that followup among the usual care group was not as complete as it was for the LDCT group.

Smoking cessation education for the LDCT group involved less than 5 minutes of smoking cessation counseling by a certified smoking cessation nurse at annual visits. PFT results (abnormal and normal) were used to motivate participants to stop smoking. From the publication, it is unclear whether this counseling occurred at the initial visit or only at the annual followup visits.

Multi-Centric Italian Lung Detection

The Multi-centric Italian Lung Detection (MILD) study was a poor-quality trial of lung cancer screening comparing LDCT, either annually or biennially, with usual care (no lung cancer screening).⁵³ The trial was conducted from September 2005 through January 2011 in a single center in Italy. Eligible subjects were men and women ages 49 years or older who were either current or former (quit ≥ 10 years ago) smokers with at least 20 pack-years of smoking and no history of cancer within the previous 5 years. Of the 4,099 subjects enrolled, 1,190 were randomized to annual LDCT, 1,186 to biennial LDCT, and 1,723 to usual care, with a median followup of 4.4 years. All subjects in this trial underwent PFT, blood testing, and a program of smoking cessation.

Evaluation of positive or suspicious LDCT scans was coordinated through the study center.⁵³ Solid lesions with volume of 6 mm³ or less (diameter of ≤ 4.8 mm) were considered nonsuspicious. Solid nodules of approximately 5 to 8 mm received further evaluation, typically repeat LDCT at 3 months. Nodules greater than 250 mm³ were referred for additional evaluation, including positron emission tomography (PET) scanning or biopsy. Computer-aided detection that showed volumetric growth of 25 percent or more was considered suggestive of malignancy.

Participants in all three groups were similar at baseline in age (median of 57, 58, and 57 years for annual, biennial, and usual care, respectively), percent male (68%, 69%, and 63%, respectively), and smoking history (median of 39, 39, and 38 pack-years, respectively). There were more current smokers in the usual care group compared with the annual and biennial group (90% vs.

68 vs. 68%, respectively) and less former smokers (10% vs. 31% vs. 32%, respectively). Fewer participants in the usual care group had a FEV1 percent predicted that was less than 90 percent compared with both the annual and biennial groups (19% vs. 28% vs. 28%, respectively).

This study was rated poor-quality due to significant differences in the LDCT and usual care groups at baseline, raising concerns about the adequacy of randomization. In addition, there was substantially less followup among the usual care group (44.9 vs. 56 months). Finally, the study was underpowered and did not reach its planned size of 10,000 participants.

Nederlands-Leuven Longkanker Screenings Onderzoek

The Nederlands-Leuven Longkanker Screenings Onderzoek (NELSON) study is a trial of lung cancer screening comparing LDCT with no screening.⁵⁶ The NELSON trial is currently ongoing; it began in 2003 and is being conducted in The Netherlands and Belgium. Male and female former and current smokers ages 50 to 75 years with adequate health status, no chest LDCT in the prior year, and no prior diagnosis of melanoma, renal, or breast cancer were eligible. Unlike other studies, lung cancer survivors (≥ 5 years) were eligible. To date, 15,588 subjects have been enrolled with one-to-one ratio randomization; screening results for 7,557 participants randomized to the LDCT group have been reported.

The LDCT group received LDCT at years 0, 1, and 3; the control group received no screening. In this trial, LDCT scans utilized volumetric measurements of detected nodules with calculation of VDT for evaluation. A positive test result was defined as a solid nodule with a volume greater than 500 mm³, a solid, pleural-based nodule with a diameter greater than 10 mm, or a partially solid nodule with solid component measuring greater than 500 mm³. Positive scans were also defined by VDT; a VDT less than 400 days was considered positive.

The NELSON investigators also assessed characterization and automated detection and measurement of lung nodules detected at screening,⁶³⁻⁶⁷ effect of screening on quality of life,^{68,69} smoking cessation during lung cancer screening,⁷⁰ and the role of PET scans in evaluation of screen-detected nodules.⁷¹

Smoking cessation education for the NELSON trial included a standard smoking cessation brochure or a questionnaire requesting tailored smoking cessation information from the Dutch expert center on tobacco control. The standard brochure contained brief information about the advantages of quitting, the barriers to quitting, tips about how to quit smoking and how to prevent smoking relapse, and the possibilities for smoking cessation support. The questionnaire asked about smoking history, previous attempts to quit, attitudes toward smoking cessation, and self-efficacy in smoking abstinence.

Most baseline characteristics, including those for the no screening group, have not been reported to date. The LDCT group was described as 84 percent male with a mean age of 59 years.

ITALUNG

The ITALUNG study was a trial of lung cancer screening comparing LDCT with usual care (no lung cancer screening).⁵⁷ The trial began in 2004 in Italy and baseline results were reported in 2009 for the LDCT group only. Enrolled subjects were men and women ages 55 to 69 years who

were either current or former (>10 years since quitting) smokers with at least 20 pack-years of smoking history. Of the 3,206 subjects enrolled, 1,613 were randomized to LDCT and 1,593 to usual care.

Subjects in the LDCT group underwent a baseline scan plus three annual scans. The control group received usual care. All subjects were invited for free access to a smoking cessation program. LDCT was considered positive when it showed at least one noncalcified nodule 5 mm or greater or a nonsolid nodule 10 mm or greater in size. Nodules 8 mm or greater underwent PET scanning. Management of positive screening tests was carried out using followup LDCT, fluorodeoxyglucose PET, fine needle aspiration cytology, or fiber optic bronchoscopy. Subjects with positive screening tests were phoned and invited to meet with a pulmonologist for further assessment.

The overall population was 65 percent male, with a mean age of 64 years, and 65 percent were current smokers, with a median smoking history of 39 pack-years.

Randomized Trials of Chest X-Ray Compared With Usual Care

Mayo Lung Project

The Mayo Lung Project was a fair-quality trial comparing CXR and pooled 3-day sputum cytology examination every 4 months for 6 years (intensive screening) with a control group advised to have annual CXR and sputum cytology examinations (usual care).¹ The trial was conducted from November 1971 through July 1976. There were 10,933 male smokers ages 45 years or older enrolled and after eliminating all cases of prevalent lung cancer (91 participants, or 0.8% prevalence), 4,618 subjects were randomized to intensive screening and 4,593 to usual care.⁵⁸

Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

The Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial was a good-quality trial comparing annual CXR with usual care (no screening). Participants were enrolled from 1993 through 2001 and the trial was conducted from 1993 to 2011, with screening carried out from 1993 through 2004. Men and women from the general population ages 55 to 74 years were enrolled. Of the 154,901 subjects enrolled, 77,445 were randomized to PA CXR and 77,456 to usual care, with a median followup of 12 years.⁵⁹ The population was approximately 85 percent white, 49 percent male, and 45 percent never smokers. The evaluation of abnormal tests was conducted by participants' personal health care providers, not within the study.

Key Question 1. How Effective Is Screening for Lung Cancer in Reducing Mortality and Morbidity?

Summary

One good-quality trial (n=53,454) of high-risk lung cancer participants with good generalizability found that LDCT compared with CXR conducted over three screens reduced

lung cancer mortality by 20 percent and all-cause mortality by 6.7 percent. Two smaller (n=2,472 and n=5,861) fair-quality European trials of high-risk lung cancer participants showed no benefit associated with LDCT screening compared with no LDCT screening. However, these were small trials with limited power that could have missed a true benefit. One small (n=4,099) poor-quality trial also suggested no benefit from screening with LDCT, and perhaps harm. When the three fair- or good-quality trials were combined in a meta-analysis, the combined RR of lung cancer mortality was 0.81 (95% CI, 0.72 to 0.91). When the poor-quality MILD trial was included, the RR of lung cancer mortality was 0.98 (95% CI, 0.68 to 1.40).

Two trials of screening with CXR compared with either less intense or no screening, one in the general population and one in high-risk individuals, showed no benefit associated with CXR screening. Only one study evaluated or reported findings on lung cancer screening in women and did not show a significant reduction in lung cancer mortality associated with CXR screening. No trials have reported data on lung cancer screening in different racial or ethnic populations. See **Table 3** for a summary of lung cancer outcomes in these trials; for complete details on the RCTs included in this review, see **Appendix B1**, and for the details on their quality ratings, see **Appendix B2**.

Evidence

Low-Dose Computed Tomography

To evaluate the effectiveness of screening for lung cancer with LDCT, we limited our review to RCTs of screening published since the previous evidence review that reported results in both the LDCT and control groups (**Table 2** and **Appendix B1**). We identified seven RCTs that reported results of screening with LDCT; however, only four⁵¹⁻⁵⁴ have reported results in both the intervention and control groups (**Appendix B2**).

Comparing low-dose computed tomography with chest x-ray. Only the NLST⁵⁴ has reported results for both the intervention and control groups comparing periodic LDCT with CXR. The NLST (n=53,454) reported its findings after the trial was stopped early on review by the data safety monitoring board.⁵⁴ After a median followup of 6.5 years for lung cancer incidence and all-cause mortality, the cumulative incidence of lung cancer in the LDCT group was 645 per 100,000 person-years (py) and 572 per 100,000 py in the CXR group; the RR was 1.13 (95% CI, 1.03 to 1.23) for incident lung cancer. Over 5.4 years of followup, lung cancer mortality in the LDCT group was 247 per 100,000 py and 309 per 100,000 py in the CXR group, with a reduction of lung cancer mortality of 20.0 percent (95% CI, 6.8 to 26.7; p=0.004) in the LDCT group. The RR of all-cause mortality was reduced by 6.7 percent (95% CI, 1.2 to 13.6). The authors calculated a number needed to screen (NNS) with LDCT to prevent one lung cancer death as 320 (among those undergoing ≥1 screens). Intention-to-screen analysis determined a NNS of 310 (95% CI, 190 to 840) to prevent one lung cancer death. The NNS to prevent one death from any cause was 219 (95% CI, 112 to 5,000).⁵⁴ This corresponds with an absolute risk reduction of lung cancer death of 4.6 (95% CI, 0.2 to 9.0) per 1,000 participants.⁸⁵

Comparing low-dose computed tomography with no low-dose computed tomography. Three randomized trials in four publications comparing periodic LDCT screening with no LDCT screening (“usual care”) have reported lung cancer outcomes in both groups.^{51-53,61}

Though the final results of the DANTE trial (n=2,472) have not been published, preliminary findings were reported in 2009, with a median followup of 34 months. However, as noted above, followup was longer in the LDCT group by 657 person-months (35.7 months in the LDCT group compared with 31.5 months in the control group).⁵¹ The baseline prevalence of lung cancer was 2.2 percent (28 cases) in participants randomized to LDCT and 0.7 percent (8 cases) in the control group. After approximately 3 years of followup, the cumulative incidence of lung cancer was 4.7 percent (60 cases) for LDCT and 2.9 percent (34 cases) for the control group. The corresponding incidence rate was 1,600 per 100,000 py in the LDCT group and 1,015 per 100,000 py in the usual care (nonLDCT) group. The 3-year cumulative lung cancer mortality rates were 1.6 percent (n=20) in the LDCT group and 1.7 percent (n=20) in the control group, a nonstatistically significant difference. The corresponding lung cancer mortality rates were 558 per 100,000 py in the LDCT group and 597 per 100,000 py in the control group (RR, 0.83 [95% CI, 0.45 to 1.54]). All-cause mortality was also equivalent in both groups at 3 years, with a RR of 0.85 (95% CI, 0.56 to 1.27). All rates are calculated given the person-months of followup appropriate for each study group (rather than the mean). The study had only 80 percent power to show a 35 percent reduction in lung cancer mortality.

In the DLCST (n=4,104), the cumulative incidence of lung cancer in the LDCT group was 0.7 percent (incidence, 706 per 100,000 py) and 0.5 percent (incidence, 245 per 100,000 py) in the usual care group after a median followup of 4.8 years (RR, 2.88 [95% CI, 1.85 to 4.49]).⁵² Lung cancer mortality was 0.7 percent (mortality rate, 154 per 100,000 py) in the LDCT group and 0.5 percent (mortality rate, 112 per 100,000 py) in the usual care group, with a RR of 1.37 (95% CI, 0.63 to 2.97). Overall, there were 61 deaths (3%) in the LDCT group (624 per 100,000 py) and 42 deaths (2.1%) in the usual care group (429 per 100,000 py), with a RR of 1.46 (95% CI, 0.99 to 2.15).⁵² This study had 80 percent power to show a 20 percent lung cancer mortality reduction after 5 years at the 0.05 p-value level.

In the MILD trial (n=4,099), 25 lung cancers were diagnosed (20 LDCT-detected) in the biennial LDCT group, 34 (29 LDCT-detected) in the annual LDCT group, and 20 in the control group.⁵³ The incidence rates of lung cancer per 100,000 py were reported as 457 in the LDCT biennial group, 620 in the LDCT annual group, and 311 in the control group (RR, 1.47 [95% CI, 0.82 to 2.64] for biennial vs. control and RR, 1.99 [95% CI, 1.16 to 3.43] for annual vs. control). Lung cancer mortality was not significantly different between the control and screened groups combined after adjustment for age and smoking (hazard ratio [HR], 1.64 [95% CI, 0.67 to 4.01]). When comparing the lung cancer mortality rate among the biennially screened group with the control group, the RR was 1.00 (95% CI, 0.34 to 2.98); among the annual screen group compared with the control group, the lung cancer mortality HR was 1.99 (95% CI, 0.80 to 4.96); however, this is not adjusted for age and smoking. All-cause mortality was not statistically different comparing screened groups combined with the control group (RR, 1.40 [95% CI, 0.82 to 2.38]). However, when comparing the annually screened group with the control group, the all-cause mortality RR was 1.80 (95% CI, 1.03 to 3.13). The RR of all-cause mortality among the biennially screened compared with the control group was 1.17 (95% CI, 0.63 to 2.17). Of note, 10 squamous cell cancers were identified in the annual LDCT group and one in the biennial LDCT group, with similar numbers of adenocarcinomas in each of the LDCT groups; tumor histology was not reported for the control group.⁵³ As with the DANTE trial, all rates are calculated based on the followup reported for each study group. Again, as noted above, there are

significant concerns about the adequacy of randomization in this study, as well as differences in followup between groups, with substantially more followup in the LDCT groups compared with the usual care group.

Results of pooled analysis. When the three fair- or good-quality studies were combined in a random effects meta-analysis, the RR of lung cancer incidence was 1.63 (95% CI, 0.95 to 2.80) (**Figure 2**); when the poor-quality MILD trial was included, the RR was 1.70 (95% CI, 1.07 to 2.68). For lung cancer mortality, the RR was 0.81 (95% CI, 0.72 to 0.91) (**Figure 3**); when the poor-quality MILD trial was included, the RR was 0.98 (95% CI, 0.68 to 1.40). For all-cause mortality, the RR was 1.02 (95% CI, 0.78 to 1.33) (**Figure 4**); when the poor-quality MILD study was included, the RR was 1.13 (95% CI, 0.84 to 1.53).

Chest X-Ray

To evaluate the effectiveness of screening for lung cancer with CXR, we limited our review to RCTs of screening that reported results in both the CXR and control groups published since the previous evidence review. We identified an update of the Mayo Lung Project of lung cancer screening with quarterly CXR screening conducted in the 1970s,⁵⁸ and the first major publication of lung cancer results from the PLCO Screening Trial, which evaluated the effectiveness of screening with annual CXR in reducing lung cancer mortality (**Table 2** and **Appendix B1**).⁵⁹

After 20 years of followup in the Mayo Lung Project, lung cancer mortality rates were 440 per 100,000 py (95% CI, 390 to 490) and 390 per 100,000 py (95% CI, 350 to 440) in the intensive screening group and control group, respectively. In 2006, the results of this trial were updated and continued to show no benefit for intensive versus periodic screening with CXR in reducing lung cancer mortality.⁵⁸

After 6 years of followup in the PLCO Screening Trial, the RR for lung cancer mortality among the entire CXR screened group compared with the usual care group was 0.91 (95% CI, 0.80 to 1.03). After 13 years of followup, the cumulative incidence of lung cancer in the CXR group was 200 per 100,000 py and 192 per 100,000 py in the usual care group. Over the same time period, there were 1,213 lung cancer deaths (140 per 100,000 py) in the CXR group and 1,230 (142 per 100,000 py) in the usual care group, with a RR of 0.99 (95% CI, 0.87 to 1.22). All-cause mortality rates were 1,052 per 100,000 py in the CXR group and 1,071 per 100,000 py in the usual care group, with a RR of 0.98 (95% CI, 0.95 to 1.01) after 13 years of followup.⁵⁹

In addition to the analysis of CXR screening outcomes in the general population, the PLCO Screening Trial also assessed the effectiveness of CXR screening among individuals at high risk of lung cancer by evaluating the outcomes of individuals who would be eligible for the NLST (all current and former smokers ages 55 to 74 years with ≥ 30 pack-year smoking history). Among the 30,321 individuals meeting these criteria, the cumulative incidence of lung cancer through 6 years of followup was 606 per 100,000 py in the intervention group and 608 per 100,000 py in the control group (RR, 1.00 [95% CI, 0.88 to 1.13]). Over the same period of followup, the lung cancer mortality rates were 361 per 100,000 py in the CXR group and 383 per 100,000 py in the usual care group, with a RR of 0.94 (95% CI, 0.81 to 1.10). This study also evaluated lung cancer mortality associated with screening among women and found a RR of 0.92 (95% CI, 0.81 to 1.06) after 13 years of followup.⁵⁹

Sputum Cytology

The searches did not identify any new studies that evaluated screening for lung cancer with sputum cytology. Sputum cytology was included as part of the study protocol in the DANTE trial, but results on effectiveness have not been reported.^{51,61}

Benefits by Subgroup

All of the RCTs of screening with LDCT were conducted in participants at high risk of lung cancer based on participants' history of prior or current smoking. None evaluated low- or average-risk participants. The only CXR trial evaluating annual CXR screening compared with usual care among the general population was the PLCO Screening Trial, which showed no benefit of screening, with a RR of lung cancer death of 0.94 (95% CI, 0.81 to 1.10) after 6 years of followup and 0.99 (95% CI, 0.87 to 1.22) after 13 years of followup.⁵⁹ None of the trials of LDCT reported findings by sex or race. Only the PLCO Screening Trial reported findings by sex, as noted above, and found the RR for lung cancer mortality among women from the general population (smokers and nonsmokers) screened annually with CXR was 0.92 (95% CI, 0.81 to 1.06). Data on women smokers enrolled in this trial have not yet been reported.

Key Question 2. What Are the Test Characteristics of Screening Tests for Lung Cancer?

Summary

Sensitivity of LDCT was reported in one trial and five cohort studies and ranged from 80 to 100 percent but was most often greater than 90 percent; however, the method for determining sensitivity varied among studies. Specificity was reported in two RCTs and five cohort studies and ranged from 28 to 100 percent; again the method for determining specificity varied among the studies. The calculated positive predictive value for an abnormal (positive or indeterminate) LDCT scan predicting lung cancer ranged from 2.2 to 42 percent. The calculated positive predictive value of a recommendation for biopsy or surgery based on LDCT for predicting lung cancer ranged from 50 to 92 percent. The sensitivity of CXR for lung cancer was reported in the prior review as 25 percent compared with LDCT, while specificity was not evaluated. No studies reported test parameters for sputum cytology.

Evidence

In the previous evidence review,¹ test characteristics of CXR and LDCT were summarized but not systematically reviewed; test characteristics of sputum cytology testing were not reviewed, although the effectiveness of screening with cytology was. For the current evidence review, data were included from the RCTs described above, as well as eight cohort studies meeting criteria for this review (**Appendix B3**). In addition, when data were not directly reported but were provided, we calculated the positive predictive value of LDCT both for “abnormal” or “suspicious” findings requiring further evaluation and for biopsy (or surgery if biopsy not reported) that resulted from the evaluation of an abnormal or suspicious LDCT.

Low-Dose Computed Tomography

All of the RCTs that reported data contributed to the discussion of test characteristics of LDCT. In addition, we identified eight cohort studies of LDCT that provided data on test characteristics. The findings from the cohort studies are summarized in **Appendix B3**. Because of variable ways of reporting results and/or test parameters, we did not calculate test parameters. It is important to note that there is no defined “gold standard” for evaluating either the sensitivity or specificity of LDCT.

Reported sensitivity of LDCT in prevalence and incidence screens ranged from 80 to 100 percent, with most studies reporting sensitivity greater than 90 percent.^{56,86-91} This number reflects variation in the definition of a false-negative. Most studies report a false-negative scan as LDCT that was negative within 1 year or less of the participant developing lung cancer. However, one study defined false-negative scans as those in which a participant developed greater than stage I lung cancer within 1 year of a negative screening scan.⁵⁷ In addition, some studies reviewed prior LDCT scans when a nodule was identified on an incidence scan. If the abnormality was seen on a prior LDCT scan, the sensitivity was reported as if the prior scan had identified the nodule.

Specificity was reported in two RCTs^{52,56} and five cohort studies.^{86,87,89-91} In these studies, specificity ranged from 28⁸⁷ to 100 percent.⁹¹ Variability in reporting of specificity can be attributed to heterogeneity in definitions between studies. Some trials report three categories of findings: positive, indeterminate, and negative. Also, some studies reported false-positive examinations as those categorized as “positive” on the screening LDCT scan; indeterminate examinations that were clarified by either treatment of an abnormality or another CT scan within the first few months of the indeterminate LDCT scan were not always considered or reported as false-positive examinations.⁵⁶ We considered this type of specificity program or protocol specificity. Further complicating this issue, some studies only reported the number of positive scans or the number of nodules, rather than the number of participants with a positive scan, which is the most important measure in considering potential harms. This issue also complicates the understanding of positive predictive values discussed below.

Chest X-Ray

The previous evidence review assessed the test characteristics of CXR by comparing the findings among patients subjected to both LDCT and CXR and evaluating these parameters using LDCT as the gold standard, which may be problematic because of LDCT’s low specificity. In that review, the sensitivity of CXR for detecting lung cancer compared with LDCT was 25 percent.¹ No new studies directly reporting CXR test characteristics were identified by the current evidence review.

Sputum Cytology

As noted above, the previous evidence review did not evaluate the test characteristics of sputum cytology as a screening test for lung cancer, and thus did not provide data on this measure for the current evidence review. The current evidence review did not identify any papers that reported sputum cytology test characteristics published in the medical literature since the previous evidence review. One RCT and two cohort studies included in the current evidence review collected sputum samples from participants,^{58,61,89} but no studies formally reported on the test

characteristics of sputum cytology testing. It is likely that the absence of recent data on this topic reflects the fact that sputum cytology has not been studied as a screening method since trials conducted in the mid 1970s failed to show benefit from screening with sputum cytology.¹ Accordingly, sputum cytology testing is now rarely used for lung cancer screening.

Test Characteristics by Subgroups

No studies provided data on test characteristics by subgroups other than by risk profile. Since the predictive value of tests will vary with prevalence, all screening tests will have higher predictive value in individuals at higher baseline risk of lung cancer.

Key Question 3. What Are the Harms Associated With Lung Cancer Screening and Are There Ways to Modify Harms?

Summary

Radiation Exposure

Two RCTs and two cohort studies reported radiation associated with one LDCT scan ranging from 0.61 to 1.5 mSv; however, only one study reported cumulative radiation exposure associated with the screening program, which was estimated at 6 to 7 mSv.

False-Positive Examinations and Followup Evaluations

Positive examinations ranged from 9.2 to 51 percent (of participants) in baseline screens, with calculated positive predictive values for abnormal studies ranging from 2.2 to 36 percent; most abnormal scans were resolved with further imaging. Positive examinations were lower in subsequent screens, with positive predictive values for abnormal studies predicting lung cancer of 4 to 42 percent and most abnormal scans were resolved with further imaging. Positive predictive values for abnormal LDCT scans with recommendations for biopsy ranged from 50 to 92 percent.

False Reassurance

The sensitivity of LDCT for detecting lung cancer ranged from 80 to 100 percent, implying a false-negative rate of 0 to 20 percent. The harm of false reassurance was not evaluated in any study.

Overdiagnosis

Overdiagnosis was not formally reported in any study. However, of the four RCTs of LDCT reporting results in both the LDCT and no LDCT groups, overdiagnosis was suggested in one trial showing an excess of 119 lung cancers among 26,722 participants after 6.5 years of followup. Four RCTs reported more early-stage lung cancer in LDCT-screened groups than among the control group but not a smaller number of advanced lung cancers. However, there was insufficient followup in these studies to fully evaluate overdiagnosis. Data from one older trial of lung cancer screening with CXR involving approximately 9,000 high-risk participants showed that after 20 years of followup an excess of lung cancers diagnosed in the screened group persisted. The PLCO Screening Trial of CXR screening in the general population (n=155,000) found 18 excess lung cancers in the CXR group (compared with no CXR) after 6 years of

followup (2 years after screening ended) and 76 lung cancers after 13 years of followup (RR, 1.05 [95% CI, 0.98 to 1.12]); data from the same trial evaluating overdiagnosis only among a high-risk population showed a cumulative incidence of lung cancer of 606 per 100,000 py in the CXR group and 608 per 100,000 py in the usual care group after 6 years of followup (RR, 1.00 [95% CI, 0.88 to 1.13]).

Psychosocial Consequences

Five studies evaluated psychosocial consequences among individuals undergoing LDCT screening. Overall, LDCT screening did not appear to significantly impact overall health-related quality of life and no long-term difference in anxiety was reported, although in the short-term, three studies suggested increased anxiety among those with positive or indeterminate results compared with baseline. Distress was decreased among individuals in one trial with negative results compared with baseline.

Smoking Behavior

RCTs identified no differences in smoking cessation rates, smoking relapse rates, or smoking intensity when comparing individuals randomized to LDCT with no LDCT. In RCTs, smoking behavior among subjects with abnormal scans compared with those with negative scans showed mixed results; one study showed a tendency toward smoking abstinence among those with abnormal scans and one showed no difference. Similar mixed results were seen in cohort studies that compared smoking behaviors among those with abnormal and negative scans. One cohort study suggested that physician referral for patients with abnormal screening LDCT scans (compared with nonreferral for those with negative studies) may result in higher smoking cessation rates.

Incidental Findings

Most of the studies included in this review reported incidental findings. However, there was no standardized approach to reporting these findings. Among the studies of LDCT, nonpulmonary findings were common; infections and other cancers were also diagnosed. Coronary artery calcification was identified in approximately 50 percent of participants in one cohort study evaluating LDCT.

Evidence

Radiation Exposure

One of the direct harms associated with LDCT is radiation exposure. Data on LDCT parameters and radiation exposure in trials of LDCT screening are shown in **Table 4**. Two RCTs and two cohort studies reported the radiation associated with one LDCT scan as ranging from 0.65 to 1.5 mSv. Of the seven RCTs of LDCT screening included in the current evidence review, only the ITALUNG trial accounted for cumulative radiation exposure, using estimates of exposure for specific scanners and techniques employed.⁸¹ In 1,406 subjects randomized to LDCT screening, the four screening LDCT scans accounted for 77 percent of all radiation exposure, and evaluation of abnormal findings with additional CT scans, PET/CT, and CT-guided biopsy accounted for 23 percent. The cumulative exposure from screening over 4 years averaged 6 to 7 mSv. In individual patients screened on a single detector scanner, exposure over 4 years was as high as 21.5 mSv, and with four negative studies on multidetector (MD) CT scanners, as low as

1.9 mSv.⁸² MDCT is associated with lower radiation doses than single-detector CT technology. The cumulative effective doses per 1,000 subjects were 3.3 mSv using an MDCT scanner and 5.8 or 7.1 mSv using a single-detector scanner.⁸¹ No studies reported radiation exposure among individuals enrolled in CXR trials. The reported LDCT exposures compare with background radiation exposures in the United States that average 2.4 mSv per year, with significantly higher exposures at higher elevations.⁹² Also, to provide context, other imaging radiation exposure rates are approximately 1.7 mSv for head CT, 5 mSv for lumbosacral spine x-ray, and 0.7 mSv for mammography. Notably, a roundtrip flight from New York City to London would be associated with radiation exposure of approximately 0.1 mSv.^{92,93}

False-Positive Examinations and Followup Evaluations

The RCTs of LDCT reported the number of noncalcified nodules identified on screening and associated followup evaluations in varying detail. However, the definition of a positive LDCT scan, the categorization of nodules, the methods used to follow nodules, and the method of reporting nodules (by individual or by screen) varied among the studies, making comparisons difficult. In addition, some studies reported all lung cancer and some (NSCLC) only the primary object of screening. Notably also, the evaluations occurring in patients randomized to usual care were rarely reported in the trials that only presented early information on the intervention groups or baseline data.

Since the predictive value of tests will vary with the prevalence of the disease in the population, we have summarized baseline and annual or overall prevalence rates (cumulative incidence) in **Table 5** for both intervention and control groups. In trials of LDCT that reported the prevalence of lung cancer detected at baseline in high-risk populations, the prevalence ranged from 0.6 to 2.2 percent,^{52,54,56,61,62,74,82} suggesting different baseline risk for lung cancer or different LDCT program characteristics. Among the cohort studies, reported baseline prevalence ranged from 1.1 to 4.5 percent^{58,88,91,96} in high-risk populations. The studies included in the current evidence review vary by number of incidence screens, as well as length of followup, and some only report cumulative incidence or overall rates, making it difficult to compare cumulative incidence rates. These numbers are shown in **Tables 5** and **6**. Two cohort studies conducted in Japanese populations^{89,90} evaluated LDCT screening in the general population and reported lower lung cancer prevalence rates of 0.9 to 1.0 percent overall,^{89,90} but did not separately report data on prevalence and incidence screens.

One of the most common and important harms to consider in screening for lung cancer is the evaluation of patients with positive scans, which often involves more imaging and sometimes more invasive procedures such as bronchoscopy, fine needle biopsy, and/or surgery. Importantly, surgery is used both for diagnosis and treatment of early-stage lung cancer, making it difficult to separate the two. We attempted to evaluate these harms when they were reported in the studies; however, reporting varied substantially. To address this issue, we examined rates of positive scans and the subsequent evaluation of abnormal scans in both the RCTs^{52,54-56} and the cohort studies;^{86,88,96,98} this information is summarized in **Tables 5** and **6**. The prevalence of findings defined as “positive” varied between studies. On average, the number of positive examinations was higher on baseline screens and ranged from 9.2 to 39 percent in the RCTs^{52,54-56} and 9.8 to 51 percent in the cohort studies,^{86,88,91,96} with most in the 10 to 20 percent range. The positive predictive value for an abnormal baseline finding showing cancer ranged from 2.2 to 36 percent

in the RCTs.^{55-57,73} Among the cohort studies, the positive predictive value of abnormal baseline scans requiring further evaluations ranged from 4 to 21 percent, meaning that 79 to 96 percent of positive baseline scans did not result in a diagnosis of cancer.^{86-88,91} Since most positive scans were resolved by comparison with prior scans or further imaging, we also calculated the positive predictive value for a patient being referred for biopsy in the RCTs as a measure of harm. These positive predictive values ranged from 50 to 81 percent, suggesting that most patients who undergo an invasive procedure, such as biopsy, are diagnosed with lung cancer; in the cohort studies, the positive predictive value for patients referred to biopsy or surgery ranged from 66 to 92 percent.

The NLST was the only RCT that reported complications from diagnostic procedures used to evaluate a positive LDCT scan.⁵⁴ In this study, complications from diagnostic procedures were low; the rate of at least one complication was 1.4 percent in the LDCT group and 1.6 percent in the CXR group. Major complications were infrequent in both groups of this study. Among individuals diagnosed with lung cancer, there were 75 major complications in the LDCT group (11.5% of positive screen results determined to be cancer) and 24 in the CXR group (8.6% of positive screen results determined to be cancer) that were associated with invasive diagnostic procedures. However, among individuals with positive studies who were not found to have lung cancer and underwent invasive procedures, there were 12 major complications among LDCT participants (0.1% of positive screen results determined to not be cancer) and four among CXR participants (0.1% of positive screen results determined to not be cancer). Notably, 16 participants in the LDCT group died within 60 days after an invasive procedure (10 of whom had lung cancer), as did 10 (all with lung cancer) in the CXR group. It is not known if the procedure itself was the cause of death and deaths were not reported separately by procedure.

False-Negative Examinations and False Reassurance

The sensitivity of LDCT for detecting lung cancer at baseline was reported in one RCT as 96 percent.⁵⁶ Though sensitivity of incidence screens was rarely reported, the NELSON trial reported it as 96 percent.⁵⁶ Sensitivity was reported in five cohort studies^{56,86,87,89,90} and ranged from 80 to 100 percent. These data imply false-negative examination rates in the range of 4 to 20 percent. We found no studies that evaluated the potential harm associated with false-negative examinations, although this is an important harm to consider given the potential for false reassurance of patients and/or providers, which may delay evaluation of suspicious symptoms in the future.

Overdiagnosis and Overtreatment

One of the most concerning aspects of screening for lung cancer is the issue of possible overdiagnosis and treatment of lung cancer that will not impact a patient's life either due to mild disease that does not progress, cancer that resolves spontaneously, or death from other causes (competing mortality). If screening is effective and does not cause overdiagnosis after an adequate period of followup, both groups of a RCT will have the same number of cancers, but more early-stage and less late-stage (in absolute terms) disease should be found in the screened group. Alternately, finding more cancers in the screened group compared with the control group, especially more early-stage disease with the same number of later-stage disease, would be evidence for overdiagnosis.

While the optimum followup duration for measuring overdiagnosis is not known, the NLST found 119 more lung cancers (1,060 vs. 941) in the LDCT group compared with the CXR group after a median of 6.5 years of followup, suggesting overdiagnosis.⁵⁴ In addition, we found evidence in the LDCT trials of more early-stage lung cancers in the LSS, DANTE, MILD, and DLCST trials.^{51-53,55} However, with the exception of the NLST, these studies did not report fewer stage III to IV lung cancers in the LDCT group compared either with CXR or usual care.

Recent data from the Italian Continuing Observation of Smoking Subjects cohort study involving 5,203 asymptomatic participants aged 50 years and older describing VDT as a measure of potential overdiagnosis indicates variable VDT among lung cancers diagnosed in a screening program.⁹⁹ There were 175 patients diagnosed with lung cancer either with baseline LDCT (n=55) or subsequent LDCT (n=120). Of the 120 incident lung cancers, the authors demonstrated that VDT varies continuously from very slow-growing (VDT ≥ 600 days) to fast-growing (VDT of 52 days), with 75 percent of the incident lung cancer categorized as fast-growing. The authors suggest that this pool of slow-growing tumors are potentially those that are “overdiagnosed,” but note that the growth rate of what appear to be slow-growing (indolent) cancers can increase markedly from one scan to the next, complicating decisions about appropriate followup and treatment of slower-growing lesions. In addition, the lung cancer risk profile of patients with lung cancer in this study correlated with VDT, suggesting that slow-growing cancer is more common in lower-risk people.

Data from the 1970s Mayo Lung Project of quarterly CXR screening compared with less frequent CXR screening over 4 years have shown a persistent excess of lung cancers diagnosed in the CXR group (585 vs. 500) after 20 years of followup (16 years after screening ended) without a reduction in mortality or tumors identified at late stages.⁵⁸ Interestingly, in the 16 years after the Mayo Lung Project trial ended, more lung cancer was diagnosed in the CXR group (379 cases) compared with the control group (340 cases), in the absence of a screening program. Data from the PLCO Screening Trial conducted in the general population identified 76 extra lung cancers after 13 years of followup, with a cumulative incidence RR of 1.05 (95% CI, 0.98 to 1.12), suggesting less overdiagnosis. However, data from the PLCO Screening Trial at 6 years of followup (2 years after screening stopped) showed an excess of 18 lung cancers in the CXR group compared with the usual care group.⁵⁹ More relevant to screening high-risk individuals, in PLCO participants at high risk of lung cancer due to tobacco exposure, the cumulative incidence of lung cancer after 6 years of followup was the same in both groups: 606 per 100,000 py in the CXR group and 608 per 100,000 py in the usual care group after 6 years of followup (RR, 1.00 [95% CI, 0.88 to 1.13]).

Psychosocial Consequences

Three RCTs (in five publications) of either fair- or good-quality evaluated psychosocial consequences among individuals undergoing lung cancer screening with LDCT.^{68,69,77,100,101} Overall, LDCT screening did not appear to significantly impact general health-related quality of life, regardless of whether the screen findings were negative or indeterminate. Similarly, most studies did not find a long-term difference in anxiety, regardless of the screen result. In the short-term after a LDCT, approximately half of the patients reported discomfort about waiting for the results and dread of the results.⁶⁸ Measured 2 months after baseline LDCT in the NELSON trial, distress levels increased from baseline after an indeterminate result.⁷⁷ Compared with baseline,

distress decreased for subjects with negative LDCT results.^{69,77} For subjects in the Pittsburgh Lung Screening Study (PLuSS),¹⁰⁰ compared with baseline, state anxiety increased at 1 to 2 weeks and 6 months after an indeterminate result but returned to baseline 12 months after the LDCT scan. Similarly, for 60 subjects in the Mayo Clinic Project with a family risk of lung cancer who had a nonnegative result, worry increased from baseline in the short-term but returned to baseline 6 months after the LDCT scan.¹⁰¹ In a report based on the NELSON trial,⁶⁹ the only study to compare screened subjects with usual care subjects, health-related quality of life and anxiety were similar 2 years after enrolling in the study for both screened and usual care subjects. This study did report a short-term increase from baseline in distress for subjects who received an indeterminate result after LDCT that returned to baseline 2 years after the baseline scan.

Smoking Behavior

Seven studies, including three RCTs (in four publications)^{70,72,80,102} and four cohort studies (in five publications),¹⁰³⁻¹⁰⁷ reported smoking behavior changes in lung cancer screening studies and were included (**Table 7**).

Screening versus no screening. Two RCTs compared the effect of LDCT lung cancer screening with no screening on rates of smoking cessation.^{62,70} The DLCST found smoking abstinence (defined as >4 weeks of abstinence) rates of 10 and 11 percent in the no screening and LDCT groups, respectively, after 1 year of followup.⁶² The NELSON trial reported prolonged smoking abstinence (defined as 7-day point prevalence abstinence and <5 cigarettes since 2 weeks after their quit date) rates of 15 and 13 percent in the no screening and LDCT groups, respectively, after 2 years of followup ($p=0.35$).⁷⁰ The study also reported a non-intention-to-treat analysis among only those who responded to the followup smoking behavior survey. In this analysis, the prolonged abstinence rates were 19 percent in the no screening group and 15 percent in the LDCT group (OR, 1.40 [95% CI, 1.01 to 1.92]; $p=0.04$), which the authors interpreted as an unfavorable influence of screening on smoking behavior. However, response rates differed significantly among the groups, with a 78 percent response from the no screening group and 91 percent response from the LDCT participants. Because of the significantly different response rates among LDCT and control groups, we believe the most valid measure of smoking cessation comes from evaluating the full sample rather than just the responders.

Relapse rates were only reported in the DLCST,⁶² which found baseline former smokers had a relapse rate of 9.3 percent in both the no screening and the LDCT groups after 1 year, assuming nonattendees did not restart smoking. If nonattendees resumed smoking, the relapse rates may have been as high as 21 and 17 percent in the no screening and LDCT groups, respectively. Smoking intensity changes were only reported in the NELSON trial and did not differ between the no screening and LDCT groups.⁷⁰ In the no screening group and LDCT groups, respectively, 32 compared with 29 percent maintained baseline smoking intensity, 14 compared with 18 percent increased smoking intensity, and 54 compared with 53 percent decreased smoking intensity.⁷⁰

Comparing positive, indeterminate, and negative results. Two RCTs and two cohort studies in three publications^{62,80,104,106} compared the effect of receiving a positive, negative, or indeterminate LDCT screening result on smoking cessation and relapse rates. An additional

study evaluated the effect of physician referral category on these outcomes.¹⁰⁷

The two RCTs reported on different groups and had varying followup durations, making comparisons difficult. The DLCST demonstrated a tendency toward increased smoking abstinence and decreased relapse rates after 1 year in participants with a positive LDCT result.⁶² For baseline smokers with a positive result, the quit rate was 18 versus 11 percent in the group with negative LDCT results ($p=0.04$). In baseline former smokers with a positive LDCT result, the relapse rate (smoking during the year before followup) was significantly less (4.7%) than for those with a negative result (11%; $p<0.01$). A second trial (NELSON)⁸⁰ reported no statistically significant differences in prolonged smoking abstinence between male baseline smokers who received a negative LDCT screen result and those who received an indeterminate result after 2 years of followup (8.9% vs. 12%, respectively; $p=0.19$). Prolonged abstinence rates in this study did not differ significantly between participants with a single indeterminate LDCT result and those with multiple indeterminate results, though there was a trend toward higher abstinence rates among participants with multiple indeterminate findings (11% for single indeterminate result and 15% for ≥ 2 indeterminate results; $p=0.26$).

Two cohort studies in three publications reported mixed findings for the effect of LDCT screen results on smoking behavior.^{104,106} The Mayo Clinic Project cohort study reported increased odds of smoking abstinence among current smokers who received followup recommendations based on the prior year's LDCT scan (OR, 1.37 [95% CI, 1.12 to 1.67]; $p=0.002$). At 3 years of followup, those who received three recommendations for interim followup had the highest percentage of smoking abstinence (42%). For those that received no recommendations (implying a negative screening LDCT), the smoking abstinence rate was 20 percent. The influence of followup recommendations did not reach statistical significance for relapse rates among former smokers or recent quitters. Another cohort study, the Early Lung Cancer Action Program (ELCAP),¹⁰⁴ reported that a positive LDCT scan was not a significant predictor for prolonged abstinence in participants without a lung cancer diagnosis within 1 year (HR, 1.34 [95% CI, 0.90 to 1.99]). A positive LDCT finding was also not significantly associated with relapse of baseline smokers who quit.

The PLuSS¹⁰⁷ cohort study reported the effect of physician referral category on smoking behavior. LDCT screen results were used to categorize participants by risk (based on the LDCT findings): no referral, other referral, low suspicion ($<5\%$ predicted probability for lung cancer), or moderate/high suspicion ($>5\%$ predicted probability for lung cancer). The proportion of baseline smokers who were abstinent for more than 30 days at 1 year followup increased with increasing category of risk, from 14 percent in the no referral group to 26 percent in the moderate/high suspicion group (excluding participants who received a lung cancer diagnosis over this period).

Incidental Findings

Most of the studies included in the current evidence review reported incidental findings discovered in the course of screening for lung cancer. As there is no standardized research approach to defining what is considered an important incidental finding in lung cancer screening, investigators varied in what findings they reported. For example, researchers from the PLCO Screening Trial reported the frequency of emphysema and chronic obstructive pulmonary disease

incidentally detected by screening CXR,⁵⁹ whereas the majority of other RCTs in the current evidence review did not. Additionally, some studies reported incidental findings by radiographic description, such as lymphadenopathy, but others provided a clinical diagnosis, such as lymphoma. Given the variability in reporting practices between studies and that the reported incidental findings could not always be traced to screening modality (CXR or LDCT), it was not possible to calculate the frequency of incidental findings in a meaningful way.

Among the lung cancer screening RCTs, nonpulmonary nodule lung findings were common and included diagnoses such as bronchiectasis, pulmonary fibrosis, carcinoid tumors, and hamartomas. The NLST reported clinically significant abnormalities other than lung cancer in 7.5 percent of LDCT and 2.1 percent of CXR participants.⁵⁴ Notable infections included tuberculosis and fungal diseases. Other cancers discovered in the course of lung cancer screening included esophageal, thyroid, breast, renal, parathyroid, lymphomas, and metastatic cancers, such as colon and renal cell carcinoma. Some studies described cardiovascular findings such as coronary calcifications or aortic aneurysms. The finding of coronary artery calcification was reported in the Toronto ELCAP study and was approximately 50 percent.^{86,94} None of the studies reported what evaluations occurred in response to incidental findings.

While we have included this information under the key question dealing with harms for the current evidence review, it is plausible that there may also be some benefit to patients of identifying incidental findings. However, we found no data on either the harms or benefits associated with the incidental findings identified in the studies of screening reported in the current evidence review. Clearly, potential harms and benefits will vary by the finding, the clinical situation, and the patient's perspective.

Key Question 4. How Effective Is the Treatment of Surgical Resection of Early (Stage IA) Non-Small Cell Lung Cancer?

Summary

No RCTs compared treating stage IA or IB lung cancer with surgical resection with no treatment. Five studies from four cohorts in Japan showed 5-year survival rates for resected pathologic stage IA NSCLC ranging from 71 to 90 percent. Five-year survival among cohorts evaluating pathologic stage IB resected lung cancer ranged from 70 to 74 percent. Data from two large U.S. cohorts on 5-year survival among patients with resected stage IA NSCLC showed 5-year survival rates of 58 to 66 percent for stage IA and 55 percent for stage IB lung cancer resected between 1990 and 2000 (**Table 8**).

Evidence

No RCTs that assessed the effectiveness of surgical resection for stage IA NSCLC compared with no treatment were identified. Data from the United States on 5-year survival rates among patients with resected stage I NSCLC come from four studies.^{108,110,112,119} Data from the Surveillance Epidemiology and End Results (SEER) Program on 2,090 NSCLC cases less than 1

cm, resected between 1988 and 2005, and comparing lobectomy with sublobectomy showed 67 percent of patients overall were alive at 37 months.¹¹² A large study (n=10,761) utilizing SEER data of stage IA patients with a median age of 67 years, resected between 1988 and 1997, and a mean followup of 8.3 years, reported overall 5-year survival of 58 percent (63% for women and 53% for men).¹⁰⁸ Another study (n=715) of consecutive patients with pathologic stage I NSCLC, a median age of 67 years, and resected between 1990 and 2000 reported 5-year survival rates of 66 percent for stage IA and 55 percent for stage IB NSCLC.¹¹⁰ Finally, the most relevant evidence may come from a study of various treatment strategies evaluated in a cohort of 10,923 Medicare patients age 66 years or older diagnosed with stage IA to IB NSCLC between the years of 2001 and 2007. In this study, 2-year overall mortality was 18 percent among patients treated with lobectomy (n=6,531), 25 percent with sublobar resections, 41 percent with stereotactic ablative radiation, 57 percent with conventional radiation, and 73 percent with observation without treatment. In a multivariable adjusted analysis, observation was associated with a higher risk for lung cancer–specific mortality compared with anatomic surgical resection (HR, 3.01 [95% CI, 2.51 to 3.60]) more than 6 months after treatment.¹¹⁹

Five studies of four cohorts from Japan with survival data on patients with resected stage IA NSCLC were included.^{111,113,116-118} Generally, these studies included from 510 to 12,760 subjects and reported 5-year survival rates for resected stage IA lung cancer ranging from 71 to 90 percent, with the more recent studies consistently showing approximate survival in the 85 to 90 percent range.^{111,113,116-118} Because screening often detects stage IB NSCLC, we also report survival rates for resected pathologic stage IB NSCLC. Five-year survival among the cohorts evaluating pathologic stage IB patients ranged from 70 to 74 percent in the more recent studies evaluating survival among these patients.^{113,118}

Several comparative studies evaluated secular trends in survival that support significant improvement in 5-year survival rates over time.¹¹⁶ One large study (n=12,760) of pathologic stage IA patients resected during 2004, 1999, and 1994 reported 5-year survival rates of 89, 83, and 79 percent, respectively. While these numbers likely reflect improved staging technology and surgical technique, they may also show secular changes in patient populations, since widespread lung cancer screening with LDCT was implemented in Japan in the early 2000s.¹¹¹

Two studies from Europe were also identified. In these studies, 5-year survival for stage IA NSCLC ranged from 64 to 67 percent and survival for stage IB from 42 to 49 percent.^{109,120} However, these studies reported data collected on patients resected in the 1990s, which is unlikely generalizable to current practice.

While the rates described above from the United States are likely the most generalizable to the United States, it is important to note that these survival rates reflect survival among unselected and presumably symptomatic patients, since, for the most part, there has been little lung cancer screening in the United States during the time periods reviewed. Because of this, the survival rates identified in Japan may represent the “best” estimates for long-term survival from NSCLC under ideal circumstances or are more comparable to a screening population, since screening has been widespread there for many years.

Key Question 5. What Are the Harms Associated With Surgical Resection of Early (Stage IA) Non-Small Cell Lung Cancer?

Summary

None of the RCTs of LDCT screening evaluated the harms associated with resection of screen-detected stage 1A NSCLC. Two cohort studies evaluated the harms associated with resection of stage IA NSCLC. One Japanese study reported one postoperative death among 510 individuals undergoing resection between 1992 and 2001. One Italian study conducted between 1991 and 1994 (n=548) with complete resections of stage I NSCLC reported nine postoperative deaths among those resected. Six studies reported harms among large cohorts of individuals undergoing resection but did not specify results specifically for stage IA NSCLC.

Evidence

The NLST reported 60-day mortality after surgery associated with lung cancer resection of 1 percent; however, this included all resections, not just stage IA or IB resections.⁵⁴ To more fully address the harm associated with the treatment of early-stage lung cancer, we included several cohort studies of resection.¹⁰⁸⁻¹²⁰ However, of the 13 large studies (n≥500) we reviewed, only two reported on operative complications among patients undergoing surgery for stage IA NSCLC. One study (n=510) reporting outcomes among patients with NSCLC 2 cm or less in diameter undergoing resection in Japan between 1992 and 2001 identified one postoperative death among this cohort.¹¹⁷ Another trial from Italy (n=548) conducted between 1991 and 1994 and involving the complete resection of patients with stage IA or IB lung cancer reported nine postoperative deaths among those resected.¹⁰⁹

Six studies reported harms associated with resection in all patients with resected lung cancer, not limited to those with stage IA lung cancer.^{109,115-118,120} Among these cohorts, one study reporting on patients resected between 1993 and 1999 in Norway, where resection rates are very low (16%), reported a 30-day postoperative mortality rate of 4.8 percent in the entire cohort.¹²⁰ Another study (n=1,465) of consecutive patients of all stages resected in Japan during the years 1985 to 1995 and 1996 to 2002 reported postoperative complication rates of 28 percent in the 1985 to 1995 cohort and 12 percent in the 1996 to 2002 cohort. In-hospital deaths among those resected between 1985 and 1995 were 2 percent and among those resected from 1996 to 2002 were 0.5 percent.¹¹⁶ More applicable data comes from a large cohort (n=11,663) resected in 2004 in Japan. Among those resected, 4.5 percent had postoperative complications and 0.4 percent operative deaths and 0.4 percent hospital deaths occurred.¹¹⁸ Notably, these complications were summarized for the entire cohort, including all stages and all degrees of comorbidity and symptomatology. Finally, a study of patients in the United States (n=1,100) undergoing video-assisted thorascopic surgery procedures between 1992 and 2004 reported no intraoperative deaths, nine postoperative deaths (0.8%), and 168 complications, including 56 air leaks, 32 cases of atrial fibrillation, 13 pneumonias, and 13 readmissions.¹¹⁵ Similar to the large Japanese cohort described above, these data reflect complications and adverse events associated with resection of all stages of lung cancer and symptomatic disease among patients with unknown comorbidities.

Thus, the applicability of these complication rates to screening populations is uncertain.

CHAPTER 4. DISCUSSION

Summary of Review Findings

The personal and public health importance of lung cancer in the United States and worldwide is enormous, and even a small benefit from screening could save many lives. The current evidence review found that in one large (n=53,454) good-quality trial (the NLST) of lung cancer screening with three annual LDCT scans in high-risk individuals ages 55 to 74 years, both lung cancer and all-cause mortality were reduced in the LDCT group compared with those receiving annual CXR screening by 20 and 7 percent, respectively.⁵⁴ The absolute lung cancer mortality reduction was 4 per 1,000 people screened. One fair-quality Italian trial conducted among men older than age 60 years suggested reduced lung cancer mortality but did not show statistical significance.⁵¹ Two European trials (one of fair-quality [n=4,104] and one of poor-quality [n=4,099]) in populations of lower risk and younger age showed no benefit of LDCT in reducing lung cancer mortality.^{52,53}

We found no evidence to support the use of CXR for lung cancer screening, although data from the PLCO Screening Trial evaluating CXR screening among smokers suggested there might be benefit among high-risk individuals and possibly among women of high and average risk.⁵⁹ If there is any benefit of CXR screening, then the benefits of lung cancer screening with LDCT demonstrated by the NLST may be even greater if applied to an unscreened population. We found no new data on sputum cytology for the current evidence review, although sputum samples were collected in some of the studies. **Table 9** summarizes the evidence reviewed in the current review.

Sensitivity of LDCT is relatively high but the specificity varied, with positive predictive values for abnormal LDCT findings ranging from 2.2 to 42 percent, depending on the basis of calculation (by screening round or by including only positive or indeterminate scans). These findings are comparable with other screening modalities, such as breast cancer screening with mammography.¹²¹ The low specificity of screening with LDCT suggests the benefit of screening comes at some cost in terms of positive tests requiring subsequent clinical evaluations. The range of positive or indeterminate findings at baseline screening was high (9% to 51%), and most patients required some type of further evaluation, including clinical examinations, CXR, repeat CT, PET scans, and sometimes biopsy or surgical procedures. However, while lung biopsy is a fairly invasive procedure, the majority of biopsies performed were for cancer, not benign disease, with positive predictive values for invasive procedures or biopsy ranging from 50 to 92 percent. This contrasts with the high number of false-positive examinations requiring further evaluation with imaging or clinical/imaging followup, which were predominantly done for benign disease. Screening with LDCT did not seem to reduce overall quality of life, but was associated with short-term increased worry and distress compared with baseline for those with indeterminate results and decreased distress for those with negative screening results.^{68,69,77,100,122} Smoking cessation rates were not affected by screening in seven included studies, although there was a suggestion of reduced smoking among individuals with abnormal screening LDCT scans compared with those with negative LDCT scans. Finally, LDCT detected many incidental findings that were reported in variable ways in the included studies. The most commonly reported findings were emphysema and coronary artery calcifications.

While we found no trials evaluating the effect of surgical resection of early-stage lung cancer on mortality, this treatment is universally recommended and the benefit of this approach can be inferred given the positive results shown in the NLST of screening and early treatment of screen-detected disease.²² In fact, the NLST results may be the most compelling data to date that surgical resection of NSCLC improves survival, given the absence of RCTs on this topic. These findings were similar to the results of previous reviews. In a recent review conducted on behalf of the ACCP, the authors found no evidence from RCTs on the effectiveness of surgical resection for early-stage disease.¹²³ In an earlier review for the ACCP, authors conducted a search from the founding date of multiple electronic databases through 2001 that also found no relevant trials.¹²⁴ Finally, a Cochrane review of treatment for early-stage NSCLC also found no data from RCTs on the effectiveness of surgical resection of NSCLC.¹²⁵ Despite this lack of evidence, surgical resection of stage I lung cancer has a 1A recommendation by the ACCP¹²³ and is recommended by the NCCN.²² The strength of these recommendations is based on expected NSCLC growth rates,¹²⁶ detailed information from observational studies that show clear differences in early- versus late-stage mortality,^{4,7,126} and clinical experience. For patients with early-stage NSCLC who can tolerate its adverse effects, surgical resection is universally felt to be beneficial. It is important to note that prior research evaluating the outcomes of lung cancer treatment and resection show that the best patient outcomes occur when surgery is performed by experienced surgeons in high-volume centers.¹²⁷⁻¹³¹ The NCCN recommends that patients with clinical stage I and II NSCLC be evaluated by a thoracic surgical oncologist whose practice prominently focuses on lung cancer, even if patients are being considered for nonsurgical therapies such as percutaneous ablation or stereotactic body radiation therapy.¹²³

We evaluated what might account for different findings in the four trials, with the NLST showing a benefit of screening⁵⁴ and the three European studies (MILD, DANTE, and DLCST) not showing benefit.^{51-53,61} The European studies were small, with sample sizes ranging from 2,472 to 5,861 (compared with 53,454 in NLST), and were inadequately powered to detect benefit outcomes such as lung cancer mortality. The European trials also had shorter followup durations ranging from 3 to 5 years (compared with 6.5 years in NLST), which would impact the power of the studies to show a benefit.

A subtle but important issue in all three European studies is the difference in duration of followup in the LDCT groups compared with the nonLDCT groups. In the MILD trial, this results in a significant difference in risk of lung cancer, lung cancer mortality, and all-cause mortality when true followup time is accounted for in the rate denominators then when a median duration of followup is used for calculating incidence/mortality rates. In the MILD trial, the average followup was 53 months for both groups. However, actual followup duration was 56 months in the LDCT group compared with 45 months in the control group. Thus, it is not surprising there were more lung cancer and other deaths in an older population with nearly an extra year of followup. Similarly, when we adjusted for the true denominator of followup in both the LDCT and control groups in the DANTE trial, rather than a neutral effect on lung cancer mortality, the findings suggested a benefit of screening, although it was not statistically significant. Finally, the DLCST authors note that followup of the control group was less complete than for intervention patients (the difference was not reported), which could bias the study against showing a benefit of LDCT screening as well.

Another consideration when comparing the results of studies either showing or suggesting reduced lung cancer mortality (NLST and DANTE) with those showing no benefit or harm is that the populations screened in the NLST and DANTE trial were older and had more smoking exposure, and thus were at significantly higher risk of lung cancer compared with the DLCST and MILD populations. To better understand this, we compared lung cancer incidence and mortality rates among the control groups in each of the main trials. Notably, lung cancer incidence rates in the NLST and DANTE trial are higher than in the DLCST and MILD studies (**Table 3**). Similarly, the rate of lung cancer mortality is nearly 5-fold higher in the DANTE trial and 3-fold higher in the NLST when compared with either the MILD study or DLCST. All-cause mortality among the control groups in the NLST and DANTE trial was nearly equal and approximately 4-fold higher than the all-cause mortality shown in the DLCST and MILD study. These data indicate that different risk groups were enrolled in these four trials and suggest, but do not prove, that LDCT screening might be more beneficial in higher-risk populations similar to the NLST participants. This has been suggested and modeled in a recent paper where high-risk participants in the NLST were contrasted with the minimally eligible participants.¹³² Among high-risk participants, the NNS to save one life from lung cancer over 6 years (3 years of annual screening) was 82 compared with 3,180 for the minimally eligible NLST participant.

Finally, for many of the reasons noted in the Results section, there is reason to have great concern about the randomization of the MILD trial, which impacts the evaluation of its validity. There are important differences in the control and LDCT groups that correlate with each other and suggest systematic differences in the groups randomized to LDCT compared with the control group. This is further suggested by the great differential in followup and the authors' comments suggesting that the control group may have been added at a later time.

Data from other work has described the effect of “sticky diagnosis” bias, which may result in patients with a history of malignancy erroneously being labeled as dying of that malignancy when cause of death is uncertain. This bias may differentially impact screened groups since they typically have more diagnoses of cancer given during a screening trial because of lead time and some degree of overdiagnosis. This is especially true for patients diagnosed with adenocarcinoma, and was demonstrated in the Mayo Lung Project CXR screening trial.¹³³ Thus, patients diagnosed with lung cancer in the intervention group may be more likely to be coded as dying from lung cancer than individuals in the control group, especially if cause of death is not reviewed blind to intervention or control status or prior diagnoses and in the setting of shorter durations of followup. In addition, all three European studies that showed no benefit or suggested harm from screening involved some degree of intervention in the usual care group (such as clinical evaluation or PFT). Finally, the surgical/medical care of lung cancer likely differs between Europe and the United States.

Differences in study results may also be related to differences in the LDCT method used. For example, in the DANTE trial, 5-mm single-slice spiral CT was used, which might impact the radiographic resolution of the images. In addition, all participants in the DANTE trial had CXR as well as sputum cytology as part of the baseline evaluation, which would effectively reduce the power to detect a difference associated with LDCT, since nine patients in the control group and 16 patients in the LDCT group were diagnosed with lung cancer at baseline with CXR and sputum cytology. This difference in cancers diagnosed in the two groups at baseline also raises

the issue of possible inadequate randomization or sample size, since the baseline risk of cancer diagnosed by either sputum cytology or CXR is nearly two-fold higher in the LDCT group.⁶¹ A feature that differs among the European trials is that these studies tend to have higher positive predictive values associated with abnormal studies. High positive predictive values limit followup and worry among patients, but may also reflect a loss in sensitivity (or propensity for further evaluation) that results in different patient outcomes.

An important and controversial issue in lung cancer screening is the question of overdiagnosis and consequent overtreatment. The relatively high prevalence of unrecognized lung cancer in several studies suggests there is a significant preclinical pool of lung cancer in high-risk populations. Whether all of these tumors would eventually present clinically is uncertain. In addition, there currently is no way to tell which lung cancer has lethal potential and which does not, although LDCT VDT may prove helpful in the future. Thus, all patients diagnosed with lung cancer are typically treated, resulting in harm to patients with nonlethal lung cancer or those with tumors that might naturally regress.

Overdiagnosis is supported by data from the Mayo Lung Project study of CXR screening which, after 20 years of followup, still showed more (585 vs. 500) lung cancer diagnosed in individuals randomized to intense CXR screening compared with the control group.⁵⁸ Data from this study also showed increased rates of early tumors in the intensely screened group compared with the control group, without a change in numbers of advanced tumors or subsequent mortality rates, suggesting diagnosis of a pool of indolent tumors.⁵⁸ An intriguing finding in the Mayo Lung Project is that in the 16 years after screening ended, there were 39 more lung cancers diagnosed in the intervention group (379 vs. 340), which is difficult to explain. In contrast, the PLCO Screening Trial of CXR screening did not identify significantly more lung cancer in the screened group than in the control group, either in the general population or in the high-risk smoking population over 6 years of followup (808 vs. 790), although there were 76 more lung cancers in the CXR group after 13 years of followup, approximately 9 years after screening ended (1,696 vs. 1,620).⁵⁹ While the NLST identified more lung cancer in the LDCT group (1,040 vs. 941), this finding is within the context of results that showed a 20 percent reduction in lung cancer mortality and a 6.7 percent reduction in all-cause mortality, suggesting that even with overdiagnosis, there is benefit to screening that outweighs this potential harm.⁵⁴ Other data that supports overdiagnosis comes from the DLCST, which identified more early-stage lung cancers in the LDCT group than in the control group, but no difference in advanced-stage lung cancer between the groups. However, this may relate to shorter duration of followup and less up to date information about lung cancer in the control population.⁵² Data from the MILD trial that might support overdiagnosis come from a comparison of the LDCT biennial and annual screened groups.⁵³ In contrast to many LDCT studies, which have tended to show a preponderance of adenocarcinomas diagnosed in participants undergoing LDCT, the MILD trial showed a 10-fold increase in squamous cell cancers among those who were annually screened, which may suggest there is some degree of overdiagnosis of squamous cell cancer as well. However, given concerns about this study's randomization, these findings must be interpreted cautiously.

Arguments against an important role for overdiagnosis in lung cancer come from autopsy and clinical studies. One study of 15,812 necropsies conducted between the years 1953 and 1982 identified unsuspected "surprise" lung cancer in 68 patients (0.4%) who had died of a multitude

of causes, suggesting a relatively low rate of clinically unrecognized lung cancer.¹³⁴ However, autopsy may underestimate rates of lung cancer when compared with LDCT, since the lungs are not always thinly sectioned. Moreover, whether autopsy data are generalizable to living populations is questionable, particularly given selection biases for autopsy. Other data arguing against overdiagnosis come from studies of patients involved in screening programs who were diagnosed with stage I NSCLC and not treated for variable reasons.^{135,136} In one study of 45 screen-detected but untreated stage I NSCLC patients, only two patients survived 5 years.¹³⁵

A recent study evaluating the comparative effectiveness of five treatment strategies for stage 1A and 1B NSCLC indicates that among individuals age 66 years and older who were untreated, 30-day mortality was 8.6 percent. Among those untreated, 6-month mortality was 32.8 percent and 2-year mortality was 73.4 percent overall; lung cancer specific mortality at 4 years of followup was 95.4 percent.¹¹⁹ These data do not support a large pool of indolent lung cancer among patients with clinically-detected lung cancer, which likely differs from screen-detected populations.

Overdiagnosis in lung cancer almost certainly exists but its magnitude is unknown. The optimal followup time to calculate overdiagnosis from LDCT is not known but theoretically is the lead-time of the slowest-growing cancers, though it may be shorter in practice because of competing mortality. Currently, the best way to measure the magnitude of overdiagnosis caused by LDCT will be with continued followup of lung cancer incidence in the NLST (if the participants choose not to continue screening).

One of the most difficult challenges of LDCT screening is the high false-positive rate that results in downstream evaluations, which are associated with cost, anxiety, and risk. Reducing false-positive rates without reducing sensitivity and effectiveness will be one of the major challenges associated with CT screening and will require careful study of current protocols and guidelines. Data from the NELSON trial suggest that positive results requiring followup can be decreased significantly by following indeterminate nodules for VDT.⁵⁶ However, what is not yet known from the NELSON trial is whether this protocol will show the same mortality reduction as in the NLST. Clarifying parameters for indeterminate and positive LDCT screens involves a tradeoff between sensitivity and specificity that will require the best judgment of pulmonologists and radiologists and careful study of protocols that yield the highest sensitivity and specificity, since this will greatly impact the cost, risks, and effectiveness of LDCT screening. Technologic approaches to the problem of false-positive tests may also be on the horizon. Notably, in a recent surgical series, resection of benign nodules occurred in 50 to 86 percent of cases,^{137,138} highlighting the need for better discrimination of lung cancer nodules from benign nodules preoperatively in all domains. VDT, as well as risk prediction models, may independently, or in combination with biomarkers, improve lung cancer prediction and reduce followup imaging and procedures for people with positive scans, in both screening and clinical settings.

False-positive rates also seem to vary by geographic region, with higher rates in the Midwest that are thought to be related to increased rates of granulomatous diseases. One author also notes that rates of identification of noncalcified nodules is correlated with CT collimation.¹³⁹ A Canadian study showed that the number of participants with one or more nodules increased from 36 to 60 percent when scan thickness was decreased from 7 to 1.25 mm.¹⁴⁰

Although the false-positive rate was high in the studies included in this review, false-positive results from lung cancer screening may have a different effect on patients than false-positive results associated with other types of cancer screening tests. Patients who smoke potentially have some control over their subsequent risk and may be able to more effectively modify their high-risk behavior. Data from our review of smoking cessation associated with positive or indeterminate lung cancer screening results showed mixed results, with some studies suggesting or showing a trend that patients with abnormal results reduced smoking or more frequently remained abstinent.^{62,70,106,107}

Radiation exposure is a direct harm of lung cancer screening. It is widely accepted that medical imaging radiation exposure is associated with a real and measurable future risk of cancer.¹⁴¹ Radiation-associated cancer risk increases with younger age at the time of exposure and cumulative dose, and there may be interaction with other lung cancer risks, such as smoking.¹⁴² The effective dose from one LDCT scan averaged 1.6 mSv in the NLST and varied by a factor of two over the varying number of detectors and manufacturers used.¹⁴³ In addition, as doses are adjusted for body weight, the effective dose can further increase by a factor of two.⁶⁶ LDCT on a modern 16+ MDCT can have a dose as low as 0.8 mSv. In comparison, a standard diagnostic CXR is 0.02 mSv. Given the high frequency of positive LDCT examinations in the trials to date, it is important to note there is also radiation exposure associated with followup imaging of abnormal LDCT screens. These procedures include diagnostic chest CT with an effective radiation dose of 8 mSv and PET/CT with radiation doses ranging from 7 to 14 mSv.

Estimates of cancer risk associated with medical radiation are based on extrapolations and models derived from observations in atomic bomb survivors and occupational exposures.^{144,145} In one modeling study¹⁴⁶ using a LDCT dose of 5.2 mGy (approximately 5.2 mSv) for annual screening from ages 50 to 75 years, the model suggested that the lifetime risk of lung cancer in women would increase by 5 percent and in men by 1.5 percent. Chest radiation would also likely increase the risk of breast cancer among women given prior estimates for the radiation associated with mammography, as well as from childhood radiation exposures.¹⁴⁶ However, data on radiation and breast cancer development suggest most of the harm occurs in women sustaining radiation at ages younger than 30 years, significantly younger than the current age group in which lung cancer screening is being evaluated and considered. Notably, with decreasing LDCT radiation dose and frequency, the risks of subsequent lung cancer are proportionally reduced. This highlights the importance of radiation dose, screening interval and duration, and age at onset of screening in lung cancer screening programs and investigation.

Limitations

This review has several limitations. Some of these are discussed above and relate to limitations of the studies reviewed for this report. It could be argued that the NLST results were obtained in volunteers at mostly large academic centers and that the results are not generalizable to most people who might choose to be screened. However, the large size of this trial and its conduct at several centers in the United States, as well as involvement of community physicians and health care providers, improve the odds that these results are generalizable to a community population. The NLST participants were younger, better educated, and less likely to be current smokers than

the general population in the United States that would be eligible for LDCT screening by the NLST criteria. However, this difference is likely more important to consider if LDCT screening is implemented rather than as a limit to the validity of the NLST results. It is much less likely that the European studies would be generalizable to the United States given their very small size and different clinical practices.

The previous evidence review identified a paucity of screening studies among women and found some evidence to suggest that lung cancer screening might perform differently among women. Unfortunately, in spite of the fact that lung cancer is the leading cause of cancer-related death among women, the current evidence review found very little new information in women. There was a suggestion in the PLCO Screening Trial of possible benefit of CXR screening, but the findings were not statistically significant.⁵⁹ Hopefully, some of the trials currently underway will report data separately for women. This is especially important in the NLST, given the high number of participants and the statistical chance of identifying benefit if it exists. There are biological reasons to think that screening among women may be associated with different effectiveness, including the propensity of women to develop adenocarcinomas, which are often more peripheral and may be amenable to limited resection. Similarly, the current evidence review identified no studies of screening that evaluated benefits or harms in different racial and ethnic groups.

The rates of biopsy-associated complications were rarely described in the studies reviewed. In addition, while we attempted to evaluate the benefit and harm associated with the treatment of early-stage lung cancer, we found no RCTs that had evaluated surgical resection versus observation. The harms and benefits of surgical resection of lung cancer reported in this review are derived from large series of treatment in unselected symptomatic patients with stage I NSCLC who were treated surgically. Almost certainly, the harms would be higher in such a group and the benefits likely differ as well, making generalizing these results to a screening population problematic.

We excluded nonEnglish language articles, which could result in language bias, though we identified no nonEnglish language studies that would have met inclusion criteria. We did not search for studies published only as abstracts and could not formally assess for publication bias with graphical or statistical methods because of small numbers of studies for each key question and differences in study design, populations, and outcomes assessed. We found few or no randomized trials for a number of key questions. We therefore included nonrandomized trials, as well as observational studies (for harms), which are more susceptible to bias and confounding than well-conducted randomized trials.

Emerging Issues and Future Research

Over the next several years, the large NELSON trial will be publishing information on the benefits and harms of LDCT screening. In addition, longer followup of the smaller trials that will contribute to the NELSON trial should be available. Finally, more analyses of the NLST will be forthcoming and help define whether there are subgroups that might disproportionately benefit or be harmed with LDCT screening. In addition, new studies of risk modeling which could be

applied to currently screened groups may facilitate identification of patients at higher risk who might benefit differentially from screening with LDCT.^{40,147}

At this time in the United States, smoking occurs disproportionately in more disadvantaged groups as measured by socioeconomic status and/or educational level.⁶⁰ In addition, there is some evidence that individuals of disadvantaged socioeconomic and insurance status have increased lung cancer incidence as well.^{19,33,34} While it is not clear how much these associations are mediated by smoking behaviors, these findings will have important resource allocation and financial implications if lung cancer screening is widely adopted. It is important to continue to evaluate the psychosocial consequences in patients who undergo screening. As noted, patients in trials self-select to undergo screening and may differ in their psychological responses to screening and abnormal or normal results. If screening is implemented, it will be imperative that these issues be studied carefully, especially the impact on smoking behavior. Furthermore, the method and quality of communication between clinicians and patients with nonnegative results in screening trials is likely different than occurs in routine practice.¹²² All of these factors could influence the occurrence and magnitude of anxiety and distress that patients in the general population might experience. More research among patients in clinical settings is required to better address these concerns.

There is considerable interest in the use of biomarkers to increase the benefits and minimize the harms of lung cancer screening. The goal of this research is to focus LDCT efforts among individuals at highest risk of disease, provide more accurate discrimination between benign and malignant pulmonary nodules, and to find early indicators of aggressive disease. Many studies have examined the role of biomarkers in these settings. It is beyond the scope of our review to describe all of the potential biomarkers and analytic techniques currently being evaluated, but some that have been studied include exhaled breath biomarkers, such as volatile organic compounds;^{148,149} DNA methylation analyses using serum, sputum, or exhaled breath condensate;^{150,151} circulating serum microRNA;¹⁵²⁻¹⁵⁷ and protein and proteomic analyses (such as haptoglobin and posttranslational glycan modifications of haptoglobin,¹⁵⁸ panel of proteins,¹⁵⁹ and proteomic analyses¹⁶⁰); autoantibodies for small cell lung cancer;¹⁶¹ and the use of dogs to detect scent changes.¹⁶² Of note, the NLST collected multiple biologic specimens during enrollment, though no studies have yet reported results.⁵⁴

No studies were found that evaluated the efficacy of using these biomarkers as a screening test. One paper describes a series of steps necessary for biomarker development¹⁶³ that will likely guide the clinical relevance of biomarker development. Currently, many biomarker studies have been cross-sectional and most studied in patients with known lung cancer, so it is not known if these biomarkers are present in detectable quantities prior to the development of symptomatic disease. In the near future, it is unlikely that biomarkers will be directly proven to be efficacious at defining at-risk cohorts to target for screening. They may ultimately prove informative in models to assess the baseline risk of developing lung cancer and the potential benefits of LDCT for specific groups.

Biomarkers will likely be found that help distinguish between benign and malignant nodules, the source of the majority of false-positive LDCT findings. However, experts currently recommend serial followup of nodules with repeat CT scans, even for patients with a relatively low risk of

lung cancer.¹⁶⁴ The negative predictive value of these biomarkers will likely need to be very high in order to substantially reduce the number of patients who receive followup imaging or the number of scans these patients receive.

Conclusions

The current evidence review found LDCT screening for lung cancer reduced lung cancer mortality by 20 percent and all-cause mortality by nearly 7 percent in one very large, good-quality study conducted in the United States. The NNS to prevent one lung cancer death in this trial was reported as 320 and the NNS to prevent one death overall was calculated to be 219. This compares with a number needed to invite to screen to prevent one breast cancer death of 1,905 in mammography trials following women ages 40 to 49 years for 11 to 20 years, 1,339 for women ages 50 to 59 years, and 377 for women ages 60 to 69 years.¹⁶⁵ It also compares with a NNS with flexible sigmoidoscopy of 871 to save one life from colon cancer.¹⁶⁶ A small Italian study conducted among a population similar to the NLST population suggested benefit but was not statistically significant. A reduction in lung cancer and all-cause mortality was not shown in two small European trials. However, LDCT identified a high number of patients with positive findings that are not due to lung cancer and require further evaluation, which typically involves more radiation exposure and may cause anxiety among those screened in the short-term, as well as significant costs. New data on CXR screening did not show benefit for CXR in reducing lung cancer deaths, although there was a nonstatistical suggestion of benefit among women. The rates of surgical procedures to evaluate positive findings were variable among the studies reviewed, but generally, most patients undergoing biopsy or surgical procedures were diagnosed with lung cancer. Finally, some patients will likely be diagnosed with and treated for lung cancer that would not have impacted their life (overdiagnosis), which is a net harm to the screened patient. The magnitude of this harm is currently not known. We did not find evidence that LDCT screening reduced smoking rates among those screened, but this will be important to vigilantly monitor and study if LDCT screening is broadly implemented, since smoking cessation is by far the most important intervention for reducing lung cancer risk, as well as improving overall health. More work in public health to reduce smoking rates will be the most important approach to reducing morbidity and mortality from lung cancer. However, in the meantime, given the high number of current and former smokers in the population at risk for lung cancer, work on identifying and treating early-stage lung cancer with screening will hopefully clarify the balance of benefits and harms associated with screening.

References

1. Humphrey LL, Teutsch S, Johnson M; U.S. Preventive Services Task Force. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2004;140(9):740-53.
2. U.S. Preventive Services Task Force. Lung cancer screening: recommendation statement. *Ann Intern Med.* 2004;140(9):738-9.
3. Ebeling K, Nischan P. Screening for lung cancer: results from a case-control study. *Int J Cancer.* 1987;40(2):141-4.
4. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al (eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2011. Accessed at http://seer.cancer.gov/csr/1975_2009_pops09 on 8 August 2013.
5. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol.* 2011;6(2):244-85.
6. Clark JR, Rumcheva P, Veness MJ. Analysis and comparison of the 7th edition American Joint Committee on Cancer (AJCC) nodal staging system for metastatic cutaneous squamous cell carcinoma of the head and neck. *Ann Surg Oncol.* 2012;19(13):4252-8.
7. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. *Chest.* 2009;136(1):260-71.
8. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2007 Incidence and Mortality Web-Based Report. Atlanta: Centers for Disease Control and Prevention; 2010.
9. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010.
10. Naff JL, Cote ML, Wenzlaff AS, Schwartz AG. Racial differences in cancer risk among relatives of patients with early onset lung cancer. *Chest.* 2007;131(5):1289-94.
11. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* 2011;61:69-90.
12. Vollset S, Tverdal A, Gjessing H. Smoking and deaths between 40 and 70 years of age in women and men. *Ann Intern Med.* 2006;144:381-9.
13. National Cancer Institute. Cancer Trends Progress Report—2011/2012 Update. Bethesda, MD: National Cancer Institute; 2012. Accessed at <http://progressreport.cancer.gov/index.asp> on 8 August 2013.
14. Strauss GM. Screening for lung cancer: an evidence-based synthesis. *Surg Oncol Clin N Am.* 1999;8(4):747-74.
15. Osann K. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. *Cancer Res.* 1991;51(18):4893-7.
16. Sun SS, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. *Nat Rev Cancer.* 2007;7:778-90.
17. Tockman M, Anthonisen N, Wright E, Donithan M. Airways obstruction and the risk for lung cancer. *Ann Intern Med.* 1987;106(4):512-8.

18. Hole D, Watt G, Davey-Smith G, Hart C, Gillis C, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *BMJ*. 1996;313(7059):711-5.
19. National Cancer Institute. What Do the 2006–2007 Tobacco Use Supplement Data Say About Tobacco Use? Bethesda, MD: National Cancer Institute; 2012. Accessed at <http://riskfactor.cancer.gov/studies/tus-cps/results/data0607/> on 8 August 2013.
20. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥ 18 years—United States, 2005–2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(35):1207-12.
21. Mendez D, Warner KE. Setting a challenging yet realistic smoking prevalence target for Healthy People 2020: learning from the California experience. *Am J Public Health*. 2008;98(3):556-9.
22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Lung Cancer Screening. Fort Washington, PA: National Comprehensive Cancer Network; 2012.
23. Burns DM. Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. *Cancer*. 2000;89(11 Suppl):2506-9.
24. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. *Natl Cancer Inst*. 1993;85(6):457-64.
25. Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. *Cancer*. 1996;78(5):1004-10.
26. Skillrud D, Offord K, Miller R. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. *Ann Intern Med*. 1986;105(4):503-7.
27. Fontham E, Correa P, Reynolds P, Wu-Williams A, Buffler P, Greenberg R. Environmental tobacco smoke and lung cancer in nonsmoking women. *JAMA*. 1994;271(22):1752-9.
28. Trichopoulos D, Mollo F, Tomatis L, Agapitos E, Delsedime L, Zavitsanos X. Active and passive smoking and pathological indicators of lung cancer risk in an autopsy study. *JAMA*. 1992;268(13):1697-701.
29. Davila D, Williams D. The etiology of lung cancer. *Mayo Clin. Proc*. 1993;68(2):170-82.
30. Nesbitt JC, Lee J, Komaki R, Roth JA. Cancer of the lung. In: Holland JF, Bast RC Jr, Morton DL, Frei E III, Kufe DW, Weichselbaum RR, eds. *Cancer Medicine*. Baltimore: William & Wilkins; 1997.
31. International Early Lung Cancer Action Program Investigators; Henschke CI, Yip R, Miettinen OS. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. *JAMA*. 2006;296(2):180-4.
32. Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. *Cancer*. 2007;109(5):933-8.
33. Slatore CG, Au DH, Gould MK. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes. *Am J Respir Crit Care Med*. 2010;182(9):1195-205.
34. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. 2007;132(3 Suppl):29S-55S.

35. Jett J. Current treatment of unresectable lung cancer. *Mayo Clinic Proc.* 1993;68(6):603-11.
36. Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. *Int J Cancer.* 1993;54(1):44-8.
37. Klabunde CN, Marcus PM, Han PK, et al. Lung cancer screening practices of primary care physicians: results from a national survey. *Ann Fam Med.* 2012;10(2):102-10.
38. Klabunde CN, Marcus PM, Silvestri GA, et al. U.S. primary care physicians' lung cancer screening beliefs and recommendations. *Am J Prev Med.* 2010;39(5):411-20.
39. Slatore CG, Gould MK, Au DH, Deffebach ME, White E. Lung cancer stage at diagnosis: individual associations in the prospective Vitamins and lifestyle (VITAL) cohort. *BMC Cancer.* 2011;11:228.
40. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA.* 2012;307(22):2418-29.
41. American Lung Association. Providing Guidance on Lung Cancer Screening to Patients and Physicians. Washington, DC: American Lung Association; 2012. Accessed at <http://www.lung.org/finding-cures/research-news/new-screening-guidelines/lung-cancer-screening.pdf> on 8 August 2013.
42. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thor Cardiovas Surg.* 2012;144(1):33-8.
43. Wender R, Fontham ET, Barrera E, et al. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin.* 2013;63(2):107-17.
44. Lung Cancer Alliance. Rights and Expectations for Excellence in Lung Cancer Screening and Continuum of Care. Washington, DC: Lung Cancer Alliance; 2013. Accessed at <http://www.lungcanceralliance.org/get-information/am-i-at-risk/national-framework-for-lung-screening-excellence.html> on 8 August 2013.
45. Ambrose LF, Heaton CG, Idige CR. Letter Regarding U.S. Preventive Services Task Force Review of Lung Cancer Screening. Washington, DC: Lung Cancer Alliance; 2012.
46. Ambrose LF, Lopez TJ. Letter Regarding Essential Health Benefits Bulletin. Washington, DC: Lung Cancer Alliance; 2012.
47. National Lung Cancer Partnership. Lung Cancer Screening Trial, Options [Press release]. Madison, WI: National Lung Cancer Partnership; 2010.
48. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM. Methods of the third U.S. Preventive Services Task Force. *Am J Prev Med.* 2001;20(3 Suppl):21-35.
49. DerSimonian R, Laird NM. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7(3):177-88.
50. Higgins J, Thompson S, Higgins J. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21(11):1539-58.
51. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. *Am J Respir Crit Care Med.* 2009;180(5):445-53.
52. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. *Thorax.* 2012;67(4):296-301.

53. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev.* 2012;21(3):308-15.
54. National Lung Screening Trial Research Team; Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med.* 2011;365(5):395-409.
55. Gohagan J, Marcus P, Fagerstrom R, et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. *Chest.* 2004;126(1):114-21.
56. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. *N Engl J Med.* 2009;361(23):2221-9.
57. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. *Lung Cancer.* 2009;64(1):34-40.
58. Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. *J Natl Cancer Inst.* 2006;98(11):748-56.
59. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. *JAMA.* 2011;306(17):1865-73.
60. National Lung Screening Trial Research Team; Aberle DR, Adams AM, et al. Baseline characteristics of participants in the randomized national lung screening trial. *J Natl Cancer Inst.* 2010;102(23):1771-9.
61. Infante M, Lutman FR, Cavuto S, et al. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. *Lung Cancer.* 2008;59(3):355-63.
62. Ashraf H, Tonnesen P, Pedersen JH, Dirksen A, Dossing M. Smoking habits are unaffected by CT screening at 1 year follow up in the Danish Lung Cancer Screening Trial (DLCST). *Thorax.* 2009;64(5):388-92.
63. Gietema HA, Wang Y, Xu D, et al. Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements. *Radiol.* 2006;241(1):251-7.
64. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. *Lung Cancer.* 2006;54(2):177-84.
65. Xu DM, van Klaveren RJ, de Bock GH, et al. Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. *Eur J Radiol.* 2008;68(2):347-52.
66. Xu DM, van der Zaag-Loonen HJ, Oudkerk M, et al. Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow-up. *Radiol.* 2009;250(1):264-72.
67. Xu DM, van Klaveren RJ, de Bock GH, et al. Role of baseline nodule density and changes in density and nodule features in the discrimination between benign and malignant solid indeterminate pulmonary nodules. *Eur J Radiol.* 2009;70(3):492-8.
68. van den Bergh KA, Essink-Bot ML, Bunge EM, et al. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). *Cancer.* 2008;113(2):396-404.

69. van den Bergh KA, Essink-Bot ML, Borsboom GJ, Scholten E, van Klaveren RJ, de Koning HJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. *Eur Respir J*. 2011;38:154-61.
70. van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. *Thorax*. 2010;65(7):600-5.
71. Van't Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer. *Cancer J*. 2011;17(1):3-10.
72. Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann E. Lung cancer screening as a teachable moment for smoking cessation. *Lung Cancer*. 2007;56(1):125-34.
73. Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. *Ann Intern Med*. 2010;152(8):505-12.
74. Gohagan JK, Marcus PM, Fagerstrom RM, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest x-ray screening for lung cancer. *Lung Cancer*. 2005;47(1):9-15.
75. Pinsky PF, Marcus PM, Kramer BS, et al. Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. *Cancer*. 2005;103(1):157-63.
76. Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial—overall design and results of the prevalence round. *J Thorac Oncol*. 2009;4(5):608-14.
77. van den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). *Br J Cancer*. 2010;102(1):27-34.
78. van den Bergh KA, Essink-Bot ML, van Klaveren RJ, de Koning HJ. Informed participation in a randomised controlled trial of computed tomography screening for lung cancer. *Eur Respir J*. 2009;34(3):711-20.
79. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). *Int J Cancer*. 2006;120(4):868-74.
80. van der Aalst CM, van Klaveren RJ, van den Bergh KA, Willemsen MC, de Koning HJ. The impact of a lung cancer computed tomography screening result on smoking abstinence. *Eur Respir J*. 2011;37:1466-37.
81. Mascalchi M, Belli G, Zappa M, et al. Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the ITALUNG-CT trial. *AJR Am J Roentgenol*. 2006;187(2):421-9.
82. Mascalchi M, Mazzoni LN, Falchini M, et al. Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT. *Br J Radiol*. 2012;85(1016):1134-9. [
83. Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. *Ann Fam Med*. 2009;7(3):212-22.
84. Hocking WG, Hu P, Oken MM, et al. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *J Natl Cancer Inst*. 2010;102(10):722-31.
85. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns—getting past uninformative persuasion. *N Engl J Med*. 2012;367(18):1677-9.

86. Menezes RJ, Roberts HC, Paul NS, et al. Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. *Lung Cancer*. 2010;67(2):177-83.
87. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. *Radiol*. 2005;235(1):259-65.
88. Henschke CI, Yankelevitz DF, Smith JP, et al. CT screening for lung cancer: assessing a regimen's diagnostic performance. *Clin Imaging*. 2004;28(5):317-21.
89. Toyoda Y, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. *Br J Cancer*. 2008;98(10):1602-7.
90. Tsushima K, Sone S, Hanaoka T, Kubo K. Radiological diagnosis of small pulmonary nodules detected on low-dose screening computed tomography. *Respirology*. 2008;13(6):817-24.
91. Veronesi G, Bellomi M, Mulshine JL, et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. *Lung Cancer*. 2008;61(3):340-9.
92. Mettler F, Huda W, Yoshizumi T, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. *Radiology*. 2008;248(1):254.
93. Brenner D, Doll R, Goodhead D, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. *Proc Natl Acad Sci U S A*. 2003;100(24):1363-6.
94. Wagnetz U, Menezes RJ, Boerner S, et al. CT screening for lung cancer: implication of lung biopsy recommendations. *AJR Am J Roentgenol*. 2012;198(2):351-8.
95. Liu X, Liang M, Wang Y, et al. The outcome differences of CT screening for lung cancer pre and post following an algorithm in Zhuhai, China. *Lung Cancer*. 2011;73(2):230-6.
96. Veronesi G, Bellomi M, Scanagatta P, et al. Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. *J Thorac Cardiovasc Surg*. 2008;136(3):611-7.
97. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. *Am J Respir Crit Care Med*. 2008;178(9):956-61.
98. Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. *J. Cancer Res Clin Oncol*. 2012;138:1474-86.
99. Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer. *Ann Intern Med*. 2012;157:776-84.
100. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. *Med Decis Making*. 2008;28(6):917-25.
101. Sinicropo PS, Rabe KG, Brockman TA, et al. Perceptions of lung cancer risk and beliefs in screening accuracy of spiral computed tomography among high-risk lung cancer family members. *Acad Radiol*. 2010;17(8):1012-25.
102. Ashraf H, Tonnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Dossing M. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). *Thorax*. 2009;64(5):388-92.
103. MacRedmond R, McVey G, Lee M, et al. Screening for lung cancer using low dose CT scanning: results of 2 year follow up. *Thorax*. 2006;61(1):54-6.

104. Anderson CM, Yip R, Henschke CI, Yankelevitz DF, Ostroff JS, Burns DM. Smoking cessation and relapse during a lung cancer screening program. *Cancer Epidemiol Biomarkers Prev*. 2009;18(12):3476-83.
105. Cox LS, Clark MM, Jett JR, et al. Change in smoking status after spiral chest computed tomography scan screening. *Cancer*. 2003;98(11):2495-501.
106. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. *Cancer*. 2005;103(10):2154-62.
107. Styn MA, Land SR, Perkins KA, Wilson DO, Romkes M, Weissfeld JL. Smoking behavior 1 year after computed tomography screening for lung cancer: effect of physician referral for abnormal CT findings. *Cancer Epidemiol Biomarkers Prev*. 2009;18(12):3484-9.
108. Chang MY, Mentzer SJ, Colson YL, et al. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2007;134(4):850-6.
109. Christian C, Erica S, Morandi U. The prognostic impact of tumor size in resected stage I non-small cell lung cancer: evidence for a two thresholds tumor diameters classification. *Lung Cancer*. 2006;54(2):185-91.
110. Goodgame B, Viswanathan A, Miller CR, et al. A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. *Am J Clin Oncol*. 2008;31(1):22-8.
111. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. *Lung Cancer*. 2005;50(2):227-34.
112. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer ≤ 1 cm in size: a review of SEER data. *Chest*. 2011;139(3):491-6.
113. Maeda R, Yoshida J, Ishii G, et al. Long-term survival and risk factors for recurrence in stage I non-small cell lung cancer patients with tumors up to 3 cm in maximum dimension. *Chest*. 2010;138(2):357-62.
114. Maeda H, Matsumura A, Kawabata T, et al. Adenosquamous carcinoma of the lung: surgical results as compared with squamous cell and adenocarcinoma cases. *Eur J Cardiothorac Surg*. 2012;41(2):357-61.
115. McKenna J, Robert J, Houck W, Fuller CB. Video-assisted thoracic surgery lobectomy: experience with 1,100 cases. *Ann Thorac Surg*. 2006;81(2):421-6.
116. Okada M, Nishio W, Sakamoto T, et al. Evolution of surgical outcomes for nonsmall cell lung cancer: time trends in 1465 consecutive patients undergoing complete resection. *Ann Thorac Surg*. 2004;77(6):1926-30.
117. Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. *J Thorac Cardiovasc Surg*. 2006;132(4):769-75.
118. Sawabata N, Miyaoka E, Asamura H, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. *J Thorac Oncol*. 2011;6(7):1229-35.
119. Shirvani S, Jiang J, Chang J, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. *Int J Rad Onc*. 2012;84(5):1061-70.
120. Strand TE, Rostad H, Moller B, Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. *Thorax*. 2006;61(8):710-5.

121. Humphrey L, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002;137(5 Pt 1):347-60.
122. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. What do you mean, a spot?: a qualitative analysis of patients' reactions to discussions with their doctors about pulmonary nodules. *Chest.* 2013;143(3):672-7.
123. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest.* 2007;132(3 Suppl):234S-42S.
124. Smythe WR; American College of Chest Physicians. Treatment of stage I non-small cell lung carcinoma. *Chest.* 2003;123(1 Suppl):181S-7S.
125. Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer. *Cochrane Database Syst Rev.* 2013;6:CD001991.
126. Schultz EM, Silvestri GA, Gould MK. Variation in experts' beliefs about lung cancer growth, progression, and prognosis. *J Thorac Onc.* 2008;3(4):422-6.
127. Goodney P, Lucas F, Stuke T, Birkmeyer J. Surgeon specialty and operative mortality with lung resection. *Ann Surg.* 2005;241(1):179-84.
128. Farjah F, Flum D, Varghese T, Symons R, Wood D. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. *Ann Thorac Surg.* 2009;87:995-1006.
129. Tieu B, Schipper P. Specialty matters in the treatment of lung cancer. *Semin Thoracic Surg.* 2012;24:99-105.
130. Lau K, Rathinam S, Waller D, Peake M. The effects of increased provision of thoracic surgical specialists on the variation in lung cancer resection rate in England. *J Thorac Onc.* 2013;8(1):68-71.
131. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SD, Begg CB. The influence of hospital volume on survival after resection for lung cancer. *N Engl J Med.* 2001;345(3):181-8.
132. Bach P, Gould M. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. *Ann Intern Med.* 2012;157(8):571-3.
133. Black WC. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening. *J Natl Cancer Inst.* 2000;92(16):1280-2.
134. Chan CK, Wells CK, McFarlane MJ, Feinstein AR. More lung cancer but better survival. Implications of secular trends in "necropsy surprise" rates. *Chest.* 1989;96(2):291-6.
135. Flehinger B, Kimmel M, Melamed M. The effect of surgical treatment on survival from early lung cancer: implications for screening. *Chest Surg Clin N Am.* 1992;101(4):1013.
136. Sobue T, Suzuki T, Matsuda M, Kuroishi T, Ikeda S, Naruke T. Survival for clinical stage I lung cancer not surgically treated: comparison between screen-detected and symptom-detected cases. *Cancer.* 1992;69(3):685-92.
137. Grogan EL, Stukenborg GJ, Nagji AS, et al. Radiotracer-guided thoracoscopic resection is a cost-effective technique for the evaluation of subcentimeter pulmonary nodules. *Ann Thorac Surg.* 2008;86(3):934-40.
138. Cardillo G, Regal M, Sera F, et al. Videothoracoscopic management of the solitary pulmonary nodule: a single-institution study on 429 cases. *Ann Thorac Surg.* 2003;75(5):1607-11.
139. Midthun DE. Screening for lung cancer. *Clin Chest Med.* 2011;32(4):659-68.

140. McWilliams A, Mayo J, MacDonald S, et al. Lung cancer screening: a different paradigm. *Am J Respir Crit Care Med*. 2003;168(10):1167-73.
141. O'Connor GT, Hatabu H. Lung cancer screening, radiation, risks, benefits, and uncertainty. *JAMA*. 2012;307:2434-5.
142. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. *Br J Radiol*. 2008;81(965):362-78.
143. Cody DD, Kim HJ, Cagnon CH, et al. Normalized CT dose index of the CT scanners used in the National Lung Screening Trial. *AJR Am J Roentgenol*. 2010;194(6):1539-46.
144. Boice JD Jr, Monson RR. Breast cancer in women after repeated fluoroscopic examinations of the chest. *J Natl Cancer Inst*. 1977;59(3):823-32.
145. Lester RG. Risk versus benefit in mammography. *Radiol*. 1977;124(1):1-6.
146. Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. *Radiol*. 2004;231(2):440-5.
147. Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. *Ann Intern Med*. 2012;157(4):242-50.
148. Amann A, Corradi M, Mazzone P, Mutti A. Lung cancer biomarkers in exhaled breath. *Expert Rev Mol Diagn*. 2011;11(2):207-17.
149. Barash O, Peled N, Hirsch FR, Haick H. Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles. *Small*. 2009;5(22):2618-24.
150. Anglim PP, Galler JS, Koss MN, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. *Mol Cancer*. 2008;7:62.
151. Greenberg AK, Rimal B, Felner K, et al. S-adenosylmethionine as a biomarker for the early detection of lung cancer. *Chest*. 2007;132(4):1247-52.
152. Bianchi F, Nicassio F, Veronesi G, Di Fiore PP. Circulating microRNAs: next-generation biomarkers for early lung cancer detection. *Ecancermedicalscience*. 2012;6:246.
153. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. *Proc Natl Acad Sci U S A*. 2011;108(9):3713-8.
154. Hennessey PT, Sanford T, Choudhary A, et al. Serum microrna biomarkers for detection of non-small cell lung cancer. *PLoS One*. 2012;7(2):e32307.
155. Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. *Int J Clin Exp Pathol*. 2011;4(6):575-86.
156. Wang Q, Wang S, Wang H, Li P, Ma Z. MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. *Exp Biol Med*. 2012;237(3):227-35.
157. Rotunno M, Hu N, Su H, et al. A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma. *Cancer Prev Res (Phila)*. 2011;4(10):1599-608.
158. Hoagland LF 4th, Campa MJ, Gottlin EB, et al. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. *Cancer*. 2007;110(10):2260-8.
159. Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. *J Clin Oncol*. 2007;25(35):5578-83.
160. Monari E, Casali C, Cuoghi A, et al. Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers. *Proteome Sci*. 2011;9(1):55.

161. Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. *Mol Cancer*. 2011;10:33.
162. McCulloch M, Turner K, Broffman M. Lung cancer detection by canine scent: will there be a lab in the lab? *Eur Respir J*. 2012;39(3):511-2.
163. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. *J Natl Cancer Inst*. 2008;100(20):1432-8.
164. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiol*. 2005;237:395-400.
165. Nelson H, Tyne K, Naik A, et al. Screening for Breast Cancer: Systematic Evidence Review Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2009.
166. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med*. 2012;366(25):2345-57.
167. Henschke CI; Investigators for the International Early Lung Cancer Action Program. Survival of patients with clinical stage I lung cancer diagnosed by computed tomography screening for lung cancer. *Clin Cancer Res*. 2006;13(17):4949-50.
168. Shemesh J, Henschke CI, Farooqi A, et al. Frequency of coronary artery calcification on low-dose computed tomography screening for lung cancer. *Clin Imaging*. 2006;30(3):181-5.

Figure 1. Analytic Framework






Figure 2. Meta-Analysis of Lung Cancer Incidence



*Per 100,000 person-years

Abbreviations: CI = confidence interval; Co = control; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; F/u = followup; In = intervention; NLST = National Lung Screening Trial; RR = relative risk; vs. = versus; yrs = years


Figure 3. Meta-Analysis of Lung Cancer Mortality



*Per 100,000 person-years

Abbreviations: CI = confidence interval; Co = control; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; F/u = followup; In = intervention; NLST = National Lung Screening Trial; RR = relative risk; vs. = versus; yrs = years

Figure 4. Meta-Analysis of All-Cause Mortality



*Per 100,000 person-years

Abbreviations: CI = confidence interval; Co = control; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; F/u = followup; In = intervention; NLST = National Lung Screening Trial; RR = relative risk; vs. = versus; yrs = years

Table 1. Recommendations of Professional Organizations

Organization, year	Recommendations
American Cancer Society, 2012 ⁴³	The ACS recommends clinicians discuss screening for lung cancer with high-risk patients in relatively good health who meet the NLST criteria (ages 55 to 74 years with ≥ 30 pack-year smoking history, currently smoke, or have quit ≤ 15 years ago). Discussion of screening should include the benefits, uncertainties, and harms. The ACS recommends against the use of CXR and strongly suggests all adults undergoing screening enter an organized screening program with experience in LDCT.
American Association for Thoracic Surgery ⁴²	The Lung Cancer Screening and Surveillance Task Force recommends surveillance with LDCT and annual lung cancer screening for current and former smokers ages 55 to 79 years with a 30 pack-year history of smoking. It also recommends annual screening for long-term lung cancer survivors ages 55 to 79 years. Annual screening should begin at age 50 years for patients with a 20 pack-year history of smoking and additional comorbidity that produces a cumulative risk of developing lung cancer of at least 5% over the next 5 years.
American College of Chest Physicians, American Society of Clinical Oncology, American Thoracic Society ⁴⁰	The collaborative work of these organizations recommend lung cancer screening, modeled closely on the NLST, using a LDCT program for individuals ages 55 to 74 years with a 30 pack-year history of cigarette smoking and the ability to partake in organized programs of screening.
American Lung Association, 2012 ⁴¹	Recommends LDCT for patients who meet the NLST criteria and recommends against CXR as a method for lung cancer screening.
National Comprehensive Cancer Network Guidelines, 2012 ²²	The panel recommends LDCT screening for select patients at high risk of lung cancer based on the NLST results, nonrandomized studies, and observational data. High-risk individuals are defined as: age 55 to 74 years; ≥ 30 pack-year smoking history; and if they are a former smoker, they have quit ≤ 15 years ago OR age ≥ 50 years; ≥ 20 pack-year smoking history, and one additional risk factor. Moderate-risk (age ≥ 50 years and ≥ 20 pack-year history of smoking tobacco or secondhand smoke exposure, but no additional lung cancer risk factors) and low-risk (age < 50 years and/or smoking history < 20 pack-years) individuals are not recommended for lung cancer screening.

Abbreviations: ACS = American Cancer Society; CXR = chest x-ray; LDCT = low-dose computed tomography; NLST = National Lung Screening Trial

Table 2. Summary of Included Randomized, Controlled Trials

Study, recruitment years	Population	Baseline smoking status (intervention vs. control)	Screening strategy		Total followup	Followup after screening ended
			Number of screening rounds	Screening times (years)		
LDCT vs. CXR						
NLST ^{54, 72} August 2002–April 2004	N=26,722 vs. 26,732 Ages 55–74 years 59% male	Current: 48% (n=12,862) vs. 48% (12,900) Former: 52% (n=13,860) vs. 52% (n=13,832) Mean pack-years: 56	3	0, 1, 2	Median: 6.5 years Longest: 7.4 years	NR but presumably 4.5 years
LSS ^{55, 73-75} September 2000– January 2001	N=1660 vs. 1658 Ages 55–74 years 59% male	Current: 58% (n=961) vs. 57% (n=947) Former: 42% (n=699) vs. 43% (n=711) Median pack-years: 54	2	0, 1	NR but approximately 12–24 months	None
LDCT vs. no LDCT						
DANTE ^{51, 61} 2001–2006	N=1276 vs. 1196 Ages 60–74 years 100% male	Current: 56% (n=714) vs. 57% (n=681) Former: NR Mean pack-years: 47.3 vs. 47.2	5	0, 1, 2, 3, 4	Median: 33.7 months Controls: 31.5 months LDCT: 35.7 months	Unknown (final results pending)
DLCST ^{52, 62, 76} October 2004– March 2006	N=2052 vs. 2052 Ages 50–70 years 55% male	Current: 75% (n=1545) vs. 77% (n=1579) Former: 25% (n=507) vs. 23% (n=473) Mean pack-years: 36.4 vs. 35.9	5	0, 1, 2, 3, 4	Median person-years: 4.8	NR
MILD ⁵³ September 2005– January 2011	N=2376 (1190 annual, 1186 biennial) vs. 1723 Ages ≥49 years 66% male	Current: 68% (annual) vs. 68% (biennial) vs. 90% (control) Former: 31% (annual) vs. 32% (biennial) vs. 10% (control) Median pack-years: 39 vs. 39 vs. 38	Median number of CT scans (annual vs. biennial): 5 vs. 3	Every 12 months (annual) vs. every 24 months (biennial)	Median: 4.4 years (maximum 6 years in both groups) Controls: 56 months LDCT: 45 months	Recruitment ended January 2011; followup until November 2011
NELSON ^{56, 63-67, 69- 71, 77-80} 1st phase: 2003– NR 2nd phase: October 2005–NR	N=7915 vs. 7907 Ages 50–75 years 84% male	Current: NR Former: NR Mean pack-years: NR, but had to have 15 cigarettes/day for >25 years, or >10 cigarettes/day for >30 years smoking history, and if former smoker, quit ≤10 years ago for inclusion	3	0, 1, 3	2 years	2 years
ITALUNG ^{57, 81, 82} 2004–NR	N=1406 vs. 1593 Ages 55–69 years 65% male	Current: 65% (n=2078) Former: NR Median pack -years: 39	4	0, 1, 2, 3	Baseline only	NA

Table 2. Summary of Included Randomized, Controlled Trials

Study, recruitment years	Population	Baseline smoking status (intervention vs. control)	Screening strategy		Total followup	Followup after screening ended
			Number of screening rounds	Screening times (years)		
CXR vs. usual care						
PLCO ^{59, 83, 84} 1993–2001	N=77,445 vs. 77,456 Ages 55–74 50% male	Current: 10% Former: 42% Never: Approximately 45% Mean pack-years: NR	4	0, 1, 2, 3	Median (mean): 11.9 (11.2) years (range: 10–13 years)	NR

Abbreviations: CT = computed tomography; CXR = chest x-ray; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays Trial; DLCST = Danish Lung Cancer Screening Trial; LDCT = low-dose computed tomography; LSS = Lung Screening Study; MILD = Multi-centric Italian Lung Detection; NA = not applicable; NELSON = Nederlands-Leuven Longkanker Screenings Onderzoek; NLST = National Lung Screening Trial; NR = not reported; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Table 3. Incidence Rates of Lung Cancer Outcomes

Study	N	Incidence			Lung cancer mortality			All-cause mortality			Duration of followup*
		IN	CO	RR (95% CI)	IN	CO	RR (95% CI)	IN	CO	RR (95% CI)	
LDCT vs. CXR											
NLST ^{54, 72}	53,454	645	572	1.13 (1.03–1.23)	247	309	0.80 (0.73–0.93)†	1302	1395	0.93 (0.86–0.99)†	6.5
NLST women	41%	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LDCT vs. no LDCT											
DANTE ^{51, 61}	2472	1600	1015	1.46 (0.96–2.22)†	558	597	0.83 (0.45–1.54)†	1283	1344	0.85 (0.56–1.27)†	2.9 (IN) vs. 2.6 (CO)
DANTE women	0%	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
DLCST ⁵²	4104	706	245	2.88 (1.85–4.49)†	154	112	1.37 (0.63–2.97)†	624	429	1.46 (0.99–2.15)†	4.8
DLCST women	45%	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
MILD ⁵³	4099	457‡ 620	311	1.47 (0.82–2.64)†,‡ 1.99 (1.16–3.43)†,	109‡ 216	109	1.00 (0.34–2.98)†,‡ 1.99 (0.80–4.96)†,	363‡ 558	310	1.17 (0.63–2.17)†,‡ 1.80 (1.03–3.13)†,	3.8 (IN) vs. 4.7 (CO)
MILD women	34%	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CXR vs. usual care											
PLCO ⁵⁹	154,901	200	192	1.05 (0.98–1.12)	140	142	0.99 (0.87–1.22)	1052	1071	0.98 (0.95–1.01)	11.9
PLCO¶	30,321	606	608	1.00 (0.88–1.13)	361	383	0.94 (0.81–1.10)	NR	NR	NR	6
PLCO women	50.5%	NR	NR	NR	NR	NR	0.92 (0.81–1.06)	NR	NR	NR	11.9

*Data presented as medians in years.

†Data were calculated.

‡Biennial exam group.

|| Annual exam group.

¶NLST-eligible patients only.

Abbreviations: CI = confidence interval; CO = control group; CXR = chest x-ray; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; IN = intervention group; LDCT = low-dose computed tomography; MILD = Multi-centric Italian Lung Detection; NA = not applicable; NLST = National Lung Screening Trial; NR = not reported; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; RR = relative risk

Table 4. Computed Tomography Parameters

Study	kV	mAs	Slice width (mm)	Overlap	Multi/single detector	Estimated dose/study (mSv)
Randomized, controlled trials						
NLST ^{54, 72}	120–140	40–80	1–2.5	Yes	MDCT	1.5
LSS ^{55, 73-75}	120–140	60–120	NR	NR	NR	NR
DANTE ^{51, 61}	140	40	5	NR	Both	NR
MILD ⁵³	120	30	1–5	No	Both	0.7
NELSON ^{56, 63-67, 69-71, 77-80}	80–90	40–80	1	Yes	MDCT	NR
DLCST ⁷⁶	120	40	3 and 1	Yes	16 row MDCT	NR
Cohort studies						
Canada ELCAP ^{86, 94} September 2003–May 2007	120	40–60	1–1.25	Yes	Variable row 4–64	NR
China ELCAP ⁹⁵ 2 cohorts: 1993–2002 and 2003–2009	120	80	5	NR	Both	NR
COSMOS ^{91, 96} October 2004–October 2005	140	30	2.5	NR	8–16 row MDCT	0.8 men 1.0 women
Toyoda et al, 2008 ⁸⁹ August 1998–May 2002	NR	NR	NR	NR	NR	NR
Mayo Lung Project ⁸⁷ 1999	120	40	5	NR	4 row MDCT	0.65
PLuSS ⁹⁷ March 2002–November 2006	140	40–60	2.5	NR	NR	NR
Tsushima et al, 2008 ⁹⁰ 2000–2001	120	25	5	NR	MDCT	NR
LUSI ⁹⁸	NR	NR	1	Yes	MDCT	1.62–2

Abbreviations: COSMOS = Continuing Observation of Smoking Subjects; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; ELCAP = Early Lung Cancer Action Program; LSS = Lung Screening Study; LUSI = The German Lung Cancer Screening Intervention Trial; MDCT = Multidetector computed tomography; MILD = Multi-centric Italian Lung Detection; NELSON = Nederlands-Leuven Longkanker Screenings Onderzoek; NLST = National Lung Screening Trial; NR = not reported; PLuSS = Pittsburgh Lung Screening Study

Table 5. Results of Screening Rounds in Randomized, Controlled Trials*

Author, year	Round screening	Number screened		Study positives, n (%)		Imaging followup					
						CXR, n (%)		CT, n (%)		PET, n (%)	
		IN	CO	IN	CO	IN	CO	IN	CO	IN	CO
NLST ⁵⁴ Reported by procedure, except where noted	Baseline	26,722	26,732	7191 (27)†	2387 (8.9)†	1284 (4.8)†	867 (3.2)†	5153 (19)†	1546 (5.8)†	728 (2.7)†	179 (0.7)†
	Round 1			6901 (26)†	1482 (5.5)†	613 (2.3)†	381 (1.4)†	2046 (7.7)†		350 (1.3)†	105 (0.4)†
	Round 2			4054 (15)†	1174 (4.4)†	650 (2.4)†	365 (1.4)†	1608 (6.0)†	745 (2.8)†	393 (1.5)†	113 (0.4)†
	Cumulative			18,146 (68)†	5043 (19)†	2547 (9.5)†	1613 (6.0)†	8807 (33)†	712 (2.7)†	1471 (5.5)†	397 (1.5)†
				10,421 (39)	4277 (16)				3003 (11)†		
LSS ⁵⁵	Baseline	1660	1658	325 (20)	152 (9.2)	92 (5.5)	68 (4.1)	232 (14)	76 (4.6)	NR	NR
LSS ⁷⁴	Annual	1629	1648	295 (18)	145 (8.8)	64 (3.9)	45 (2.7)	140 (8.6)	55 (3.3)	NR	NR
DLCST ⁵²	Baseline	2052 (2047 had 1st LDCT)	2052	189 (9.2) Baseline recall rate (7.6)	NR	NR	NR	155 (7.6)	NR	NR	NR
	1	1976	1953	117 (5.9)	NR	NR	NR	20 (1.0)	NR	NR	NR
	2	1944	1877	52 (2.7)	NR	NR	NR	24 (1.2)	NR	NR	NR
	3	1982	1838	82 (4.1)	NR	NR	NR	18 (0.1)	NR	NR	NR
	4	1851	1820	72 (3.9)	NR	NR	NR	24 (1.3)	NR	NR	NR
	All annual	96%	93%	198/2054 (9.6)	NR	NR	NR	24	NR	NR	NR
NELSON ⁵⁶	Baseline	7557	NR	1451 (19) indeterminate and 119 (1.6) positive; 196 (2.6) referred for further evaluation	NR	55 (0.7)	NR	1438 (19)	NR	0	0
	1	7289	NR	480 (6.6) indeterminate and 90 (1.2) positive; 118 (1.6) referred for further evaluation	NR	35 (0.5)	NR	275 (3.8)	NR	NR	NR
MILD ⁵³	Overall	Biennial 1186	1723	Biennial 158 (13)	NR	NR	NR	NR	NR	Biennial 34 (2.9)	NR
		Annual 1190		Annual 177 (15)		NR	NR	NR	NR	Annual 49 (4.1)	
ITALUNG ⁵⁷	Baseline	1406	1593	426 (30)	NR	NR	NR	366 (26)	NR	59 (4.2)	NR
DANTE ⁵¹	Overall	1276	1196	351 (28) (226 further evaluation)	153 (12.8)	NR	38 (3.2)	199 (16)	22 (1.8)	57 (4.5)	4 (0.3)

Table 5. Results of Screening Rounds in Randomized, Controlled Trials*

Author, year	Biopsy†, n (%)		Surgery†, n (%)		Bronchoscopy, n (%)		Screen-detected lung cancer, n (%)		Total lung cancer, n (%)	
	IN	CO	IN	CO	IN	CO	IN	CO	IN	CO
NLST ⁵⁴	155‡ (0.6)† 74 (0.3)† 93 (0.3)† 322 (1.2)†	83 (0.3)† 37 (0.1)† 52 (0.2)† 172 (0.6)†	297 (1.1)† 197 (0.7)† 219 (0.8)† 713 (2.7)†	121 (0.5)† 51 (0.2)† 67 (0.3)† 239 (0.9)†	306 (1.1)† 178 (0.7)† 187 (0.7)† 671 (2.5)†	107 (0.4)† 56 (0.2)† 62 (0.2)† 225 (0.8)†	270 (1.0)† 168 (0.6)† 211 (0.8)† 649 (2.4)†	136 (0.5)† 65 (0.2)† 78 (0.3)† 279 (1.0)†	1060 (4.0)† 367 after screening or among those missing LDCT; 44 interval	941 (3.5)† 527 among those missing a screen or after screening ended; 137 interval
LSS ⁷⁵	63	NR	46 (2.8)	12 (0.7)	29 (1.7)	8 (0.5)	30 (1.8)	7 (0.4)		
LSS ⁷⁶	63	NR	18 (1.1)	19 (1.2)	14 (0.9)	8 (0.5)	8 (0.5)	9 (0.5)	40 (2.5)	20 (1.2)
DLCST ⁵²	NR	NR	NR	NR	NR	NR	17 (0.8)	1 (0.05)		
	2 (0.1)	NR	18 (0.9)	NR	13 (0.7)	NR	11 (0.6)	4 (0.2)		
	NR	NR	NR	NR	NR	NR	13 (0.7)	6 (0.3)		
	NR	NR	NR	NR	NR	NR	12 (0.6)	7 (0.4)		
	NR	NR	NR	NR	NR	NR	16 (0.9)	6 (0.3)		
	NR	NR	NR	NR	NR	NR	69	24	69 (3.8)	24 (1.2)
NELSON ⁵⁶	13 (0.2)	NR	92 (1.2) invasive procedures	NR	149 (2.0)	NR	70 (0.9)	NR	74 (1.0)	NR
	3 (0.04)	NR	61 (0.4) invasive procedures	NR	98 (1.3)	NR	54 (0.7)	NR	Uncertain	NR
MILD ⁵³	NR	NR	NR	NR	NR	NR	20 (1.7)	20 (1.2)	25 (2.1)	20 (1.2)
	NR		NR		NR		29 (2.4)		34 (2.9)	NR
ITALUNG ⁵⁷	16 (1.1) FNA	NR	16 (1.1) for treatment	NR	NR	NR	20 (1.4)	NR	20 (1.4)	NR
DANTE ⁵¹	NR	NR	96 (7.5) invasive procedures, 46 (3.6) thoracotomy, 20 (1.6) VATS	36 (3.0) any invasive procedure, 20 (1.7) thoracotomy, 6 (0.5) VATS	NR	NR	47 (3.7)	11 (0.9)	60 (4.7)	34 (2.8)

* Per individual, unless otherwise noted.

†Per test.

‡Per study definition.

Abbreviations: CO = control group; CT = computed tomography; CXR = chest x-ray; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays Trial; DLCST = Danish Lung Cancer Screening Trial; FNA = fine needle aspiration; IN = intervention group; LDCT = low-dose computed tomography; LSS = The Lung Screening Study; MILD = Multi-centric Italian Lung Detection; NELSON = Nederlands-Leuven Longkanker Screenings Onderzoek; NLST = National Lung Screening Trial; NR = not reported; PET = positron emission tomography; VATS = video-assisted thoracic surgery

Table 6. Results of Screening Rounds in Cohort Studies

Study	Round of screening	Number screened	Study positives, n (%)	Repeat CT or PET, n (%)	Biopsy*, n (%)	Surgery*, n (%)	Lung cancer, n (%)
Cornell ELCAP ⁸⁸	Baseline	2968	368/2968 (12)	NR	NR	NR	79/2968; 77 screen-detected (2.7)
	Repeat	4538	254/4538 (5.6)	NR	NR	NR	29/4538; 28 screen-detected (0.6)
China ELCAP ⁹⁵	Baseline	3582	351/3582 (10)	313/3582 (8.7)	NR	37/3582 (1.0)	34/3582 (0.95); interval cancers NR
Canada ELCAP ⁸⁶	Baseline	3352	600/3352 (18)	NR	57/3352 (1.7)	NR	44/3352 (1.3)
	Repeat	2286	259/2286 (11)	NR	25/2286 (1.1) 78 done		21/2286 (0.9); 18 screen-detected
COSMOS ^{91, 96}	Baseline	5201	560/5201 (11)	561/5201 (11)	NR	62/5201 (1.2)	55/5201 (1.0)
	Round 1	4821	500/4821 (10)	NR	101/5201 overall (1.9)	46/4821 (0.9)	37/4821 (0.8); 36 screen-detected
Mayo Lung Project ⁸⁷	Baseline	1520	780/1520 (51)	NR	NR	NR	31/1520 (2.0)
	Repeat (4)		1118/1520 (73)	NR	NR	NR	35/1520 (2.2); 34 screen-detected
Japan Toyoda et al, 2008 ⁸⁹	Overall	4689	NR	NR	NR	NR	45/4689 (0.96) - all screen detected
PLuSS ⁹⁷	Baseline	3642	1477/3642 (40)	821/3642 (22)	NR	90/3642; 54 for cancer (2.5)	80/3642 (2.2); interval cancers NR
Japan Tsushima et al, 2008 ⁹⁰	Overall	2486	214/2486 (8.6)	170/2486 HRCT (6.8)	NR	7/2486 (0.3)	8/2486 (0.3); all screen-detected
LUSI ⁹⁸	Baseline	2029	540/2029 (27)	NR	31/2029 (1.5)	19/2029 (0.9)	23/2029 (1.1); 22 screen-detected

* Per study definition.

Abbreviations: COSMOS = Continuing Observation of Smoking Subjects; CT = computed tomography; ELCAP = Early Lung Cancer Action Program; HRCT = high-resolution computed tomography; LUSI = The German Lung Cancer Screening Intervention Trial; NR = not reported; PET = positron emission tomography; PLuSS = Pittsburgh Lung Screening Study

Table 7. Smoking Rates

Study	N	Quit rates (for baseline smokers)	Relapse rate	Measure for abstinence
Randomized, controlled trials				
NELSON ⁷⁰ Random sample of baseline smokers	1284	24 months: CT group: 13% (84/641)* Control group: 15% (96/643)* p=0.35	NR	7 day PPA plus <5 cigarettes since 2 weeks after quit date
NELSON ⁸⁰ Random sample of baseline smokers in CT group	990	24 months: Negative CT group: 8.9% (46/519)* Indeterminate CT group: 11% (48/419)* p=0.19	NR	7 day PPA plus <5 cigarettes since 2 weeks after quit date
DLCST ⁸²	4104	12 months: CT group: 11% (174/1545)* Control group: 10% (165/1579)* p=0.47	Former smokers: CT: 9.3% (47/507)*† Control: 9.3% (44/473)*†	>4 weeks PPA
Cohorts from randomized, controlled trials				
NLST ⁷² LSS	NLST: 169 LSS: 144	1 month: NLST: 6.3% (5/79)*† LSS: 4.8% (4/83)*†	Former smokers: NLST: 4.4% (4/90)*† LSS: 3.3% (2/61)*†	
Cohorts				
ELCAP ¹⁰⁴	2078	Up to 72 months: 14% (103/730)*‡	Recent quitters (during study) with followup: 34% (52/155) Recent quitters (<12 months prior to study): 42% (51/121) Former smokers: 4.4% (54/1227)	30 day PPA
Mayo Lung Project ¹⁰⁵ 12-month followup	1475	12 months: 14% (129/901)	Former smokers: 10% (numerator/denominator NR)	PPA
Mayo Lung Project ¹⁰⁶ 36-month followup	1520	12 months: 14% (129/926)*† 24 months: 22% (202/926)*† 36 months: 23% (211/926)*† Repeat 7 day PPA x 36 months: 9.3% (86/926)*†	Recent quitters (during study) 12 months: NA 24 months: 26% (33/129)*† 36 months: 31% (62/202)*† Recent quitters (<12 months prior to study) 12 months: 32% (48/151)*† 24 months: 26% (40/151)*† 36 months: 27% (41/151)*† Former smokers: 12 months: 2.3% (10/439)*† 24 months: 2.7% (12/439)*† 36 months: 3.0% (13/439)*†	7 day PPA
PLuSS ¹⁰⁷	2094	12 months: 16% (325/2094)	Recent quitters (during study): 12 months: 12% (244/2094)	>30 day PPA
PALCAD ¹⁰³	449	24 months: 19% (59/307)	24 months: 1.6%	PPA

*Intention-to-treat analysis.

†Calculated.

‡Point abstinent with subsequent followup.

Abbreviations: CT = computed tomography; DLCST = Danish Lung Cancer Screening Trial; ELCAP = Early Lung Cancer Action Program; LSS = Lung Screening Study; NELSON = Nederlands-Leuven Longkanker Screenings Onderzoek; NLST = National Lung Screening Trial; NR = not reported; PALCAD = ProActive Lung Cancer Detection; PLuSS = Pittsburgh Lung Screening Study; PPA = point prevalence abstinence

Table 8. Survival Benefit and Adverse Events After Treatment of Stage I Lung Cancer

Author, year Recruitment years	Population	Duration of followup	Stage IA (n)	Stage IB (n)	Surgery	5-year survival	Harms
Chang et al, 2007 ¹⁰⁸ 1988–1997	N=10,761 stage IA 5320 women, 5441 men Median age: 67 years Other: SEER population	NR	10,761	0	Lobectomy: 79% Sublobectomy: 21%	Overall: 58% Women: 63% Men: 53%	NR
Christian et al, 2006 ¹⁰⁹ 1991–2004	N=1421 NSCLC resection, 548 complete resection stage IA/IB Mean age: 67 years Location: Italy	Median 49 months	250	298	Complete resection	Overall: 57% IA: 67% IB: 49%	9 postoperative deaths
Goodgame et al, 2008 ¹¹⁰ 1990–2000	N=715 consecutive patients undergoing resection 46% female 45% adenocarcinoma Location: United States Other: pathologic stage IA/IB Median age: 67 years	4.7 years	378	336	Wedge: 34% Lobectomy: 21% Pneumonectomy: 40%	Overall: 61% IA: 66% IB: 55%	NR
Goya et al, 2005 ¹¹¹ 1994	N=6644 resected NSCLC 70% male Mean age: 64.5 years Location: Japan	At least 5 years	2423	1542	NR	IA: 80% IB: 60% All stages: Men: 49% Women: 62%	NR
Kates et al, 2011 ¹¹² 1988–2005	N=2090 resected tumors ≤1 cm Lobectomy vs. sublobectomy Location: United States Other: SEER	37 months	2090	0	1402 lobectomy 688 “limited” resection	64% alive after 37 months Not clear	NR
Maeda et al, 2010 ¹¹³ 1994–2003	N=713 consecutive, 569 stage I 80% adenocarcinoma 46% female Location: Japan	NR	249	320	Wedge: 14% Lobectomy: 86%	85%	NR
Maeda et al, 2012 ¹¹⁴ 1997–2003	N=4668 all stages resected Location: Japan	Retrospective cohort with followup until March 2010	1487	1214	NR by stage	IA: 42% ASC 89% AC 63% SC IB: 19% ASC 65% AC 47% SC	NR

Table 8. Survival Benefit and Adverse Events After Treatment of Stage I Lung Cancer

Author, year Recruitment years	Population	Duration of followup	Stage IA (n)	Stage IB (n)	Surgery	5-year survival	Harms
McKenna et al, 2006 ¹¹⁵ 1992–2004	N=1100 patients of all stages undergoing VATS Location: NR	NR but data out to 10 years	561	248	VATS lobectomy	NR	Entire cohort: Benign dissection: 53/1100 (4.8%) Lung cancer: 1015/1100 (92%) No intraoperative deaths 9 postoperative deaths (0.8%) 168 had complications: 56 air leak, 32 atrial fibrillation, 13 readmission, 13 pneumonia
Okada et al, 2004 ¹¹⁶ 1985–1995 1996–2002	N=1465 consecutive patients, of which 859 stage I Location: Japan Other: NSCLC	103 months early era 41 months later era	523	326	NR by stage	IA: 71% early era 90% later era IB: 63% early era 75% later era	Entire cohort: 6.3% operative deaths Postoperative complications: Early era: 28% Late era: 12% In-hospital deaths: Early era: 2% Late era: 0.5%
Okada et al, 2006 ¹¹⁷ 1992–2001	N=510, ≤2 cm undergoing sublobar, lobar, or wedge resection Location: Japan Other: Peripheral NSCLC	72 months	510	0	Wedge: 30 Segmentectomy: 230 Lobectomy: 260	90% 89%	1 operative death (29 days postoperative MI)
Sawabata et al, 2011 ¹¹⁸ 2004 1999 1994	N=11,663 (2004), 13,344 (1999), 7393 (1994), 7530 stage I Location: Japan Other: NSCLC undergoing resection in 2004	2–78 months	Pathologic: 2004: 5611 1999: 5007 1994: 2142 Overall: 12,760	Pathologic: 2004: 2398 1999: 2803 1994: 1488 Overall: 6689	NR	2004 IA: 87% IB: 74% 1999 IA: 83% IB: 66% 1994 IA: 79% IB: 66%	Entire cohort: Postoperative complications: 2004: 4.5% 1999: 11% 1994: NR Operative deaths: 2004: 0.4% 1999: 0.9% 1994: 1.4% Hospital death: 2004: 0.4% 1999: 1.1% 1994: 1.7% Cause of death original cancer: 2004: 21% 1999: 25% 1994: 57%

Table 8. Survival Benefit and Adverse Events After Treatment of Stage I Lung Cancer

Author, year Recruitment years	Population	Duration of followup	Stage IA (n)	Stage IB (n)	Surgery	5-year survival	Harms
Shirvani et al, 2012 ¹¹⁹ 2001–2007	N=7808 (3582 men; 4226 women) Location: United States Other: SEER	Retrospective cohort with followup through May 2010	6047	1761	Lobectomy: 6531 Sublobar resection: 1277	NR	NR
Strand et al, 2006 ¹²⁰ 1993–1999	N=3211 resected 2061 men, 1150 women (resection rate in country 16%, of which 1375=stage I) Location: Norway	NR	559	816	NR by stage	IA: 64% IB: 42%	Entire cohort 30-day mortality: 4.8%

Abbreviations: AC = adenocarcinoma; ASC = adenosquamous carcinoma; MI = myocardial infarction; NR = not reported; NSCLC = non-small cell lung cancer; SC = squamous cell carcinoma; SEER = Surveillance Epidemiology and End Results; VATS = video-assisted thoracic surgery

Table 9. Summary of Evidence

Number of studies	Design	Limitations	Consistency	Applicability	Overall quality	Findings
Key Question 1. How effective is screening for lung cancer in reducing mortality and morbidity?						
6 studies (7 publications)	RCTs	3 RCTs evaluating LDCT had short followup and were underpowered	Low	High	Fair	<ul style="list-style-type: none"> 1 good-quality trial (n=53,454) of high-risk participants with good generalizability showed that LDCT compared with CXR conducted over 3 screens reduced lung cancer mortality by 20% and all-cause mortality by 6.7%. 3 smaller (n=2472, 4099, and 4104) European trials of fair- and poor-quality included high-risk participants and showed no benefit associated with LDCT screening compared with no LDCT screening. Meta-analysis of 3 fair- or good-quality trials showed RR of lung cancer mortality of 0.81 (95% CI, 0.72–0.91) and of all-cause mortality of 1.02 (95% CI, 0.78–1.33). 2 trials of CXR screening compared with no screening (1 in the general population and 1 in high-risk individuals) showed no benefit associated with CXR screening. 1 study reported findings on screening in women and did not show a significant reduction in lung cancer mortality associated with CXR screening. No trials reported data on lung cancer screening in different racial or ethnic populations.
Key Question 2. What are the test characteristics (sensitivity, specificity, predictive value) of screening tests for lung cancer?						
15 studies (24 publications)	RCTs Cohort	Variable methods of determining sensitivity and specificity	High	High	Fair	<ul style="list-style-type: none"> Sensitivity of LDCT was reported in 1 trial and 5 cohort studies and ranged from 80%–100%. Specificity of LDCT was reported in 2 RCTs and 5 cohort studies and ranged from 28%–100%. The calculated positive predictive value for an abnormal (positive or indeterminate) LDCT scan predicting lung cancer ranged from 2.2%–42%. The sensitivity of CXR for lung cancer was reported in the prior review as 25% when compared with LDCT; specificity was not evaluated. No studies reported test parameters for sputum cytology.
Key Question 3. What are the harms associated with lung cancer screening and are there ways to modify harms (e.g., unnecessary biopsy, radiation exposure, overdiagnosis, and psychosocial harms)?						
13 studies (32 publications)	RCTs Cohort	Harms variably reported among the studies	Fair	High	Fair	<p>Radiation:</p> <ul style="list-style-type: none"> 2 RCTs and 2 cohort studies reported radiation associated with 1 LDCT scan ranged from 0.6 mSv–1.5 mSv. 1 study reported cumulative radiation exposure associated with its screening program estimated at 6 mSv–7 mSv. <p>False-positive examinations and followup evaluations:</p> <ul style="list-style-type: none"> Positive examinations at baseline screen ranged from 9.2%–51% (of participants) with calculated positive predictive values for abnormal scans ranging from 2.2%–36%; most were resolved with further imaging. Positive examinations were lower in subsequent screens with positive predictive values for abnormal scans predicting lung cancer of 4%–42%; most were resolved with further imaging. Positive predictive values for abnormal LDCT scans with recommendations for biopsy ranged from 50%–92%. <p>False reassurance:</p> <ul style="list-style-type: none"> Sensitivity of LDCT ranged from 80%–100%, implying a false-negative rate of 0%–20%. The harms of false reassurance were not evaluated in any study. <p>Overdiagnosis:</p> <ul style="list-style-type: none"> Overdiagnosis was not formally reported in any study. It was suggested in 1 trial of LDCT compared with no LDCT that showed an excess of 119 lung cancers among approximately 26,000 participants after 6.5 years of followup. 3 RCTs with limited followup reported more early-stage lung cancer in LDCT screened groups than among controls but not a smaller number of advanced lung cancer. 1 older trial of CXR screening of approximately 9000 high-risk participants reported that an excess of lung cancers diagnosed in the screened group persisted after 20 years of followup.

Table 9. Summary of Evidence

Number of studies	Design	Limitations	Consistency	Applicability	Overall quality	Findings
						<ul style="list-style-type: none"> 1 trial of CXR screening compared with no screening in the general population (n=155,000) showed 18 excess lung cancers in the screened group after 6 years of followup and 76 excess lung cancers after 13 years of followup (RR, 1.05 [95% CI, 0.98–1.12]); data from the same trial evaluating overdiagnosis among a high-risk population showed a cumulative incidence of lung cancer of 606/100,000 py in the CXR group and 608/100,000 py in the usual care group after 6 years of followup (RR, 1.00 [95% CI, 0.88–1.13]). <p>Psychosocial consequences:</p> <ul style="list-style-type: none"> 5 studies showed that LDCT screening did not significantly impact overall health-related quality of life. Most studies reported no long-term difference in anxiety among participants, although 3 studies suggested increased short-term anxiety among those with positive or indeterminate results. Distress was decreased among individuals with negative results (compared with baseline) in 1 trial. <p>Smoking behavior:</p> <ul style="list-style-type: none"> 3 RCTs identified no differences in smoking cessation rates, smoking relapse rates, or smoking intensity between LDCT and no LDCT screening groups. In RCTs, smoking behavior among subjects with abnormal scans and those with negative scans showed mixed results, with 1 study showing a tendency toward smoking abstinence among those with abnormal scans. Mixed results were also seen in cohort studies. 1 cohort study suggested that physician referral for patients with abnormal screening LDCT may result in higher smoking cessation rates. <p>Incidental findings:</p> <ul style="list-style-type: none"> There was no standardized approach to reporting incidental findings. Among LDCT studies, nonpulmonary lung findings were common; infections and other cancers were also diagnosed. Coronary artery calcification was identified in approximately 50% of participants in 1 cohort study evaluating CT scans retrospectively.
Key Question 4. How effective is surgical resection for the treatment of early (stage IA) non-small cell lung cancer?						
12 studies	Cohorts	No RCTs evaluated surgical resection of stage IA or IB NSCLC. All reported survival among patients with clinically-detected lung cancer and not selected for comorbidity	Fair	Moderate	Fair	<ul style="list-style-type: none"> No RCTs have compared treating stage IA or IB lung cancer with surgical resection compared with no treatment. 5 studies from 4 cohorts in Japan showed 5-year survival rates for resected pathologic stage IA NSCLC ranging from 71%–90%. Five-year survival among cohorts evaluating pathologic stage IB resected lung cancer ranged from 70%–74%. 2 large U.S. cohorts showed 5-year survival rates of 58%–66% for stage IA and 55% for stage IB lung cancer resected between 1990 and 2000.
Key Question 5. What are the harms associated with surgical resection of early (stage IA) non-small cell lung cancer?						
6 studies	Cohorts	Studies reflect harms of surgical resection in patients identified in clinical practice with comorbidities; not necessarily a population eligible for screening	Fair	Low	Fair	<ul style="list-style-type: none"> No RCTs of LDCT screening evaluated the harms associated with resection of screen-detected NSCLC. 2 cohort studies reported harms associated with resection of stage IA NSCLC. 1 Japanese study reported 1 postoperative death among 510 individuals undergoing resection between 1992 and 2001. 1 Italian study reported 9 postoperative deaths among 548 patients with resections of stage I NSCLC between 1991 and 1994. 6 studies reported harms among large cohorts of individuals undergoing resection but did not specify results specifically for stage IA NSCLC.

Abbreviations: CI = confidence interval; CT = computed tomography; CXR = chest x-ray; LDCT = low-dose computed tomography; NSCLC = non-small cell lung cancer; py = person-years; RCT = randomized, controlled trial; RR = relative risk

Appendix A1. Search Strategies

Screening key questions 1, 2, and 3:

Database: Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) <1947 to 2012>

Search Strategy:

1 exp Lung Neoplasms/ (146585)
2 exp Mass Screening/ (85357)
3 screen\$.mp. (381192)
4 ((early or earlier or earliest) adj5 (detect\$ or diagnos\$ or discover\$ or find or finding)).mp. [mp=protocol
supplementary concept, rare disease supplementary concept, title, original title, abstract, name of
substance word, subject heading word, unique identifier] (123562)
5 exp early diagnosis/ (9549)
6 2 or 3 or 4 or 5 (492801)
7 1 and 6 (7310)
8 limit 7 to (english language and humans and yr="2000 -Current") (3399)

Database: EBM Reviews - Database of Abstracts of Reviews of Effects <4th Quarter 2012>

Search Strategy:

1 ((Lung or lungs or bronchi\$ or alveol\$ or respiratory tract\$ or pulmonar\$) adj5 (Neoplas\$ or cancer\$
or malig\$ or tumor\$ or tumour\$ or carcino\$ or adenocarcino\$ or metastas\$)).mp. [mp=title, full text,
keywords] (276)
2 screen\$.mp. (2503)
3 ((early or earlier or earliest) adj5 (detect\$ or diagnos\$ or discover\$ or find or finding)).mp. [mp=title, full
text, keywords] (132)
4 2 or 3 (2562)
5 1 and 4 (52)

Database: EBM Reviews - NHS Economic Evaluation Database <4th Quarter 2012>

Search Strategy:

1 ((Lung or lungs or bronchi\$ or alveol\$ or respiratory tract\$ or pulmonar\$) adj5 (Neoplas\$ or cancer\$ or
malig\$ or tumor\$ or tumour\$ or carcino\$ or adenocarcino\$ or metastas\$)).mp. [mp=title, text, subject
heading word] (416)
2 screen\$.mp. (2484)
3 ((early or earlier or earliest) adj5 (detect\$ or diagnos\$ or discover\$ or find or finding)).mp. [mp=title, text,
subject heading word] (259)
4 2 or 3 (2575)
5 1 and 4 (50)

Database: EBM Reviews - Cochrane Central Register of Controlled Trials <4th Quarter 2012>

Search Strategy:

1 ((Lung or lungs or bronchi\$ or alveol\$ or respiratory tract\$ or pulmonar\$) adj5 (Neoplas\$ or cancer\$ or
malig\$ or tumor\$ or tumour\$ or carcino\$ or adenocarcino\$ or metastas\$)).mp. [mp=title, original title,
abstract, mesh headings, heading words, keyword] (6652)
2 screen\$.mp. (11379)
3 ((early or earlier or earliest) adj5 (detect\$ or diagnos\$ or discover\$ or find or finding)).mp. [mp=title,
original title, abstract, mesh headings, heading words, keyword] (2242)
4 2 or 3 (13141)
5 1 and 4 (252)

Appendix A1. Search Strategies

Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to 2012>

Search Strategy:

-
- 1 ((Lung or lungs or bronchi\$ or alveol\$ or respiratory tract\$ or pulmonar\$) adj5 (Neoplas\$ or cancer\$ or malig\$ or tumor\$ or tumour\$ or carcino\$ or adenocarcino\$ or metastas\$)).mp. [mp=title, abstract, full text, keywords, caption text] (227)
 - 2 screen\$.mp. (3227)
 - 3 ((early or earlier or earliest) adj5 (detect\$ or diagnos\$ or discover\$ or find or finding)).mp. [mp=title, abstract, full text, keywords, caption text] (527)
 - 4 2 or 3 (3431)
 - 5 1 and 4 (142)

Database: EBM Reviews - Cochrane Database of Systematic Reviews <2005 to 2012>

Search Strategy:

-
- 1 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$)).mp. [mp=title, abstract, full text, keywords, caption text] (242)
 - 2 ((x ray\$ or radiogra\$ or sputum\$ or cytolog\$) adj5 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. [mp=title, abstract, full text, keywords, caption text] (302)
 - 3 1 and 2 (17)
 - 4 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$) adj7 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. (55)
 - 5 ((chest\$ or thorax\$ or thoracic\$) adj5 (x-ray\$ or radiogra\$)).mp. [mp=title, abstract, full text, keywords, caption text] (233)
 - 6 4 and 5 (9)
 - 7 sputum.mp. [mp=title, abstract, full text, keywords, caption text] (221)
 - 8 4 and 7 (5)
 - 9 3 or 6 or 8 (23)
 - 10 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$)).mp. [mp=title, abstract, full text, keywords, caption text] (242)
 - 11 ((x ray\$ or xray\$ or radiogra\$ or sputum\$) adj5 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. [mp=title, abstract, full text, keywords, caption text] (260)
 - 12 10 and 11 (11)
 - 13 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$) adj7 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. (55)
 - 14 ((chest\$ or thorax\$ or thoracic\$) adj5 (x-ray\$ or xray\$ or radiogra\$)).mp. [mp=title, abstract, full text, keywords, caption text] (236)
 - 15 13 and 14 (9)
 - 16 sputum.mp. [mp=title, abstract, full text, keywords, caption text] (221)
 - 17 13 and 16 (5)
 - 18 12 or 15 or 17 (18)

Database: EBM Reviews - Health Technology Assessment <4th Quarter 2012>

Search Strategy:

-
- 1 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$)).mp. [mp=title, text, subject heading word] (186)
 - 2 ((x ray\$ or radiogra\$ or sputum\$ or cytolog\$) adj5 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. [mp=title, text, subject heading word] (52)
 - 3 1 and 2 (3)
 - 4 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$) adj7 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. (42)

Appendix A1. Search Strategies

- 5 ((chest\$ or thorax\$ or thoracic\$) adj5 (x-ray\$ or radiogra\$)).mp. [mp=title, text, subject heading word] (19)
- 6 4 and 5 (8)
- 7 sputum.mp. [mp=title, text, subject heading word] (8)
- 8 4 and 7 (2)
- 9 3 or 6 or 8 (8)
- 10 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$)).mp. [mp=title, text, subject heading word] (186)
- 11 ((x ray\$ or xray\$ or radiogra\$ or sputum\$) adj5 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. [mp=title, text, subject heading word] (26)
- 12 10 and 11 (3)
- 13 ((lung\$ or pulmonar\$ or bronch\$ or alveol\$) adj5 (cancer\$ or carcino\$ or adenocarcino\$ or malig\$ or tumor\$ or tumour\$ or neopla\$) adj7 (test\$ or diagno\$ or screen\$ or find\$ or found\$ or discover\$ or uncover\$)).mp. (42)
- 14 ((chest\$ or thorax\$ or thoracic\$) adj5 (x-ray\$ or xray\$ or radiogra\$)).mp. [mp=title, text, subject heading word] (19)
- 15 13 and 14 (8)
- 16 sputum.mp. [mp=title, text, subject heading word] (8)
- 17 13 and 16 (2)
- 18 12 or 15 or 17 (8)

Intervention key questions 4 and 5:

Database: Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) <1946 to 2012>

Search Strategy:

-
- 1 exp Lung Neoplasms/su [Surgery] (21220)
 - 2 (stag\$ adj (one or "1" or I or two or "2" or II or 1a or Ia or 1b or Ib or 1c or Ic or 2a or IIa or 2b or IIb)).mp. (54937)
 - 3 ((early or earlier or earliest) adj5 (discover\$ or found or find or finding or uncover\$ or diagnos\$ or detect\$ or stage\$ or staging)).mp. (239290)
 - 4 2 or 3 (286513)
 - 5 1 and 4 (3023)
 - 6 exp lung neoplasms/ (157194)
 - 7 exp Surgical Procedures, Operative/ (2186270)
 - 8 4 and 6 and 7 (2707)
 - 9 5 or 8 (3945)
 - 10 exp "Outcome and Process Assessment (Health Care)"/ (602752)
 - 11 9 and 10 (748)
 - 12 exp Mortality/ (249169)
 - 13 mo.fs. (367310)
 - 14 12 or 13 (507080)
 - 15 9 and 14 (1650)
 - 16 exp survival analysis/ (150994)
 - 17 9 and 16 (823)
 - 18 exp Postoperative Complications/ (382994)
 - 19 exp Intraoperative Complications/ (33158)
 - 20 18 or 19 (405151)
 - 21 9 and 20 (291)
 - 22 ae.fs. (1238248)
 - 23 ((advers\$ or undesir\$ or unwanted\$) adj5 (effect\$ or outcome\$ or result\$)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (131512)
 - 24 exp "Wounds and Injuries"/et [Etiology] (109143)
 - 25 22 or 23 or 24 (1394472)
 - 26 9 and 25 (490)
 - 27 exp "Quality of Life"/ (99185)

Appendix A1. Search Strategies

```
28  exp Quality-Adjusted Life Years/ (5646)
29  27 or 28 (103891)
30  9 and 29 (49)
31  exp "Costs and Cost Analysis"/ (164677)
32  9 and 31 (34)
33  11 or 15 or 17 or 21 or 26 or 30 or 32 (2450)
34  limit 33 to yr="2000 -Current" (1725)
```

Appendix A2. Inclusion and Exclusion Criteria

	Include	Exclude
Population	<p><u>Key questions 1–3:</u> Asymptomatic adults (ages ≥18 years) from large screening trials and/or studies who are generalizable to the United States</p> <p><u>Key questions 4–5:</u> Adults (ages ≥18 years) with early (stage IA) non-small cell lung cancer who are generalizable to the United States</p>	<p><u>Key questions 1–3:</u> Children Symptoms of lung cancer Prior lung cancer diagnosis</p> <p><u>Key questions 4–5:</u> Children Not primary lung cancer Greater than stage IA lung cancer</p>
Interventions	<p><u>Key questions 1–3:</u> Chest x-ray, computed tomography, and/or sputum cytology</p> <p><u>Key questions 4–5:</u> Surgical resection</p>	<p><u>Key questions 1–3:</u> No screening</p> <p><u>Key questions 4–5:</u> Chemotherapy, radiation therapy, and natural therapies</p>
Outcomes	<p>Reduction in morbidity and/or all-cause mortality Reduction in lung cancer mortality/morbidity 5-year and 10-year survival rates Impact on smoking cessation Detection of other abnormalities Quality of life Direct harms from screening and/or treatment interventions</p>	<p>Cost-effectiveness</p>
Study types and designs	<p>Randomized, controlled trials; systematic reviews/meta-analyses; cohorts; case-control studies; and case series Published in or after 2001</p>	<p>Opinions, editorials, case reports, no comparison group</p> <p><u>Key questions 1–3:</u> Sample size less than 1000</p> <p><u>Key questions 4–5:</u> Sample size less than 500</p>
Duration	<p><u>Key questions 1–3:</u> Any length of duration</p> <p><u>Key questions 4–5:</u> At least 5 years of followup</p>	<p><u>Key questions 1–3:</u> None</p> <p><u>Key Questions 4–5:</u> Less than 5 years of followup</p>

Appendix A3. U.S. Preventive Services Task Force Quality Rating Criteria for Randomized, Controlled Trials

Randomized, Controlled Trials (RCTs)

Criteria:

- Initial assembly of comparable groups: RCTs—adequate randomization, including concealment and whether potential confounders were distributed equally among groups; cohort studies—consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
- Maintenance of comparable groups (includes attrition, cross-overs, adherence, contamination)
- Important differential loss to followup or overall high loss to followup
- Measurements: equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- Important outcomes considered
- Analysis: adjustment for potential confounders for cohort studies or intention-to-treat analysis for RCTs; for cluster RCTs, correction for correlation coefficient

Definition of ratings based on above criteria:

- Good:** Meets all criteria: comparable groups are assembled initially and maintained throughout the study (followup $\geq 80\%$); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention to confounders in analysis.
- Fair:** Studies will be graded “fair” if any or all of the following problems occur, without the important limitations noted in the “poor” category below: generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred in followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for.
- Poor:** Studies will be graded “poor” if any of the following major limitations exists: groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied at all equally among groups (including not masking outcome assessment); and key confounders are given little or no attention.

Sources: Harris et al, 2001⁴⁸

Appendix A4. List of Reviewers

Expert Reviewers

Peter B. Bach, MD, MAPP, Full Member, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center

Harold Sox, MD, Associate Director for Faculty, The Dartmouth Institute, Dartmouth Medical School

David J. Ballard, MD, MSPH, PhD, FACP, Senior Vice President and Chief Quality Officer, Baylor Health Care System, Executive Director and BHCS Endowed Chair, Institute for Health Care Research and Improvement

Federal Reviewers


Joseph Chin, MD, Office of Clinical Standards and Quality, Centers for Medicare and Medicaid Services

Barnett Kramer, MD, MPH, Associate Director for Disease Prevention, Director Office of Medical Applications of Research, Office of Disease Prevention, Office of the Director, National Institutes of Health

Linda Kinsinger, MD, MPH, VHA, National Center for Health Promotion and Disease Prevention

Paul Pinsky, PhD, National Institutes of Health

Appendix A5. Literature Flow Diagram



*Cochrane databases include the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews.

†Identified from reference lists, hand searching, and suggestions by experts.

‡Studies that provided data and contributed to the body of evidence were considered “included.”

Abbreviations: COSMOS = Continuing Observation of Smoking Subjects; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; I-ELCAP = International Early Lung Cancer Action Program; LSS = Lung Screening Study; MILD = Multicentric Italian Lung Detection; NELSON = Nederlands-Leuven Longkanker Screenings Onderzoek; NLST = National Lung Screening Trial; PALCAD = ProActive Lung Cancer Detection; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; PLUSS = Pittsburgh Lung Screening Study; SCTS = Spiral Chest Computed Tomography Study

Appendix A6. List of Excluded Full-Text Papers

Key to exclusion codes

2	Background
3	Wrong population
4	Wrong intervention
5	Wrong publication
6	Non-English, otherwise relevant
7	Wrong outcome
8	Conducted/Published prior to 2000
9	Followup too short
10	Sample size too small

Listing of excluded papers

Screening for lung cancer. *Med Lett Drugs Ther.* 2001;43(1109):61-62. [PMID: 11468601]

Exclusion code: 5

Smoking cessation counseling needed with spiral CT screening for lung cancer. *Oncology (Williston).* 2002;16(6):816, 839, [PMID: 12088301]

Exclusion code: 5

National Lung Screening Trial (NLST). 2002; <http://clinicaltrials.gov/ct/gui/show/NCT00047385;jsessionid=20DAB829F5C5A123FB490104A003A4BA?order=1>. Accessed May 23, 2011

Exclusion code: 2

Lung cancer can be diagnosed early. *Health News.* 2005;11(12):14, [PMID: 16419178]

Exclusion code: 5

Screening for cancer: colon, lung and skin cancers. *Harv. Mens Health Watch.* 2005;10(3):1-5, [PMID: 16296122]

Exclusion code: 5

Electronic nose shows promise for detecting early-stage lung cancer. *Disease Management Advisor.* 2005;11(6):71-72, 61, [PMID: 16060297]

Exclusion code: 5

Eleventh international conference on screening for lung cancer. *Clin. Imaging.* 2005;29(4):298-299, [PMID: 15967325]

Exclusion code: 5

Medicare Lung Cancer Screening Benefit Act of 2006. Shaw C, trans. 109th Congress 2006

Exclusion code: 5

Potential new options for lung cancer screening. *Disease Management Advisor.* 2007;13(6):68-70, 61, [PMID: 17595920]

Exclusion code: 2

Can lung cancer screening save lives? *Johns Hopkins Med. Lett. Health After 50.* 2007;19(2):7, [PMID: 17443995]

Exclusion code: 5

Lung cancer screening in women. Women seem to have a special vulnerability to lung cancer, whether they smoke or not. Is it time to be tested? *Harvard Women's Health Watch.* 2007;14(7):1-2, [PMID: 17393589]

Exclusion code: 5

Screening for lung cancer. *Vopr. Onkol.* 2009;55(1):7-14, [PMID: 19435192]

Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Clinical implications. *Cancer Treat. Res.* 2010;154:201-214
Exclusion code: 5

Study shows CT scans can reduce lung cancer deaths in smokers. *Mayo Clin Womens Healthsource.* 2011;15(5):3, [PMID: 21467956]
Exclusion code: 5

Why aren't you being screened for lung cancer? Research suggests CT scans may help pinpoint problems early enough to make a difference. *Johns Hopkins Med. Lett. Health After 50.* 2011;23(2):4-5, [PMID: 21523950]
Exclusion code: 5

Abe H, Ishida T, Shiraishi J, et al. Effect of temporal subtraction images on radiologists' detection of lung cancer on CT: results of the observer performance study with use of film computed tomography images. *Acad. Radiol.* 2004;11(12):1337-1343, [PMID: 15596371]
Exclusion code: 7

Abe Y, Hanai K, Nakano M, et al. A computer-aided diagnosis (CAD) system in lung cancer screening with computed tomography. *Anticancer Res.* 2005;25(1B):483-488, [PMID: 15816616]
Exclusion code: 2

Aberle DR, Brown K. Lung cancer screening with CT. *Clin. Chest Med.* 2008;29(1):1-14, v, [PMID: 18267181]
Exclusion code: 5

Aberle DR, Gamsu G, Henschke CI, Naidich DP, Swensen SJ. A consensus statement of the Society of Thoracic Radiology: screening for lung cancer with helical computed tomography. *J. Thorac.*

Imaging. 2001;16(1):65-68, [PMID: 11149694]
Exclusion code: 5

ACOG Committee. ACOG committee opinion. Routine cancer screening. Number 247, December 2000. *Int. J. Gynaecol. Obstet.* 2003;82(2):241-245, [PMID: 12926412]
Exclusion code: 2

Adachi H, Maehara T. [Surgical treatment and outcome of multiple primary lung cancers]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2010;63(5):347-351; discussion 351-344, [PMID: 20446600]
Exclusion code: 6

Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. *Lung Cancer.* 2010;68(3):398-402, [PMID: 19762109]
Exclusion code: 9

Ahn MI, Gleeson TG, Chan IH, et al. Perifissural nodules seen at CT screening for lung cancer. *Radiology.* 2010;254(3):949-956, [PMID: 20177105]
Exclusion code: 2

Aisner J. CT screening for lung cancer: are we ready for wide-scale application? *Clin. Cancer Res.* 2007;13(17):4951-4953, [PMID: 17785542]
Exclusion code: 5

Ak I, Sivrikoz MC, Entok E, Vardareli E. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. *Eur. J.*

Appendix A6. List of Excluded Full-Text Papers

Cardiothorac. Surg. 2010;37(4):792-796, [PMID: 20015657]

Exclusion code: 4

Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. *J. Cancer Res. Clin. Oncol.* 2000;126(10):560-574, [PMID: 11043393]

Exclusion code: 5

Akata S, Yoshimura M, Nishio R, et al. High-resolution computed tomographic findings of small peripherally located squamous cell carcinoma. *Clin. Imaging.* 2008;32(4):259-263, [PMID: 18603179]

Exclusion code: 4

Aketa A, Yamada G, Aketa K, et al. [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma]. *Nihon Kokyuki Gakkai Zasshi.* 2004;42(2):164-169, [PMID: 15007917]

Exclusion code: 6

Akopov AL, Dvorakovskaia IV. [Vascular invasion by tumor in the absence of regional lymph node metastases in patients with locally advanced non-small cell lung cancer]. *Vopr. Onkol.* 2004;50(4):417-420, [PMID: 15605763]

Exclusion code: 6

Alam N, Flores RM. Video-assisted thoracic surgery (VATS) lobectomy: the evidence base. *J. Soc. Laparoendosc. Surg.* 2007;11(3):368-374, [PMID: 17931521]

Exclusion code: 5

Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest.* 2007;132(3 Suppl):29S-55S, [PMID: 17873159]

Exclusion code: 2

Alexandersson A, Jonsson S, Isaksson HJ, Gudbjartsson T. [Sublobar resection for non-small cell lung cancer in Iceland]. *Laeknabladid.* 2011;97(5):303-308, [PMID: 21586802]

Exclusion code: 6

Alexiou C, Beggs D, Onyeaka P, et al. Pneumonectomy for stage I (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival. *Ann. Thorac. Surg.* 2003;76(4):1023-1028, [PMID: 14529978]

Exclusion code: 10

Alexiou C, Onyeaka CVP, Beggs D, et al. Do women live longer following lung resection for carcinoma? *Eur. J. Cardiothorac. Surg.* 2002;21(2):319-325, [PMID: 11825743]

Exclusion code: 3

Allen JW, Farooq A, O'Brien TF, Osarogiagbon RU. Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. *Cancer.* 2011;117(1):134-142, [PMID: 20737568]

Exclusion code: 3

Allen MS, Darling GE, Pechet TTV, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. *Ann. Thorac. Surg.* 2006;81(3):1013-1019; discussion 1019-1020, [PMID: 16488712]

Exclusion code: 2

Altorki N, Kent M, Pasmantier M. Detection of early-stage lung cancer: computed tomographic scan or chest radiograph? *J. Thorac. Cardiovasc. Surg.*

Appendix A6. List of Excluded Full-Text Papers

2001;121(6):1053-1057, [PMID: 11385370]

Exclusion code: 2

Amann A, Corradi M, Mazzone P, Mutti A. Lung cancer biomarkers in exhaled breath. *Expert Rev Mol Diagn.* 2011;11(2):207-217, [PMID: 21405971]

Exclusion code: 2

Amann A, Ligor M, Ligor T, et al. Analysis of exhaled breath for screening of lung cancer patients. *Memo - Magazine of European Medical Oncology.* Vol 32010:106-112

Exclusion code: 4

Ambrose LF. Lung cancer screening. *CMAJ Canadian Medical Association Journal.* 2009;180(13):1330, [PMID: 19546459]

Exclusion code: 5

Ambrose LF, Heaton CG, Idige CR. Letter regarding US Preventive Services Task Force Review of Lung Cancer Screening. In: The Honorable Kathleen Sebelius S, US Department of Health and Human Services, ed. Washington, D.C. 2012

Exclusion code: 2

Ambrose LF, Lopez TJ. Essential Health Benefits Bulletin. In: The Honorable Kathleen Sebelius S, US Department of Health and Human Services, ed. Washington, D.C. 2012

Exclusion code: 2

American Cancer Society. *Cancer Facts and Figures 2000*

Exclusion code: 2

American Cancer Society. *Cancer Facts & Figures 2010*: Atlanta;2010

Exclusion code: 2

American Cancer Society. *Cancer Facts & Figures for African Americans 2011-12.* Atlanta2011

Exclusion code: 2

American Cancer Society. *Cancer Facts & Figures 2011*: Atlanta;2011

Exclusion code: 2

American Lung Association. Providing Guidance on Lung Cancer Screening To Patients and Physicians. 2012.

<http://www.lung.org/finding-cures/research-news/new-screening-guidelines/lung-cancer-screening.pdf>.

Accessed 30 Sept 2012

Exclusion code: 2

Andersen KB, Dirksen A. [Screening for lung cancer]. *Ugeskr. Laeger.*

2000;162(14):2013, [PMID: 10815513]

Exclusion code: 6

Anderson MW, Goodin C, Zhang Y, et al. Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice. *Carcinogenesis.* 2008;29(8):1594-1600, [PMID: 18515278]

Exclusion code: 3

Andrade RS, Maddaus MA. Thoracoscopic lobectomy for stage I non-small cell lung cancer. *Semin. Thorac. Cardiovasc. Surg.* 2010;22(1):14-21, [PMID: 20813312]

Exclusion code: 3

Andreas S, Gamarra F, Herth F, et al. Prevention and early detection. *Prävention und frühherkennung.* 2011;34(SUPPL. 4):2-10, [PMID: 21677467]

Exclusion code: 6

Andriani F, Conte D, Mastrangelo T, et al. Detecting lung cancer in plasma with the use of multiple genetic markers. *Int. J.*

Appendix A6. List of Excluded Full-Text Papers

Cancer. 2004;108(1):91-96, [PMID: 14618621]

Exclusion code: 4

Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK, Committee PS. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. *Urologic Oncology*. 2004;22(4):358-361, [PMID: 15283897]

Exclusion code: 5

Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. *Molecular Cancer*. 2008;7:81, [PMID: 18947422]

Exclusion code: 5

Anglim PP, Galler JS, Koss MN, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. *Mol Cancer*. 2008;7:62, [PMID: 18616821]

Exclusion code: 4

Aoki T, Tsuchida M, Watanabe T, et al. Surgical strategy for clinical stage I non-small cell lung cancer in octogenarians. *Eur. J. Cardiothorac. Surg*. 2003;23(4):446-450, [PMID: 12694757]

Exclusion code: 10

Arenberg D, Kazerooni EA. Setting up a lung cancer screening program. *Journal of the National Comprehensive Cancer Network*. 2012;10(2):277-285, [PMID: 22308520]

Exclusion code: 5

Arimura H, Katsuragawa S, Suzuki K, et al. Computerized scheme for automated detection of lung nodules in low-dose computed tomography images for lung cancer screening. *Acad. Radiol*. 2004;11(6):617-629, [PMID: 15172364]

Exclusion code: 7

Armato SG, 3rd, Roy AS, Macmahon H, et al. Evaluation of automated lung nodule detection on low-dose computed tomography scans from a lung cancer screening program(1). *Acad. Radiol*. 2005;12(3):337-346, [PMID: 15766694]

Exclusion code: 7

Population screening for lung cancer (Brief record). John Wiley & Sons, Ltd. Chichester, UK; 2011.

<http://dx.doi.org/10.1002/14651858>

<http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=cleed&AN=NHSEED-22004008915>.

Exclusion code: 2

Armstrong P, Husband JE, Holemans JA. Population screening for lung cancer.

Hospital Medicine (London).

2004;65(7):404-411, [PMID: 15287344]

Exclusion code: 5

Arsen'ev AI, Kanaev SV, Barchuk AS, et al. [Use of endotracheobronchial surgery in conjunction with radiochemotherapy for advanced non-small lung cancer]. *Vopr. Onkol*. 2007;53(4):461-467, [PMID: 17969412]

Exclusion code: 6

Artinian V, Kvale PA. Update in screening of lung cancer. *Respirology*.

2005;10(5):558-566, [PMID: 16268907]

Exclusion code: 2

Asamura H. Treatment of choice for stage I non-small cell lung cancer: surgery or radiotherapy? *J Thorac Oncol*.

2006;1(8):766-767, [PMID: 17409957]

Exclusion code: 5

Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study:

Appendix A6. List of Excluded Full-Text Papers

prognosis of 13,010 resected lung cancers. *J Thorac Oncol.* 2008;3(1):46-52, [PMID: 18166840]

Exclusion code: 7

Asaph JW, Handy JR, Jr., Grunkemeier GL, et al. Median sternotomy versus thoracotomy to resect primary lung cancer: analysis of 815 cases.[Erratum appears in *Ann Thorac Surg* 2000 Dec;70(6):2187]. *Ann. Thorac. Surg.* 2000;70(2):373-379, [PMID: 10969647]

Exclusion code: 3

Ashizawa K. Problem of diagnosis and follow-up for pulmonary nodules detected on low-dose CT screening. *Japanese Journal of Lung Cancer.* Vol 472007:769-776

Exclusion code: 5

Ashraf H, de Hoop B, Shaker SB, et al. Lung nodule volumetry: segmentation algorithms within the same software package cannot be used interchangeably. *Eur. Radiol.* 2010;20(8):1878-1885, [PMID: 20306082]

Exclusion code: 7

Ashraf H, Tonnesen P, Holst Pedersen J, Dirksen A, Thorsen H, Dossing M. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). *Thorax.* 2009;64(5):388-392, [PMID: 19052048]

Exclusion code: 2

Ashton RW, Jett JR. Screening for non-small cell lung cancer. *Semin. Oncol.* 2005;32(3):253-258, [PMID: 15988679]

Exclusion code: 5

Aust W, Sandner A, Neumann K, Lowe S, Knipping S, Bloching M. [Stomal metastases after translaryngeal tracheotomy (TLT) according to Fantoni: a rare

complication]. *HNO.* 2007;55(2):114-117, [PMID: 16758210]

Exclusion code: 6

Austin JH, Stellman SD, Pearson GD. Screening for lung cancer. *N. Engl. J. Med.* 2001;344(12):935; author reply 936, [PMID: 11263429]

Exclusion code: 5

Austin JHM, Pearson GDN, Thomashow B. CT screening for early stage lung cancer. *Chest.* 2002;121(5):1725-1726, [PMID: 12006478]

Exclusion code: 5

Austin JHM, Yip R, D'Souza BM, Yankelevitz DF, Henschke CI, International Early Lung Cancer Action Program I. Small-cell carcinoma of the lung detected by CT screening: stage distribution and curability. *Lung Cancer.* 2012;76(3):339-343, [PMID: 22189270]

Exclusion code: 2

Avery JK. Early error: deadly consequences. *Tenn. Med.* 2009;102(2):33, [PMID: 19260553]

Exclusion code: 5

Avila RS, Zulueta JJ, Shara NM, et al. A quantitative method for estimating individual lung cancer risk. *Acad. Radiol.* 2010;17(7):830-840, [PMID: 20540908]

Exclusion code: 4

Cost-effectiveness decision analysis of mass screening for lung cancer (Structured abstract). John Wiley & Sons, Ltd. Chichester, UK; 2011.

<http://dx.doi.org/10.1002/14651858>.

Exclusion code: 2

Bach P. Computed tomography screening for lung cancer.[Erratum appears in *Clin Cancer Res.* 2008 Jun 15;14(12):4025].

Appendix A6. List of Excluded Full-Text Papers

Clin. Cancer Res. 2008;14(8):2511; author reply 2511-2512, [PMID: 18413846]
Exclusion code: 5

Bach P, Gould M. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. *Ann. Intern. Med.* 2012;157(8):571-573, [PMID: 22893040]
Exclusion code: 2

Bach PB. CT screening for lung cancer. *Cleve. Clin. J. Med.* 2007;74(11):769-770; author reply 770, [PMID: 18019997]
Exclusion code: 5

Bach PB. Untreated patients in "CT screening for lung cancer: update 2007". *Oncologist.* 2008;13(9):1030-1032; author reply 1033, [PMID: 18820170]
Exclusion code: 2

Bach PB. Is our natural-history model of lung cancer wrong? *Lancet Oncol.* 2008;9(7):693-697, [PMID: 18598934]
Exclusion code: 5

Bach PB. Response to "CT screening for lung cancer: update 2007". *Oncologist.* 2008;13(5):608-609; author reply 610-602, [PMID: 18581655]
Exclusion code: 2

Bach PB. Lung cancer screening. *Journal of the National Comprehensive Cancer Network.* 2008;6(3):271-275, [PMID: 18377845]
Exclusion code: 2

Bach PB. Inconsistencies in findings from the early lung cancer action project studies of lung cancer screening. *J. Natl. Cancer Inst.* 2011;103(13):1002-1006, [PMID: 21685356]
Exclusion code: 5

Bach PB. Response: Re: Inconsistencies in Findings from the Early Lung Cancer Action Project Studies of Lung Cancer Screening. *J. Natl. Cancer Inst.* 2012;104(3):255-256
Exclusion code: 5

Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SD, Begg CB. The influence of hospital volume on survival after resection for lung cancer. *N. Engl. J. Med.* 2001;345(3):181-188, [PMID: 11463014]
Exclusion code: 2

Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes.[Erratum appears in JAMA. 2007 Aug 1;298(5):518]. *JAMA.* 2007;297(9):953-961, [PMID: 17341709]
Exclusion code: 2

Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. *J. Natl. Cancer Inst.* 2003;95(6):470-478, [PMID: 12644540]
Exclusion code: 2

Bach PB, Kelley MJ, Tate RC, McCrory DC. Screening for lung cancer: a review of the current literature. *Chest.* 2003;123(1 Suppl):72S-82S, [PMID: 12527566]
Exclusion code: 2

Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: A systematic review. *JAMA.* 2012;307(22):2418-2429, [PMID: 22610500]
Exclusion code: 2

Bach PB, Silvestri GA, Hanger M, Jett JR, American College of Chest P. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Appendix A6. List of Excluded Full-Text Papers

Chest. 2007;132(3 Suppl):69S-77S, [PMID: 17873161]

Exclusion code: 5

Baecke E, de Koning HJ, Otto SJ, van Iersel CA, van Klaveren RJ. Limited contamination in the Dutch-Belgian randomized lung cancer screening trial (NELSON). *Lung Cancer*. 2010;69(1):66-70, [PMID: 19801174]

Exclusion code: 4

Baker RR, Tockman M, Marsh BR, Stitik FP, Ball WC, Jr., Eggleston JC. Screening for bronchogenic carcinoma: the surgical experience. *J. Thorac. Cardiovasc. Surg*. 1979;78(6):876-882, [PMID: 502570]

Exclusion code: 5

Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. *Thorax*. 2011;66(4):308-313, [PMID: 21317179]

Exclusion code: 2

Baldwin DR, White B, Schmidt-Hansen M, Champion AR, Melder AM, Guideline Development G. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. *BMJ*. 2011;342:d2110, [PMID: 21525094]

Exclusion code: 2

Balevi B. Evidence-based decision making: Should the general dentist adopt the use of the VELscope for routine screening for oral cancer. *Prise de décision fondée sur les données probantes: Le dentiste généraliste devrait-il adopter le VELscope pour le dépistage systématique du cancer de la bouche?* 2007;73(7):603-606, [PMID: 17868507]

Exclusion code: 3

Ball CG, Correa-Gallego C, Howard TJ, et al. Radiation Dose from Computed Tomography in Patients with Necrotizing Pancreatitis: How Much Is Too Much? *J. Gastrointest. Surg*. 2010;14(10):1529-1535, [PMID: 20824381]

Exclusion code: 3

Banerjee S. Multi-slice/helical computed tomography for lung cancer screening. *Issues in Emerging Health Technologies*. 2003(48):1-4, [PMID: 12812212]

Exclusion code: 2

Banks SB, Rose DM, Moore JM, Kline AL. The spectrum of treatment and future diagnosis of early non-small cell lung carcinoma. *Curr. Surg*. 2003;60(2):199-203, [PMID: 14972296]

Exclusion code: 7

Bao R. Screening for lung cancer with low-dose helical CT: Current date and outlook. *Chinese Journal of Clinical Oncology*. 2009;36(6):301-307

Exclusion code: 5

Barash O, Peled N, Hirsch FR, Haick H. Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles. *SMALL*. 2009;5(22):2618-2624, [PMID: 19705367]

Exclusion code: 2

Barba M, Felsani A, Rinaldi M, Giunta S, Malorni W, Paggi MG. Reducing the risk of overdiagnosis in lung cancer: a support from molecular biology. *J. Cell. Physiol*. 2011;226(9):2213-2214, [PMID: 21660943]

Exclusion code: 4

Barchuk AS, Arsen'ev AI, Pozharisskii KM. [Clinical and morphologic correlations in bronchoalveolar cancer].

Appendix A6. List of Excluded Full-Text Papers

Vopr. Onkol. 2003;49(3):316-322, [PMID: 12926213]

Exclusion code: 6

Baryshnikova E, Destro A, Infante MV, et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. *Clin. Cancer Res.* 2008;14(6):1913-1919, [PMID: 18347195]

Exclusion code: 4

Bastarrika G, Alonso A, Saiz-Mendiguren R, Arias J, Cosín O. Coronary artery calcium quantification with non-ECG-gated low-radiation dose CT of the chest. *Cuantificación de la calcificación coronaria en tomografía computarizada torácica de baja dosis de radiación sin sincronización cardíaca.* 2010;52(1):30-36, [PMID: 20035960]

Exclusion code: 7

Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. *Am. J. Respir. Crit. Care Med.* 2005;171(12):1378-1383, [PMID: 15790860]

Exclusion code: 2

Bastarrika G, Pueyo JC, Lozano MD, Montuenga L, Zulueta JJ. [Screening for lung cancer with low-dose spiral CT: results in 150 asymptomatic subjects]. *Med. Clin. (Barc).* 2003;121(2):41-47, [PMID: 12828882]

Exclusion code: 6

Bastarrika G, Pueyo JC, Mulshine JL. Radiologic screening for lung cancer. *Expert Rev Anticancer Ther.* 2002;2(4):385-392, [PMID: 12647981]

Exclusion code: 5

Bastarrika G, Wisnivesky JP, Pueyo JC, et al. Low-dose volumetric computed tomography for quantification of emphysema in asymptomatic smokers participating in an early lung cancer detection trial. *J. Thorac. Imaging.* 2009;24(3):206-211, [PMID: 19704324]

Exclusion code: 7

Battafarano RJ, Piccirillo JF, Meyers BF, Hsu HS, Guthrie TJ, Cooper JD. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. *J. Thorac. Cardiovasc. Surg.* 2002;123(2):280-287, [PMID: 11828287]

Exclusion code: 4

Bauer AK, Rondini EA. Review Paper: The role of inflammation in mouse pulmonary neoplasia. *Vet. Pathol.* 2009;46(3):369-390, [PMID: 19176494]

Exclusion code: 5

Bauer T. Lung cancer screening. *Hematology - Oncology Clinics of North America.* 2005;19(2):209-217, v, [PMID: 15833403]

Exclusion code: 5

Baumann M. [Does chemotherapy improve the results of postoperative radiotherapy in completely resected stage II and IIIA non-small-cell bronchial cancer?]. *Strahlenther. Onkol.* 2001;177(4):220-221, [PMID: 11370558]

Exclusion code: 6

Beane J, Spira A, Lenburg ME. Clinical impact of high-throughput gene expression studies in lung cancer. *J Thorac Oncol.* 2009;4(1):109-118, [PMID: 19096318]

Exclusion code: 5

Bechtel JJ, Kelley W, Coons T, Klein G, Slagel D, Petty TL. Lung cancer detection

Appendix A6. List of Excluded Full-Text Papers

in asymptomatic patients with airflow obstruction. *Chest*. 2004;125(no. 5 Suppl):163s, [PMID: 15136488]
Exclusion code: 2

Bechtel JJ, Kelley WA, Coons TA, Klein MG, Slagel DD, Petty TL. Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice. *Chest*. 2005;127(4):1140-1145, [PMID: 15821187]
Exclusion code: 2

Bechtel JJ, Kelley WA, Coons TA, et al. Five-year outcome of lung cancer detection in patients with and without airflow obstruction in a primary care outpatient practice. *J Thorac Oncol*. 2009;4(11):1347-1351, [PMID: 19861904]
Exclusion code: 2

Strategies in lung cancer detection: achieving early identification in patients at high risk (Brief record). John Wiley & Sons, Ltd. Chichester, UK; 2011. <http://dx.doi.org/10.1002/14651858>.
Exclusion code: 5

Becker C. Support for scans. Studies present strong case for CT screening. *Mod. Healthc*. 2003;33(49):16, [PMID: 14712597]
Exclusion code: 5

Behera D, Balamugesh T. Lung cancer in India. *Indian J. Chest Dis. Allied Sci*. 2004;46(4):269-281, [PMID: 15515828]
Exclusion code: 5

Cost-effectiveness of whole-body CT screening (Structured abstract). John Wiley & Sons, Ltd. Chichester, UK; 2011. <http://dx.doi.org/10.1002/14651858>.
Exclusion code: 4

Belda-Iniesta C, de Castro Carpeno J, Carrasco JA, et al. New screening method for lung cancer by detecting volatile organic compounds in breath. *Clin Transl Oncol*. 2007;9(6):364-368, [PMID: 17594950]
Exclusion code: 5

Belialova NS, Belialov FI. [Screening of cancer of the most frequent localizations]. *Klin. Med. (Mosk)*. 2005;83(10):4-9, [PMID: 16320836]
Exclusion code: 6

Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. *Nature Reviews. Cancer*. 2004;4(9):707-717, [PMID: 15343277]
Exclusion code: 2

Bellomi M, Rampinelli C, De Fiori E, Preda L, Veronesi G. Lung cancer screening update. *Cancer Imaging*. 2009;9 Spec No A:S122-125, [PMID: 19965303]
Exclusion code: 5

Bellomi M, Veronesi G, Rampinelli C, Ferretti S, De Fiori E, Maisonneuve P. Evolution of lung nodules \leq 5 mm detected with low-dose CT in asymptomatic smokers. *Br. J. Radiol*. 2007;80(957):708-712, [PMID: 17928499]
Exclusion code: 2

Bellomi M, Veronesi G, Trifiro G, et al. Computed tomography-guided preoperative radiotracer localization of nonpalpable lung nodules. *Ann. Thorac. Surg*. 2010;90(6):1759-1764, [PMID: 21095303]
Exclusion code: 2

Ben-Dor I, Waksman R, Hanna NN, et al. Utility of Radiologic Review for Noncardiac Findings on Multislice Computed Tomography in Patients With

Appendix A6. List of Excluded Full-Text Papers

Severe Aortic Stenosis Evaluated for Transcatheter Aortic Valve Implantation. *Am. J. Cardiol.* 2010;105(10):1461-1464, [PMID: 20451695]
Exclusion code: 5

Benko I, Horvath OP, Nagy K, et al. [Role of surgery for lung cancer in elderly patients]. *Magy Seb.* 2008;61(1):33-37, [PMID: 18296283]
Exclusion code: 6

Bepler G, Goodridge Carney D, Djulbegovic B, Clark RA, Tockman M. A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. *Cancer Control.* 2003;10(4):306-314, [PMID: 12915809]
Exclusion code: 2

Berg CD, Aberle DR. Computed tomography screening for lung cancer. *JAMA.* 2007;298(5):513-514; author reply 515-516, [PMID: 17666667]
Exclusion code: 2

Berg CD, Aberle DR, National Lung Screening Trial Executive C. CT screening for lung cancer. *N. Engl. J. Med.* 2007;356(7):743-744; author reply 746-747, [PMID: 17310522]
Exclusion code: 2

Berger VW, Semanick L. Refining the assessment of the sensitivity and specificity of diagnostic tests, with applications to prostate cancer screening and non-small cell lung cancer staging. *Pan American Journal of Public Health.* 2005;18(1):64-70, [PMID: 16105328]
Exclusion code: 4

Berlin NI. Overview of the NCI Cooperative Early Lung Cancer Detection

Program. *Cancer.* 2000;89(11 Suppl):2349-2351, [PMID: 11147610]
Exclusion code: 2

Berlin NI. The prospects for the control of cancer through screening-1976-today-the future. *Trans. Am. Clin. Climatol. Assoc.* 2004;115:221-232; discussion 232, [PMID: 17060969]
Exclusion code: 5

Berlin NI, Buncher CR, Fontana RS, Frost JK, Melamed MR. The National cancer Institute Cooperative Early Lung Cancer Detection Program. Results of the initial screen (prevalence). Early lung cancer detection: Introduction. *Am. Rev. Respir. Dis.* 1984;130(4):545-549, [PMID: 6548343]
Exclusion code: 5

Bermejo JL, Hemminki K. Familial risk of cancer shortly after diagnosis of the first familial tumor. *J. Natl. Cancer Inst.* 2005;97(21):1575-1579, [PMID: 16264177]
Exclusion code: 3

Bernardo WM, Jatene FB, Nobre MRC. [What is the survival rate for limited resection of lung cancer in stage I?]. *Rev. Assoc. Med. Bras.* 2005;51(3):123-125, [PMID: 16007288]
Exclusion code: 6

Berrington de Gonzalez A, Kim KP, Berg CD. Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. *J. Med. Screen.* 2008;15(3):153-158, [PMID: 18927099]
Exclusion code: 2

Berrington de Gonzalez A, Mahesh M, Kim K-P, et al. Projected cancer risks from

Appendix A6. List of Excluded Full-Text Papers

computed tomographic scans performed in the United States in 2007. *Arch. Intern. Med.* 2009;169(22):2071-2077, [PMID: 20008689]

Exclusion code: 2

Bessho Y, Yamaguchi M, Fujita H, Azuma M. Usefulness of reduced image display size in softcopy reading: evaluation of lung nodules in chest screening. *Acad. Radiol.* 2009;16(8):940-946, [PMID: 19446475]

Exclusion code: 7

Betticher DC. [Docetaxel in neoadjuvant therapy of early-stage non-small cell carcinoma]. *Onkologie.* 2003;26 Suppl 7:33-36, [PMID: 14716140]

Exclusion code: 6

Bianchi F, Hu J, Pelosi G, et al. Lung cancers detected by screening with spiral computed tomography have a malignant phenotype when analyzed by cDNA microarray. *Clin. Cancer Res.* 2004;10(18 Pt 1):6023-6028, [PMID: 15447986]

Exclusion code: 4

Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. *EMBO Mol Med.* 2011;3(8):495-503, [PMID: 21744498]

Exclusion code: 4

Bianchi F, Nicassio F, Veronesi G, Di Fiore PP. Circulating microRNAs: Next-generation biomarkers for early lung cancer detection. *ecancermedalscience.* 2012;6(1), [PMID: 22518197]

Exclusion code: 4

Bilfinger TV. Surgical aspects in the treatment of lung cancer. *Curr. Opin. Pulm. Med.* 2004;10(4):261-265, [PMID: 15220749]

Exclusion code: 5

Bilfinger TV, Baram D. Sublobar resection in nonsmall cell lung carcinoma. *Curr. Opin. Pulm. Med.* 2008;14(4):292-296, [PMID: 18520261]

Exclusion code: 5

Billmeier SE, Ayanian JZ, Zaslavsky AM, Nerenz DR, Jaklitsch MT, Rogers SO. Predictors and outcomes of limited resection for early-stage non-small cell lung cancer. *J. Natl. Cancer Inst.* 2011;103(21):1621-1629, [PMID: 21960708]

Exclusion code: 3

Birdas TJ. Effects of pneumonectomy on survival of patients with stage I lung cancer. *Ann. Thorac. Surg.* 2005;79(1):384; author reply 384-385, [PMID: 15620995]

Exclusion code: 5

Birim O, Kappetein AP, van Klaveren RJ, Bogers AJJC. Prognostic factors in non-small cell lung cancer surgery. *Eur. J. Surg. Oncol.* 2006;32(1):12-23, [PMID: 16297591]

Exclusion code: 5

Birring SS, Peake MD. Symptoms and the early diagnosis of lung cancer. *Thorax.* 2005;60(4):268-269, [PMID: 15790977]

Exclusion code: 5

Bisenkov LN, Shalaev SA, Orzheshkovskii OV, Platunov SK, Efremov FA. [One-stage operations on the lungs and other organs in multifocal and metastatic cancer]. *Khirurgiia (Sofia).* 2005(4):33-36, [PMID: 15940177]

Exclusion code: 6

Lung cancer screening using tumour markers? A view in consideration of socioeconomic aspects (Brief record). John

Appendix A6. List of Excluded Full-Text Papers

Wiley & Sons, Ltd. Chichester, UK; 2011.
<http://dx.doi.org/10.1002/14651858>.
Exclusion code: 5

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases [Systematic Review]: Cochrane Database of Systematic Reviews; 2012
Exclusion code: 4

Black C, Bagust A, Boland A, et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. *Health Technology Assessment (Winchester, England)*. 2006;10(3):iii-iv, ix-x, 1-90, [PMID: 16409881]
Exclusion code: 5

Black C, de Verteuil R, Walker S, et al. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. *Thorax*. 2007;62(2):131-138, [PMID: 17287305]
Exclusion code: 5

Black WC. Unexpected observations on tumor size and survival in stage 1a non-small cell lung cancer [editorial]. *Chest*. 2000;117(6):1532-1534, [PMID: 10858376]
Exclusion code: 5

Black WC. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. *J. Natl. Cancer Inst.* 2000;92(16):1280-1282, [PMID: 10944539]
Exclusion code: 2

Black WC. Computed tomography screening for lung cancer: review of

screening principles and update on current status. *Cancer*. 2007;110(11):2370-2384, [PMID: 17941031]
Exclusion code: 5

Black WC, Aberle DR, Berg CD. Large field trial for lung cancer screening: putting the wrong cart before the horse? *Radiology*. 2007;243(2):314-316; discussion 317-318, [PMID: 17456862]
Exclusion code: 2

Black WC, Baron JA. CT screening for lung cancer: spiraling into confusion? *JAMA*. 2007;297(9):995-997, [PMID: 17341714]
Exclusion code: 5

Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. *J. Natl. Cancer Inst.* 2002;94(3):167-173, [PMID: 11830606]
Exclusion code: 5

Blanchon T, Brechot JM, Grenier P, Group FtD. Baseline results of the Depiscan study: A French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). *Lung Cancer*. 2007;58(1):50-58, [PMID: 17624475]
Exclusion code: 2

Blanchon T, Lukasiewicz-Hajage E, Lemarle E, Milleron B, Brechot JM, Flahault A. DEPISCAN - a pilot study to evaluate low dose spiral CT scanning as a screening method for bronchial carcinoma. *Rev. Mal. Respir.* 2002;19(6):701-705, [PMID: 12524489]
Exclusion code: 6

Blomquist T, Crawford EL, Mullins D, et al. Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer

Appendix A6. List of Excluded Full-Text Papers

diagnosis. *Cancer Res.* 2009;69(22):8629-8635, [PMID: 19887610]
Exclusion code: 7

Bluoss C. [Lung metastases secondary to bronchopulmonary cancer]. *Pneumologia.* 2010;59(2):68-72, [PMID: 20695360]
Exclusion code: 6

Boedeker E, Friedel G, Walles T. Sniffer dogs as part of a bimodal bionic research approach to develop a lung cancer screening. *Interact Cardiovasc Thorac Surg.* 2012;14(5):511-515, [PMID: 22345057]
Exclusion code: 4

Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. *Proc. Natl. Acad. Sci. U. S. A.* 2011;108(9):3713-3718, [PMID: 21300873]
Exclusion code: 2

Boffa D, Allen M, Grab J, Gaissert H, Harpole D, Wright C. Data from the Society of Thoracic Surgeons General Thoracic Surgery database: The surgical management of primary lung tumors. *J. Thorac. Cardiovasc. Surg.* 2008;135:247-254, [PMID: 18242243]
Exclusion code: 2

Boffetta P, Mannetje At, Zaridze D, et al. Occupational X-ray examinations and lung cancer risk. *Int. J. Cancer.* 2005;115(2):263-267, [PMID: 15688400]
Exclusion code: 3

Boffetta P, Tarone RE, Blot WJ. Survival in women after diagnosis of lung cancer. *JAMA.* 2007;297(2):153; author reply 153-154, [PMID: 17213394]
Exclusion code: 2

Boice J, J. D., Monson RR. Breast cancer in women after repeated fluoroscopic examinations of the chest. *J. Natl. Cancer Inst.* 1977;59(3):823-832, [PMID: 894747]
Exclusion code: 2

Bolca C, Brontos ML, Conti M, Frechette E. [Video-assisted thoracoscopic lobectomy--the treatment of choice for stage I NSCLC]. *Pneumologia.* 2010;59(4):201-203, [PMID: 21365802]
Exclusion code: 6

Bondiau PY, Doyen J, Mammar H, et al. [Reirradiation of spine and lung tumor with CyberKnife]. *Cancer Radiother.* 2010;14(6-7):438-441, [PMID: 20724188]
Exclusion code: 6

Bonfill X, Puig MT, Bolívar I, Quintana MJ. Lung cancer in Spain: The current situation. 2008 SESPAS report. *El control del cáncer de pulmón en España: Un análisis de la situación actual. Informe SESPAS 2008.* 2008;22(SUPPL. 1):169-178, [PMID: 18405567]
Exclusion code: 5

Bonnet F, Donay JL, Fieux F, Marie O, de Kerviler E, Jacob L. [Postoperative nocardiosis caused by *Nocardia otitidiscaviarum*: pitfalls and delayed diagnosis]. *Ann. Fr. Anesth. Reanim.* 2007;26(7-8):680-684, [PMID: 17572044]
Exclusion code: 6

Bonnette P. [Surgery for stage 1[NON-BREAKING SPACE]lung cancer]. *Cancer Radiother.* 2011;15(6-7):518-521, [PMID: 21802335]
Exclusion code: 6

Boughton B. Large screening trial launched by NCI. *Lancet Oncol.* 2002;3(11):647, [PMID: 12424054]
Exclusion code: 7

Appendix A6. List of Excluded Full-Text Papers

Boyd JA, Hubbs JL, Kim DW, Hollis D, Marks LB, Kelsey CR. Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. *J Thorac Oncol.* 2010;5(2):211-214, [PMID: 19901853]

Exclusion code: 3

Boyle P. Current situation of screening for cancer. *Ann. Oncol.* 2002;13 Suppl 4:189-198, [PMID: 12401689]

Exclusion code: 2

Brambilla C, Fievet F, Jeanmart M, et al. Early detection of lung cancer: role of biomarkers. *European Respiratory Journal - Supplement.* 2003;39:36s-44s, [PMID: 12572700]

Exclusion code: 5

Brant-Zawadzki MN. Screening CT: rationale. *Radiographics.* 2002;22(6):1532-1536; discussion 1536-1539, [PMID: 12432125]

Exclusion code: 5

Brant-Zawadzki MN. The role of computed tomography in screening for cancer. *Eur. Radiol.* 2005;15 Suppl 4:D52-54, [PMID: 16479647]

Exclusion code: 5

Brawner EJ, Patrick Nana-Sinkam S, Jett JR. Lung cancer screening in 2008: A review and update. *Respiratory Medicine CME.* 2008;1(1):2-9, [PMID: 18046031]

Exclusion code: 5

Brechot JM, Blanchon T, Lemarie E, et al. Preliminary results of a French randomised feasibility trial of lung cancer screening with multislice-spiral CT scan (MSCT) vs chest x-ray (CXR): Depiscan [Abstract]. Vol 26: *European Respiratory Journal*; 2005:Abstract No. 4434

Exclusion code: 5

Bremnes RM, Hirsch FR. [Lung cancer screening--what now?]. *Tidsskr. Nor. Laegeforen.* 2001;121(13):1600-1604, [PMID: 11446046]

Exclusion code: 6

Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? *Lung Cancer.* 2005;49(1):1-12, [PMID: 15949585]

Exclusion code: 4

Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. *The Lancet Oncology.* 2011;12(4):399-408, [PMID: 20951091]

Exclusion code: 5

Brenner D, Dolic R, Goodhead D, et al. Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know. *Proc Natl Acad Sci USA.* 2003;100(24):1363-1366, [PMID: 14610281]

Exclusion code: 2

Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. *Radiol.* 2004;231(2):440-445, [PMID: 15128988]

Exclusion code: 2

Brenner DJ, Hall EJ. Computed tomography - An increasing source of radiation exposure. *N. Engl. J. Med.* 2007;357(22):2277-2284, [PMID: 18046031]

Exclusion code: 2

Brice J. Low-dose CT. The promise and the paradox of lung cancer screening. *Diagn. Imaging.* 2000;22(5):44-53, [PMID: 10947614]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Brodersen J, Thorsen H, Kreiner S. Consequences of screening in lung cancer: development and dimensionality of a questionnaire. *Value in Health*. 2010;13(5):601-612, [PMID: 20345552]
Exclusion code: 5

Brooks JD. Translational genomics: The challenge of developing cancer biomarkers. *Genome Res*. 2012;22(2):183-187, [PMID: 22301132]
Exclusion code: 4

Brouchet L, Mazieres J, Bauvin E, et al. [Surgical management and outcomes of lung cancer in women - results from the Epithor database]. *Rev. Mal. Respir*. 2007;24(7):877-882, [PMID: 17925670]
Exclusion code: 6

Brower V. Biomarker studies abound for early detection of lung cancer. *J. Natl. Cancer Inst*. 2009;101(1):11-13, [PMID: 19116384]
Exclusion code: 2

Bu L, Yun L, Fan Y, et al. Completely video-assisted thoracoscopic lobectomy versus open lobectomy for non-small cell lung cancer greater than 5 cm: a retrospective study. *Chin. Med. J. (Engl)*. 2012;125(3):434-439, [PMID: 22490398]
Exclusion code: 3

Buckler AJ, Mulshine JL, Gottlieb R, Zhao B, Mozley PD, Schwartz L. The use of volumetric CT as an imaging biomarker in lung cancer. *Acad. Radiol*. 2010;17(1):100-106, [PMID: 19969253]
Exclusion code: 2

Budoff MJ, Gopal A. Incidental findings on cardiac computed tomography. Should we look? *Journal of Cardiovascular Computed Tomography*. 2007;1(2):97-105, [PMID: 19083887]

Exclusion code: 5

Buls N, de Mey J, Covens P, Stadnik T. Health screening with CT: prospective assessment of radiation dose and associated detriment. *Jbr-Btr*. 2005;88(1):12-16, [PMID: 15792162]
Exclusion code: 2

Bunge EM, van den Bergh KAM, Essink-Bot M-L, van Klaveren RJ, de Koning HJ. High affective risk perception is associated with more lung cancer-specific distress in CT screening for lung cancer. *Lung Cancer*. 2008;62(3):385-390, [PMID: 18468717]
Exclusion code: 2

Burns DM. Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. *Cancer*. 2000;89(11 Suppl):2506-2509, [PMID: 11147637]
Exclusion code: 2

Buyx AM, Streh D, Schmidt H. Ethical issues raised by direct-to-consumer personal genome analysis and whole body scans: Discussion and contextualisation of a report by the Nuffield Council on Bioethics. *Zur Ethik einer Vorsorge durch (direct-to-consumer) individuelle Genanalysen und Ganzkörper-MRTs. Erläuterung und Diskussion der Empfehlungen des Nuffield Council on Bioethics*. 2012;106(1):29-39, [PMID: 22325105]
Exclusion code: 5

Byers T, Wolf HJ, Franklin WA, et al. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. *Cancer Epidemiol. Biomarkers Prev*. 2008;17(1):158-162, [PMID: 18199720]
Exclusion code: 4

Appendix A6. List of Excluded Full-Text Papers

Byrne MM, Koru-Sengul T, Zhao W, Weissfeld JL, Roberts MS. Healthcare use after screening for lung cancer. *Cancer*. 2010;116(20):4793-4799, [PMID: 20597136]
Exclusion code: 2

Cagirici U, Cakan A, Samancilar O, Veral A, Ozhan M. [Surgical results of large cell neuroendocrine carcinoma of the lung]. *Tuberk*. 2006;54(1):30-33, [PMID: 16615015]
Exclusion code: 6

Cagirici U, Turhan K, Goksel T, Posacioglu H, Veral A, Bilkay O. [Results of surgical treatment for lung cancer in advanced age]. *Tuberk*. 2003;51(3):253-257, [PMID: 15143402]
Exclusion code: 6

Cagnon CH, Cody DD, McNitt-Gray MF, Seibert JA, Judy PF, Aberle DR. Description and implementation of a quality control program in an imaging-based clinical trial. *Acad. Radiol*. 2006;13(11):1431-1441, [PMID: 17111584]
Exclusion code: 2

Cajoto IV, Prim JMG, Barcala FJG, et al. Reason for a medical visit in the diagnosis of lung cancer. A review of 481 cases. *Motivo de consulta en el diagnóstico de cáncer de pulmón. Revisión de 481 casos*. 2009;209(2):67-72, [PMID: 19798842]
Exclusion code: 5

Calabro E, Randi G, La Vecchia C, et al. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. *Eur. Respir. J*. 2010;35(1):146-151, [PMID: 19679603]
Exclusion code: 2

Callol L, Roig F, Cuevas A, et al. Low-dose CT: a useful and accessible tool for the early diagnosis of lung cancer in selected populations. *Lung Cancer*. 2007;56(2):217-221, [PMID: 17316889]
Exclusion code: 10

Calvo Medina V, Padilla Alarcon J, Paris Romeu F, Blasco Armengod E, Pastor Guillem J, Garcia Zarza A. [Postoperative survival in stage II non-small-cell bronchogenic carcinoma]. *Arch. Bronconeumol*. 2001;37(1):19-26, [PMID: 11181226]
Exclusion code: 6

Canadian Task Force on Preventive Health Care. Hormone Replacement Therapy for the Primary Prevention of Chronic Diseases. 2004;
http://www.canadiantaskforce.ca/recommendations/2003_01_eng.html
Exclusion code: 2.

Cardillo G, Regal M, Sera F, et al. Videothoroscopic management of the solitary pulmonary nodule: A single-institution study on 429 cases. *Ann. Thorac. Surg*. 2003;75(5):1607-1611, [PMID: 12735587]
Exclusion code: 2

Cardinale L, Cortese G, Borasio P, et al. Low dose CT in early lung cancer diagnosis: Prevalence data. *Radiol. Med. (Torino)*. 2005;110(5-6):532-543, [PMID: 16437039]
Exclusion code: 4

Cardinale L, Giaj Levra M, Novello S, et al. Low-dose spiral computer tomography screening for lung cancer. *Minerva Pneumologica*. 2007;46(3):235-242, [PMID: Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Carel RS. Periodical multiphasic screening and lung cancer prevention. *Methods Inf. Med.* 1998;37(2):182-187, [PMID: 9656662]
Exclusion code: 4

Caro JJ, Klittich WS, Strauss G. Could chest X-ray screening for lung cancer be cost-effective? *Cancer.* 2000;89(11 Suppl):2502-2505, [PMID: 11147636]
Exclusion code: 7

Carozzi FM, Bisanzi S, Falini P, et al. Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis. *Lung Cancer.* 2010;68(2):216-221, [PMID: 19646775]
Exclusion code: 2

Carpagnano GE, Foschino-Barbaro MP, Mule G, et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. *Am. J. Respir. Crit. Care Med.* 2005;172(6):738-744, [PMID: 15947287]
Exclusion code: 3

Carr SR, Schuchert MJ, Pennathur A, et al. Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. *J. Thorac. Cardiovasc. Surg.* 2012;143(2):390-397, [PMID: 22169444]
Exclusion code: 7

Carre PC, Zalcman G. [Adjuvant chemotherapy for stage IB non small cell lung cancer: the standard of care?]. *Rev. Mal. Respir.* 2006;23(4 Pt 1):295-297, [PMID: 17127903]
Exclusion code: 6

Carter D, Vazquez M, Flieder DB, et al. Comparison of pathologic findings of

baseline and annual repeat cancers diagnosed on CT screening. *Lung Cancer.* 2007;56(2):193-199, [PMID: 17239983]
Exclusion code: 4

Cassidy A, Duffy SW, Myles JP, Liloglou T, Field JK. Lung cancer risk prediction: a tool for early detection. *Int. J. Cancer.* 2007;120(1):1-6, [PMID: 17058200]
Exclusion code: 5

Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. *Br. J. Cancer.* 2008;98(2):270-276, [PMID: 18087271]
Exclusion code: 5

Castagnaro A, Marangio E, Verduri A, et al. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. *Exp. Lung Res.* 2007;33(6):289-301, [PMID: 17694439]
Exclusion code: 3

Castelao JE, Bart RD, 3rd, DiPerna CA, Sievers EM, Bremner RM. Lung cancer and cyclooxygenase-2. *Ann. Thorac. Surg.* 2003;76(4):1327-1335, [PMID: 14530048]
Exclusion code: 4

Castells X, Sala M, Salas D, Ascunce N, Zubizarreta R, Casamitjana M. Reflections on practices for early cancer diagnosis in Spain. *Reflexiones sobre las prácticas de diagnóstico precoz del cáncer en España.* 2009;23(3):244-249, [PMID: 19286278]
Exclusion code: 5

Castleberry AW, Smith D, Anderson C, Rotter AJ, Grannis FW, Jr. Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening. *Br. J. Cancer.* 2009;101(6):882-896, [PMID: 19690541]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 7

Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening (Brief record). John Wiley & Sons, Ltd. Chichester, UK; 2011.
<http://dx.doi.org/10.1002/14651858>.

Exclusion code: 5

Catalano O, Tamburrini O, Siani A. Ethic, deontologic, social, and economic reflections on screening with helical CT. Part II: specific aspects. *Radiol. Med.* (Torino). 2004;108(4):310-319, [PMID: 15525885]

Exclusion code: 5

Catarino PA, Goldstraw P. The future in diagnosis and staging of lung cancer: surgical techniques. *Respiration*. 2006;73(6):717-732, [PMID: 17119351]

Exclusion code: 5

Cattaneo SM, Park BJ, Wilton AS, et al. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. *Ann. Thorac. Surg.* 2008;85(1):231-235; discussion 235-236, [PMID: 18154816]

Exclusion code: 10

Centers for Disease Control and Prevention. Cigarette smoking among adults and trends in smoking cessation - United States, 2008. *MMWR* 2009;58(44):1227-1232, [PMID: 19910909]

Exclusion code: 2

Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥ 18 years--United States, 2005-2010. *MMWR*. 2011;60(35):1207-1212, [PMID: 21900875]

Exclusion code: 2

Centre for Reviews and Dissemination. Lung cancer screening: an update for the U.S. Preventive Services Task Force (Provisional abstract): Database of Abstracts of Reviews of Effects; 2011
Exclusion code: 2

Centre for Reviews and Dissemination. Systematic review of baseline low-dose CT lung cancer screening (Structured abstract): Database of Abstracts of Reviews of Effects; 2011

Exclusion code: 2

Centre for Reviews and Dissemination. A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest (Structured abstract): Database of Abstracts of Reviews of Effects; 2011

Exclusion code: 2

Centre for Reviews and Dissemination. Screening for lung cancer with low-dose computed tomography: a systematic review and meta-analysis of the baseline findings of randomized controlled trials (Provisional abstract): Database of Abstracts of Reviews of Effects; 2011

Exclusion code: 2

Centre for Reviews and Dissemination. Prevalence of incidental findings in computed tomographic screening of the chest: a systematic review (Structured abstract): Database of Abstracts of Reviews of Effects; 2011

Exclusion code: 2

Cerfolio RJ, Bryant AS. Survival and outcomes of pulmonary resection for non-small cell lung cancer in the elderly: a nested case-control study. *Ann. Thorac.*

Appendix A6. List of Excluded Full-Text Papers

Surg. 2006;82(2):424-429; discussion 429-430, [PMID: 16863740]

Exclusion code: 3

Cerfolio RJ, Bryant AS. Survival of patients with true pathologic stage I non-small cell lung cancer. *Ann. Thorac. Surg.* 2009;88(3):917-922; discussion 922-913, [PMID: 19699920]

Exclusion code: 10

Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. *Chest.* 2006;130(6):1796-1802, [PMID: 17166999]

Exclusion code: 3

Chabner BA. Smoke, then fire: lung cancer screening studies under further scrutiny. *Oncologist.* 2008;13(4):348-349, [PMID: 18448547]

Exclusion code: 2

Chabowski M, Orlowski TM, Rabczenko D. [Analysis of prognostic factors and efficacy of surgical treatment for non-small cell lung cancer: department of surgery NTLDR (1998-1999)]. *Pneumonol. Alergol. Pol.* 2008;76(1):1-10, [PMID: 18283649]

Exclusion code: 6

Chambers A, Routledge T, Pilling J, Scarci M. In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life?

Interact Cardiovasc Thorac Surg. 2010;10(6):1015-1021, [PMID: 20354037]

Exclusion code: 5

Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than limited pulmonary

resection for T1N0M0 non-small cell lung cancer patients? *Interact Cardiovasc Thorac Surg.* 2009;8(3):364-372, [PMID: 18641014]

Exclusion code: 5

Champeaux-Orange E, Wachter T, Bouscayrol H, Barillot I. [Stereotactic radiotherapy for stage I and II lung cancer: a study of 33 patients]. *Cancer Radiother.* 2011;15(3):192-196, [PMID: 21330178]

Exclusion code: 6

Champion VL, Rawl SM, Menon U. Population-based cancer screening. *Oncol. Nurs. Forum.* 2002;29(5):853-861, [PMID: 12058160]

Exclusion code: 5

Chan CK, Wells CK, McFarlane MJ, Feinstein AR. More lung cancer but better survival. Implications of secular trends in 'necropsy surprise' rates. *Chest.* 1989;96(2):291-296, [PMID: 2787730]

Exclusion code: 2

Chan HP, Hadjiiski L, Zhou C, Sahiner B. Computer-Aided Diagnosis of Lung Cancer and Pulmonary Embolism in Computed Tomography-A Review. *Acad. Radiol.* 2008;15(5):535-555, [PMID: 18423310]

Exclusion code: 4

Chan HP, Lewis C, Thomas PS. Exhaled breath analysis: novel approach for early detection of lung cancer. *Lung Cancer.* 2009;63(2):164-168, [PMID: 18599152]

Exclusion code: 2

Chandy D, Maguire G, Aronow WS. Lung cancer: the importance of early intervention. *Compr. Ther.* 2009;35(1):18-23, [PMID: 19351101]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Chang ET, Shema SJ, Wakelee HA, Clarke CA, Gomez SL. Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California. *Cancer Epidemiol. Biomarkers Prev.* 2009;18(8):2248-2255, [PMID: 19622719]
Exclusion code: 7

Chang JW, Asamura H, Kawachi R, Watanabe S-i. Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? *J. Thorac. Cardiovasc. Surg.* 2009;137(4):807-812, [PMID: 19327500]
Exclusion code: 3

Chang-Ming A, Bin Z, Zhen-Gang X, Ping-Zhang T. [Results of stage I and II tongue squamous cell carcinomas treated with different modalities]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2008;30(4):302-305, [PMID: 18788638]
Exclusion code: 6

Chanin TD, Merrick DT, Franklin WA, Hirsch FR. Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. *Curr. Opin. Pulm. Med.* 2004;10(4):242-247, [PMID: 15220746]
Exclusion code: 4

Chansky K, Sculier J-P, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *J Thorac Oncol.* 2009;4(7):792-801, [PMID: 19458556]
Exclusion code: 3

Chapman BE, Yankelevitz DF, Henschke CI, Gur D. Lung cancer screening: simulations of effects of imperfect

detection on temporal dynamics. *Radiology.* 2005;234(2):582-590, [PMID: 15671008]
Exclusion code: 2

Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.[Erratum appears in *Thorax.* 2008 Apr;63(4):385]. *Thorax.* 2008;63(3):228-233, [PMID: 17932110]
Exclusion code: 7

Chek K, Tribuna J, Nashelsky J. Clinical inquiries. Is yearly chest x-ray screening helpful in reducing mortality for smokers? *J. Fam. Pract.* 2005;54(9):815-816, [PMID: 16144598]
Exclusion code: 5

Chen C, Chen P, Zhang C-C, Li N, Jin Z-L, Li K. [Clinical characteristics and prognosis of large cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2010;32(12):932-934, [PMID: 21223803]
Exclusion code: 6

Chen J, Shen-Tu Y. [Research progress of lobe-specific lymphadenectomy on early stage lung cancer operation]. *Zhongguo Fei Ai Za Zhi.* 2011;14(1):63-68, [PMID: 21219835]
Exclusion code: 6

Chen P-C, Zhou X-M, Chen Q-X, Liu J-S, Yan F-L, Jiang Y-H. [Sleeve resection for lung cancer: a report of 82 cases]. *Ai Zheng.* 2008;27(5):510-515, [PMID: 18479601]
Exclusion code: 6

Chen X, Gorlov IP, Merriman KW, et al. Association of smoking with tumor size at diagnosis in non-small cell lung cancer.

Appendix A6. List of Excluded Full-Text Papers

Lung Cancer. 2011;74(3):378-383, [PMID: 21645942]

Exclusion code: 7

Chhajed PN, Shibuya K, Hoshino H, et al. A comparison of video and autofluorescence bronchoscopy in patients at high risk of lung cancer. *Eur. Respir. J.* 2005;25(6):951-955, [PMID: 15929947]

Exclusion code: 4

Chien CC, Zhang G, Hwu Y, et al. Detecting small lung tumors in mouse models by refractive-index microradiology. *Analytical and Bioanalytical Chemistry*. 2011;401(3):827-835, [PMID: 21626185]

Exclusion code: 3

Chien C-R, Chen TH-H. Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. *Int. J. Cancer*. 2008;122(11):2594-2599, [PMID: 18302157]

Exclusion code: 2

Chien C-R, Lai M-S, Chen TH-H. Estimation of mean sojourn time for lung cancer by chest X-ray screening with a Bayesian approach. *Lung Cancer*. 2008;62(2):215-220, [PMID: 18400331]

Exclusion code: 7

Chiles C. Lung cancer screening: achieving a reduction in mortality. *Semin. Roentgenol.* 2011;46(3):230-240, [PMID: 21726707]

Exclusion code: 2

Chirieac LR, Flieder DB. High-resolution computed tomography screening for lung cancer: unexpected findings and new controversies regarding adenocarcinogenesis. *Arch. Pathol. Lab. Med.* 2010;134(1):41-48, [PMID: 20073604]

Exclusion code: 2

Screening for lung cancer with CT: a preliminary cost-effectiveness analysis (Structured abstract). John Wiley & Sons, Ltd. Chichester, UK; 2011. <http://dx.doi.org/10.1002/14651858>.

Exclusion code: 4

Chiu C-H, Chern M-S, Wu M-H, et al. Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. *J. Thorac. Cardiovasc. Surg.* 2003;125(6):1300-1305, [PMID: 12830048]

Exclusion code: 3

Chkhikvadze VD, Sokolova VS, Lisitskii AN, Klimov AB, Gass MV, Rukavichnikov VM. [Results of surgical treatment of lung cancer in patients over 70 years old]. *Khirurgiia (Sofia)*. 2003(5):15-16, [PMID: 12792954]

Exclusion code: 6

Cho S, Lee EB. A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. *J. Thorac. Cardiovasc. Surg.* 2010;139(6):1447-1451, [PMID: 20005529]

Exclusion code: 3

Choi J-I, Choi HJ, Jung DC, et al. Diagnostic value of early-phase-enhanced computed tomography for the differentiation of pulmonary metastases from hepatocellular carcinoma and primary lung cancer. *Acta Radiol.* 2009;50(9):1005-1010, [PMID: 19863410]

Exclusion code: 3

Choi YS, Shim YM, Kim K, Kim J. Pattern of recurrence after curative resection of

Appendix A6. List of Excluded Full-Text Papers

local (stage I and II) non-small cell lung cancer: difference according to the histologic type. *J. Korean Med. Sci.* 2004;19(5):674-676, [PMID: 15483342]
Exclusion code: 3

Chong S, Lee KS, Chung MJ, et al. Lung cancer screening with low-dose helical CT in Korea: experiences at the Samsung Medical Center. *J. Korean Med. Sci.* 2005;20(3):402-408, [PMID: 15953860]
Exclusion code: 3

Chorostowska-Wynimko J, Szpechcinski A. The impact of genetic markers on the diagnosis of lung cancer: a current perspective. *J Thorac Oncol.* 2007;2(11):1044-1051, [PMID: 17975498]
Exclusion code: 2

Christie B. Screening trial of blood test for lung cancer is set to start in Scotland. *BMJ.* 2012;344:e2312, [PMID: 22451495]
Exclusion code: 4

Chua S, Gnanasegaran G, Cook GJR. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. *Seminars in Nuclear Medicine.* 2009;39(6):416-430, [PMID: 19801221]
Exclusion code: 5

Chung SY, Lee JH, Kim TH, et al. F-18 FDG PET scan findings in patients with Loeffler's syndrome. *Clin. Nucl. Med.* 2009;34(9):570-575, [PMID: 19692816]
Exclusion code: 3

Church TR, National Lung Screening Trial Executive C. Chest radiography as the comparison for spiral CT in the National Lung Screening Trial. *Acad. Radiol.* 2003;10(6):713-715, [PMID: 12809426]
Exclusion code: 2

Cicenas S, Kurtinaitis J, Smailyte G. Outcome and treatment strategy in female lung cancer: a single institution experience. *Adv Med Sci.* 2010;55(2):273-280, [PMID: 21097446]
Exclusion code: 10

Cicenas S, Naujokaitis P, Jackevicius A, Piscikas D, Krasauskas A, Tikuisis R. [Bronchoplastic operations for lung cancer]. *Medicina (Kaunas).* 2002;38 Suppl 2:23-25, [PMID: 12560613]
Exclusion code: 6

Cilli A, Ozkaynak C, Onur R, et al. Lung cancer detection with low-dose spiral computed tomography in chronic obstructive pulmonary disease patients. *Acta Radiol.* 2007;48(4):405-411, [PMID: 17453521]
Exclusion code: 2

Cirincione R, Lintas C, Conte D, et al. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. *Int. J. Cancer.* 2006;118(5):1248-1253, [PMID: 16152615]
Exclusion code: 2

Clark JR, Rumcheva P, Veness MJ. Analysis and Comparison of the 7th Edition American Joint Committee on Cancer (AJCC) Nodal Staging System for Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck. *Ann Surg Oncol.* 2012;Jul 18. [Epub ahead of print], [PMID: 22805870]
Exclusion code: 2

Clark KW, Gierada DS, Marquez G, et al. Collecting 48,000 CT exams for the lung screening study of the National Lung Screening Trial. *J. Digit. Imaging.* 2009;22(6):667-680, [PMID: 18777192]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 2

Clark KW, Gierada DS, Moore SM, et al. Creation of a CT Image Library for the Lung Screening Study of the National Lung Screening Trial. *J. Digit. Imaging.* 2007;20(1):23-31, [PMID: 16783598]
Exclusion code: 2

Clark MM, Cox LS, Jett JR, et al. Effectiveness of smoking cessation self-help materials in a lung cancer screening population. *Lung Cancer.* 2004;44(1):13-21, [PMID: 15013579]
Exclusion code: 4

Clark MM, Jett JR. Change in smoking status after low-dose spiral chest CT screening for lung cancer: opportunity for smoking intervention. *Thorax.* 2009;64(5):371-372, [PMID: 19401483]
Exclusion code: 5

Clarke LP, Croft BY, Staab E, Baker H, Sullivan DC. National Cancer Institute initiative: Lung image database resource for imaging research. *Acad. Radiol.* 2001;8(5):447-450, [PMID: 11345275]
Exclusion code: 5

Clement-Duchene C, Guillemin F, Paris C, Regent D, Martinet Y. [Protocols for lung cancer screening: Limitations, and consequences]. *Rev. Mal. Respir.* 2010;27(4):314-328, [PMID: 20403542]
Exclusion code: 6

Clin B, Morlais F, Guittet L, et al. Performance of chest radiograph and CT scan for lung cancer screening in asbestos-exposed workers. *Occup. Environ. Med.* 2009;66(8):529-534, [PMID: 19273475]
Exclusion code: 2

Coche E. Screening for lung cancer with low-dose CT. *Jbr-Btr.* 2008;91(1):1-5,

[PMID: 18447122]

Exclusion code: 5

Coche E. What's new in lung cancer screening? *Où en est le dépistage du cancer broncho-pulmonaire ?* 2008;64(4):183-186, [PMID: 19019286]
Exclusion code: 5

Cody DD, Kim H-J, Cagnon CH, et al. Normalized CT dose index of the CT scanners used in the National Lung Screening Trial. *AJR. Am. J. Roentgenol.* 2010;194(6):1539-1546, [PMID: 20489094]
Exclusion code: 2

Colby TV, Tazelaar HD, Travis WD, Bergstralh EJ, Jett JR. Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group?.[Erratum appears in *Cancer.* 2003 Mar 1;97(5):1367]. *Cancer.* 2002;95(11):2361-2365, [PMID: 12436443]
Exclusion code: 2

Collins LG, Wynn DT, Barash JH. The future of cancer screening. *Prim. Care.* 2009;36(3):623-639, [PMID: 19616158]
Exclusion code: 5

Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. *J. Gen. Intern. Med.* 2008;23 Suppl 1:78-84, [PMID: 18095050]
Exclusion code: 4

Conti B, Aquilini F, Pistelli F, et al. Lung function in a group of smokers or ex smokers enrolled in a randomized controlled trial (RCT) with low-dose computed tomography (CT) for lung cancer

Appendix A6. List of Excluded Full-Text Papers

screening (ITALUNG-CT study)
[Abstract]. Paper presented at: European
Respiratory Society Annual Congress,
Barcelona, Spain, September 2010
Exclusion code: 5

Cooke DT, Nguyen DV, Yang Y, Chen SL,
Yu C, Calhoun RF. Survival comparison of
adenosquamous, squamous cell, and
adenocarcinoma of the lung after
lobectomy. *Ann. Thorac. Surg.*
2010;90(3):943-948, [PMID: 20732522]
Exclusion code: 3

Corradi M, Poli D, Goldoni M. Molecular
diagnosis of lung cancer. *Diagnosi
molecolare di tumore del polmone.*
2008;30(3 SUPPL.):115-116, [PMID:
19288801]
Exclusion code: 5

Coulibaly B, de Biasi C, Gisserot O, de
Jaureguiberry J-P, Patte J-H. [Testicular
carcinoma and sarcoid-like necrotizing
granulomatosis]. *Ann. Pathol.*
2009;29(3):238-240, [PMID: 19619833]
Exclusion code: 6

Coultas DB, Samet JM. Occupational lung
cancer. *Clin. Chest Med.* 1992;13(2):341-
354, [PMID: 1511558]
Exclusion code: 2

Crestanello JA, Allen MS, Jett JR, et al.
Thoracic surgical operations in patients
enrolled in a computed tomographic
screening trial. *J. Thorac. Cardiovasc.
Surg.* 2004;128(2):254-259, [PMID:
15282462]
Exclusion code: 2

Crino L, Weder W, van Meerbeeck J, Felip
E, Group EGW. Early stage and locally
advanced (non-metastatic) non-small-cell
lung cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and

follow-up. *Ann. Oncol.* 2010;21 Suppl
5:v103-115, [PMID: 20555058]
Exclusion code: 4

Criqui M, McClelland R, McDermott M, et
al. The ankle-brachial index and incident
cardiovascular events in the MESA (Multi-
ethnic Study of Atherosclerosis). *JACC.*
2010;56(18):1506 - 1512 [PMID:
20951328]
Exclusion code: 7

Cronin KA, Gail MH, Zou Z, Bach PB,
Virtamo J, Albanes D. Validation of a
model of lung cancer risk prediction among
smokers. *J. Natl. Cancer Inst.*
2006;98(9):637-640, [PMID: 16670389]
Exclusion code: 5

Cuffe S, Moua T, Summerfield R, Roberts
H, Jett J, Shepherd FA. Characteristics and
outcomes of small cell lung cancer patients
diagnosed during two lung cancer
computed tomographic screening programs
in heavy smokers. *J Thorac Oncol.*
2011;6(4):818-822, [PMID: 21623258]
Exclusion code: 2

Cullen J, Schwartz MD, Lawrence WF,
Selby JV, Mandelblatt JS. Short-term
impact of cancer prevention and screening
activities on quality of life. *J. Clin. Oncol.*
2004;22(5):943-952, [PMID: 14990651]
Exclusion code: 3

Dab W. Fundamentals of «screenology»?
Éléments de «dépiologie». 2007;23(6-
7):640-643, [PMID: 17631840]
Exclusion code: 6

Dacic S. Pulmonary preneoplasia. *Arch.
Pathol. Lab. Med.* 2008;132(7):1073-1078,
[PMID: 18605763]
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Dai W, Yu C, Sun Ye. [Prognosis of non-small cell lung cancer patients with microscopic residual disease at bronchial stump after lung resection]. *Chung Hua I Hsueh Tsa Chih*. 2002;82(15):1022-1024, [PMID: 12194790]

Exclusion code: 6

Dai Y, Long H, Lin P, et al. [Impact of the number of resected and involved lymph nodes on the outcome in patients with stage II non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2010;32(6):436-440, [PMID: 20819485]

Exclusion code: 6

Dales LG, Friedman GD, Collen MF. Evaluating periodic multiphasic health checkups: a controlled trial. *J Chron Dis*. 1979;32(5):385-404, [PMID: 109452]

Exclusion code: 5

Dalrymple-Hay MJ, Drury NE. Screening for lung cancer. *J. R. Soc. Med*. 2001;94(1):2-5, [PMID: 11220063]

Exclusion code: 5

D'Amico TA. Long-term outcomes of thorascopic lobectomy. *Thorac Surg Clin*. 2008;18(3):259-262, [PMID: 18831500]

Exclusion code: 5

D'Amico TA. Operative techniques in early-stage lung cancer. *Journal of the National Comprehensive Cancer Network*. 2010;8(7):807-813, [PMID: 20679539]

Exclusion code: 5

Dammas S, Patz EF, Jr., Goodman PC. Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. *Lung Cancer*. 2001;33(1):11-16, [PMID: 11429191]

Exclusion code: 5

D'Andrea N, Sanguinetti CM. Lung cancer screening with low-dose CT: Its effectiveness in early diagnosis and in mortality reduction. *Multidisciplinary Respiratory Medicine*. 2009;4(5):334-343

Exclusion code: 5

Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. *J. Thorac. Cardiovasc. Surg*. 2011;141(3):662-670, [PMID: 21335122]

Exclusion code: 7

Das M, Muhlenbruch G, Mahnken AH, et al. Asbestos Surveillance Program Aachen (ASPA): initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT. *Eur. Radiol*. 2007;17(5):1193-1199, [PMID: 17047960]

Exclusion code: 2

Das P, Ng AK, Earle CC, Mauch PM, Kuntz KM. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. *Ann. Oncol*. 2006;17(5):785-793, [PMID: 16500905]

Exclusion code: 3

Date H, Andou A, Shimizu N. The value of limited resection for 'clinical' stage I peripheral non-small cell lung cancer in poor-risk patients: Comparison of limited resection and lobectomy by a computer-assisted matched study. *Tumori*. 1994;80(6):422-426, [PMID: 7900230]

Exclusion code: 8

Appendix A6. List of Excluded Full-Text Papers

Davila D, Williams D. The etiology of lung cancer. *Mayo Clin. Proc.* 1993;68(2):170-182, [PMID: 8423698]

Exclusion code: 2

de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? *Lung Cancer.* 2005;50(2):199-209, [PMID: 16043258]

Exclusion code: 4

De Gonzalez AB. Computed tomography screening: Safe and effective? *J. Med. Screen.* 2007;14(4):165-168, [PMID: 18078559]

Exclusion code: 5

de Hoop B, De Boo DW, Gietema HA, et al. Computer-aided detection of lung cancer on chest radiographs: effect on observer performance. *Radiology.* 2010;257(2):532-540, [PMID: 20807851]

Exclusion code: 2

de Hoop B, Gietema H, van de Vorst S, Murphy K, van Klaveren RJ, Prokop M. Pulmonary ground-glass nodules: increase in mass as an early indicator of growth. *Radiology.* 2010;255(1):199-206, [PMID: 20123896]

Exclusion code: 7

de Hoop B, Schaefer-Prokop C, Gietema HA, et al. Screening for lung cancer with digital chest radiography: sensitivity and number of secondary work-up CT examinations. *Radiology.* 2010;255(2):629-637, [PMID: 20413773]

Exclusion code: 2

de Leyn P, Decker G. [Surgical treatment of non-small cell lung cancer]. *Rev. Mal. Respir.* 2004;21(5 Pt 1):971-982, [PMID:

15622344]

Exclusion code: 6

De Marinis F, Cipri A, Ricciardi S. Is an effective screening for lung cancer possible in COPD? *Contra. Multidisciplinary Respiratory Medicine.* 2009;4(5):368-371

Exclusion code: 5

De Marinis F, De Petris L. [The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery]. *Suppl Tumori.* 2004;3(4):S50-51, [PMID: 15206212]

Exclusion code: 6

de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. *Chest.* 2007;132(6):1932-1938, [PMID: 18079226]

Exclusion code: 7

Debus J, Eberhardt W, Hoffmann H, Passlick B, Rube C, Thomas M. [The boundaries of curation]. *Onkologie.* 2010;33 Suppl 5:12-20, [PMID: 20523102]

Exclusion code: 6

Deghaidy AA, Nofal LM, Abd-Elmoneium SE, Mahdy NH. Meta-analysis of survival models of lung cancer. *J. Egypt. Public Health Assoc.* 2005;80(1-2):77-126, [PMID: 16922149]

Exclusion code: 5

Dehavenon A. CT screening for lung cancer. *N. Engl. J. Med.* 2007;356(7):745-746; author reply 746-747, [PMID: 17310515]

Exclusion code: 5

Dement J, Welch L, Haile E, Myers D. Mortality among sheet metal workers participating in a medical screening

Appendix A6. List of Excluded Full-Text Papers

program. *Am. J. Ind. Med.* 2009;52(8):603-613, [PMID: 19562730]

Exclusion code: 2

Deng C, Zhang X, Li N. Investigation of volatile biomarkers in lung cancer blood using solid-phase microextraction and capillary gas chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2004;808(2):269-277, [PMID: 15261821]

Exclusion code: 4

Deppermann K-M. Lung cancer screening--where we are in 2004 (take home messages). *Lung Cancer.* 2004;45 Suppl 2:S39-42, [PMID: 15552780]

Exclusion code: 5

DerSimonian R, Laird NM. Meta-analysis in clinical trials. *Control. Clin. Trials.* 1986;7(3):177-188, [PMID: 3802833]

Exclusion code: 2

Deslauriers J. Should screening for lung cancer be revisited? *J. Thorac. Cardiovasc. Surg.* 2001;121(6):1031-1032, [PMID: 11385366]

Exclusion code: 5

Deslauriers J, Ginsberg RJ, Piantadosi S, Fournier B. Prospective assesment of 30-day operative morbidity for surgical resections in lung cancer. *Chest.* 1994;106(6 Suppl):329S-330S, [PMID: 7988256]

Exclusion code: 5

Deslauriers J, Gregoire J, Jacques LF, Piraux M, Guojin L, Lacasse Y. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. *Ann. Thorac. Surg.* 2004;77(4):1152-1156; discussion 1156, [PMID: 15063224]

Exclusion code: 10

Desmetz C, Mange A, Maudelonde T, Solassol J. Autoantibody signatures: Progress and perspectives for early cancer detection. *Journal of Cellular and Molecular Medicine.* 2011;15(10):2013-2024, [PMID: 21651719]

Exclusion code: 5

Detterbeck F. The fruits of our efforts: time for a different view of lung cancer and CT screening. *Thorax.* 2009;64(6):465-466, [PMID: 19478118]

Exclusion code: 5

Detterbeck FC. Lumping, splitting, and sorting. *Journal of Thoracic Oncology.* 2007;2(7):581-582, [PMID: 17607109]

Exclusion code: 5

Detterbeck FC. Maintaining aim at a moving target. *Journal of Thoracic Oncology.* 2011;6(3):417-422, [PMID: 21317740]

Exclusion code: 5

Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. *Chest.* 2009;136(1):260-271, [PMID: 19584208]

Exclusion code: 2

Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. *J Thorac Oncol.* 2008;3(7):781-792, [PMID: 18594326]

Exclusion code: 2

Dewey M. Coronary CT versus MR angiography: Pro CT - The role of CT angiography. *Radiology.* 2011;258(2):329-339, [PMID: 21273517]

Exclusion code: 5

Dexter EU, Jahangir N, Kohman LJ. Resection for lung cancer in the elderly patient. *Thorac Surg Clin.* 2004;14(2):163-171, [PMID: 15382292]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 5

Diciotti S, Lombardo S, Coppini G, Grassi L, Falchini M, Mascalchi M. The LoG characteristic scale: a consistent measurement of lung nodule size in CT imaging. *IEEE Trans. Med. Imaging*. 2010;29(2):397-409, [PMID: 20129846]
Exclusion code: 4

Diciotti S, Picozzi G, Falchini M, Mascalchi M, Villari N, Valli G. 3-D segmentation algorithm of small lung nodules in spiral CT images. *IEEE Transactions on Information Technology in Biomedicine*. 2008;12(1):7-19, [PMID: 18270032]
Exclusion code: 4

Diederich S. Screening for early lung cancer with low-dose spiral computed tomography. *Lancet*. 2003;362(9384):588-589, [PMID: 12944053]
Exclusion code: 5

Diederich S. CT screening for lung cancer. *Cancer Imaging*. 2008;8 Spec No A:S24-26, [PMID: 18852077]
Exclusion code: 5

Diederich S, Hansen J, Wormanns D. Resolving small pulmonary nodules: CT features. *Eur. Radiol*. 2005;15(10):2064-2069, [PMID: 16003507]
Exclusion code: 2

Diederich S, Lenzen H. Radiation exposure associated with imaging of the chest: comparison of different radiographic and computed tomography techniques. *Cancer*. 2000;89(11 Suppl):2457-2460, [PMID: 11147626]
Exclusion code: 2

Diederich S, Thomas M, Semik M, et al. Screening for early lung cancer with low-

dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. *Eur. Radiol*. 2004;14(4):691-702, [PMID: 14727146]
Exclusion code: 2

Diederich S, Wormanns D. Impact of low-dose CT on lung cancer screening. *Lung Cancer*. 2004;45 Suppl 2:S13-19, [PMID: 15552777]
Exclusion code: 5

Diederich S, Wormanns D, Heindel W. Low-dose CT: new tool for screening lung cancer? *Eur. Radiol*. 2001;11(10):1916-1924, [PMID: 11702123]
Exclusion code: 5

Diederich S, Wormanns D, Heindel W. [Radiologic screening for lung cancer: present status and future perspectives]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*. 2001;173(10):873-882, [PMID: 11588672]
Exclusion code: 6

Diederich S, Wormanns D, Heindel W. [Bronchial carcinoma screening with low dosage CT. Current status]. *Radiologe*. 2001;41(3):256-260, [PMID: 11322071]
Exclusion code: 6

Diederich S, Wormanns D, Heindel W. Lung cancer screening with low-dose CT. *Eur. J. Radiol*. 2003;45(1):2-7, [PMID: 12499059]
Exclusion code: 5

Diederich S, Wormanns D, Lenzen H, Semik M, Thomas M, Peters PE. Screening for asymptomatic early bronchogenic carcinoma with low dose CT of the chest. *Cancer*. 2000;89(11 Suppl):2483-2484, [PMID: 11147631]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Diederich S, Wormanns D, Lenzen H, et al. Screening for early lung cancer with low-dose computed tomography of the chest: results of baseline examinations in 919 asymptomatic smokers. *Eur. Radiol.* 2000;10(1):S253

Exclusion code: 8

Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. *Radiology.* 2002;222(3):773-781, [PMID: 11867800]

Exclusion code: 2

Dienemann H. Principles of surgical treatment in localized non-small cell lung cancer. *Lung Cancer.* 2001;33 Suppl 1:S3-8, [PMID: 11576701]

Exclusion code: 5

Dienemann H, Hoffmann H, Herth F. [Thoracic surgery in the elderly]. *Chirurg.* 2005;76(2):126-130, [PMID: 15551005]

Exclusion code: 6

Ding Z, Zhang J, Shao J. [ERCC1 expression as a predictor of survival after operation in stage I non-small cell lung cancer patients]. *Zhongguo Fei Ai Za Zhi.* 2010;13(5):522-525, [PMID: 20677653]

Exclusion code: 6

Divisi D, Di Tommaso S, De Vico A, Crisci R. Early diagnosis of lung cancer using a SAFE-3000 autofluorescence bronchoscopy. *Interact Cardiovasc Thorac Surg.* 2010;11(6):740-744, [PMID: 20852332]

Exclusion code: 3

Dixon GD. Computed tomography for screening purposes: a review of the literature--2003. *Mo. Med.* 2003;100(2):140-144, [PMID: 12710165]

Exclusion code: 5

Dobbins Iii JT, McAdams HP. Chest tomosynthesis: Technical principles and clinical update. *Eur. J. Radiol.* 2009;72(2):244-251, [PMID: 19616909]

Exclusion code: 5

Dobbins JT. Tomosynthesis imaging: At a translational crossroads. *Med. Phys.* 2009;36(6):1956-1967, [PMID: 19610284]

Exclusion code: 5

Dobbins JT, McAdams HP, Godfrey DJ, Li CM. Digital tomosynthesis of the chest. *J. Thorac. Imaging.* 2008;23(2):86-92, [PMID: 18520565]

Exclusion code: 5

Dobson R. Screening trial for lung cancer planned for UK. *BMJ.*

2000;320(7230):270, [PMID: 10650017]

Exclusion code: 5

Doddoli C, Aragon A, Barlesi F, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? *Eur. J. Cardiothorac. Surg.* 2005;27(4):680-685, [PMID: 15784374]

Exclusion code: 3

Doddoli C, Thomas P, Reynaud-Gaubert M, Giudicelli R, Papazian L, Fuentes P. [Postoperative complications after radiochemotherapy or chemotherapy for bronchial cancers]. *Rev. Mal. Respir.* 2000;17(6):1081-1087, [PMID: 11217503]

Exclusion code: 6

Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. *Br. Med. J.* 1950;2(4682):739-748, [PMID: 14772469]

Exclusion code: 5

Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in

Appendix A6. List of Excluded Full-Text Papers

human non-small cell lung cancer. *Cancer Res.* 2006;66(14):7341-7347, [PMID: 16849585]

Exclusion code: 4

Dominioni L, Imperatori A, Rovera F, Ochetti A, Paolucci M, Dionigi G. Lung cancer screening in cigarette smokers in the province of Varese, Italy. *Cancer.* 2000;89(11 Suppl):2345-2348, [PMID: 11147609]

Exclusion code: 5

Dominioni L, Rotolo N, Mantovani W, et al. A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up. *BMC Cancer.* 2012;12:18, [PMID: 22251777]

Exclusion code: 5

Dominioni L, Rotolo N, Poli A, et al. Self-selection effects in smokers attending lung cancer screening: a 9.5-year population-based cohort study in Varese, Italy. *J Thorac Oncol.* 2010;5(4):428-435, [PMID: 20142770]

Exclusion code: 2

Dominioni L, Strauss GM, Imperatori A, Rovera F, Dionigi G. Screening for lung cancer. *Chest Surg. Clin. N. Am.* 2000;10(4):729-736, [PMID: 11091922]

Exclusion code: 5

Doria-Rose VP, Marcus PM, Szabo E, Tockman MS, Melamed MR, Prorok PC. Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. *Cancer.* 2009;115(21):5007-5017, [PMID: 19637354]

Exclusion code: 5

Doria-Rose VP, White MC, Klabunde CN, et al. Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. *Cancer Epidemiol. Biomarkers Prev.*

2012;21(7):1049-1059, [PMID: 22573798]

Exclusion code: 2

Dougeni E, Faulkner K, Panayiotakis G. A review of patient dose and optimisation methods in adult and paediatric CT scanning. *Eur. J. Radiol.* 2012;81(4):e665-e683, [PMID: 21684099]

Exclusion code: 5

Douglas PS, Cerqueria M, Rubin GD, Chin ASL. Extracardiac Findings: What Is a Cardiologist to Do? *JACC: Cardiovascular Imaging.* 2008;1(5):682-687, [PMID: 19356500]

Exclusion code: 5

Dowie J, Wildman M. Choosing the surgical mortality threshold for high risk patients with stage Ia non-small cell lung cancer: insights from decision analysis. *Thorax.* 2002;57(1):7-10, [PMID: 11809982]

Exclusion code: 5

Duan Y, Bai L-q. [Long-term results of surgical plus chemotherapy for stage I lung adenocarcinoma]. *Chung Hua I Hsueh Tsa Chih.* 2009;89(23):1630-1632, [PMID: 19957512]

Exclusion code: 6

Duan Y, Bai L-Q, Gong C-F, Yan D-J, Dou X-J. [Preoperative chemotherapy for long-term results of small cell lung cancer]. *Chung Hua I Hsueh Tsa Chih.* 2009;89(31):2199-2201, [PMID: 20058599]

Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Duarte IG, Gal AA, Mansour KA, Lee RB, Miller JJ. Pathologic findings in lung volume reduction surgery. *Chest*. 1998;113(3):660-664, [PMID: 9515839]
Exclusion code: 4

Dubey S, Powell CA. Update in lung cancer 2007. *Am. J. Respir. Crit. Care Med*. 2008;177(9):941-946, [PMID: 18434333]
Exclusion code: 5

Duncan MW. Place for biochemical markers in early-stage lung cancer detection? *J. Clin. Oncol*. 2009;27(17):2749-2750, [PMID: 19414662]
Exclusion code: 5

Duque JK, Lopez-Encuentra A, Porta RR, Bronchogenic Carcinoma Cooperative Group of the Spanish Society of P, Thoracic S. Survival of 2,991 patients with surgical lung cancer: the denominator effect in survival. *Chest*. 2005;128(4):2274-2281, [PMID: 16236884]
Exclusion code: 5

Ebeling K, Nischan P. Screening for lung cancer - Results from a case-control study. *Int. J. Cancer*. 1987;40(2):141-144, [PMID: 3610384]
Exclusion code: 8

Eberini I, Gianazza E, Pastorino U, Sirtori CR. Assessment of individual lung cancer risk by the proteomic analysis of exhaled breath condensate. *Expert Opinion on Medical Diagnostics*. 2008;2(12):1309-1315
Exclusion code: 4

Eckardt SM, Ashton RW. Lung cancer screening: Is it time for a change in policy? *South. Med. J*. 2008;101(1):5-6
Exclusion code: 5

Eckert R. [Recommendations for follow-up of malignant diseases]. *Praxis*. 2006;95(15):567-573, [PMID: 16640176]
Exclusion code: 6

Edey AJ, Hansell DM. CT lung cancer screening in the UK. *Br. J. Radiol*. 2009;82(979):529-531, [PMID: 19541944]
Exclusion code: 5

Ehmann R, Boedeker E, Friedrich U, et al. Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon. *Eur. Respir. J*. 2012;39(3):669-676, [PMID: 21852337]
Exclusion code: 4

El-Bayoumi E, Silvestri GA. Bronchoscopy for the diagnosis and staging of lung cancer. *Semin*. 2008;29(3):261-270, [PMID: 18506664]
Exclusion code: 5

Elliott A. Issues in medical exposures. *J. Radiol. Prot*. 2009;29(2):A107-A121, [PMID: 19454810]
Exclusion code: 5

Ellis JR, Gleeson FV. Lung cancer screening. *Br. J. Radiol*. 2001;74(882):478-485, [PMID: 11459725]
Exclusion code: 2

Ellis SM, Husband JE, Armstrong P, Hansell DM. Computed tomography screening for lung cancer: back to basics. *Clin. Radiol*. 2001;56(9):691-699, [PMID: 11585391]
Exclusion code: 2

El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. *Ann. Thorac. Surg*. 2006;82(2):408-415; discussion 415-406, [PMID: 16863738]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 3

Elwood M, Campbell DA, de Campo MP. Helical computed tomography for lung cancer screening. *Med. J. Aust.* 2003;179(3):125-126, [PMID: 12885278]
Exclusion code: 5

Ely S. Personalized medicine: individualized care of cancer patients. *Translational Research.* 2009;154(6):303-308, [PMID: 19931196]
Exclusion code: 5

El-Zein RA, Fenech M, Lopez MS, Spitz MR, Etzel CJ. Cytokinesis-blocked micronucleus cytome assay biomarkers identify lung cancer cases amongst smokers. *Cancer Epidemiol. Biomarkers Prev.* 2008;17(5):1111-1119, [PMID: 18483333]
Exclusion code: 2

Emmons KM. Smoking cessation and tobacco control: an overview. *Chest.* 1999;116(6 Suppl):490S-492S, [PMID: 10619516]
Exclusion code: 5

Endo C, Sagawa M, Sakurada A, Sato M, Kondo T, Fujimura S. Surgical treatment of stage I non-small cell lung carcinoma. *Ann. Thorac. Cardiovasc. Surg.* 2003;9(5):283-289, [PMID: 14672523]
Exclusion code: 5

Endo S, Saito N, Otani S, et al. [Clinicopathologic features of small-sized peripheral lung cancer; is intentional limited resection appropriate for selected patients?]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2004;57(1):46-50, [PMID: 14733098]
Exclusion code: 6

Endo T, Endo S, Hasegawa T, et al. [Clinical outcome after video-assisted thoracic surgery (VATS) for clinical stage I lung cancer with pathologically nodal involvement]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2012;65(1):42-45, [PMID: 22314156]
Exclusion code: 6

Enquobahrie AA, Reeves AP, Yankelevitz DF, Henschke CI. Automated detection of small pulmonary nodules in whole lung CT scans. *Acad. Radiol.* 2007;14(5):579-593, [PMID: 17434072]
Exclusion code: 4

Erasmus JJ. Fluorodeoxyglucose uptake predicts survival in a CT screening trial. *J Thorac Oncol.* 2009;4(11):1305-1306, [PMID: 19861902]
Exclusion code: 5

Ernst I, Lucking PS, Eickmeyer F, et al. [Stereotactic body radiotherapy (SBRT) -- an overview under special consideration of SBRT and LITT in the therapy of liver metastases]. *Zentralbl. Gynakol.* 2006;128(2):71-75, [PMID: 16673248]
Exclusion code: 6

Escarguel B, D'Amore D, Chapel F, et al. [Early diagnosis of lung cancer: impact of autofluorescence bronchoscopy]. *Rev. Pneumol. Clin.* 2009;65(5):287-291, [PMID: 19878802]
Exclusion code: 6

Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. *JAMA - Journal of the American Medical Association.* 2009;302(15):1685-1692, [PMID: 19843904]
Exclusion code: 3

Appendix A6. List of Excluded Full-Text Papers

Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer: Clinical practice guidelines in oncology. *JNCCN Journal of the National Comprehensive Cancer Network*. 2010;8(7):740-741+771-801, [PMID: 20679538]
Exclusion code: 2

Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. *JNCCN Journal of the National Comprehensive Cancer Network*. 2008;6(3):228-269, [PMID: 16813724]
Exclusion code: 5

Etzel CJ, Bach PB. Estimating individual risk for lung cancer. *Semin*. 2011;32(1):3-9, [PMID: 21500119]
Exclusion code: 5

Etzel CJ, Lu M, Merriman K, Liu M, Vaporciyan A, Spitz MR. An epidemiologic study of early onset lung cancer. *Lung Cancer*. 2006;52(2):129-134, [PMID: 16564601]
Exclusion code: 4

Fadeyi OO, Adamson ST, Myles EL, Okoro CO. Novel fluorinated acridone derivatives. Part 1: Synthesis and evaluation as potential anticancer agents. *Bioorg. Med. Chem. Lett*. 2008;18(14):4172-4176, [PMID: 18541426]
Exclusion code: 5

Fan J, Wang L, Jiang G-N, Gao W. Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies. *Ann. Surg. Oncol*. 2012;19(2):661-668, [PMID: 21769464]
Exclusion code: 5

Fan Y-G, Hu P, Jiang Y, et al. Association between sputum atypia and lung cancer risk in an occupational cohort in Yunnan,

China. *Chest*. 2009;135(3):778-785, [PMID: 19265088]
Exclusion code: 2

Fang D, Zhang D, Huang G, Zhang R, Wang L. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1,905 cases. *Ann. Thorac. Surg*. 2001;72(4):1155-1159, [PMID: 11603429]
Exclusion code: 10

Farjah F, Flum D, Varghese T, Symons R, Wood D. Surgeon Specialty and Long-Term Survival After Pulmonary Resection for Lung Cancer. *Ann. Thorac. Surg*. 2009;87:995-1006, [PMID: 19324119]
Exclusion code: 2

Farjah F, Wood DE, Mulligan MS, et al. Safety and efficacy of video-assisted versus conventional lung resection for lung cancer. *J. Thorac. Cardiovasc. Surg*. 2009;137(6):1415-1421, [PMID: 19464458]
Exclusion code: 10

Farjah F, Wood DE, Yanez ND, 3rd, et al. Racial disparities among patients with lung cancer who were recommended operative therapy. *Arch. Surg*. 2009;144(1):14-18, [PMID: 19153319]
Exclusion code: 3

Farlow EC, Vercillo MS, Coon JS, et al. A multi-analyte serum test for the detection of non-small cell lung cancer. *Br. J. Cancer*. 2010;103(8):1221-1228, [PMID: 20859284]
Exclusion code: 2

Farmer I, Paulus T, Mollus S, Von Busch H, Buurman J, Verbeek XAAM. Oncology: The care cycle approach. *Medicamundi*. 2007;51(2-3):6-13+100+102+104+106
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Fasola G, Belvedere O, Aita M, et al. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). *Oncologist*. 2007;12(10):1215-1224, [PMID: 17962615]

Exclusion code: 3

Favre L, Rochat T. [Screening for lung cancer with low-dose chest computed tomography]. *Med. Hyg. (Geneve)*. 2003;61(2458):2197-2200, [PMID: 12899506]

Exclusion code: 6

Felix L, Lantuejoul S, Jankowski A, Ferretti G. [Localized pure or mixed ground-glass lung opacities]. *J. Radiol.* 2009;90(11 Pt 2):1869-1892, [PMID: 19953078]

Exclusion code: 6

Feragalli B, Bonomo L. [Non-small cell lung carcinoma. Early diagnosis: applicability of a screening]. *Suppl Tumori*. 2004;3(2):S5-8, [PMID: 15067955]

Exclusion code: 6

Ferguson MK, Karrison T. Does pneumonectomy for lung cancer adversely influence long-term survival? *J. Thorac. Cardiovasc. Surg.* 2000;119(3):440-448, [PMID: 10694601]

Exclusion code: 3

Ferketich AK, Otterson GA, King M, Hall N, Browning KK, Wewers ME. A pilot test of a combined tobacco dependence treatment and lung cancer screening program. *Lung Cancer*. 2012;76(2):211-215, [PMID: 22088938]

Exclusion code: 2

Fernandes OJCB, Almgren S-O, Thaning L, et al. Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer. *Acta Oncol.* 2003;42(4):338-341, [PMID: 12899506]

Exclusion code: 10

Fernandez FG, Force SD, Pickens A, Kilgo PD, Luu T, Miller DL. Impact of laterality on early and late survival after pneumonectomy. *Ann. Thorac. Surg.* 2011;92(1):244-249, [PMID: 21718850]

Exclusion code: 3

Fernández Ladrón V, Alonso JL, Munuera L, et al. Analysis of lung cancer cases diagnosed in an Internal Medicine Department: From January 2001 to September 2006. *Anales del Sistema Sanitario de Navarra*. 2007;30(3):353-362, [PMID: 18227892]

Exclusion code: 5

Fernández Sacasas JA, Díaz Novás J. Some theoretical considerations on the active inquiry. *Revista Cubana de Medicina General Integral*. 2009;25(4):107-116

Exclusion code: 6

Fernando HC, Landreneau RJ, Mandrekar SJ, et al. The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial. *J. Thorac. Cardiovasc. Surg.* 2011;142(3):554-562, [PMID: 21724195]

Exclusion code: 10

Ferretti G. What are the tools for post-occupational follow-up, how should they be performed and what are their performance, limits and benefit/risk ratio? Chest X-Ray and CT scan. *Revue des Maladies*

Appendix A6. List of Excluded Full-Text Papers

Respiratoires. 2011;28(6):761-772, [PMID: 21742237]

Exclusion code: 6

Ferretti G. Exposure to asbestos: Radiography and chest CT. *Journal de Radiologie*. 2011;92(5):450-460, [PMID: 21621114]

Exclusion code: 5

Ferretti G, Brichon P, Jankowski A, Coulomb M. [Postoperative complications after thoracic surgery]. *J. Radiol*. 2009;90(7-8 Pt 2):1001-1012, [PMID: 19752837]

Exclusion code: 6

Ferretti G, Jankowski A, Calizzano A, Moro-Sibilot D, Vuillez JP. Imaging and PET/CT of lung cancer. *J Radiol*. 2008;89(3 C2):387-402, [PMID: 18408640]

Exclusion code: 6

Fibla Alfara JJ, Gomez Sebastian G, Farina Rios C, Carvajal Carrasco A, Estrada Salo G, Leon Gonzalez C. [Lobectomy versus limited resection to treat non-small cell lung cancer in stage I: a study of 78 cases]. *Arch. Bronconeumol*. 2003;39(5):217-220, [PMID: 12749804]

Exclusion code: 6

Field JK, Duffy SW. Lung cancer screening: the way forward. *Br. J. Cancer*. 2008;99(4):557-562, [PMID: 18665179]

Exclusion code: 2

Field JK, Raji OY. The potential for using risk models in future lung cancer screening trials. *Medicine Reports*. 2010;2, [PMID: 20948847]

Exclusion code: 5

Field JK, Smith DL, Duffy S, Cassidy A. The Liverpool Lung Project research

protocol. *Int. J. Oncol*. 2005;27(6):1633-1645, [PMID: 16273220]

Exclusion code: 4

Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 Report. *Journal of Thoracic Oncology* 2012;7(1):10-19, [PMID: 22173661]

Exclusion code: 2

Field JK, Smith RA, Duffy SW, et al. The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. *J Thorac Oncol*. 2006;1(5):497-498, [PMID: 17409906]

Exclusion code: 3

Field JK, Youngson JH. The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection. *Eur. Respir. J*. 2002;20(2):464-479, [PMID: 12212983]

Exclusion code: 2

Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. *Lancet Oncol*. 2001;2(11):659-666, [PMID: 11902536]

Exclusion code: 7

Flahault A, Costagliola D. [Is lung cancer screening by the helical scanner justified?]. *MS Md Sci*. 2007;23(3):333-334, [PMID: 17349299]

Exclusion code: 6

Flahault A, Lemarie MD. GranDepiscan: Evaluation of early lung cancer screening in a randomized trial in France Paper presented at: International Symposium on

Appendix A6. List of Excluded Full-Text Papers

Predictive Oncology and Intervention Strategies 2004
Exclusion code:5

Flehinger B, Kimmel M, Melamed M. The effect of surgical treatment on survival from early lung cancer: implications for screening. *Chest Surg. Clin. N. Am.* 1992;101(4):1013, [PMID: 1313349]
Exclusion code: 2

Flehinger BJ, Kimmel M, Polyak T, Melamed MR. Screening for lung cancer. The Mayo Lung Project revisited. *Cancer.* 1993;72(5):1573-1580, [PMID: 8394199]
Exclusion code: 5

Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. *Am. Rev. Respir. Dis.* 1984;130(4):555-560, [PMID: 6091506]
Exclusion code: 5

Flieder DB. Screen-detected adenocarcinoma of the lung. Practical points for surgical pathologists. *Am. J. Clin. Pathol.* 2003;119 Suppl:S39-57, [PMID: 12951843]
Exclusion code: 2

Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. *Am. J. Surg. Pathol.* 2006;30(5):606-613, [PMID: 16699315]
Exclusion code: 7

Flores RM. Video-assisted thoracic surgery (VATS) lobectomy: focus on technique. *World J. Surg.* 2010;34(4):616-620, [PMID: 20082195]
Exclusion code: 5

Flores RM, Park BJ, Dycoco J, et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. *J. Thorac. Cardiovasc. Surg.* 2009;138(1):11-18, [PMID: 19577048]
Exclusion code: 7

Fong KM, Yang IA, Zimmerman PV, Bowman RV. Cochrane systematic reviews of treatments for lung cancer. *Respir. Med.* 2005;99(9):1071-1078, [PMID: 15955688]
Exclusion code: 5

Fontana RS. The Mayo Lung Project: a perspective. *Cancer.* 2000;89(11 Suppl):2352-2355, [PMID: 11147611]
Exclusion code: 5

Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. *Am. Rev. Respir. Dis.* 1984;130(4):561-565, [PMID: 6091507]
Exclusion code: 5

Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. *J. Occup. Med.* 1986;28(8):746-750, [PMID: 3528436]
Exclusion code: 5

Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. *Cancer.* 1991;67(4 SUPPL.):1155-1164, [PMID: 1991274]
Exclusion code: 5

Fontana TR, Sanderson DR, Woolner LB, Miller WE, Bernatz PE, Payne WS. The Mayo Lung Project for early detection and localization of bronchogenic carcinoma: a status report. *Chest.* 1975;67(5):511-522, [PMID: 1126186]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 5

Fontham E, Correa P, Reynolds P, Wu-Williams A, Buffler P, Greenberg R. Environmental tobacco smoke and lung cancer in nonsmoking women. *JAMA*. 1994;271(22):1752-1759, [PMID: 8196118]

Exclusion code: 2

Ford ME, Havstad SL, Flickinger L, Johnson CC. Examining the effects of false positive lung cancer screening results on subsequent lung cancer screening adherence. *Cancer Epidemiol. Biomarkers Prev*. 2003;12(1):28-33, [PMID: 12540500]

Exclusion code: 2

Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. *J Thorac Oncol*. 2011;6(3):482-488, [PMID: 21258252]

Exclusion code: 4

Foucault C, Berna P, Le Pimpec Barthes F, Souilamas R, Dujon A, Riquet M. [Lung cancer in women: surgical aspects related to gender]. *Rev. Mal. Respir*. 2006;23(3 Pt 1):243-253, [PMID: 16788525]

Exclusion code: 6

Foy M, Chen X, Kimmel M, Gorlova OY. Adjusting a cancer mortality-prediction model for disease status-related eligibility criteria. *BMC Medical Research Methodology*. 2011;11, [PMID: 21569346]

Exclusion code: 4

Foy M, Spitz MR, Kimmel M, Gorlova OY. A smoking-based carcinogenesis model for lung cancer risk prediction. *Int. J. Cancer*. 2011;129(8):1907-1913, [PMID: 1140453]

Exclusion code: 5

Foy M, Yip R, Chen X, Kimmel M, Gorlova OY, Henschke CI. Modeling the mortality reduction due to computed tomography screening for lung cancer.[Erratum appears in *Cancer*. 2011 Jul 15;117(14):3286]. *Cancer*. 2011;117(12):2703-2708, [PMID: 21656748]

Exclusion code: 2

Fraioli F, Bertoletti L, Napoli A, et al. Computer-aided detection (CAD) in lung cancer screening at chest MDCT: ROC analysis of CAD versus radiologist performance. *J. Thorac. Imaging*. 2007;22(3):241-246, [PMID: 17721333]

Exclusion code: 2

Fraioli F, Catalano C, Almberger M, et al. Evaluation of effectiveness of a computer system (CAD) in the identification of lung nodules with low-dose MSCT: scanning technique and preliminary results. *Radiol. Med. (Torino)*. 2005;109(1-2):40-48, [PMID: 15729185]

Exclusion code: 4

Freedman M. State-of-the-art screening for lung cancer (part 1): the chest radiograph. *Thorac Surg Clin*. 2004;14(1):43-52, [PMID: 15382307]

Exclusion code: 7

Freedman M, Chang EH, Zhou Q, Pirollo KF. Nanodelivery of MRI Contrast Agent Enhances Sensitivity of Detection of Lung Cancer Metastases. *Acad. Radiol*. 2009;16(5):627-637, [PMID: 19345904]

Exclusion code: 4

Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. *J Chron Dis*. 1986;39(6):453-463, [PMID: 3711252]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Frohlich J, Rischke C, Rentschler J, Dreves J, Stremmel C, Passlick B. [Isolated lymph node metastasis in pericardial fat flap after bronchial stump coverage]. *Chirurg*. 2010;81(10):930-932, [PMID: 19940968]
Exclusion code: 6

Frost JK, Ball WC, Jr. , Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. *Am. Rev. Respir. Dis.* 1984;130(4):549-554, [PMID: 6091505]
Exclusion code: 5

Fujikawa A, Takiguchi Y, Mizuno S, et al. Lung cancer screening--comparison of computed tomography and X-ray. *Lung Cancer*. 2008;61(2):195-201, [PMID: 18242764]
Exclusion code: 2

Fujimura S. [Limited surgery for bronchogenic carcinoma]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2001;54(8 Suppl):707-714, [PMID: 11517536]
Exclusion code: 6

Fujimura S, Sakurada A, Sagawa M, et al. A therapeutic approach to roentgenographically occult squamous cell carcinoma of the lung. *Cancer*. 2000;89(11 Suppl):2445-2448, [PMID: 11147623]
Exclusion code: 7

Fukino S, Fukata T, Hayashi E, et al. [Cases of death after surgery for pathologic stage I non-small cell lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2002;55(2):110-115, [PMID: 11842546]
Exclusion code: 6

Fukino S, Fukata T, Hayashi E, Okada K, Tamai N, Morio S. [Lobectomy of two or

more lobes in patients with lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2001;54(3):219-224, [PMID: 11244755]
Exclusion code: 6

Fukui T, Mori S, Hatoooka S, Shinoda M, Mitsudomi T. Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. *J. Thorac. Cardiovasc. Surg.* 2008;136(5):1343-1348, [PMID: 19026826]
Exclusion code: 5

Fukuoka M. [Progress in diagnosis and treatment of lung cancer]. *Nippon Naika Gakkai Zasshi - Journal of Japanese Society of Internal Medicine*. 2002;91 Suppl:15-22, [PMID: 11989256]
Exclusion code: 6

Furak J, Trojan I, Szoke T, Tiszlavicz L, Morvay Z, Balogh A. [The occurrence of bronchioloalveolar lung cancer among our patients]. *Magy Onkol*. 2003;47(4):349-353, [PMID: 14716429]
Exclusion code: 6

Futamura Y, Sawa T, Horiba A, et al. [The efficacy and safety of stereotactic radiotherapy for non-resectable non-small cell lung cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2010;37(12):2744-2746, [PMID: 21224699]
Exclusion code: 6

Gabrecht T, Radu A, Grosjean P, et al. Improvement of the specificity of cancer detection by autofluorescence imaging in the tracheo-bronchial tree using backscattered violet light. *Photodiagnosis Photodyn Ther*. 2008;5(1):2-9, [PMID: 19356630]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 4

Gagnon F, Courchesne M, Levesque B, et al. Assessment of the effectiveness of radon screening programs in reducing lung cancer mortality. *Risk Anal.* 2008;28(5):1221-1230, [PMID: 18761730]

Exclusion code: 4

Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. *J. Clin. Oncol.* 2003;21(6):1029-1034, [PMID: 12637467]

Exclusion code: 10

Galus M. Preventive medicine and screening. *Cleve. Clin. J. Med.* 2001;68(1):82-83, [PMID: 11204369]

Exclusion code: 5

Gamarra F. The role of lung cancer screening. *Med. Welt.* 2008;59(10):376-379

Exclusion code: 5

Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. *J. Clin. Oncol.* 2009;27(21):3540-3546, [PMID: 19470925]

Exclusion code: 2

Ganti AK, Huang CH, Klein MA, Keefe S, Kelley MJ. Lung cancer management in 2010. *Oncology (Williston).* 2011;25(1):64-73, [PMID: 21361246]

Exclusion code: 5

Ganti AK, Mulshine JL. Lung cancer screening. *Oncologist.* 2006;11(5):481-487, [PMID: 16720848]

Exclusion code: 5

Gao L, Li F, Thrall MJ, et al. On-the-spot lung cancer differential diagnosis by label-free, molecular vibrational imaging and knowledge-based classification. *Journal of Biomedical Optics.* 2011;16(9), [PMID: 21950918]

Exclusion code: 5

Gao W, Xu J, Shu YQ. MiRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer. *Expert Rev Respir Med.* 2011;5(5):699-709, [PMID: 21955239]

Exclusion code: 4

Gao Y-S, Xing X-Z, Shao K, Feng X-L, He J. [Analysis of prognostic factors in 1826 patients with completely resected non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2008;30(2):134-137, [PMID: 18646698]

Exclusion code: 6

Gao Y-S, Zhang D-C, He J, Sun K-L, Zhang D-W, Zhang R-G. [Diagnosis and surgical treatment for stage I non-small-cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2005;27(1):52-55, [PMID: 15771801]

Exclusion code: 6

Garcia-Yuste M, Matilla JM, Duque JL, Heras F, Cerezal LJ, Ramos G. [Surgical treatment of lung cancer: comparative assessment of the staging systems of 1986 and 1997. Results in 500 consecutive patients]. *Arch. Bronconeumol.* 2000;36(5):245-250, [PMID: 10916664]

Exclusion code: 6

Garg K, Keith RL, Byers T, et al. Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results. *Radiology.* 2002;225(2):506-510, [PMID: 12409588]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 5

Gasent Blesa JM, Esteban Gonzalez E, Alberola Candel V. Screening and chemoprevention in lung cancer. *Clin Transl Oncol*. 2008;10(5):274-280, [PMID: 18490244]

Exclusion code: 2

Gavelli G, Giampalma E. Sensitivity and specificity of chest X-ray screening for lung cancer: review article. *Cancer*. 2000;89(11 Suppl):2453-2456, [PMID: 11147625]

Exclusion code: 5

Gazelle GS, Kessler L, Lee DW, et al. A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research. *Radiology*. 2011;261(3):692-698, [PMID: 22095993]

Exclusion code: 5

Geddes DM. The natural history of lung cancer: a review based on rates of tumor growth. *Br. J. Dis. Chest*. 1979;73(1):1-17, [PMID: 435370]

Exclusion code: 2

Gelmann EP, Reding D, Buys S, et al. Multicenter screening trial for prostate, lung, colorectal and ovarian cancer (PLCO) [abstract]. *Proceedings of the American Society of Clinical Oncology*. 1997;16

Exclusion code: 5

Ghosal R, Kloer P, Lewis KE. A review of novel biological tools used in screening for the early detection of lung cancer. *Postgrad. Med. J*. 2009;85(1005):358-363, [PMID: 19581246]

Exclusion code: 5

Ghosh SK, Roland NJ, Kumar A, et al. Detection of synchronous lung tumors in

patients presenting with squamous cell carcinoma of the head and neck. *Head Neck*. 2009;31(12):1563-1570, [PMID: 19475554]

Exclusion code: 2

Ghraiiri H, Kartas S, Ammar J, et al. [Prognosis of mucoepidermoid carcinoma of the bronchi]. *Rev. Pneumol. Clin*. 2007;63(1):29-34, [PMID: 17457281]

Exclusion code: 6

Giarelli E. To screen or not to screen: using spiral computerized tomography in the early detection of lung cancer. *Clin. J. Oncol. Nurs*. 2002;6(4):223-224, [PMID: 12180375]

Exclusion code: 5

Gibson L, Spiegelhalter DJ, Camilleri-Ferrante C, Day NE. Trends in invasive cervical cancer incidence in East Anglia from 1971 to 1993. *J. Med. Screen*. 1997;4(1):44-48, [PMID: 9200063]

Exclusion code: 8

Gierada DS, Garg K, Nath H, Strollo DC, Fagerstrom RM, Ford MB. CT quality assurance in the lung screening study component of the National Lung Screening Trial: implications for multicenter imaging trials. *AJR. Am. J. Roentgenol*. 2009;193(2):419-424, [PMID: 19620438]

Exclusion code: 2

Gierada DS, Pilgram TK, Ford M, et al. Lung cancer: interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. *Radiology*. 2008;246(1):265-272, [PMID: 18024436]

Exclusion code: 2

Gietema HA, Wang Y, Xu D, et al. Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements.

Appendix A6. List of Excluded Full-Text Papers

Radiol. 2006;241(1):251-257, [PMID: 16908677]

Exclusion code: 2

Gietema HA, Zanen P, Schilham A, et al. Distribution of emphysema in heavy smokers: impact on pulmonary function. *Respir. Med.* 2010;104(1):76-82, [PMID: 19734030]

Exclusion code: 4

Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung Cancer after Treatment for Hodgkin's Disease: Focus on Radiation Effects. *Radiat. Res.* 2003;159:161-173, [PMID: 12537521]

Exclusion code: 3

Gilliland FD, Hunt WC, Archer VE, Saccomanno G. Radon progeny exposure and lung cancer risk among non-smoking uranium miners. *Health Phys.* 2000;79(4):365-372, [PMID: 11007458]

Exclusion code: 3

Gilljam H. [Screening for lung cancer--expensive and inefficient]. *Lakartidningen.* 2001;98(24):2952, [PMID: 11449902]

Exclusion code: 6

Gimferrer JM, Belda J, Catalan M, Serra M, Rubio M, Iglesias M. [Video-assisted lobectomy through the auscultatory triangle for the surgical treatment of bronchopulmonary carcinoma. Preliminary experience]. *Arch. Bronconeumol.* 2003;39(2):87-90, [PMID: 12586049]

Exclusion code: 6

Girard N, Mornex F. [Stereotactic radiotherapy for non-small cell lung cancer: From concept to clinical reality. 2011 update]. *Cancer Radiother.* 2011;15(6-7):522-526, [PMID: 21889901]

Exclusion code: 6

Gleeson FV. Is screening for lung cancer using low dose spiral CT scanning worthwhile? *Thorax.* 2006;61(1):5-7, [PMID: 16396951]

Exclusion code: 5

Gleeson FV. Screening for lung cancer with spiral CT is not justified. *Nat Clin Pract Oncol.* 2007;4(8):442-443, [PMID: 17579599]

Exclusion code: 5

Godoy MCB, Cooperberg PL, Maizlin ZV, et al. Detection sensitivity of a commercial lung nodule CAD system in a series of pathologically proven lung cancers. *J. Thorac. Imaging.* 2008;23(1):1-6, [PMID: 18347512]

Exclusion code: 2

Goeckenjan G. [Lung cancer - historical development, current status, future prospects]. *Pneumologie.* 2010;64(9):555-559, [PMID: 20827638]

Exclusion code: 6

Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate LC, Ovarian Cancer Screening Trial Project T. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. *Control. Clin. Trials.* 2000;21(6 Suppl):251S-272S, [PMID: 11189683]

Exclusion code: 2

Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. *The Journal of urology.* 1994;152(5 Pt 2):1905-1909, [PMID: 7523735]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Gohagan JK, Prorok PC, Kramer BS, Hayes RB, Cornett JE. The prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. *Cancer*. 1995;75(7 SUPPL.):1869-1873
Exclusion code: 5

Goldberg KB. *NCI Lung Cancer Screening Trial: The Cancer Letter* 2002
Exclusion code: 5

Goldin JG, Brown MS, Petkovska I. Computer-aided diagnosis in lung nodule assessment. *J. Thorac. Imaging*. 2008;23(2):97-104, [PMID: 18520567]
Exclusion code: 4

Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. *The Lancet*. 2011;378(9804):1727-1740, [PMID: 21565398]
Exclusion code: 5

Goldwasser DL, Kimmel M. Modeling excess lung cancer risk among screened arm participants in the Mayo Lung Project. *Cancer*. 2010;116(1):122-131, [PMID: 19918924]
Exclusion code: 5

Gomez M, Silvestri GA. Lung cancer screening. *Am. J. Med. Sci*. 2008;335(1):46-50, [PMID: 18195583]
Exclusion code: 2

Gomez SL, Chang ET, Shema SJ, et al. Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked. *Cancer Epidemiol. Biomarkers Prev*. 2011;20(3):545-554, [PMID: 21239685]
Exclusion code: 3

Gomi S, Muramatsu Y, Tsukagoshi S, et al. Low-dose CT screening for lung cancer

with automatic exposure control: phantom study. *Radiol Phys Technol*. 2008;1(2):244-250, [PMID: 20821155]
Exclusion code: 7

Goo JM, Lee JW, Lee HJ, Kim S, Kim JH, Im J-G. Automated lung nodule detection at low-dose CT: preliminary experience. *Korean Journal of Radiology*. 2003;4(4):211-216, [PMID: 14726637]
Exclusion code: 2

Goodgame B, Viswanathan A, Zoole J, et al. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. *J Thorac Oncol*. 2009;4(11):1370-1374, [PMID: 19692932]
Exclusion code: 3

Goodman PC. Computed tomography scanning for lung cancer screening: an update. *Int. J. Tuberc. Lung Dis*. 2010;14(7):789-791, [PMID: 20550758]
Exclusion code: 5

Goodney P, Lucas F, Stuke T, Birkmeyer J. Surgeon Specialty and Operative Mortality With Lung Resection. *Ann. Surg*. 2005;241(1):179-184, [PMID: 15622006]
Exclusion code: 2

Gopal A, Budoff MJ. Computed tomography screening for lung cancer. *JAMA*. 2007;298(5):513; author reply 515-516, [PMID: 17666668]
Exclusion code: 2

Gopal M, Abdullah SE, Grady JJ, Goodwin JS. Screening for lung cancer with low-dose computed tomography: a systematic review and meta-analysis of the baseline findings of randomized controlled trials. *J Thorac Oncol*. 2010;5(8):1233-1239, [PMID: 20548246]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Gorenstein LA, Sonett JR. The Surgical Management of Stage I and Stage II Lung Cancer. *Surg. Oncol. Clin. N. Am.* 2011;20(4):701-720, [PMID: 21986267]
Exclusion code: 5

Gori IF, M.E., Martinez AP. An automated system for lung nodule detection in low-dose computed tomography. Paper presented at: Computer-Aided Diagnosis2007; San Diego, CA
Exclusion code: 4

Gorlova OY, Amos C, Henschke C, et al. Genetic susceptibility for lung cancer: interactions with gender and smoking history and impact on early detection policies. *Hum. Hered.* 2003;56(1-3):139-145, [PMID: 14614248]
Exclusion code: 4

Gossot D, Girard P, Raynaud C, et al. [Totally endoscopic major pulmonary resection for stage I bronchial carcinoma: initial results]. *Rev. Mal. Respir.* 2009;26(9):961-970, [PMID: 19953042]
Exclusion code: 6

Gossot D, Girard P, Raynaud C, et al. Fully endoscopic major pulmonary resection for stage I bronchial carcinoma: initial results. *Rev. Mal. Respir.* 2011;28(9):e123-130, [PMID: 22123151]
Exclusion code: 10

Goulart BHL, Bensink ME, Mummy DG, Ramsey SD. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. *Journal of the National Comprehensive Cancer Network.* 2012;10(2):267-275, [PMID: 22308519]
Exclusion code: 7

Gould MK. CT screening for lung cancer. *N. Engl. J. Med.* 2007;356(7):743; author

reply 746-747, [PMID: 17301309]
Exclusion code: 5

Gould MK. Evaluation of screening-detected lung nodules: minimising the risk of unnecessary biopsy and surgery. *Thorax.* 2011;66(4):277-279, [PMID: 21357585]
Exclusion code: 2

Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.[Erratum appears in J Clin Oncol. 2008 Mar 10;26(8):1394]. *J. Clin. Oncol.* 2008;26(2):313-325, [PMID: 18086794]
Exclusion code: 5

Granat P. Lung cancer screening. *JAMA.* 2001;285(2):163; author reply 163-164, [PMID: 11176796]
Exclusion code: 5

Granell E, Hidalgo A, Martínez A, et al. Evaluation of the quick diagnosis and treatment program for lung cancer. *Evaluación del programa de diagnóstico y tratamiento rápido del cáncer de pulmón.* 2009;51(3):294-299, [PMID: 19286231]
Exclusion code: 4

Grannis FW. Overestimation of lung cancer mortality in a computed tomography-screened population. *J. Clin. Oncol.* 2005;23(10):2439-2440; author reply 2440-2431, [PMID: 15800348]
Exclusion code: 5

Grannis FW, Jr. There are major problems with the American College of Chest Physicians Second Lung Cancer Guidelines. *Chest.* 2008;133(4):1049; author reply 1050-1041, [PMID: 18398132]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 5

Gray SW, Landrum MB, Lamont EB, McNeil BJ, Jaklitsch MT, Keating NL. Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer. *Cancer*. 2012;118(5):1404-1411, [PMID: 21800285]

Exclusion code: 3

Green PM, Davis MA. Lung cancer in African-Americans. *J. Natl. Black Nurses Assoc.* 2004;15(2):54-60, [PMID: 15853287]

Exclusion code: 5

Greenberg AK, Rimal B, Felner K, et al. S-adenosylmethionine as a biomarker for the early detection of lung cancer. *Chest*. 2007;132(4):1247-1252, [PMID: 17934114]

Exclusion code: 5

Greenwald HP, Polissar NL, Borgatta EF, McCorkle R, Goodman G. Social factors, treatment, and survival in early-stage non-small cell lung cancer. *Am. J. Public Health*. 1998;88(11):1681-1684, [PMID: 9807536]

Exclusion code: 5

Gren L, Broski K, Childs J, et al. Recruitment methods employed in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Clinical Trials*. 2009;6(1):52-59, [PMID: 19254935]

Exclusion code: 2

Gridelli C, Rossi A, Maione P. 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy. *Eur. J. Cancer*. 2011;47 Suppl 3:S248-257, [PMID: 21943982]

Exclusion code: 2

Grogan EL, Stukenborg GJ, Nagji AS, et al. Radiotracer-Guided Thoracoscopic Resection is a Cost-Effective Technique for the Evaluation of Subcentimeter Pulmonary Nodules. *Ann. Thorac. Surg.* 2008;86(3):934-940, [PMID: 18721586]

Exclusion code: 4

Groth SS, Rueth NM, Hodges JS, et al. Conditional cancer-specific versus cardiovascular-specific survival after lobectomy for stage I non-small cell lung cancer. *Ann. Thorac. Surg.* 2010;90(2):375-382, [PMID: 20667314]

Exclusion code: 7

Guessous I, Cornuz J, Paccaud F. Lung cancer screening: current situation and perspective. *Swiss Med Wkly*. 2007;137(21-22):304-311, [PMID: 17629808]

Exclusion code: 5

Guntheroth WG. The cost benefits of early detection. *Science*. 2008;321(5889):639, [PMID: 18669840]

Exclusion code: 5

Gupta KB, Tandon S, Tandon M. Screening of early detection of lung cancer. *Indian J. Chest Dis. Allied Sci.* 2002;44(3):177-181, [PMID: 12206477]

Exclusion code: 5

Gur D. Lung cancer screening: radiology's opportunity here and now. *Radiology*. 2006;238(2):395-397, [PMID: 16436806]

Exclusion code: 5

Gutz S. [Chemotherapy in cancer of the lung]. *MMW Fortschr Med*. 2006;148(22):33-34, [PMID: 16821578]

Exclusion code: 6

Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of

Appendix A6. List of Excluded Full-Text Papers

findings tables. *J. Clin. Epidemiol.* 2011;64(4):383-394, [PMID: 21195583]
Exclusion code: 2

Haas JS, Earle CC, Orav JE, Brawarsky P, Neville BA, Williams DR. Racial segregation and disparities in cancer stage for seniors. *J. Gen. Intern. Med.* 2008;23(5):699-705, [PMID: 18338215]
Exclusion code: 5

Hakama M. Screening for lung cancer. *J. Clin. Oncol.* 2002;20(18):3931; author reply 3931-3934, [PMID: 12228216]
Exclusion code: 5

Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC. Evaluation of screening programmes for gynaecological cancer. *Br. J. Cancer.* 1985;52(4):669-673, [PMID: 4063143]
Exclusion code: 8

Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. *Br. J. Radiol.* 2008;81(965):362-378, [PMID: 18440940]
Exclusion code: 5

Hall WB, Truitt SG, Scheunemann LP, et al. The prevalence of clinically relevant incidental findings on chest computed tomographic angiograms ordered to diagnose pulmonary embolism. *Arch. Intern. Med.* 2009;169(21):1961-1965, [PMID: 19933956]
Exclusion code: 3

Haller MA, Moreau L. [Screening, prevention, and tobacco]. *Rev. Pneumol. Clin.* 2000;Suppl 3:4-6, [PMID: 11280979]
Exclusion code: 6

Halmos B, Powell CA. Update in lung cancer and oncological disorders 2010. *Am. J. Respir. Crit. Care Med.* 2011;184(3):297-302, [PMID: 21804121]

Exclusion code: 5

Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. *J. Natl. Cancer Inst.* 1993;85(6):457-464, [PMID: 8445673]
Exclusion code: 2

Hamatake D, Miyahara S, Yoshida Y, et al. [Surgical management for lung cancer in less than 1 cm]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2012;65(1):25-28, [PMID: 22314153]
Exclusion code: 6

Hammerschmidt S. [Early diagnosis of lung cancer: where do we stand?]. *MMW Fortschr Med.* 2006;148(22):28, 30-21, [PMID: 16821577]
Exclusion code: 6

Hampton T. New screening techniques show potential for early detection of lung cancer. *JAMA.* 2007;298(17):1997, [PMID: 17986689]
Exclusion code: 5

Han K-Q, Huang G, Gao C-F, et al. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. *Am. J. Clin. Oncol.* 2008;31(2):133-139, [PMID: 18391596]
Exclusion code: 4

Hanagiri T, Sugio K, Mizukami M, et al. Postoperative prognosis in patients with non-small cell lung cancer according to the method of initial detection. *J Thorac Oncol.* 2007;2(10):907-911, [PMID: 17909352]
Exclusion code: 2

Hanaoka T, Sone S, Takayama F, Hayano T, Yamaguchi S, Okada M. Presence of

Appendix A6. List of Excluded Full-Text Papers

local pleural adhesion in CT screening-detected small nodule in the lung periphery suggests noncancerous, inflammatory nature of the lesion. *Clin. Imaging*. 2007;31(6):385-389, [PMID: 17996600]
Exclusion code: 3

Hanibuchi M, Yano S, Nishioka Y, et al. Autofluorescence bronchoscopy, a novel modality for the early detection of bronchial premalignant and malignant lesions. *J. Med. Invest.* 2007;54(3-4):261-266, [PMID: 17878675]
Exclusion code: 4

Hara Y, Matsuura Y, Takiguchi H, et al. [Reversal of pulmonary hypertrophic osteoarthropathy in surgically treated lung cancer]. *Nihon Kokyuki Gakkai Zasshi*. 2010;48(12):966-971, [PMID: 21226306]
Exclusion code: 6

Harpole D.H, Jr., DeCamp M.M, Jr., Daley J, et al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. *J. Thorac. Cardiovasc. Surg.* 1999;117(5):969-979, [PMID: 10220692]
Exclusion code: 8

Hartman TE, Swensen SJ. Lung cancer screening with low-dose computed tomography. *Semin. Roentgenol.* 2003;38(1):34-38, [PMID: 12698589]
Exclusion code: 5

Hartman TE, Swensen SJ. CT screening for lung cancer. *Semin. Roentgenol.* 2005;40(2):193-196, [PMID: 15898415]
Exclusion code: 5

Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. *Br. J. Radiol.* 2000;73(876):1252-1259, [PMID: 11205667]

Exclusion code: 4

Hashimoto M, Miyauchi T, Heianna J, et al. Accurate diagnosis of peripheral small cell lung cancer with computed tomography. *Tohoku J. Exp. Med.* 2009;217(3):217-221, [PMID: 19282657]
Exclusion code: 7

Haskell CM, Holmes EC. Non-small cell lung cancer. *Dis. Mon.* 1988;34(2):53-108, [PMID: 2834155]
Exclusion code: 5

Hatayama O, Kobayashi T, Fujimoto K, Kubo K. Utility of single-slice high-resolution CT in upper lung field combined with low-dose spiral CT for lung-cancer screening in the detection of emphysema. *Intern. Med.* 2007;46(18):1519-1525, [PMID: 17878637]
Exclusion code: 4

Haussinger K, Becker H, Stanzel F, et al. Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial. *Thorax*. 2005;60(6):496-503, [PMID: 15923251]
Exclusion code: 7

Hayashi H, Ashizawa K, Uetani M, et al. Detectability of peripheral lung cancer on chest radiographs: effect of the size, location and extent of ground-glass opacity. *Br. J. Radiol.* 2009;82(976):272-278, [PMID: 19029222]
Exclusion code: 4

Hayashi Y, Tomiyama I, Ishii H, et al. [Prognostic assessment of the new UICC TNM classification for resected lung cancer]. *Kyobu Geka - Japanese Journal of*

Appendix A6. List of Excluded Full-Text Papers

Thoracic Surgery. 2000;53(11):919-925, [PMID: 11048442]
Exclusion code: 6

Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. *Control. Clin. Trials*. 2000;21(6 Suppl):349S-355S, [PMID: 11189687]
Exclusion code: 2

Hazelrigg SR, Boley TM, Weber D, Magee MJ, Naunheim KS. Incidence of lung nodules found in patients undergoing lung volume reduction. *Ann. Thorac. Cardiovasc. Surg*. 1997;64(2):303-306, [PMID: 9262565]
Exclusion code: 4

He J, Shao W, Cao C, et al. Long-term outcome and cost-effectiveness of complete versus assisted video-assisted thoracic surgery for non-small cell lung cancer. *J. Surg. Oncol*. 2011;104(2):162-168, [PMID: 21387321]
Exclusion code: 7

He T, Xue Z, Wong KK, et al. A minimally invasive multimodality image-guided (MIMIG) molecular imaging system for peripheral lung cancer intervention and diagnosis. Vol 6135 LNCS2010:102-112
Exclusion code: 4

Heelan RT, Flehinger BJ, Melamed MR, Zaman MB, Perchick WB, Caravelli JF. Non-small-cell lung cancer: results of the New York screening program. *Radiology*. 1984;151(2):289-293, [PMID: 6324279]
Exclusion code: 5

Heigener DF, Reck M, Gatzemeier U. [Non-small cell lung cancer - diagnostics and stage-adapted therapy]. *Med. Klin*.

2007;102(12):981-988; quiz 989-990, [PMID: 18075718]
Exclusion code: 6

Henderson S, DeGross A, Richards TB, et al. A qualitative analysis of lung cancer screening practices by primary care physicians. *J. Community Health*. 2011;36(6):949-956, [PMID: 21442338]
Exclusion code: 5

Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. *PLoS ONE*. 2012;7(2), [PMID: 22389695]
Exclusion code: 2

Henschke. Computed tomographic screening for lung cancer: individualising the benefit of the screening. *Eur. Respir. J*. 2007;30(5):843-847, [PMID: 17652316]
Exclusion code: 2

Henschke C. International Early Lung Cancer Action Program: Enrollment and Screening Protocol. 2011; <http://www.ielcap.org/professionals/docs/ielcap.pdf>. Accessed 18 Oct 2011
Exclusion code: 2.

Henschke C, McCauley D, Yankelevitz D, Naidich DP, McGuinness G, Miettinen OS. Early Lung Cancer Action Project: overall design and findings from baseline screening. *Lancet*. 1999;354(9173):99-105, [PMID: 10408484]
Exclusion code: 8

Henschke C, Smith JP, Miettinen OS. CT screening for lung cancer-author's response. *N. Engl. J. Med*. 2007;356(7):746-747
Exclusion code: 2

Henschke C, Wisnivesky JP, Yankelevitz D, Miettinen OS. Screen-diagnosed small stage I cancers of the lung: genuineness and

Appendix A6. List of Excluded Full-Text Papers

curability. *Lung Cancer*. 2003;39(3):327-330, [PMID: 12609571]

Exclusion code: 3

Henschke CI. Early lung cancer action project: overall design and findings from baseline screening. *Cancer*. 2000;89(11 Suppl):2474-2482, [PMID: 11147630]

Exclusion code: 5

Henschke CI. Medicine on lung cancer screening: a different paradigm.[Erratum appears in Am J Respir Crit Care Med. 2008 Sep 1;178(5):542]. *Am. J. Respir. Crit. Care Med*. 2003;168(10):1143-1144, [PMID: 14607819]

Exclusion code: 5

Henschke CI. Computed tomography screening for lung cancer: principles and results. *Clin. Cancer Res*. 2005;11(13 Pt 2):4984s-4987s, [PMID: 16000600]

Exclusion code: 5

Henschke CI. Clarifying enrollment procedures in the trial of CT screening for lung cancer. *N. Engl. J. Med*. 2008;359(8):871-873, [PMID: 18669421]

Exclusion code: 5

Henschke CI. Reply to the letters to the editor from Bach and Silvestri. *Clin. Cancer Res*. 2008;14(8):2511

Exclusion code: 5

Henschke CI. Correspondence. *J. Natl. Cancer Inst*. 2012;104(3):254-255

Exclusion code: 5

Henschke CI, Austin JHM, Berlin N, et al. Minority opinion: CT screening for lung cancer. *J. Thorac. Imaging*. 2005;20(4):324-325, [PMID: 16282919]

Exclusion code: 2

Henschke CI, Investigators for the International Early Lung Cancer Action Program. Survival of patients with clinical stage I lung cancer diagnosed by computed tomography screening for lung cancer.

Clin. Cancer Res. 2006;13(17):4949-4950, [PMID: 17785541]

Exclusion code: 2

Henschke CI, Investigators IE. CT screening for lung cancer: update 2005. *Surg. Oncol. Clin. N. Am*. 2005;14(4):761-776, [PMID: 16226690]

Exclusion code: 5

Henschke CI, Lee I-J, Wu N, et al. CT screening for lung cancer: prevalence and incidence of mediastinal masses. *Radiology*. 2006;239(2):586-590, [PMID: 16641357]

Exclusion code: 4

Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: a summary of the findings on baseline screening. *Oncologist*. 2001;6(2):147-152, [PMID: 11306726]

Exclusion code: 5

Henschke CI, Miettinen OS. Women's susceptibility to tobacco carcinogens. *Lung Cancer*. 2004;43(1):1-5, [PMID: 14698531]

Exclusion code: 2

Henschke CI, Miettinen OS, Yankelevitz DF, Libby DM, Smith JP. Radiographic screening for cancer: Proposed paradigm for requisite search. *Clin. Imaging*. 1994;18(1):16-20, [PMID: 8180854]

Exclusion code: 5

Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screening. *Cancer*. 2001;92(1):153-159, [PMID: 11443621]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 2

Henschke CI, Shaham D, Farooqi A, Yankelevitz DF. Computerized tomography screening for lung cancer: new findings and diagnostic work-up. *Semin. Thorac. Cardiovasc. Surg.* 2003;15(4):397-404, [PMID: 14710382]

Exclusion code: 5

Henschke CI, Shaham D, Yankelevitz DF, Altorki NK. CT screening for lung cancer: past and ongoing studies. *Semin. Thorac. Cardiovasc. Surg.* 2005;17(2):99-106, [PMID: 16087075]

Exclusion code: 5

Henschke CI, Shaham D, Yankelevitz DF, et al. CT screening for lung cancer: significance of diagnoses in its baseline cycle. *Clin. Imaging.* 2006;30(1):11-15, [PMID: 16377478]

Exclusion code: 2

Henschke CI, Yankelevitz D, Smith JP, Miettinen OS. Computed tomography screening for lung cancer.[Erratum appears in JAMA.2008 Apr 16;299(15):1775]. *JAMA.* 2007;298(5):514-515; author reply 515-516, [PMID: 17666669]

Exclusion code: 5

Henschke CI, Yankelevitz DF. CT screening for lung cancer. *Radiol. Clin. North Am.* 2000;38(3):487-495, viii, [PMID: 10855256]

Exclusion code: 2

Henschke CI, Yankelevitz DF. Screening for lung cancer. *J. Thorac. Imaging.* 2000;15(1):21-27, [PMID: 10634658]

Exclusion code: 2

Henschke CI, Yankelevitz DF. CT screening for lung cancer: update 2007. *Oncologist.* 2008;13(1):65-78, [PMID:

18245013]

Exclusion code: 5

Henschke CI, Yankelevitz DF. In reply. *Oncologist.* 2008;13(5):610-612

Exclusion code: 5

Henschke CI, Yankelevitz DF. Unreported financial disclosures. *JAMA - Journal of the American Medical Association.*

2008;299(15):1770, [PMID: 18362124]

Exclusion code: 5

Henschke CI, Yankelevitz DF, Altorki NK. The role of CT screening for lung cancer. *Thorac Surg Clin.* 2007;17(2):137-142, [PMID: 17626392]

Exclusion code: 5

Henschke CI, Yankelevitz DF, Kostis WJ. CT screening for lung cancer. *Semin. Ultrasound. CT MR.* 2003;24(1):23-32, [PMID: 12708641]

Exclusion code: 5

Henschke CI, Yankelevitz DF, Libby D, Kimmel M. CT screening for lung cancer: the first ten years. *Cancer J.* 2002;8 Suppl 1:S47-54, [PMID: 12075702]

Exclusion code: 5

Henschke CI, Yankelevitz DF, Libby D, McCauley D, Pasmantier M, Smith JP. Computed tomography screening for lung cancer. *Clin. Chest Med.* 2002;23(1):49-57, viii, [PMID: 11901919]

Exclusion code: 5

Henschke CI, Yankelevitz DF, Libby DM, et al. Early lung cancer action project: annual screening using single-slice helical CT. *Ann. N. Y. Acad. Sci.* 2001;952:124-134, [PMID: 11795431]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Henschke CI, Yankelevitz DF, McCauley D, Libby D, Pasmantier M, Smith JP. CT screening for lung cancer. *Cancer Chemotherapy & Biological Response Modifiers*. 2002;20:665-676, [PMID: 12703229]

Exclusion code: 2

Henschke CI, Yankelevitz DF, McCauley DI, Libby DM, Pasmantier MW, Smith JP. Guidelines for the use of spiral computed tomography in screening for lung cancer. *European Respiratory Journal - Supplement*. 2003;39:45s-51s, [PMID: 12572701]

Exclusion code: 5

Henschke CI, Yankelevitz DF, Miettinen OS, International Early Lung Cancer Action Program I. Computed tomographic screening for lung cancer: the relationship of disease stage to tumor size. *Arch. Intern. Med.* 2006;166(3):321-325, [PMID: 16476872]

Exclusion code: 8

Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. *AJR. Am. J. Roentgenol.* 2002;178(5):1053-1057, [PMID: 11959700]

Exclusion code: 7

Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. *Radiology*. 2004;231(1):164-168, [PMID: 14990809]

Exclusion code: 4

Henschke CI, Yankelevitz DF, Smith JP, Miettinen OS. The use of spiral CT in lung cancer screening. In: DeVita VT, Hellman S, Rosenberg SA, eds. *Progress in*

Oncology 2002. Sudbury: Jones and Barlett; 2002:202-213

Exclusion code: 2

Henschke CI, Yankelevitz DF, Smith JP, Miettinen OS, Group E. Screening for lung cancer: the early lung cancer action approach. *Lung Cancer*. 2002;35(2):143-148, [PMID: 11804686]

Exclusion code: 2

Henschke CI, Yankelevitz DF, Yip R, et al. Lung cancers diagnosed at annual CT screening: volume doubling times. *Radiology*. 2012;263(2):578-583, [PMID: 22454506]

Exclusion code: 2

Henschke CI, Yip R, Yankelevitz DF. CT screening for lung cancer: Update 2008. *Japanese Journal of Lung Cancer*. 2009;49(4):477-490

Exclusion code: 2

Henschke CI, Yip R, Yankelevitz DF, Miettinen OS. Computed tomography screening for lung cancer: prospects of surviving competing causes of death. *Clin Lung Cancer*. 2006;7(5):323-325, [PMID: 16640803]

Exclusion code: 7

Herth F, Becker HD. New aspects in early detection and local staging of early lung cancer. *Lung Cancer*. 2001;34 Suppl 3:S7-11, [PMID: 11740987]

Exclusion code: 5

Herth FJ, Eberhardt R. [Screening for bronchial carcinoma -- contra]. *Dtsch. Med. Wochenschr.* 2005;130(9):467, [PMID: 15731961]

Exclusion code: 6

Herth FJF, Eberhardt R, Anantham D, Gompelmann D, Zakaria MW, Ernst A.

Appendix A6. List of Excluded Full-Text Papers

Narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection. *J Thorac Oncol.* 2009;4(9):1060-1065, [PMID: 19704335]

Exclusion code: 2

Heuberger J, Schneider K, Bodis S. [Role of radiotherapy in non-small cell lung cancer]. *Praxis.* 2002;91(33):1307-1314, [PMID: 12224413]

Exclusion code: 6

Heuvers ME, Stricker BH, Aerts JG. Generalizing lung-cancer screening results. *N. Engl. J. Med.* 2012;366(2):192-193, [PMID: 22236243]

Exclusion code: 5

Heyneman LE, Herndon JE, Goodman PC, Patz EF, Jr. Stage distribution in patients with a small (\leq 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. *Cancer.* 2001;92(12):3051-3055, [PMID: 11753983]

Exclusion code: 4

Higgins J, Thompson S, Higgins J. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* 2002;21(11):1539-1558, [PMID: 12111919]

Exclusion code: 2

Hilbe W, Dirnhofer S, Greil R, Woll E. Biomarkers in non-small cell lung cancer prevention. *Eur. J. Cancer Prev.* 2004;13(5):425-436, [PMID: 15452456]

Exclusion code: 5

Hillerdal G. Indolent lung cancers--time for a paradigm shift: a review. *J Thorac Oncol.* 2008;3(3):208-211, [PMID: 18317061]

Exclusion code: 5

Hillerdal G, Henschke C, Sone S. [Screening for lung cancer--new possibilities with new methods!]. *Lakartidningen.* 2001;98(17):2047-2051, [PMID: 11374234]

Exclusion code: 6

Hillerdal G, Koyi H, Branden E. [Smoking cessation or lung cancer screening--an artificial antagonism]. *Lakartidningen.* 2001;98(32-33):3453, [PMID: 11526671]

Exclusion code: 6

Hillman BJ. Author's Reply. *JACR Journal of the American College of Radiology.* 2007;4(6):430

Exclusion code: 5

Hillman BJ, Acrin. Economic, legal, and ethical rationales for the ACRIN national lung screening trial of CT screening for lung cancer. *Acad. Radiol.* 2003;10(3):349-350, [PMID: 12643562]

Exclusion code: 2

Hinshaw LB, Jackson SA, Chen MY. Direct mailing was a successful recruitment strategy for a lung-cancer screening trial. *J. Clin. Epidemiol.* 2007;60(8):853-857, [PMID: 17606183]

Exclusion code: 5

Hirokawa R, Fujino S, Inoue S, et al. [Squamous cell type lung cancer that produced granulocyte colony-stimulating factor]. *Nihon Kokyuki Gakkai Zasshi.* 2000;38(5):398-402, [PMID: 10921288]

Exclusion code: 6

Hirsch FR, Franklin WA, Gazdar AF, Bunn PA, Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. *Clin. Cancer Res.* 2001;7(1):5-22, [PMID: 11205917]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Hirsch FR, Merrick DT, Franklin WA. Role of biomarkers for early detection of lung cancer and chemoprevention. *Eur. Respir. J.* 2002;19(6):1151-1158, [PMID: 12108871]
Exclusion code: 2

Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. *J. Natl. Cancer Inst.* 2001;93(18):1385-1391, [PMID: 11562389]
Exclusion code: 4

Hirschowitz EA. Biomarkers for lung cancer screening: interpretation and implications of an early negative advanced validation study. *Am. J. Respir. Crit. Care Med.* 2009;179(1):1-2, [PMID: 19098155]
Exclusion code: 5

Hjelde H, Sundstrom S, Odegard A, Hatlinghus S, Abusland AB, Haaverstad R. [Recurrence and survival after surgical treatment of lung cancer]. *Tidsskr. Nor. Laegeforen.* 2010;130(1):25-28, [PMID: 20094119]
Exclusion code: 6

Hoagland I, L. F. M., Campa MJ, Gottlin EB, Herndon Jr JE, Patz Jr EF. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. *Cancer.* 2007;110(10):2260-2268, [PMID: 17918261]
Exclusion code: 4

Hof H, Herfarth K, Debus J. [Stereotactic irradiation of lung tumors]. *Radiologe.* 2004;44(5):484-490, [PMID: 15107979]
Exclusion code: 6

Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable

effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983-1996. *Eur. J. Cancer Prev.* 2001;10(2):131-137, [PMID: 11330453]
Exclusion code: 4

Hole D, Watt G, Davey-Smith G, Hart C, Gillis C, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *BMJ.* 1996;313(7059):711-715, [PMID: 8819439]
Exclusion code: 7

Holemans JA. Comments on Diederich et al.: low dose CT: new tool for screening lung cancer. *Eur. Radiol.* 2002;12(8):2123; author reply 2124, [PMID: 12211180]
Exclusion code: 5

Hollaus PH, Wurnig PN, Pridun NS. [Bronchoplastic procedures for the resection of malignant bronchial neoplasms]. *Chirurg.* 2002;73(11):1115-1122, [PMID: 12430063]
Exclusion code: 6

Hollingsworth AB, Stough RG. Breast MRI Screening for High-Risk Patients. *Seminars in Breast Disease.* 2008;11(2):67-75
Exclusion code: 3

Hooi LN, Hamzah KM, Jahizah H. Survival of patients surgically treated for lung cancer. *Med. J. Malaysia.* 2003;58(4):490-498, [PMID: 15190623]
Exclusion code: 10

Horinouchi H, Kobayashi K. [Surgical indications for lung cancer: influence of the M factor]. *Nippon Geka Gakkai Zasshi.* 2001;102(7):517-520, [PMID: 11505503]
Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Horinouchi H, Yamamoto M, Goto T, et al. [Clinical analysis of surgically resected multiple primary lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2002;55(1):45-50, [PMID: 11797409]
Exclusion code: 6

Hoshi K, Kanbara T, Kawasaki Y, Ikeda Y, Namima T, Ohnuma T. [Pulmonary and lymph node metastases of renal cell carcinoma which completely responded to oral administration of UFT--a case report]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2007;34(8):1315-1317, [PMID: 17687222]
Exclusion code: 6

Hosokawa Y, Matsuge S, Murakami Y, et al. [Validity and controversies in the new postoperative pathologic TNM classification based on the results of surgical treatment of non-small cell lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2000;53(11):910-914, [PMID: 11048440]
Exclusion code: 6

Hourani MH, Nassar L, Haydar M, Hourany-Rizk RG. Imaging in oncology. *Journal Medical Libanais*. 2009;57(3):156-166, [PMID: 19938400]
Exclusion code: 5

Howlader N, Noone A, Krapcho M, et al. *SEER Cancer Statistics Review 1975 - 2008*. Bethesda, MD 2011
Exclusion code: 2

Howlader N, Noone AM, Krapcho M, et al. *SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)*. 2011. http://seer.cancer.gov/csr/1975_2009_pops09/.
Exclusion code: 2

Hsu Y-B, Chu P-Y, Liu J-C, et al. Role of chest computed tomography in head and neck cancer. *Arch. Otolaryngol. Head Neck Surg*. 2008;134(10):1050-1054, [PMID: 18936349]
Exclusion code: 4

Huang H, Shen L, Ford J, Gao L, Pearlman J. Early lung cancer detection based on registered perfusion MRI. *Oncol. Rep*. 2006;15 Spec no.:1081-1084, [PMID: 16525705]
Exclusion code: 7

Huang J-s, Dong Q-g, Bao G-l, Han B-h. [Implication of micrometastatic cancer cells in the peripheral blood on prognosis of non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2004;26(5):294-296, [PMID: 15312367]
Exclusion code: 6

Huang Y, Shaham D, Austin JHM, Yankelevitz DF, Henschke CI, Investigators IE. Pulmonary lymphoma identified as a result of low-dose CT screening for lung cancer. *Clin. Imaging*. 2008;32(4):264-268, [PMID: 18603180]
Exclusion code: 2

Hubbard RB, Baldwin DR. Diagnosing lung cancer earlier in the UK. *Thorax*. 2010;65(9):756-758, [PMID: 20805161]
Exclusion code: 5

Huber RM, Stratakis DF. Molecular oncology--perspectives in lung cancer. *Lung Cancer*. 2004;45 Suppl 2:S209-213, [PMID: 15552801]
Exclusion code: 5

Humphrey L, Helfand M, Chan BK, SH. W. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann. Intern. Med*.

Appendix A6. List of Excluded Full-Text Papers

2002;137(5 Part 1):347-360., [PMID: 2204020]

Exclusion code: 2

Humphrey LL, Teutsch S, Johnson M, Force USPST. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. *Ann. Intern. Med.*

2004;140(9):740-753, [PMID: 15126259]

Exclusion code: 2

Hung JJ, Jeng WJ, Hsu WH, Huang BS, Wu YC. Time trends of overall survival and survival after recurrence in completely resected stage I non-small cell lung cancer. *Journal of Thoracic Oncology.*

2012;7(2):397-405, [PMID: 22173701]

Exclusion code: 7

Hung J-J, Wang C-Y, Huang M-H, Huang B-S, Hsu W-H, Wu Y-C. Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival. *J. Thorac. Cardiovasc. Surg.* 2007;134(3):638-643, [PMID: 17723811]

Exclusion code: 3

Hunink MGM, Gazelle GS. CT screening: a trade-off of risks, benefits, and costs. *J. Clin. Invest.* 2003;111(11):1612-1619, [PMID: 12782661]

Exclusion code: 5

Hunt I, Siva M, Southon R, Treasure T. Does lung cancer screening with low-dose computerised tomography (LDCT) improve disease-free survival? *Interact Cardiovasc Thorac Surg.* 2006;5:612-615, [PMID: 17670661]

Exclusion code: 2

Huppmann MV, Johnson WB, Javitt MC. Radiation risks from exposure to chest computed tomography. *Semin. Ultrasound. CT MR.* 2010;31(1):14-28, [PMID: 20102692]

Exclusion code: 2

Hutchinson E. Caution over use of lung-cancer screening as standard practice. *Lancet.* 2000;356(9231):742, [PMID: 11085700]

Exclusion code: 5

Huuskonen MS, Lehtola H, Kivisaari L. Early diagnosis of asbestos-related diseases by CT scanning. *International Congress Series.* 1997;1153:913-915, [PMID: 9251153]

Exclusion code: 7

Hwang J, Chung MJ, Bae Y, Shin KM, Jeong SY, Lee KS. Computer-aided detection of lung nodules: influence of the image reconstruction kernel for computer-aided detection performance. *J. Comput. Assist. Tomogr.* 2010;34(1):31-34, [PMID: 20118719]

Exclusion code: 7

Hwang S-J, Cheng LS-C, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. *Hum. Genet.* 2003;113(3):238-243, [PMID: 12802680]

Exclusion code: 2

Iaitskii NA, Gerasin VA, Orlov SV, et al. [Photodynamic therapy in treatment of lung cancer]. *Vestnik Khirurgii Imeni i - i - Grekova.* 2010;169(5):31-34, [PMID: 21137256]

Exclusion code: 6

Iakovou I, Karavida N, Kotzassarlidou M. The computerized tomography scans and

Appendix A6. List of Excluded Full-Text Papers

their dosimetric safety. *Hellenic J Nucl Med.* 2008;11(2):82-85, [PMID: 18815660]
Exclusion code: 5

Ichinose J, Kohno T, Fujimori S. [Video-assisted thoracic surgery for metachronous lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2010;63(11):969-972, [PMID: 20954352]
Exclusion code: 6

Ichinose J, Kohno T, Fujimori S, Mun M. Locoregional control of thoracoscopic lobectomy with selective lymphadenectomy for lung cancer. *Ann. Thorac. Surg.* 2010;90(1):235-239, [PMID: 20609783]
Exclusion code: 4

Ichinose Y. [Postoperative adjuvant treatment for non-small cell lung cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy].* 2002;29(13):2470-2474, [PMID: 12506468]
Exclusion code: 6

Ikeda N, Honda H, Hayashi A, et al. Early detection of bronchial lesions using newly developed videoendoscopy-based autofluorescence bronchoscopy. *Lung Cancer.* 2006;52(1):21-27, [PMID: 16497411]
Exclusion code: 2

Ilonen IK, Rasanen JV, Knuuttila A, Salo JA, Sihvo EI. Anatomic thoracoscopic lung resection for non-small cell lung cancer in stage I is associated with less morbidity and shorter hospitalization than thoracotomy. *Acta Oncol.* 2011;50(7):1126-1132, [PMID: 21314296]
Exclusion code: 10

Imdahl A, Jenkner S, Brink I, et al. Validation of FDG positron emission

tomography for differentiation of unknown pulmonary lesions. *Eur. J. Cardiothorac. Surg.* 2001;20(2):324-329, [PMID: 11463551]
Exclusion code: 4

Infante M, Chiesa G, Solomon D, et al. Surgical procedures in the DANTE trial, a randomized study of lung cancer early detection with spiral computed tomography: comparative analysis in the screening and control arm. *J Thorac Oncol.* 2011;6(2):327-335, [PMID: 21178639]
Exclusion code: 10

Infante MV, Fabio LR, Cavuto S, et al. Dante a randomized study on lung cancer screening with low dose spiral CT (LDCT) end of accrual and preliminary results [Abstract]. *Chest.* 2006;130(4 Suppl):114s, [PMID: 12409588]
Exclusion code: 5

International Early Lung Cancer Program Investigators. An update of CT screening for lung cancer. *Semin. Ultrasound. CT MR.* 2005;26(5):348-356, [PMID: 16274003]
Exclusion code: 5

Isgum I, Rutten A, Prokop M, et al. Automated aortic calcium scoring on low-dose chest computed tomography. *Med. Phys.* 2010;37(2):714-723, [PMID: 20229881]
Exclusion code: 2

Ishikawa H, Satoh H, Yamashita YT, Ohtsuka M, Sekizawa K. CEA and survival in patients with stage IA-B NSCLC. *Thorac. Cardiovasc. Surg.* 2002;50(4):253, [PMID: 12165878]
Exclusion code: 5

Ishiyama T, Aoyama T, Hirahara H, Iwashima A, Tsukada H, Souma T.

Appendix A6. List of Excluded Full-Text Papers

[Successful resection of endotracheal metastatic lung cancer using percutaneous cardiopulmonary support system: a case report]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2001;54(1):19-23, [PMID: 11197904]
Exclusion code: 6

Itani Y, Sone S, Nakayama T, et al. Coronary artery calcification detected by a mobile helical computed tomography unit and future cardiovascular death: 4-year follow-up of 6120 asymptomatic Japanese. *Heart Vessels*. 2004;19(4):161-163, [PMID: 15278387]
Exclusion code: 7

Ito Y, Ohno Y, Rachet B, Coleman MP, Tsukuma H, Oshima A. Cancer survival trends in Osaka, Japan: the influence of age and stage at diagnosis. *Jpn. J. Clin. Oncol*. 2007;37(6):452-458, [PMID: 17635966]
Exclusion code: 7

Itoh S, Ikeda M, Isomura T, et al. Screening helical CT for mass screening of lung cancer: Application of low-dose and single-breath-hold scanning. *Radiation Medicine - Medical Imaging and Radiation Oncology*. 1998;16(2):75-83, [PMID: 9650893]
Exclusion code: 10

Itoh S, Koyama S, Ikeda M, et al. Further reduction of radiation dose in helical CT for lung cancer screening using small tube current and a newly designed filter. *J. Thorac. Imaging*. 2001;16(2):81-88, [PMID: 11292209]
Exclusion code: 2

Iwano S, Makino N, Ikeda M, et al. Videotaped helical CT images for lung cancer screening. *J. Comput. Assist. Tomogr*. 2000;24(2):242-246, [PMID: 10752885]
Exclusion code: 2

Iwazaki M, Inoue K. [Multidisciplinary treatment of lung cancer: 2008]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2008;61(1):47-49, [PMID: 18186273]
Exclusion code: 6

Iyen-Omofoman B, Hubbard RB, Smith CJP, et al. The distribution of lung cancer across sectors of society in the United Kingdom: a study using national primary care data. *BMC Public Health*. 2011;11:857, [PMID: 22074413]
Exclusion code: 7

Jackevicius A, Cicenass S, Naujokaitis P, Piscikas D. [The experience of surgical treatment of lung cancer during fifty years]. *Medicina (Kaunas)*. 2004;40 Suppl 1:124-126, [PMID: 15079119]
Exclusion code: 6

Jackevicius A, Cicenass S, Piscikas DA. [The treatment of lung cancer relapse after the lung resection]. *Medicina (Kaunas)*. 2004;40 Suppl 1:139-141, [PMID: 15079123]
Exclusion code: 6

Jackson BR. The Dangers of False-Positive and False-Negative Test Results: False-Positive Results as a Function of Pretest Probability. *Clin. Lab. Med*. 2008;28(2):305-319, [PMID: 18436073]
Exclusion code: 5

Jacobs PC, Gondrie MJA, van der Graaf Y, et al. Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer. *AJR American Journal of Roentgenology*. 2012;198(3):505-511, [PMID: 22357989]
Exclusion code: 4

Appendix A6. List of Excluded Full-Text Papers

Jacobs PCA, Isgum I, Gondrie MJA, et al. Coronary artery calcification scoring in low-dose ungated CT screening for lung cancer: interscan agreement. *AJR. Am. J. Roentgenol.* 2010;194(5):1244-1249, [PMID: 20410410]
Exclusion code: 7

Jacobs PCA, Mali WPTM, Grobbee DE, van der Graaf Y. Prevalence of incidental findings in computed tomographic screening of the chest: a systematic review. *J. Comput. Assist. Tomogr.* 2008;32(2):214-221, [PMID: 18379305]
Exclusion code: 2

Jacobson FL. Multidetector-row CT of lung cancer screening. *Semin. Roentgenol.* 2003;38(2):168-175, [PMID: 12854440]
Exclusion code: 5

Jacot W, Lhermitte L, Dossat N, et al. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes. *J Thorac Oncol.* 2008;3(8):840-850, [PMID: 18670301]
Exclusion code: 2

Jain P, Arroliga AC. Spiral CT for lung cancer screening: is it ready for prime time? *Cleve. Clin. J. Med.* 2001;68(1):74-81, [PMID: 11204368]
Exclusion code: 5

Jaklitsch MT, Jacobson FL, Austin JHM, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thor Cardiovas Surg.* 2012;144(1):33-38, [PMID: 22710039]
Exclusion code: 2

Jakupciak JP, Maragh S, Markowitz ME, et al. Performance of mitochondrial DNA

mutations detecting early stage cancer. *BMC Cancer.* 2008;8:285, [PMID: 18834532]
Exclusion code: 7

Jankowski A, Martinelli T, Timsit JF, et al. Pulmonary nodule detection on MDCT images: evaluation of diagnostic performance using thin axial images, maximum intensity projections, and computer-assisted detection. *Eur. Radiol.* 2007;17(12):3148-3156, [PMID: 17763856]
Exclusion code: 2

Jassem J, Skokowski J, Dziadziuszko R, et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. *J. Thorac. Cardiovasc. Surg.* 2000;119(6):1141-1146, [PMID: 10838530]
Exclusion code: 10

Jazieh AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. *Ann. Thorac. Surg.* 2000;70(4):1168-1171, [PMID: 11081863]
Exclusion code: 3
Jazieh AR, Kyasa MJ, Sethuraman G, Howington J. Disparities in surgical resection of early-stage non-small cell lung cancer. *J. Thorac. Cardiovasc. Surg.* 2002;123(6):1173-1176, [PMID: 12063465]
Exclusion code: 5

Jemal A, Thun MJ, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. *J. Natl. Cancer Inst.* 2008;100(23):1672-1694, [PMID: 19033571]
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Jeremic B. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. *J. Thorac. Cardiovasc. Surg.* 2003;125(2):444-445, [PMID: 12579133]
Exclusion code: 5

Jett JR. Limitations of screening for lung cancer with low-dose spiral computed tomography. *Clin. Cancer Res.* 2005;11(13 Pt 2):4988s-4992s, [PMID: 16000601]
Exclusion code: 2

Jett JR, Midthun DE. Screening for lung cancer: current status and future directions: Thomas A. Neff lecture. *Chest.* 2004;125(5 Suppl):158S-162S, [PMID: 15136487]
Exclusion code: 5

Jett JR, Midthun DE. Commentary: CT screening for lung cancer--caveat emptor. *Oncologist.* 2008;13(4):439-444, [PMID: 18448559]
Exclusion code: 2

Jett JR, Miller YE. Update in lung cancer 2005. *Am. J. Respir. Crit. Care Med.* 2006;173(7):695-697, [PMID: 16556699]
Exclusion code: 5

Jiang T, Zheng X, Tao X, Liu H, Liu S. How to choose PET-CT or CT in the diagnosis and staging of lung cancer. Practical experience in China. *Nucl. Med. (Stuttg).* 2010;49(1):28-34, [PMID: 19847358]
Exclusion code: 3

Jiang Z-q, Jiang G-l, Shi D-r, Zhang R-x, Fu X-l, Qian H. [Study of prognostic factors in patients with stage I non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2004;26(6):364-368, [PMID: 15312349]
Exclusion code: 6

Jin S-M, Choi S-H, Yoo C-G, et al. Small solid noncalcified pulmonary nodules detected by screening chest computed tomography. *Respir. Med.* 2007;101(9):1880-1884, [PMID: 17587561]
Exclusion code: 2

Johkoh T, Kozuka T, Tomiyama N, et al. Temporal subtraction for detection of solitary pulmonary nodules on chest radiographs: evaluation of a commercially available computer-aided diagnosis system. *Radiology.* 2002;223(3):806-811, [PMID: 12034953]
Exclusion code: 4

Johnson DA, Helft PR, Rex DK. CT and radiation-related cancer risktime for a paradigm shift? *Nature Reviews Gastroenterology and Hepatology.* 2009;6(12):738-740, [PMID: 19946306]
Exclusion code: 5

Jonsson S, Varella-Garcia M, Miller YE, et al. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. *Am. J. Respir. Crit. Care Med.* 2008;177(3):342-347, [PMID: 17989344]
Exclusion code: 5

Jung KJ, Kyung Soo L, Su Young K, Tae Sung K, Yong Seon P, Ji Yeaon L. Low-dose, volumetric helical CT: Image quality, radiation dose, and usefulness for evaluation of bronchiectasis. *Invest. Radiol.* 2000;35(9):557-563, [PMID: 10982001]
Exclusion code: 7

Kagna O, Solomonov A, Keidar Z, et al. The value of FDG-PET/CT in assessing single pulmonary nodules in patients at high risk of lung cancer. *Eur J Nucl Med Mol Imaging.* 2009;36(6):997-1004, [PMID: 19194704]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 4

Kaji M, Kobayashi R, Hino Y, et al. [Strategy for marginally resectable lung cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2011;38(8):1256-1260, [PMID: 21829062]
Exclusion code: 6

Kaji M, Sakurai H, Masai K, Suemasu K. [Is video-assisted thoracic surgery lobectomy better than minimally invasive open thoracotomy?]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2009;62(4):302-307, [PMID: 19348215]
Exclusion code: 6

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. *J. Clin. Oncol.* 2006;24(14):2137-2150, [PMID: 16682732]
Exclusion code: 2

Kamath AV, Chhajed PN. Role of bronchoscopy in early diagnosis of lung cancer. *Indian J. Chest Dis. Allied Sci.* 2006;48(4):265-269, [PMID: 16970293]
Exclusion code: 5

Kamerow D. Screening for early detection of lung cancer. *BMJ.* 2010;341:c6544, [PMID: 21084372]
Exclusion code: 5

Kamiyoshihara M, Ibe T. [Surgical approach to primary lung cancer using video-assisted thoracic surgery]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2009;62(4):309-315, [PMID: 19348216]
Exclusion code: 6

Kamposioras K, Casazza G, Mauri D, et al. Screening chest radiography: results from a Greek cross-sectional survey. *BMC Public Health.* 2006;6:113, [PMID: 16646992]
Exclusion code: 2

Kanashiki M, Sairenchi T, Saito Y, Ishikawa H, Satoh H, Sekizawa K. Body mass index and lung cancer: a case-control study of subjects participating in a mass-screening program. *Chest.* 2005;128(3):1490-1496, [PMID: 16162748]
Exclusion code: 3 Japan

Kanashiki M, Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K. Time from finding abnormality on mass-screening to final diagnosis of lung cancer. *Oncol. Rep.* 2003;10(3):649-652, [PMID: 12684638]
Exclusion code: 2

Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K. Peripheral lung cancer: screening and detection with low-dose spiral CT versus X-ray. *Radiology.* 1996;201(3):798-802, [PMID: 8939234]
Exclusion code: 5

Kaneko M, Kusumoto M, Kobayashi T, et al. Computed tomography screening for lung carcinoma in Japan. *Cancer.* 2000;89(11 Suppl):2485-2488, [PMID: 11147632]
Exclusion code: 2

Kanemoto K, Satoh H, Ishikawa H, Kagohashi K, Kurishima K, Sekizawa K. Diagnostic procedures for small pulmonary nodules detected by mass-screening. *Anticancer Res.* 2008;28(5B):3153-3155, [PMID: 19031974]
Exclusion code: 7

Appendix A6. List of Excluded Full-Text Papers

Kao CH, Hsieh JF, Tsai SC, Ho YJ, Lee JK. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. *Clin. Cancer Res.* 2000;6(3):820-824, [PMID: 10741702]
Exclusion code: 7

Karadayi S, Kayi Cangir A, Ozturk S, Dizbay Sak S, Akal M, Akay H. [The prognostic effect of natural killer cell infiltration to tumoral tissues in stage I non-small cell lung cancer]. *Tuberk.* 2008;56(3):251-256, [PMID: 18932025]
Exclusion code: 6

Karadi RL. Radiation risk of screening with low dose CT. *Thorax.* 2006;61(6):548, [PMID: 16738051]
Exclusion code: 5

Kashiwabara K, Kohshi S-i. Outcome in patients with lung cancer invisible on chest roentgenograms but detected only by helical computed tomography. *Respirology.* 2006;11(5):592-597, [PMID: 16916332]
Exclusion code: 2

Kashiwabara K, Koshi S-i, Itonaga K, Nakahara O, Tanaka M, Toyonaga M. Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. *Lung Cancer.* 2003;40(1):67-72, [PMID: 12660008]
Exclusion code: 2

Kashiwabara K, Koshi S-i, Ota K, Tanaka M, Toyonaga M. Outcome in patients with lung cancer found retrospectively to have had evidence of disease on past lung cancer mass screening roentgenograms. *Lung*

Cancer. 2002;35(3):237-241, [PMID: 11844596]
Exclusion code: 2

Katanoda K, Yako-Suketomo H. Trends in lung cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. *Jpn. J. Clin. Oncol.* 2012;42(3):239-240, [PMID: 22375029]
Exclusion code: 2

Katsimpoula S, Patrino-Georgoula M, Makrilia N, et al. Overexpression of hnRNPA2/B1 in bronchoscopic specimens: a potential early detection marker in lung cancer. *Anticancer Res.* 2009;29(4):1373-1382, [PMID: 19414390]
Exclusion code: 4

Katz RL, Zaidi TM, Fernandez RL, et al. Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer.[Erratum appears in Mod Pathol. 2009 May;22(5):734-6]. [Erratum appears in Mod Pathol. 2008 Aug;21(8):1065 Note: Jiang, Xiaoying Gao Feng [corrected to Gao, Xiaoying]; Jiang, Feng [added]]. *Mod. Pathol.* 2008;21(8):950-960, [PMID: 18500269]
Exclusion code: 7

Kawachi R, Tsukada H, Nakazato Y, et al. Early recurrence after surgical resection in patients with pathological stage I non-small cell lung cancer. *Thorac. Cardiovasc. Surg.* 2009;57(8):472-475, [PMID: 20013621]
Exclusion code: 7

Kawachi R, Watanabe S-i, Asamura H. Clinicopathological characteristics of screen-detected lung cancers.[Erratum appears in J Thorac Oncol. 2009 Aug;4(8):1045]. *J Thorac Oncol.* 2009;4(5):615-619, [PMID: 19318993]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Kawada K, Yonei T, Ueoka H, et al. Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. *Acta Med. Okayama*. 2002;56(3):129-134, [PMID: 12108583]
Exclusion code: 7

Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: A collaborative epidemiologic study of the national hospital organization study group for lung cancer (NHSGLC) in japan and a southern california regional cancer registry databases. *Journal of Thoracic Oncology*. 2010;5(7):1001-1010, [PMID: 20526205]
Exclusion code: 2

Kawaguchi Y, Noriyuki T, Kuroda Y, et al. [Right lung cancer with right aortic arch]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2008;61(2):113-117, [PMID: 18268946]
Exclusion code: 6

Kawahara M. Screening for lung cancer. *Curr. Opin. Oncol*. 2004;16(2):141-145, [PMID: 15075906]
Exclusion code: 5

Kawano R, Tamaki K, Karita S, Yokota T, Ikeda S, Hata E. [Surgical treatment for clinical stage II and III small cell lung cancer patients]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2006;59(10):879-883; discussion 883-876, [PMID: 16986681]
Exclusion code: 6

Kawashima O, Ibe T, Kakegawa S, Nakano T, Shimizu K. [Surgical treatment and outcome for postoperative recurrent or second primary lung cancer]. *Kyobu Geka -*

Japanese Journal of Thoracic Surgery. 2010;63(11):935-939, [PMID: 20954346]
Exclusion code: 6

Kawashima O, Sugano M, Kakegawa S, et al. [The clinicopathological features of peripheral small-sized (2 cm or less) squamous cell carcinoma of the lung]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2004;57(1):56-60, [PMID: 14733100]
Exclusion code: 6

Kayser G, Gunzenhauser I, Becker HD, Herth F, Kayser K. [Proliferation rate of small cell lung carcinoma. A cytomorphometric parameter with prognostic significance]. *Pathologie*. 2001;22(5):326-332, [PMID: 11572113]
Exclusion code: 6

Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. *Mol Cancer*. 2011;10:33, [PMID: 21450098]
Exclusion code: 3

Kazerooni EA. Lung cancer screening. *Eur. Radiol*. 2005;15 Suppl 4:D48-51, [PMID: 16479646]
Exclusion code: 5

Kazerooni EA, Chow LC, Whyte RI, Martinez FJ, Lynch JP. Preoperative examination of lung transplant candidates: Value of chest CT compared with chest radiography. *AJR: American Journal of Roentgenology*. 1995;165:1343-1348, [PMID: 7484560]
Exclusion code: 7

Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. *Cancer*.

Appendix A6. List of Excluded Full-Text Papers

2009;115(22):5218-5227, [PMID: 19672942]

Exclusion code: 3

Kemp RA, Reinders DM, Turic B. Detection of lung cancer by automated sputum cytometry. *J Thorac Oncol.* 2007;2(11):993-1000, [PMID: 17975489]
Exclusion code: 2

Kennedy TC, Hirsch FR. Using molecular markers in sputum for the early detection of lung cancer: a review. *Lung Cancer.* 2004;45 Suppl 2:S21-27, [PMID: 15552778]
Exclusion code: 5

Kennedy TC, Hirsch FR, Miller YE, et al. A randomized controlled trial of fluorescence bronchoscopy versus white-light bronchoscopy for early detection of lung cancer in high risk patients. *Lung Cancer.* 2000;29(9 Suppl 1):244-245
Exclusion code: 5

Kennedy TC, Miller Y, Prindiville S. Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy in a high-risk group. *Chest.* 2000;117(4 Suppl 1):72S-79S, [PMID: 10777459]
Exclusion code: 5

Kent MS, Port JL, Altorki NK. Current state of imaging for lung cancer staging. *Thorac Surg Clin.* 2004;14(1):1-13, [PMID: 15382304]
Exclusion code: 5

Kenzaki K, Sakiyama S, Tomimoto H, et al. [Clinical analysis of elderly patients with primary lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2010;63(7):519-523; discussion 524-516, [PMID: 20662228]
Exclusion code: 6

Kepka L, Bujko K. [Postoperative radiotherapy for non-small cell lung cancer: evidence based data and clinical practice]. *Pneumonol. Alergol. Pol.* 2007;75(3):256-261, [PMID: 17966101]
Exclusion code: 6

Kesting MR, Robitzky L, Al-Benna S, et al. Bronchoscopy screening in primary oral squamous cell carcinoma: a 10-year experience. *Br. J. Oral Maxillofac. Surg.* 2009;47(4):279-283, [PMID: 19243866]
Exclusion code: 3

Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. *J. Clin. Oncol.* 2004;22(12):2363-2370, [PMID: 15197197]
Exclusion code: 2

Kim HR, Kim TH, Chung J-H, et al. The detection of peripheral lung cancer by MAGE A1-6 RT-nested PCR in bronchial washing specimens. *Lung Cancer.* 2009;65(2):166-169, [PMID: 19168258]
Exclusion code: 2

Kim IH, Patel MJ, Hirt SL, Kantor ML. Clinical research and diagnostic efficacy studies in the oral and maxillofacial radiology literature: 1996-2005. *Dentomaxillofacial Radiology.* 2011;40(5):274-281, [PMID: 21697152]
Exclusion code: 3

Kim K, Kim HK, Park JS, et al. Video-assisted thoracic surgery lobectomy: single institutional experience with 704 cases. *Ann. Thorac. Surg.* 2010;89(6):S2118-2122, [PMID: 20493994]
Exclusion code: 10

Kim TJ, Han DH, Jin KN, Won Lee K. Lung cancer detected at cardiac CT: prevalence, clinicoradiologic features, and

Appendix A6. List of Excluded Full-Text Papers

importance of full-field-of-view images.
Radiology. 2010;255(2):369-376, [PMID:
20413751]

Exclusion code: 4

Kita H, Koshiishi Y, Masui K, et al. [Risk factors of recurrence in resected stage I non-small cell lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2007;60(10):883-887, [PMID: 17877005]

Exclusion code: 6

Kitajima T, Nishii K, Ueoka H, et al. Recent improvement in lung cancer screening: a comparison of the results carried out in two different time periods. *Acta Med. Okayama*. 2006;60(3):173-179, [PMID: 16838046]

Exclusion code: 3 Japan

Kjellgren O. Mass screening in Sweden for cancer of the uterine cervix: Effect on incidence and mortality. An overview. *Gynecol. Obstet. Invest*. 1986;22(2):57-63, [PMID: 3770533]

Exclusion code: 8

Klabunde CN, Marcus PM, Han PKJ, et al. Lung cancer screening practices of primary care physicians: Results from a national survey. *Ann Fam Med*. 2012;10(2):102-110, [PMID: 22412001]

Exclusion code: 5

Klabunde CN, Marcus PM, Silvestri GA, et al. U.S. primary care physicians' lung cancer screening beliefs and recommendations. *Am. J. Prev. Med*. 2010;39(5):411-420, [PMID: 20965378]

Exclusion code: 2

Klar E, Puschel A, Schiffmann L, Pertschy A. [The role of intensive care medicine in early postoperative complications. Is surgical expertise in danger?]. *Chirurg*. 2009;80(9):773-779, [PMID: 19707724]

Exclusion code: 6

Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and screening. *AJR. Am. J. Roentgenol*. 2011;196(2):287-295, [PMID: 21257878]

Exclusion code: 2

Kloecker GH, Studts JL, Laber DA, Bousamra M. Lung cancer in the US and in Kentucky. *J. Ky. Med. Assoc*. 2007;105(4):159-164, [PMID: 17494278]

Exclusion code: 5

Kobayashi K. [Guide line for the treatment of stage I and stage II non small cell lung cancer]. *Nippon Geka Gakkai Zasshi*. 2004;105(7):392-403, [PMID: 15303438]

Exclusion code: 6

Kodama K, Oda K, Okami J, et al. [The value of long-term postoperative follow-up after curative resection of lung cancer and common problems associated with it]. *Nippon Geka Gakkai Zasshi*. 2007;108(3):107-112, [PMID: 17533945]

Exclusion code: 6

Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature*. 2007;450(7171):903-907, [PMID: 18026089]

Exclusion code: 5

Kohno T, Kakinuma R, Iwasaki M, et al. Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs. *Carcinogenesis*. 2010;31(10):1794-1799, [PMID: 20688833]

Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Koike T, Tsuchiya R, Goya T, Sohara Y, Miyaoka E. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. *J Thorac Oncol.* 2007;2(5):408-413, [PMID: 17473656]

Exclusion code: 7

Koizumi K. [Thoracoscopic surgery and postoperative respiratory complications]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2006;59(8 Suppl):760-767, [PMID: 16910528]

Exclusion code: 6

Kojima A, Takeshita K, Fukuchi Y, Dambara T. [Usefulness of low-dose single-slice CT (SSCT) for mass screening to detect various thoracic diseases including lung cancer]. *Nihon Kokyuki Gakkai Zasshi.* 2004;42(10):887-892, [PMID: 15566002]

Exclusion code: 6

Kolodziejczyk M, Kepka L, Tyc-Szczepaniak D, Wierzchowski M. [Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy]. *Pneumonol. Alergol. Pol.* 2011;79(5):326-336, [PMID: 21861256]

Exclusion code: 6

Kondo R, Yoshida K, Kawakami S, et al. Efficacy of CT screening for lung cancer in never-smokers: Analysis of Japanese cases detected using a low-dose CT screen. *Lung Cancer.* 2011;74(3):426-432, [PMID: 21663997]

Exclusion code: 2

Kondo R, Yoshida K, Kawakami S, et al. Different efficacy of CT screening for lung cancer according to histological type:

analysis of Japanese-smoker cases detected using a low-dose CT screen. *Lung Cancer.* 2011;74(3):433-440, [PMID: 21663995]
Exclusion code: 10

Konno S, Morishita Y, Fukasawa M, et al. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma. *Cancer.* 2004;102(6):348-354, [PMID: 15481085]

Exclusion code: 3

Kono Y, Endo S, Otani S, et al. [Non-tuberculous mycobacterial infection along the staple-suture line after segmentectomy for small peripheral lung cancer; report of a case]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2005;58(2):165-168, [PMID: 15724484]

Exclusion code: 6

Korenkov M, Gonner U, Dunschede F, Junginger T. [Rectal melanoma: the value of modern treatment]. *Zentralbl. Chir.* 2008;133(6):564-567, [PMID: 19090435]

Exclusion code: 6

Kovacs A, Dobrossy L, Budai A, Cornides A, Boncz I. [The state of the organized screening in Hungary in 2006]. *Orv. Hetil.* 2007;148(10):435-440, [PMID: 17350908]

Exclusion code: 6

Kovacs G. [Risk group chest X-ray for the early detection of lung cancer]. *Orv. Hetil.* 2008;149(21):975-982, [PMID: 18487112]

Exclusion code: 6

Kovacs G, Dulka E, Mark Z, et al. [Our experience using autofluorescence bronchoscopy]. *Orv. Hetil.* 2004;145(28):1473-1478, [PMID: 15366714]

Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Kovacs G, Gaudi I, Kovi R. [An interdisciplinary malignancy, the lung cancer in Hungary in 2006: epidemiology, prevention and access to therapy]. *Magy Onkol.* 2006;50(3):207, [PMID: 17099779]
Exclusion code: 6

Kraev A, Rassias D, Vetto J, et al. Wedge resection vs lobectomy: 10-year survival in stage I primary lung cancer. *Chest.* 2007;131(1):136-140, [PMID: 17218567]
Exclusion code: 10

Kramer BS. Spiral computed tomography screening. *J. Med. Screen.* 2000;7(3):121-122, [PMID: 11126157]
Exclusion code: 2

Kramer BS. Spiral computed tomography screening: study begins to determine its efficacy in lung cancer prevention. *West. J. Med.* 2001;174(4):230-231, [PMID: 11290662]
Exclusion code: 5

Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). *J. Med. Screen.* 2011;18(3):109-111, [PMID: 22045816]
Exclusion code: 2

Kramer BS, Brawley OW. Cancer screening. *Hematology - Oncology Clinics of North America.* 2000;14(4):831-848, [PMID: 10949776]
Exclusion code: 4

Krotz D. Low-dose CT screening reduces lung cancer deaths. *Diagn. Imaging.* 2000;Suppl:7-9, [PMID: 10848422]
Exclusion code: 5

Krupinski EA, Jiang Y. Anniversary Paper: Evaluation of medical imaging systems.

Med. Phys. 2008;35(2):645-659, [PMID: 18383686]
Exclusion code: 5

Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. *Int. J. Cancer.* 1990;45(1):26-33, [PMID: 2404878]
Exclusion code: 5

Kubik A, Polak J. Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. *Cancer.* 1986;57(12):2427-2437, [PMID: 3697941]
Exclusion code: 5

Kubik AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. *Cancer.* 2000;89(11 Suppl):2363-2368, [PMID: 11147613]
Exclusion code: 8

Kucharczyk MJ, Menezes RJ, McGregor A, Paul NS, Roberts HC. Assessing the impact of incidental findings in a lung cancer screening study by using low-dose computed tomography. *Can. Assoc. Radiol. J.* 2011;62(2):141-145, [PMID: 20382501]
Exclusion code: 2

Kulaga S, Karp I. CT screening for lung cancer. *N. Engl. J. Med.* 2007;356(7):744; author reply 746-747, [PMID: 17310520]
Exclusion code: 5

Kuller LH, Ockene JK, Meilahn E, Wentworth DN, Svendsen KH, Neaton JD. Cigarette smoking and mortality. MRFIT Research Group. *Prev. Med.* 1991;20(5):638-654, [PMID: 1758843]
Exclusion code: 4

Appendix A6. List of Excluded Full-Text Papers

Kurishima K, Kagohashi K, Nakayama H, Satoh H. Incidentally detected lung cancer. *South. Med. J.* 2009;102(9):986, [PMID: 19668041]

Exclusion code: 5

Kuroda H, Kawamura M. [The management of post operative chylothorax]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2008;61(8 Suppl):700-704, [PMID: 20715413]

Exclusion code: 6

Kusano S, Nakagawa T, Aoki T, et al. Efficacy of computer-aided diagnosis in lung cancer screening with low-dose spiral computed tomography: receiver operating characteristic analysis of radiologists' performance. *Jpn J Radiol.*

2010;28(9):649-655, [PMID: 21113748]

Exclusion code: 3

Kuschner WG, Hsu JL, Banerjee D. Understanding and identifying bias and confounding in the medical literature. *South. Med. J.* 2008;101(12):1240-1245, [PMID: 19005435]

Exclusion code: 5

Kusunoki Y, Imamura F, Uda H, Mano M, Horai T. Early detection of lung cancer with laser-induced fluorescence endoscopy and spectrofluorometry. *Chest.* 2000;118(6):1776-1782, [PMID: 11115472]

Exclusion code: 7

Kusunoki Y, Nakayama T. [CT diagnosis of lung cancer--current topics]. *Nippon Rinsho - Japanese Journal of Clinical Medicine.* 2002;60 Suppl 5:170-173, [PMID: 12101649]

Exclusion code: 6

Kuzniar T, Masters GA, Ray DW. Screening for lung cancer--a review. *Med*

Sci Monit. 2004;10(2):RA21-30, [PMID: 14737058]

Exclusion code: 5

Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P, von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. *Int. J. Cancer.*

2001;92(1):1-8, [PMID: 11279599]

Exclusion code: 2

Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC. The economic impact of false-positive cancer screens. *Cancer Epidemiol. Biomarkers Prev.* 2004;13(12):2126-2132, [PMID: 15598770]

Exclusion code: 2

The economic impact of false-positive cancer screens (Brief record). John Wiley & Sons, Ltd. Chichester, UK; 2011. <http://dx.doi.org/10.1002/14651858>.

Exclusion code: 5

Lam B, Lam SY, Wong MP, et al. Sputum cytology examination followed by autofluorescence bronchoscopy: a practical way of identifying early stage lung cancer in central airway. *Lung Cancer.*

2009;64(3):289-294, [PMID: 19010567]

Exclusion code: 4

Lam S, Lam B, Petty TL. Early detection for lung cancer. New tools for casefinding. *Can. Fam. Physician.* 2001;47:537-544, [PMID: 11281087]

Exclusion code: 5

Lam S, MacAulay C, leRiche JC, Palcic B. Detection and localization of early lung cancer by fluorescence bronchoscopy. *Cancer.* 2000;89(11 Suppl):2468-2473, [PMID: 11147629]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 7

Lamerato LE, Marcus PM, Jacobsen G, Johnson CC. Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System. *Cancer Epidemiol. Biomarkers Prev.* 2008;17(4):827-833, [PMID: 18398023]
Exclusion code: 2

Landrum MB, Keating NL, Lamont EB, et al. Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. *J. Clin. Oncol.* 2012;30(10):1072-1079, [PMID: 22393093]
Exclusion code: 3

Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. *Thorax.* 1990;45(8):579-585, [PMID: 2402719]
Exclusion code: 8

Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial. *AJR. Am. J. Roentgenol.* 2011;197(5):1165-1169, [PMID: 22021510]
Exclusion code: 2

LaRocca RV, Falk R, Cerrito P, Lord R, Goldman S. Early results of a randomized prospective screening trial of annual low-dose spiral chest computed tomography scanning versus annual chest radiography of Kentucky patients at increased risk for lung cancer: Jewish Hospital Lung Cancer Screening and Early Detection Study [abstract]. Paper presented at: Proceedings

of the American Society of Clinical Oncology 2002
Exclusion code: 5

Larsen IK, Grotmol T, Almendingen K, Hoff G. Impact of Colorectal Cancer Screening on Future Lifestyle Choices: A Three-Year Randomized Controlled Trial. *Clinical Gastroenterology and Hepatology.* 2007;5(4):477-483, [PMID: 17363335]
Exclusion code: 4

Lau K, Rathinam S, Waller D, Peake M. The Effects of Increased Provision of Thoracic Surgical Specialists on the Variation in Lung Cancer Resection Rate in England. *J Thorac Onc.* 2013;8(1):68-71, [PMID: 23242439]
Exclusion code: 2

Lauer MS, Murthy SC, Blackstone EH, Okereke IC, Rice TW. [18F]Fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: impact of verification bias. *Arch. Intern. Med.* 2007;167(2):161-165, [PMID: 17242317]
Exclusion code: 6

Lautin EM, Novick MK, Jean-Baptiste R. Tailored CT: Primum non nocere. *Br. J. Radiol.* 2008;81(966):442-443, [PMID: 18347029]
Exclusion code: 5

Lawson JD, Sandhu A, Jiang S, Mundt AJ. Emerging role of stereotactic radiotherapy (SRT) in the treatment of early stage non-small cell lung cancer. *Current Cancer Therapy Reviews.* 2009;5(4):281-287, [PMID: Exclusion code: 4

Lazoura O, Vassiou K, Kanavou T, Vlychou M, Arvanitis DL, Fezoulidis IV. Incidental non-cardiac findings of a coronary angiography with a 128-slice

Appendix A6. List of Excluded Full-Text Papers

multi-detector CT scanner: Should we only concentrate on the heart? *Korean Journal of Radiology*. 2010;11(1):60-68, [PMID: 20046496]

Exclusion code: 5

Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, et al. Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. *Contemp Clin Trials*. 2010;31(6):612-619, [PMID: 20719253]

Exclusion code: 4

Le Chevalier T. [Adjuvant chemotherapy in the early stages of non-small cell bronchial cancers]. *Rev. Pneumol. Clin*. 2002;58(5 Pt 2):3S31-32, [PMID: 12538932]

Exclusion code: 6

Leader JK, Warfel TE, Fuhrman CR, et al. Pulmonary nodule detection with low-dose CT of the lung: agreement among radiologists. *AJR. Am. J. Roentgenol*. 2005;185(4):973-978, [PMID: 16177418]

Exclusion code: 2

Lee CI, Forman HP. CT screening for lung cancer: implications on social responsibility. *AJR. Am. J. Roentgenol*. 2007;188(2):297-298, [PMID: 17242233]

Exclusion code: 5

Lee JY, Chung MJ, Yi CA, Lee KS. Ultra-low-dose MDCT of the chest: influence on automated lung nodule detection. *Korean Journal of Radiology*. 2008;9(2):95-101, [PMID: 18385555]

Exclusion code: 2

Lee P, Colt HG. Bronchoscopy in lung cancer: appraisal of current technology and for the future. *J Thorac Oncol*. 2010;5(8):1290-1300, [PMID: 20661089]

Exclusion code: 7

Lee P, Postmus PE, Sutedja TG. CT screening for lung cancer. *N. Engl. J. Med*. 2007;356(7):745; author reply 746-747, [PMID: 17310516]

Exclusion code: 5

Lee P, Sutedja TG. Lung cancer screening: has there been any progress? Computed tomography and autofluorescence bronchoscopy. *Curr. Opin. Pulm. Med*. 2007;13(4):243-248, [PMID: 17534167]

Exclusion code: 5

Lee P, Sutedja TG. Population screening for lung cancer using CT. *Thorax*. 2008;63(1):87, [PMID: 18156577]

Exclusion code: 5

Lee P, van den Berg RM, Lam S, et al. Color fluorescence ratio for detection of bronchial dysplasia and carcinoma in situ. *Clin. Cancer Res*. 2009;15(14):4700-4705, [PMID: 19584169]

Exclusion code: 3

Lee PC, Korst RJ, Port JL, Kerem Y, Kansler AL, Altorki NK. Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size. *J. Thorac. Cardiovasc. Surg*. 2006;132(6):1382-1389, [PMID: 17140961]

Exclusion code: 10

Lee SM, Park CM, Goo JM, et al. Transient part-solid nodules detected at screening thin-section CT for lung cancer: comparison with persistent part-solid nodules. *Radiology*. 2010;255(1):242-251, [PMID: 20173104]

Exclusion code: 4

Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology screening tests. *N. Engl. J. Med*. 2002;346(7):529-531, [PMID: 11844859]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 5

Lehman SJ, Abbara S, Cury RC, et al. Significance of Cardiac Computed Tomography Incidental Findings in Acute Chest Pain. *Am. J. Med.* 2009;122(6):543-549, [PMID: 19486717]

Exclusion code: 3

Lehrer S. Inhaled insulin for the early detection of lung cancer. *Med. Hypotheses.* 2008;71(4):615-616, [PMID: 18602221]

Exclusion code: 5

Leidinger P, Keller A, Heisel S, et al. Identification of lung cancer with high sensitivity and specificity by blood testing. *Respir Res.* 2010;11:18, [PMID: 20146812]

Exclusion code: 2

Lenzer J, Brownlee S. Knowing me, knowing you. *BMJ.* 2008;336(7649):858-860, [PMID: 18420689]

Exclusion code: 5

Lester RG. Risk versus benefit in mammography. *Radiol.* 1977;124(1):1-6, [PMID: 866625]

Exclusion code: 2

Levin ML, Tockman MS, Frost JK, Ball WC, Jr. Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: a preliminary report. *Recent Results Cancer Res.* 1982;82:138-146, [PMID: 7111836]

Exclusion code: 5

Lew WJ, Jung YJ, Song JW, et al. Combined use of QuantiFERON®-TB gold assay and chest computed tomography in a tuberculosis outbreak. *Int. J. Tuberc. Lung Dis.* 2009;13(5):633-639, [PMID: 19383198]

Exclusion code: 5

Lewis PD, Lewis KE, Ghosal R, et al. Evaluation of FTIR spectroscopy as a diagnostic tool for lung cancer using sputum. *BMC Cancer.* 2010;10:640, [PMID: 21092279]

Exclusion code: 7

Li C, Zhang R. [Lung cancer: new staging system and prognosis]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 2000;38(3):189-191, [PMID: 11832024]

Exclusion code: 6

Li F, Sone S, Abe H, MacMahon H, Armato SG, 3rd, Doi K. Lung cancers missed at low-dose helical CT screening in a general population: comparison of clinical, histopathologic, and imaging findings. *Radiology.* 2002;225(3):673-683, [PMID: 12461245]

Exclusion code: 3

Li F, Sone S, Abe H, MacMahon H, Doi K. Low-dose computed tomography screening for lung cancer in a general population: characteristics of cancer in non-smokers versus smokers. *Acad. Radiol.* 2003;10(9):1013-1020, [PMID: 13678090]

Exclusion code: 2

Li F, Sone S, Abe H, Macmahon H, Doi K. Malignant versus benign nodules at CT screening for lung cancer: comparison of thin-section CT findings. *Radiology.* 2004;233(3):793-798, [PMID: 15498895]

Exclusion code: 3

Li G-h, Wu Y, Zhang X-j, Cui Y-s. [A comparative study of survival time of surgery combined with chemotherapy and non-surgical chemotherapy in SCLC]. *Chung Hua I Hsueh Tsa Chih.* 2010;90(31):2212-2214, [PMID: 21029664]

Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Li H-h, Zhang Q-z, Xu L, Chen L, Wei Y-x, Wang Y-h. [Diagnosis and treatment for postoperative lobar torsion]. *Chung Hua I Hsueh Tsa Chih*. 2007;87(27):1915-1917, [PMID: 17923017]

Exclusion code: 6

Li Q, Li F, Doi K. Computerized detection of lung nodules in thin-section CT images by use of selective enhancement filters and an automated rule-based classifier. *Acad. Radiol*. 2008;15(2):165-175, [PMID: 18206615]

Exclusion code: 4

Li Y, Swensen SJ, Karabekmez LG, et al. Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. *Cancer Prev Res (Phila Pa)*. 2011;4(1):43-50, [PMID: 21119049]

Exclusion code: 2

Libby DM, Wu N, Lee I-J, et al. CT screening for lung cancer: the value of short-term CT follow-up. *Chest*. 2006;129(4):1039-1042, [PMID: 16608955]

Exclusion code: 7

Licker MJ, Widikker I, Robert J, et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. *Ann. Thorac. Surg*. 2006;81(5):1830-1837, [PMID: 16631680]

Exclusion code: 7

Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. *N. Engl. J. Med*. 2000;343(3):162-168, [PMID: 10900274]

Exclusion code: 8

Lillington GA. Lung cancer. *Curr. Opin. Pulm. Med*. 2003;9(4):298-300, [PMID: 12806243]

Exclusion code: 5

Lin D-m, Ma Y, Liu X-y, et al. [Prognostic significance of micropapillary pattern in pulmonary adenocarcinoma]. *Chung-Hua Ping Li Hsueh Tsa Chih - Chinese Journal of Pathology*. 2006;35(3):151-154, [PMID: 16630503]

Exclusion code: 6

Lin RS, Plevritis SK. Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. *Cancer Causes Control*. 2012;23(1):175-185, [PMID: 22116537]

Exclusion code: 7

Lin X-l, Yang S-y, Du J, et al. Detection of lung adenocarcinoma using magnetic beads based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling. *Chin. Med. J. (Engl)*. 2010;123(1):34-39, [PMID: 20137572]

Exclusion code: 2

Lin Z-C, Long H, Rong T-H, et al. [Surgical treatment efficacy of bronchioloalveolar carcinoma: a retrospective analysis of 130 patients]. *Ai Zheng*. 2006;25(9):1123-1126, [PMID: 16965654]

Exclusion code: 6

Lindell RM, Hartman TE, Swensen SJ, et al. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. *AJR. Am. J. Roentgenol*. 2005;185(1):126-131, [PMID: 15972412]

Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. *Radiology*. 2007;242(2):555-562, [PMID: 17255425]

Exclusion code: 2

Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. *Cancer Causes Control*. 2004;15(8):819-827, [PMID: 15456995]

Exclusion code: 2

Liu B, Liu L, Li Y, et al. [Survival after radiofrequency ablation for 100 cases of lung neoplasms]. *Zhongguo Fei Ai Za Zhi*. 2011;14(4):335-339, [PMID: 21496432]

Exclusion code: 6

Liu D, Awai K, Funama Y, et al. Identification and characterization of focal ground-glass opacity in the lungs by high-resolution CT using thin-section multidetector helical CT: Experimental study using a chest CT phantom. *Radiation Medicine - Medical Imaging and Radiation Oncology*. 2008;26(1):21-27, [PMID: 18236130]

Liu X-b, Yuan Z-y, Song Y-c, et al. [An initial report of cyberknife radiosurgery for primary hepatic carcinoma]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2010;32(3):229-233, [PMID: 20450595]

Exclusion code: 6

Liu Y, Wang M. Advances in early diagnosis of lung cancer. *Zhongguo Fei Ai Za Zhi*. 2011;14(5):429-434, [PMID: 1569649]

Exclusion code: 5

Lo DS, Zeldin RA, Skrastins R, et al. Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. *J Thorac Oncol*. 2007;2(11):1001-1006, [PMID: 17975490]

Exclusion code: 3

Lobrano MB. Partnerships in oncology and radiology: the role of radiology in the detection, staging, and follow-up of lung cancer. *Oncologist*. 2006;11(7):774-779, [PMID: 16880236]

Exclusion code: 5

Loewen G, Reid M, Tan D, et al. Bimodality lung cancer screening in high-risk patients: a preliminary report. *Chest*. 2004;125(5 Suppl):163S-164S, [PMID: 15136489]

Exclusion code: 5

Loewen GL, Natarajan N, Tan D, et al. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment *Thorax*. 2007;62(4):335-340, [PMID: 17101735]

Exclusion code: 4

Long H, Lin Z-C, Lin Y-B, Situ D-R, Wang Y-N, Rong T-H. [Quality of life after lobectomy for early stage non-small cell lung cancer--video-assisted thoracoscopic surgery versus minimal incision thoracotomy]. *Ai Zheng*. 2007;26(6):624-628, [PMID: 17562269]

Exclusion code: 6

Long H, Lin Z-c, Situ D-r. [Injuries after lobectomy: a prospective randomized comparison of video-assisted thoracoscopic surgery and mini-thoracotomy]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 2008;46(6):401-404, [PMID: 18785569]

Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Lopes Pegna A, Picozzi G. Lung cancer screening update. *Curr. Opin. Pulm. Med.* 2009;15(4):327-333, [PMID: 19395971]
Exclusion code: 2

Lopez Diaz M, Anton-Pacheco Sanchez JL, Tejedor Sanchez R, et al. [Primary lung tumors]. *Cir. Pediatr.* 2006;19(4):223-227, [PMID: 17352111]
Exclusion code: 6

Lotti M, Bergamo L, Murer B. Occupational toxicology of asbestos-related malignancies. *Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists.* 2010;48(6):485-496, [PMID: 20849338]
Exclusion code: 5

Lou W, Zhan X, Xiang X, Guan W. [Effect of VATS wedge resection and mediastinal lymph node sampling in elderly patients with early peripheral lung cancer]. *Zhongguo Fei Ai Za Zhi.* 2012;15(1):49-51, [PMID: 22237125]
Exclusion code: 6

Lovgren M, Levealahti H, Tishelman C, Runesdotter S, Hamberg K. Time spans from first symptom to treatment in patients with lung cancer--the influence of symptoms and demographic characteristics. *Acta Oncol.* 2008;47(3):397-405, [PMID: 17882556]
Exclusion code: 7

Luboldt W, Wetter A, Eichler K, Vogl TJ, Wagner TOF, Seemann MD. Determination of the optimal MRI sequence for the detection of malignant lung nodules. *Eur. J. Med. Res.* 2006;11(8):336-342, [PMID: 17052969]
Exclusion code: 7

Ludovini V, Pistola L, Gregorc V, et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. *J Thorac Oncol.* 2008;3(4):365-373, [PMID: 18379354]
Exclusion code: 4

Ludwig C, Stoelben E, Olschewski M, Hasse J. Comparison of morbidity, 30-day mortality, and long-term survival after pneumonectomy and sleeve lobectomy for non-small cell lung carcinoma. *Ann. Thorac. Surg.* 2005;79(3):968-973, [PMID: 15734415]
Exclusion code: 3

Lumbreras B, Aguado IH. Enthusiasm for diagnostic tests: Health effects and their surveillance. 2008 SESPAS report. *El entusiasmo por las pruebas diagnósticas: Efectos en la salud y formas de control. Informe SESPAS 2008.* 2008;22(SUPPL. 1):216-222, [PMID: 18405573]
Exclusion code: 5

Lumbreras B, Hernández-Aguado I. Latrogeny attributable to diagnostic tests. *Revista de Calidad Asistencial.* 2007;22(6):272-276, [PMID: Exclusion code: 6

Lung Cancer Alliance. Screen for Lung Cancer. *Rights and Expectations for Excellence in Lung Cancer Screening and Continuum of Care* <http://www.screenforlungcancer.org/national-framework/>. Accessed 19 September 2012, 2012
Exclusion code: 2

Lyons G, Quadrelli S, Chimondegy D, Iotti A, Silva C. [Bronchioalveolar carcinoma:

Appendix A6. List of Excluded Full-Text Papers

five year survival]. *Medicina (Mex)*. 2006;66(4):313-318, [PMID: 16977966]
Exclusion code: 6

Lyons G, Quadrelli S, Chimondegy D, Iotti A, Silva C. [Tumor size and survival in lung cancer, stage IA]. *Medicina (Mex)*. 2008;68(1):23-30, [PMID: 18416316]
Exclusion code: 6

Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. *Am. J. Respir. Crit. Care Med*. 2005;171(11):1286-1291, [PMID: 15750044]
Exclusion code: 3

MacMahon H, Austin JH, Gamsu G, et al. Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society. *Radiol*. 2005;237:395-400, [PMID: 16244247]
Exclusion code: 2

MacRedmond R, Logan PM, Lee M, Kenny D, Foley C, Costello RW. Screening for lung cancer using low dose CT scanning. *Thorax*. 2004;59(3):237-241, [PMID: 14985561]
Exclusion code: 5

Maeda M. [Tracheobronchoplasty for lung cancer: operative indications by limited category]. *Nippon Geka Gakkai Zasshi*. 2000;101(7):503-508, [PMID: 10944771]
Exclusion code: 6

Maeda R, Yoshida J. [Lung cancer -- CT screening for lung cancer dramatically improved survival after surgical resection]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2011;38(2):197-201, [PMID: 21368484]
Exclusion code: 6

Maeda R, Yoshida J, Ishii G, et al. Long-term outcome and late recurrence in patients with completely resected stage IA non-small cell lung cancer. *J Thorac Oncol*. 2010;5(8):1246-1250, [PMID: 20559152]
Exclusion code: 7

Maggi F. Lung cancer screening with spiral CT. *Rays*. 2004;29(4):377-382, [PMID: 15852723]
Exclusion code: 5

Mahadevia P, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: A decision and cost-effectiveness analysis. *JAMA*. 2003;289(3):313-322, [PMID: 12525232]
Exclusion code: 7

Mahon SM. Screening for lung cancer: what is the evidence? *Clin. J. Oncol. Nurs*. 2004;8(2):188-189, [PMID: 15108420]
Exclusion code: 5

Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk prediction to select smokers for screening CT - A model based on the Italian COSMOS trial. *Cancer Prev Res (Phila Pa)*. 2011;4(11):1778-1789, [PMID: 21813406]
Exclusion code: 4

Maldonado A, Gonzalez-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. *Clin Transl Oncol*. 2007;9(8):494-505, [PMID: 17720652]
Exclusion code: 5

Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis.

Appendix A6. List of Excluded Full-Text Papers

Chest. 2010;138(6):1295-1302, [PMID: 20348193]

Exclusion code: 2

Manning DJ, Ethell SC, Donovan T. Detection or decision errors? Missed lung cancer from the posteroanterior chest radiograph. *Br. J. Radiol*.

2004;77(915):231-235, [PMID: 15020365]

Exclusion code: 4

Manser R. Screening for lung cancer: a review. *Curr. Opin. Pulm. Med*.

2004;10(4):266-271, [PMID: 15220750]

Exclusion code: 5

Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting (Structured abstract). John Wiley & Sons, Ltd. Chichester, UK; 2011.

<http://dx.doi.org/10.1002/14651858>.

Exclusion code: 7

Manser RL, Dodd M, Byrnes G, Irving LB, Campbell DA. Incidental lung cancers identified at coronal autopsy: implications for overdiagnosis of lung cancer by screening. *Respir. Med*. 2005;99(4):501-507, [PMID: 15763458]

Exclusion code: 4

Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. *Thorax*. 2003;58(9):784-789, [PMID: 12947138]

Exclusion code: 2

Manser RL, Irving LB, de Campo MP, et al. Overview of observational studies of low-dose helical computed tomography screening for lung cancer. *Respirology*. 2005;10(1):97-104, [PMID: 15691245]

Exclusion code: 5

Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer. *Cochrane Database of Systematic Reviews*. 2010(CD001991).

Exclusion code: 2

Mao Y, Zhang D, Zhang R, et al. [Surgical treatment for lung cancer patients with poor pulmonary function]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2002;24(3):300-302, [PMID: 12515633]

Exclusion code: 6

Marchiano A, Calabro E, Civelli E, et al. Pulmonary nodules: volume repeatability at multidetector CT lung cancer screening. *Radiology*. 2009;251(3):919-925, [PMID: 19380692]

Exclusion code: 2

Marcus PM. Lung cancer screening, once again. *Chest*. 2002;122(1):3-4, [PMID: 12114327]

Exclusion code: 5

Marcus PM, Bergstrahl EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. *J. Natl. Cancer Inst*. 2000;92(16):1308-1316, [PMID: 10944552]

Exclusion code: 2

Marek W, Kotschy-Lang N, Muti A, et al. Can semi-automated image cytometry on induced sputum become a screening tool for lung cancer? Evaluation of quantitative semi-automated sputum cytometry on radon- and uranium-exposed workers. *Eur. Respir. J*. 2001;18(6):942-950, [PMID: 11829100]

Exclusion code: 2

Marek W, Richartz G, Philippou S, Marek L, Kotschy-Lang N. Sputum screening for lung cancer in radon exposed uranium

Appendix A6. List of Excluded Full-Text Papers

miners: a comparison of semi-automated sputum cytometry and conventional cytology. *J. Physiol. Pharmacol.* 2007;58 Suppl 5(Pt 1):349-361, [PMID: 18204147]
Exclusion code: 2

Marel M, Stranska P, Mericka O, et al. [Diagnostics and indications of surgical treatment of patients with lung carcinoma at the first clinic of TRN of the first faculty of medicine and the VFN Prague in years 2004 to 2005]. *Cas. Lek. Cesk.* 2006;145(11):849-854, [PMID: 17168418]
Exclusion code: 6

Markowitz SB, Miller A, Miller J, et al. Ability of low-dose helical CT to distinguish between benign and malignant noncalcified lung nodules. *Chest.* 2007;131(4):1028-1034, [PMID: 17426206]
Exclusion code: 2

Márquez-Calderón S. Negative effects of individual-based preventive interventions. 2008 SESPAS Report. *Los efectos negativos de las intervenciones preventivas basadas en el individuo. Informe SESPAS 2008.* 2008;22(SUPPL. 1):205-215, [PMID: 18405572]
Exclusion code: 5

Marshall D, Simpson KN, Earle CC, Chu CW. Economic decision analysis model of screening for lung cancer. *Eur. J. Cancer.* 2001;37(14):1759-1767, [PMID: 11549429]
Exclusion code: 2

Marshall E. Medicine. A bumper crop of conflicts. *Science.* 2008;320(5876):602-603, [PMID: 18451276]
Exclusion code: 5
Marten K, Engelke C. Computer-aided detection and automated CT volumetry of

pulmonary nodules. *Eur. Radiol.* 2007;17(4):888-901, [PMID: 17047961]
Exclusion code: 2

Martini N. Results of the Memorial Sloan-Kettering study in screening for early lung cancer *Chest.* 1986;89(4 Suppl):S325, [PMID: 6734291]
Exclusion code: 5

Marugame T, Sobue T, Satoh H, et al. Lung cancer death rates by smoking status: Comparison of the three-prefecture cohort study in Japan to the cancer prevention study II in the USA. *Cancer Science.* 2005;96(2):120-126, [PMID: 15723657]
Exclusion code: 2

Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR. Early detection and screening of lung cancer. *Expert Review of Molecular Diagnostics.* 2010;10(6):799-815, [PMID: 20843203]
Exclusion code: 2

Massion PP, Zou Y, Uner H, et al. Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer. *PLoS ONE.* 2009;4(6), [PMID: 19547694]
Exclusion code: 3

Mastrangelo G, Ballarin MN, Bellini E, et al. Feasibility of a screening programme for lung cancer in former asbestos workers. *Occupational Medicine (Oxford).* 2008;58(3):175-180, [PMID: 18346953]
Exclusion code: 2

Matsumoto K, Ohno Y, Koyama H, et al. 3D automatic exposure control for 64-detector row CT: Radiation dose reduction in chest phantom study. *Eur. J. Radiol.* 2011;77(3):522-527, [PMID: 19836179]
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Matsumura K, Opiekun M, Oka H, et al. Urinary volatile compounds as biomarkers for lung cancer: A proof of principle study using odor signatures in mouse models of lung cancer. *PLoS ONE*. 2010;5(1), [PMID: 20111698]

Exclusion code: 4

Matsuura N, Nakashima N, Igai H, et al. [Prognosis of surgically treated large cell neuroendocrine carcinoma]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2011;64(3):187-190, [PMID: 21404553]

Exclusion code: 6

Matz R. Lung cancer screening. *JAMA*. 2001;285(2):163-164, [PMID: 11176797]

Exclusion code: 5

Maurel M, Stoufflet A, Thorel L, et al. Factors associated with cancer distress in the Asbestos Post-Exposure Survey (APEXS). *Am. J. Ind. Med.* 2009;52(4):288-296, [PMID: 19152347]

Exclusion code: 2

Mazzone P. Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. *J Thorac Oncol*. 2008;3(7):774-780, [PMID: 18594325]

Exclusion code: 5

Mazzone P, Obuchowski N, Mekhail T, Meziane M, Ahmad M. Lung cancer screening: is it time for a change in policy? *Cleve. Clin. J. Med.* 2007;74(6):441-448, [PMID: 17569202]

Exclusion code: 5

Mazzone PJ, Mekhail T. Lung cancer screening. *Curr Oncol Rep*. 2007;9(4):265-274, [PMID: 17588350]

Exclusion code: 2

McBride D. Early detection with computed tomography scans can detect lung cancer,

may save lives. *ONS Connect*. 2007;22(2):24, [PMID: 17393640]

Exclusion code: 5

McCarthy PM, Jelsing NC. An advocacy perspective on screening and early diagnosis of lung cancer. *Cancer*. 2000;89(11 Suppl):2510-2514, [PMID: 11147638]

Exclusion code: 5

McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. *Integ Cancer Ther*. 2006;5(1):30-39, [PMID: 16484712]

Exclusion code: 2

McCulloch M, Turner K, Broffman M. Lung cancer detection by canine scent: will there be a lab in the lab? *Eur. Respir. J*. 2012;39(3):511-512, [PMID: 22379142]

Exclusion code: 2

McCunney RJ. Should we screen for occupational lung cancer with low-dose computed tomography? *J. Occup. Environ. Med*. 2006;48(12):1328-1333, [PMID: 17159649]

Exclusion code: 2

McFarlane MJ, Feinstein AR, Wells CK. Clinical features of lung cancers discovered as a postmortem "surprise". *Chest*. 1986;90(4):520-523, [PMID: 3757562]

Exclusion code: 2

McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR. False-positive cancer screens and health-related quality of life. *Cancer Nurs*. 2004;27(5):347-352, [PMID: 15525861]

Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

McKenna RJ, Jr. , Fischel RJ, Brenner M, Gelb AF. Combined operations for lung volume reduction surgery and lung cancer. *Chest*. 1996;110:885-888, [PMID: 8874240]
Exclusion code: 4

McMahon PM, Christiani DC. Computed tomography screening for lung cancer. *BMJ*. 2007;334(7588):271, [PMID: 17289689]
Exclusion code: 5

McMahon PM, Gazelle SG. Response to "comentary: lung cancer screening--progress or peril. *Oncologist*. 2008;13(6):733, [PMID: 18649407]
Exclusion code: 5

McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. *Journal of Thoracic Oncology*. 2011;6(11):1841-1848, [PMID: 21892105]
Exclusion code: 7

McMahon PM, Kong CY, Johnson BE, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. *Radiology*. 2008;248(1):278-287, [PMID: 18458247]
Exclusion code: 2

McMahon PM, Kong CY, Weinstein MC, et al. Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. *Cancer*. 2008;113(12):3440-3449, [PMID: 18988293]
Exclusion code: 2

McNiel A, Blackmon S. VATS lobectomy to treat early-stage non-small cell lung cancer. *Jaapa*. 2008;21(9):31-33, 37, [PMID: 18822588]

Exclusion code: 5

McWilliams A, Lam S. Lung cancer screening. *Curr. Opin. Pulm. Med*. 2005;11(4):272-277, [PMID: 15928490]
Exclusion code: 5

McWilliams A, Mayo J. Computed tomography-detected noncalcified pulmonary nodules: a review of evidence for significance and management. *Proc*. 2008;5(9):900-904, [PMID: 19056713]
Exclusion code: 5

McWilliams A, Mayo J, MacDonald S, et al. Lung cancer screening: a different paradigm. *Am. J. Respir. Crit. Care Med*. 2003;168(10):1167-1173, [PMID: 12882756]
Exclusion code: 4

McWilliams AM, Mayo JR, Ahn MI, MacDonald SLS, Lam SC. Lung cancer screening using multi-slice thin-section computed tomography and autofluorescence bronchoscopy. *J Thorac Oncol*. 2006;1(1):61-68, [PMID: 17409828]
Exclusion code: 2

Mehta P, Smith-Bindman R. Airport full-body screening: What is the risk? *Arch. Intern. Med*. 2011;171(12):1112-1115, [PMID: 21444831]
Exclusion code: 5

Melamed MR. Lung cancer screening results in the National Cancer Institute New York study. *Cancer*. 2000;89(11 Suppl):2356-2362, [PMID: 11147612]
Exclusion code: 5

Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in

Appendix A6. List of Excluded Full-Text Papers

New York. *Chest*. 1984;86(1):44-53, [PMID: 6734291]
Exclusion code: 5

Mendez D, Warner KE. Setting a challenging yet realistic smoking prevalence target for healthy people 2020: Learning from the California experience. *Am. J. Public Health*. 2008;98(3):556-559, [PMID: 17901429]
Exclusion code: 5

Merget R, Johnen G, Pesch B, Bruning T. [Lung cancer screening revisited -- are we merely combing a giraffe?]. *Pneumologie*. 2005;59(3):165-166, [PMID: 15756628]
Exclusion code: 6

Merget R, Straif K. [Screening for bronchial carcinoma still not recommended]. *Pneumologie*. 2001;55(9):445-446, [PMID: 11536069]
Exclusion code: 6

Merkx MAW, Boustahji AH, Kaanders JHAM, et al. A half-yearly chest radiograph for early detection of lung cancer following oral cancer. *Int. J. Oral Maxillofac. Surg*. 2002;31(4):378-382, [PMID: 12361070]
Exclusion code: 3

Mery CM, Pappas AN, Bueno R, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. *Chest*. 2005;128(1):237-245, [PMID: 16002941]
Exclusion code: 3

Mets OM, Buckens CFM, Zanen P, et al. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. *JAMA*.

2011;306(16):1775-1781, [PMID: 22028353]
Exclusion code: 2

Mettler F, Huda W, Yoshizumi T, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. *Radiol. Manage*. 2008;248(1):254, [PMID:]
Exclusion code: 2

Meyer G, Besse B, Friard S, et al. [Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]. *Rev. Mal. Respir*. 2011;28(5):654-659, [PMID: 21645836]
Exclusion code: 6

Meziane M, Decamp M. Low-dose spiral CT for lung cancer screening. *Cleve. Clin. J. Med*. 2001;68(1):84, [PMID: 11204370]
Exclusion code: 5

Mhaskar AR, Quinn G, Vadaparampil S, Djulbegovic B, Gwede CK, Kumar A. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials. *Cancer Treat. Rev*. 2010;36(8):621-628, [PMID: 20444550]
Exclusion code: 2

Michetti G, Pugliese C, Mandalà M. Low-dose CT screening for an early diagnosing of lung cancer. All that glitters is not gold? *Rassegna di Patologia dell'Apparato Respiratorio*. 2007;22(2):86-88, [PMID:]
Exclusion code: 6

Midthun DE. Caution: Screening for lung cancer. *Expert Rev Respir Med*. 2009;3(3):203-205, [PMID: 20477313]
Exclusion code: 5

Midthun DE. Screening for Lung Cancer. *Clin. Chest Med*. 2011;32(4):659-668, [PMID: 22054878]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 5

Midthun DE, Jett JR. Update on screening for lung cancer. *Semin.* 2008;29(3):233-240, [PMID: 18506661]

Exclusion code: 5

Midthun DE, Swensen SJ, Hartman TE, Jett JR. Lung cancer screening results: easily misunderstood. *Mayo Clin. Proc.* 2007;82(1):14-15, [PMID: 17285781]

Exclusion code: 5

Miettinen OS. Screening for lung cancer. *Radiol. Clin. North Am.* 2000;38(3):479-486, [PMID: 10855255]

Exclusion code: 5

Miettinen OS, Henschke CI. CT screening for lung cancer: coping with nihilistic recommendations. *Radiology.* 2001;221(3):592-596; discussion 597, [PMID: 11719649]

Exclusion code: 5

Miettinen OS, Yankelevitz DF, Henschke CI. Screening for lung cancer. *N. Engl. J. Med.* 2001;344(12):935; author reply 936, [PMID: 11263430]

Exclusion code: 5

Miksad RA. When a decision must be made: Role of computer modeling in clinical cancer research. *J. Clin. Oncol.* 2011;29(35):4602-4604, [PMID: 22067392]

Exclusion code: 5

Miller A, Markowitz S, Manowitz A, Miller JA. Lung cancer screening using low-dose high-resolution CT scanning in a high-risk workforce: 3500 nuclear fuel workers in three US states. *Chest.* 2004;125(5 Suppl):152S-153S, [PMID: 15136477]

Exclusion code: 5

Miller A, Markowitz S, Miller JA. CT screening for lung cancer. *N. Engl. J. Med.* 2007;356(7):745; author reply 746-747, [PMID: 17310517]

Exclusion code: 5

Miller A, Markowitz SB, Miller JA. Follow-up diagnostic procedures in lung cancer screening. *Am. J. Respir. Crit. Care Med.* 2009;180(1):102-103; author reply 103, [PMID: 19535669]

Exclusion code: 5

Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial (Brief record). John Wiley & Sons, Ltd. Chichester, UK; 2011. <http://dx.doi.org/10.1002/14651858>.

Exclusion code: 5

Miller AB, Yurgalevitch S, Weissfeld JL, Prostate LC, Ovarian Cancer Screening Trial Project T. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control. Clin. Trials.* 2000;21(6 Suppl):400S-406S, [PMID: 11189691]

Exclusion code: 2

Miller DL, Rowland CM, Deschamps C, Allen MS, Trastek VF, Pairolero PC. Surgical treatment of non-small cell lung cancer 1 cm or less in diameter. *Ann. Thorac. Surg.* 2002;73(5):1545-1550; discussion 1550-1541, [PMID: 12022547]

Exclusion code: 4

Miller YE. Minimizing unintended consequences of detecting lung nodules by computed tomography. *Am. J. Respir. Crit. Care Med.* 2008;178(9):891-892, [PMID: 18945870]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Milleron B. [Screening for lung cancer]. *Rev. Pneumol. Clin.* 2004;60(5 Pt 2):3S11-15, [PMID: 15536346]
Exclusion code: 6

Milleron B. Screening for lung cancer: Feasibility study of a randomized trial comparing low dose spiral CT and chest X-ray [abstract]. Paper presented at: Annual Meeting Proceedings of the American Society of Clinical Oncology. 658p. 2004
Exclusion code: 5

Milleron B, Mornex F, Martin E, Epaul C, Massiani MA. [Preoperative chemotherapy and chemoradiotherapy for non-small-cell bronchial cancers]. *Cancer Radiother.* 2002;6 Suppl 1:105s-113s, [PMID: 12587388]
Exclusion code: 6

Milleron B, Westeel V, Depierre A. [Neoadjuvant chemotherapy of non-small cell bronchial cancers (NSCLC)]. *Presse Med.* 2002;31(17):797-801, [PMID: 12148364]
Exclusion code: 6

Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. *Cancer.* 2007;109(5):933-938, [PMID: 17279584]
Exclusion code: 2

Mina K, Byrne MJ, Ryan G, et al. Surgical management of lung cancer in Western Australia in 1996 and its outcomes. *ANZ J Surg.* 2004;74(12):1076-1081, [PMID: 15574152]
Exclusion code: 10

Minai OA, Shah S, Mazzone P, et al. Bronchogenic carcinoma after lung transplantation: Characteristics and

outcomes. *Journal of Thoracic Oncology.* 2008;3(12):1404-1409, [PMID: 19057264]
Exclusion code: 7

Minami H, Yoshimura M, Matsuoka H, Toshihiko S, Tsubota N. Lung cancer treated surgically in patients <50 years of age. *Chest.* 2001;120(1):32-36, [PMID: 11451812]
Exclusion code: 3

Miser WF. Cancer screening in the primary care setting: the role of the primary care physician in screening for breast, cervical, colorectal, lung, ovarian, and prostate cancers. *Prim. Care.* 2007;34(1):137-167, [PMID: 17481991]
Exclusion code: 5

Mitas M, Cole DJ, Hoover L, et al. Real-time reverse transcription PCR detects KS1/4 mRNA in mediastinal lymph nodes from patients with non-small cell lung cancer. *Clin. Chem.* 2003;49(2):312-315, [PMID: 12560358]
Exclusion code: 5

Miyazawa M, Shiina T, Kurai M, et al. [Assessment of the new TNM classification for resected lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2000;53(11):915-918, [PMID: 11048441]
Exclusion code: 6

Moghissi K, Dixon K, Stringer MR. Current indications and future perspective of fluorescence bronchoscopy: a review study. *Photodiagnosis Photodyn Ther.* 2008;5(4):238-246, [PMID: 19356663]
Exclusion code: 5

Moghissi K, Thorpe JA. Screening for lung cancer. *J. R. Soc. Med.* 2001;94(4):206, [PMID: 11317631]
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Mohammadi S, Bonnet N, Leprince P, et al. Long-term survival of heart transplant recipients with lung cancer: the role of chest computed tomography screening. *Thorac. Cardiovasc. Surg.* 2007;55(7):438-441, [PMID: 17902066]

Exclusion code: 3

Monari E, Casali C, Cuoghi A, et al. Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers. *Proteome Sci.* 2011;9(1):55, [PMID: 21929752]

Exclusion code: 4

Mondello B, Sibilio M, Pavone A, et al. ["Intentionally" limited pulmonary resection versus lobectomy for the treatment of peripheral stage IA non-small cell lung cancers]. *G. Chir.* 2007;28(1-2):7-12, [PMID: 17313726]

Exclusion code: 6

Montes U, Seijo LM, Campo A, Alcaide AB, Bastarrika G, Zulueta JJ. Factors determining early adherence to a lung cancer screening protocol. *Eur. Respir. J.* 2007;30(3):532-537, [PMID: 17567671]

Exclusion code: 4

Montuenga LM, Mulshine JL. New molecular strategies for early lung cancer detection. *Cancer Invest.* 2000;18(6):555-563, [PMID: 10923104]

Exclusion code: 5

Morabia A, Markowitz S. Re: Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. *J. Natl. Cancer Inst.* 2007;99(11):898-899; author reply 899, [PMID: 17551151]

Exclusion code: 2

Mornex F, Loubeyre P, Giraud P, et al. [Gross tumor volume and clinical target volume in radiotherapy: lung cancer].

Cancer Radiother. 2001;5(5):659-670, [PMID: 11715317]

Exclusion code: 6

Moro D. [Neoadjuvant treatment for early stages of non-small-cell lung carcinoma (NSCLC)]. *Rev. Pneumol. Clin.* 2001;57(5 Pt 2):S22-24, [PMID: 11924237]

Exclusion code: 6

Motas N, Motas C, Davidescu M, et al. [Solitary pulmonary nodule--150 resected cases]. *Chirurgia (Bucuresti).* 2010;105(2):195-201, [PMID: 20540232]

Exclusion code: 6

Motohiro A, Ueda H, Komatsu H, Yanai N, Mori T, National Chest Hospital Study Group for Lung C. Prognosis of non-surgically treated, clinical stage I lung cancer patients in Japan. *Lung Cancer.* 2002;36(1):65-69, [PMID: 11891035]

Exclusion code: 2

Moy B. Medical integrity up in smoke? Conflicts of interest and the lung cancer screening controversy. *Oncologist.* 2008;13(5):474-476, [PMID: 18515732]

Exclusion code: 5

Mulshine JL. Screening for lung cancer: in pursuit of pre-metastatic disease. *Nature Reviews. Cancer.* 2003;3(1):65-73, [PMID: 12509768]

Exclusion code: 5

Mulshine JL. Current issues in lung cancer screening. *Oncology (Williston).* 2005;19(13):1724-1730; discussion 1730-1721, [PMID: 16425524]

Exclusion code: 5

Mulshine JL. Commentary: lung cancer screening--progress or peril. *Oncologist.* 2008;13(4):435-438, [PMID: 18448558]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Mulshine JL, Day RW. Screening for lung cancer. *N. Engl. J. Med.* 2001;344(12):935-936, [PMID: 11263428]
Exclusion code: 5

Mulshine JL, Hong S, Martinez A, et al. Moving to the routine management of pre symptomatic lung cancer. *Lung Cancer.* 2001;34 Suppl 2:S1-5, [PMID: 11720735]
Exclusion code: 5

Mulshine JL, Jablons DM. Volume CT for diagnosis of nodules found in lung-cancer screening. *N. Engl. J. Med.* 2009;361(23):2281-2282, [PMID: 19955529]
Exclusion code: 5

Mulshine JL, Smith RA. Lung cancer. 2: screening and early diagnosis of lung cancer. *Thorax.* 2002;57(12):1071-1078, [PMID: 12454304]
Exclusion code: 5

Mulshine JL, Weinstein JN. Is the gene expression pattern of lung cancer detected by screening with spiral computed tomography different from that of symptom-detected lung cancer? *Clin. Cancer Res.* 2004;10(18 Pt 1):5973-5974, [PMID: 15447979]
Exclusion code: 5

Murakami T, Yasuhara Y, Yoshioka S, Uemura M, Mochizuki T, Ikezoe J. Pulmonary lesions detected in population-based CT screening for lung cancer: reliable findings of benign lesions. *Radiat. Med.* 2004;22(5):287-295, [PMID: 15553008]
Exclusion code: 4

Murray CP, Wong PM, Louw J, Waterer GW. Western Australian cigarette smokers have fewer small lung nodules than North Americans on CT screening for lung

cancer. *Journal of Medical Imaging & Radiation Oncology.* 2009;53(4):339-344, [PMID: 19695039]
Exclusion code: 4

Mutti A. Molecular diagnosis of lung cancer: an overview of recent developments. *Acta Biomed. Ateneo Parmense.* 2008;79 Suppl 1:11-23, [PMID: 18924306]
Exclusion code: 5

Nackaerts K, Vansteenkiste J. Low-dose CT screening for lung cancer: trial and error? *J Thorac Oncol.* 2009;4(5):563-564, [PMID: 19395908]
Exclusion code: 5

Nagahiro I, Miyamoto M, Sugiyama H, et al. [A case of drug-induced eosinophilic pneumonia due to tegafur-uracil]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy].* 2011;38(10):1679-1682, [PMID: 21996966]
Exclusion code: 6

Nagahiro I, Nouse H, Kawai T, et al. [Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma accompanied with cystic change]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2010;63(4):332-335, [PMID: 20387510]
Exclusion code: 6

Nair A, Hansell DM. European and North American lung cancer screening experience and implications for pulmonary nodule management. *Eur. Radiol.* 2011;21(12):2445-2454, [PMID: 21830100]
Exclusion code: 2

Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival following lobectomy vs limited resection for stage I lung cancer:

Appendix A6. List of Excluded Full-Text Papers

a meta-analysis. *Br. J. Cancer*. 2005;92(6):1033-1037, [PMID: 15756281]
Exclusion code: 10

Nakamura H, Taniguchi Y, Miwa K, et al. Comparison of the surgical outcomes of thoroscopic lobectomy, segmentectomy, and wedge resection for clinical stage I non-small cell lung cancer. *Thorac. Cardiovasc. Surg*. 2011;59(3):137-141, [PMID: 21480132]
Exclusion code: 10

Nakanishi R, Nakagawa M, Tokufuchi H, Okumura T, Kuboi S, Kido M. [Effects of smoking on video-assisted thoracic surgery lobectomy for lung cancer]. *J Uoeh*. 2010;32(1):45-52, [PMID: 20232646]
Exclusion code: 6

Nakayama T, Baba T, Suzuki T, Sagawa M, Kaneko M. An evaluation of chest X-ray screening for lung cancer in gunma prefecture, Japan: a population-based case-control study. *Eur. J. Cancer*. 2002;38(10):1380-1387, [PMID: 12091070]
Exclusion code: 2

Nam HS, Yang DH, Kim JS, et al. Clinical characteristics of slowly growing lung cancer: 6 Case-series evaluation. *Tuberculosis and Respiratory Diseases*. 2010;68(3):180-184
Exclusion code: 5

National Cancer Institute. Lung cancer trial results show mortality benefit with low-dose CT: Twenty percent fewer lung cancer deaths seen among those who were screened with low-dose spiral CT than with chest X-ray *National Cancer Institute at the National Institutes of Health* 2010; <http://www.cancer.gov/newscenter/pressreleases/2010/NLSTresultsRelease> Accessed May 20, 2011

Exclusion code: 5

National Cancer Institute. What Do the 2006-2007 TUS Data Say about Tobacco Use? 2012; <http://riskfactor.cancer.gov/studies/tus-cps/results/data0607/> Accessed 27 June 2012
Exclusion code: 5

National Cancer Institute. Cancer Trends Progress Report - 2011/2012 Update. *Person-Years of Life Lost* 2012; http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2009&chid=96&coid=930&mid Accessed 28 Jan 2012
Exclusion code: 2

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology: Lung Cancer Screening. *NCCN Guidelines*. 2012. http://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf Accessed 30 Sept 2012
Exclusion code: 2

National Lung Cancer Partnership. Lung Cancer Screening Trial, Options. <http://www.nationallungcancerpartnership.org/news-center/press-releases/screening>. Accessed 19 September 2012
Exclusion code: 2

National Lung Screening Trial Research T, Aberle DR, Berg CD, et al. The National Lung Screening Trial: overview and study design. *Radiology*. 2011;258(1):243-253, [PMID: 21045183]
Exclusion code: 2

Nawa T, Nakagawa T, Kusano S, Kawaski Y, Sugawara Y, Nakata H. Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies. *Chest*. 2002;122(1):15-20, [PMID: 12114333]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 2

Nawa T, Nakagawa T, Mizoue T, et al. Long-term prognosis of patients with lung cancer detected on low-dose chest computed tomography screening. *Lung Cancer*. 2012;75(2):197-202, [PMID: 21813201]

Exclusion code: 3

Neal RD, Allgar VL, Ali N, et al. Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes. *Br. J. Gen. Pract.* 2007;57(536):212-219, [PMID: 17359608]

Exclusion code: 2

Negrin-Dastis S, Butenda D, Dorzee J, Fastrez J, d-Odent JP. Complete disappearance of lung abnormalities on high resolution computed tomography: a case of histiocytosis X. *Can. Respir. J.* 2007;14(4):235-237, [PMID: 17551600]

Exclusion code: 5

Nelson H, Tyne K, Naik A, et al. *Screening for Breast Cancer: Systematic Evidence Review Update for the U. S. Preventive Services Task Force*. Rockville, MD 2009

Exclusion code: 2

Neugut AI, Murray T, Santos J, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. *Cancer*. 1994;73(6):1615-1620, [PMID: 8156488]

Exclusion code: 7

New York Early Lung Cancer Action Project I. CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project. *Radiology*. 2007;243(1):239-249, [PMID: 17392256]

Exclusion code: 4

Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. *J. Natl. Cancer Inst.* 1992;84(20):1572-1575, [PMID: 1404450]

Exclusion code: 7

Noel G, Mazeron JJ. [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer]. *Cancer Radiother.* 2001;5(2):195-196, [PMID: 11355584]

Exclusion code: 6

Nojo T, Imanaka Y, Ishizaki T, et al. Lung cancer incidence in middle-aged men estimated by low-dose computed tomography screening. *Lung Cancer*. 2009;65(1):56-61, [PMID: 19019487]

Exclusion code: 4

Novello S, Fava C, Borasio P, et al. Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers. *Ann. Oncol.* 2005;16(10):1662-1666, [PMID: 16006584]

Exclusion code: 4

Nowak D, Ochmann U, Huber RM, Diederich S. [Lung cancer screening -- state of the art]. *Pneumologie*. 2005;59(3):178-191, [PMID: 15756631]

Exclusion code: 6

O'Brien B, Nichaman L, Browne JE, et al. Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control. Clin. Trials*. 2000;21(6 Suppl):310S-328S, [PMID: 11189685]

Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Obuchowski NA. Estimating sample size for a randomized clinical trial of lung cancer screening. *Contemp Clin Trials*. 2008;29(4):466-477, [PMID: 18088564]
Exclusion code: 4

Obuchowski NA, Graham RJ, Baker ME, Powell KA. Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers. *AJR. Am. J. Roentgenol*. 2001;176(6):1357-1362, [PMID: 11373191]
Exclusion code: 5

O'Connor GT, Hatabu, H. Lung Cancer Screening, Radiation, Risks, Benefits, and Uncertainty. *JAMA*. 2012;307:2434-2435, [PMID: 22692175]
Exclusion code: 2

Oda M, Kanamori T, Marukawa Y, et al. [Evaluation of new TNM classification for lung cancer, especially T3N0M0, stage IIIA, stage IIIB, and pm]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2000;53(11):905-909, [PMID: 11048439]
Exclusion code: 6

Oda M, Matsumoto I, Tamura M, et al. [Video-assisted thoracic surgery for clinical stage I lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2009;62(4):281-284, [PMID: 19348211]
Exclusion code: 6

Oertel S, Debus J, Hof H, Bischof M. [Radiation therapy of lung carcinoma]. *Radiologe*. 2010;50(8):669-674, [PMID: 20628725]
Exclusion code: 6

Ohmatsu H, Kakinuma R. [Lung cancer screening using low-dose helical CT]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*. 2002;60 Suppl 5:653-

656, [PMID: 12101756]
Exclusion code: 6

Ohno Y, Koyama H, Kono A, et al. Influence of detector collimation and beam pitch for identification and image quality of ground-glass attenuation and nodules on 16- and 64-detector row CT systems: Experimental study using chest phantom. *Eur. J. Radiol*. 2007;64(3):406-413, [PMID: 17884323]
Exclusion code: 5

Ohta S, Hirose M, Ishibashi H, Muro H. [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2007;60(7):519-522; discussion 522-515, [PMID: 17642210]
Exclusion code: 6

Oji Y, Kitamura Y, Kamino E, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. *Int. J. Cancer*. 2009;125(2):381-387, [PMID: 19384943]
Exclusion code: 2

Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. *J. Thorac. Cardiovasc. Surg*. 2005;129(1):87-93, [PMID: 15632829]
Exclusion code: 3

Okada M, Sakamoto T, Nishio W, Uchino K, Tsubota N. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension. *Cancer*. 2003;98(3):535-541, [PMID: 12879471]
Exclusion code: 10

Appendix A6. List of Excluded Full-Text Papers

Okada S, Ishimori S, Sato M, Sato S. [Thoracoscopic lung resection for a peripheral lung cancer by a single surgeon with a voice-controlled robot]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2001;54(11):968-971, [PMID: 11593737]
Exclusion code: 6

Okada Y, Kondo T. [Thoracoscopic surgery for elderly patients]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2005;58(8 Suppl):751-755, [PMID: 16097631]
Exclusion code: 6

Okami J, Higashiyama M, Asamura H, et al. Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications. *J Thorac Oncol*. 2009;4(10):1247-1253, [PMID: 19609223]
Exclusion code: 10

Okami J, Ito Y, Higashiyama M, et al. Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. *Ann. Thorac. Surg*. 2010;90(5):1651-1656, [PMID: 20971281]
Exclusion code: 10

Okamoto N. Cost-effectiveness of lung cancer screening in Japan. *Cancer*. 2000;89(11 Suppl):2489-2493, [PMID: 11147633]
Exclusion code: 7

Okamoto N, Suzuki T, Hasegawa H. Evaluation of a clinic-based screening program for lung cancer with a case-control design in Kanagawa, Japan. *Lung Cancer*. 1999;25(2):77-85, [PMID: 10470841]
Exclusion code: 5

Okamoto T, Ichinose Y. [Adjuvant chemotherapy for non-small cell lung cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2006;33(13):1985-1990, [PMID: 17197740]
Exclusion code: 6

Oken MM, Marcus PM, Hu P, et al. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *J. Natl. Cancer Inst*. 2005;97(24):1832-1839, [PMID: 16368945]
Exclusion code: 4

Omatsu H, Kakinuma R, Kaneko M, Moriyama N, Kusumoto M, Eguchi K. Successful lung cancer screening with low-dose helical CT in addition to chest x-ray and sputum cytology: the comparison of two screening periods with or without helical CT. *Radiology*. 2000;217(Suppl):242.
Exclusion code: 5

Omori H, Sata K, Saitoh R, et al. Case report of intralobar pulmonary sequestration detected by lung cancer screening with low-dose spiral CT. *J Uoeh*. 2007;29(3):259-263, [PMID: 17900005]
Exclusion code: 5

Onaitis MW, Petersen RP, Balderson SS, et al. Thoracoscopic lobectomy is a safe and versatile procedure: experience with 500 consecutive patients. *Ann. Surg*. 2006;244(3):420-425, [PMID: 16926568]
Exclusion code: 3

Osaki T, Oyama T, Takenoyama M, et al. [Results of surgical treatment for primary lung cancer; time trends of survival and clinicopathologic features]. *J Uoeh*. 2001;23(3):277-283, [PMID: 11570051]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 6

Osako T, Shiraishi I, Oorui H. [Video-assisted thoracic surgery for lung cancer at Kyoto City Hospital]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2009;62(4):271-276, [PMID: 19348209]
Exclusion code: 6

Osann K. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. *Cancer Res*. 1991;51(18):4893-4897, [PMID: 1654203]
Exclusion code: 2

Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. *Int. J. Cancer*. 1993;54(1):44-48, [PMID: 8386708]
Exclusion code: 5

Oshima A. [Prevention of lung cancer through smoking control activities in Japan]. *Nihon Kyobu Shikkan Gakkai Zasshi*. 1995;33 Suppl:13-16, [PMID: 8752476]
Exclusion code: 6

Oskarsdottir GN, Skuladottir R, Isaksson HJ, Jonsson S, Thorsteinsson H, Gudbjartsson T. [Factors predictive of survival after lobectomy for non-small cell lung cancer in Iceland during 1999-2008]. *Laeknabladid*. 2010;96(4):251-257, [PMID: 20339164]
Exclusion code: 6

Ostroff JS, Buckshee N, Mancuso CA, Yankelevitz DF, Henschke CI. Smoking cessation following CT screening for early detection of lung cancer. *Prev. Med*. 2001;33(6):613-6221, [PMID: 11716658]
Exclusion code: 5

Osuch-Wojcikiewicz E, Rzepakowska A, Bruzgielewicz A, Wieczorek J. [Follicular (nodular) non Hodgkin's lymphoma of tonsil--case report]. *Otolaryngol. Pol*. 2007;61(2):203-206, [PMID: 17668812]
Exclusion code: 6

Oura H, Hirose M, Aikawa H, Ishiki M. [Abdominal organ infarction encountered immediately after surgery of primary lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2005;58(2):137-142, [PMID: 15724477]
Exclusion code: 6

Oura H, Hirose M, Ishiki M. [Diplopia and blepharoptosis associated with orbital emphysema following thoracotomy with lung cancer; report of a case]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2004;57(6):501-504, [PMID: 15202274]
Exclusion code: 6

Oura H, Hirose M, Ishiki M, Takeuchi K, Hirano H, Tomichi N. [Conservative therapy for recurrent bronchial stump fistula occurred after surgery for lung cancer with cerebrovascular disease]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2003;56(10):829-833, [PMID: 13677917]
Exclusion code: 6

Oura H, Ueda S, Sawada T, Watanabe Y, Handa M, Tomichi N. [Reoperation for left main bronchial stump fistula developing after pneumonectomy]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2008;61(6):466-469, [PMID: 18536295]
Exclusion code: 6

Ozols RF, Herbst RS, Colson YL, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Appendix A6. List of Excluded Full-Text Papers

J. Clin. Oncol. 2007;25(1):146-162, [PMID: 17158528]
Exclusion code: 5

Paci E. Observational, one-arm studies and randomized population-based trials for evaluation of the efficacy of lung cancer screening. *J Thorac Oncol.* 2007;2(5 Suppl):S45-46, [PMID: 17457234]
Exclusion code: 5

Padilla J, Penalver JC, Calvo V, et al. [Small-cell nonanaplastic bronchogenic carcinoma. The new stage I]. *Arch. Bronconeumol.* 2000;36(2):68-72, [PMID: 10726193]
Exclusion code: 6

Padilla J, Penalver JC, Jorda C, et al. [Non-small cell bronchogenic cancer in stage IA: mortality patterns after surgery]. *Arch. Bronconeumol.* 2005;41(4):180-184, [PMID: 15826526]
Exclusion code: 6

Padley SP. Thoracic radiology. *Clin. Radiol.* 2001;56(3):191-192, [PMID: 11247694]
Exclusion code: 5

Paleari L, Cesario A, Granone P, D'Angelillo RM, Russo P. Early detection of cancer: lessons from lung cancer CT screening.[Erratum appears in *Thorax*. 2008 Sep;63(9):844]. *Thorax*. 2008;63(6):566, [PMID: 18511643]
Exclusion code: 5

Paleari L, Granone P, Cesario A, Russo P. Re: Computed tomography screening for lung cancer: review of screening principles and update on current status. *Cancer*. 2008;112(11):2520-2521; author reply 2521, [PMID: 18438783]
Exclusion code: 5

Paleari L, Granone P, Grozio A, Cesario A, Russo P. Commentary: early diagnosis of lung cancer: where do we stand? *Oncologist.* 2007;12(12):1433-1436, [PMID: 18165620]
Exclusion code: 5

Palussiere J, Descat E, Fonck M, et al. [Radiofrequency ablation in the treatment of liver and lung tumors]. *Bull. Cancer (Paris)*. 2009;96(11):1099-1109, [PMID: 19858044]
Exclusion code: 6

Pan H, Li L, Zuo C-T, et al. [Relationship between combined multigene detection and response to adjuvant chemotherapy in early-stage non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2008;30(7):528-531, [PMID: 19062721]
Exclusion code: 6

Pandharipande PV, Gazelle GS. Comparative effectiveness research: What it means for radiology. *Radiology*. 2009;253(3):600-605, [PMID: 19952024]
Exclusion code: 5

Paoletti L, Pastis N, Denlinger C, Silvestri G. A Decade of Advances in Treatment of Early-Stage Lung Cancer. *Clin. Chest Med.* 2011;32(4):827-838, [PMID: 22054889]
Exclusion code: 5

Papadakis E. [Adjuvant treatment for early stages of non-small-cell lung carcinoma (NSCLC)]. *Rev. Pneumol. Clin.* 2001;57(5 Pt 2):S25-28, [PMID: 11924238]
Exclusion code: 6

Parissis H, Leotsinidis M, Hughes A, McGovern E, Luke D, Young V. Comparative analysis and outcomes of sleeve resection versus pneumonectomy.

Appendix A6. List of Excluded Full-Text Papers

- Asian Cardiovasc Thorac Ann.* 2009;17(2):175-182, [PMID: 19592550]
Exclusion code: 10
- Park BJ, Altorki NK. Diagnosis and management of early lung cancer. *Surg. Clin. North Am.* 2002;82(3):457-476, v, [PMID: 12371580]
Exclusion code: 5
- Park BJ, Melfi F, Mussi A, et al. Robotic lobectomy for non-small cell lung cancer (NSCLC): long-term oncologic results. *J. Thorac. Cardiovasc. Surg.* 2012;143(2):383-389, [PMID: 22104677]
Exclusion code: 10
- Park ER, Ostroff JS, Rakowski W, et al. Risk perceptions among participants undergoing lung cancer screening: baseline results from the National Lung Screening Trial. *Ann. Behav. Med.* 2009;37(3):268-279, [PMID: 19711141]
Exclusion code: 2
- Parles K. Low-dose spiral CT screening. *Chest.* 2001;120(3):1042-1043, [PMID: 11555555]
Exclusion code: 2
- Parshin VD, Belov IV, Tarabrin EA, Komarov RN, Parshin VV, Khovrin VV. [Resection and aorta replacement in extended and combined operations for lung cancer]. *Vestnik Khirurgii Imeni i - i - Grekova.* 2011;170(1):66-69, [PMID: 21506360]
Exclusion code: 6
- Parshin VD, Grigor'eva SP, Mirzoian OS, et al. [Surgery for lung cancer in elderly]. *Khirurgiia (Sofiia).* 2010(10):11-16, [PMID: 21169924]
Exclusion code: 6
- Partain CL. Focus on thoracic imaging. *J. Magn. Reson. Imaging.* 2010;32(6):1271-1272, [PMID: 21105133]
Exclusion code: 5
- Pasini F, Verlato G, Durante E, et al. Persistent excess mortality from lung cancer in patients with stage I non-small-cell lung cancer, disease-free after 5 years. *Br. J. Cancer.* 2003;88(11):1666-1668, [PMID: 12771977]
Exclusion code: 10
- Pass HI, Altorki NK. Computerized tomographic nodule heterogeneity: present and future impact on indications for sublobar resections. *Clin Lung Cancer.* 2004;6(1):20-27, [PMID: 15310413]
Exclusion code: 5
- Pastorino U. Lung cancer: diagnosis and surgery. *Eur. J. Cancer.* 2001;37 Suppl 7:S75-90, [PMID: 11888008]
Exclusion code: 2
- Pastorino U. Early detection of lung cancer. *Respiration.* 2006;73(1):5-13, [PMID: 16498267]
Exclusion code: 5
- Pastorino U. Lung cancer screening. *Br. J. Cancer.* 2010;102(12):1681-1686, [PMID: 20424610]
Exclusion code: 5
- Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. *J. Clin. Oncol.* 1997;15(8):2858-2865, [PMID: 9256129]
Exclusion code: 10
- Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. *Lancet.* 2003;362(9384):593-597, [PMID: 12944057]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 4

Pastorino U, Borasio P, Francese M, et al. Lung cancer stage is an independent risk factor for surgical mortality. *Tumori*. 2008;94(3):362-369, [PMID: 18705405]
Exclusion code: 7

Pastorino U, Landoni C, Marchiano A, et al. Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. *J Thorac Oncol*. 2009;4(11):1352-1356, [PMID: 19861905]
Exclusion code: 4

Patz EF, Jr. Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project. *J. Natl. Cancer Inst*. 2006;98(11):724-725, [PMID: 16757691]
Exclusion code: 2

Patz EF, Jr., Black WC, Goodman PC. CT screening for lung cancer: not ready for routine practice. *Radiology*. 2001;221(3):587-591; discussion 598-589, [PMID: 11719648]
Exclusion code: 5

Patz EF, Jr., Caporaso NE, Dubinett SM, et al. National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers. *J Thorac Oncol*. 2010;5(10):1502-1506, [PMID: 20871260]
Exclusion code: 5

Patz EF, Jr., Goodman PC. Low-dose spiral computed tomography screening for lung cancer: not ready for prime time. *Am. J.*

Respir. Crit. Care Med. 2001;163(4):813-814, [PMID: 11282746]

Exclusion code: 5

Patz EF, Jr., Goodman PC, Bepler G. Screening for lung cancer. *N. Engl. J. Med*. 2000;343(22):1627-1633, [PMID: 11096172]
Exclusion code: 5

Patz EF, Jr., Rossi S, Harpole DH, Jr., Herndon JE, Goodman PC. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. *Chest*. 2000;117(6):1568-1571, [PMID: 10858384]
Exclusion code: 4

Patz EF, Jr., Swensen SJ, Herndon JE, 2nd. Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. *J. Clin. Oncol*. 2004;22(11):2202-2206, [PMID: 15169809]
Exclusion code: 2

Patz J, E. F., Campa MJ, Gottlin EB, Kusmartseva I, Xiang RG, Herndon JE. Panel of serum biomarkers for the diagnosis of lung cancer. *J. Clin. Oncol*. 2007;25(35):5578-5583, [PMID: 18065730]
Exclusion code: 4

Pedersen JH, Dirksen A, Olsen JH. [Screening for lung cancer with low-dosage CT]. *Ugeskr. Laeger*. 2002;164(2):167-170, [PMID: 11831081]
Exclusion code: 6

Peek LJ. Immunology for detection of early-stage lung cancer. *MLO. Med. Lab. Obs*. 2010;42(10):16, [PMID: 21090050]
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Pegna AL, Picozzi G. Lung cancer screening update. *Curr. Opin. Pulm. Med.* 2009;15(4):327-333, [PMID: 19395971]
Exclusion code: 5

Pei J, Han B, Zhang J, Gu A. [Multivariate survival analysis of patients with stage I NSCLC]. *Zhongguo Fei Ai Za Zhi.* 2011;14(12):926-932, [PMID: 22152692]
Exclusion code: 6

Pelosi G, Sonzogni A, Veronesi G, et al. Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study. *Lung Cancer.* 2008;62(2):202-214, [PMID: 18450320]
Exclusion code: 2

Penalver JC, Padilla J, Jorda C, et al. [Use of blood products in patients treated surgically for stage I non-small cell lung cancer]. *Arch. Bronconeumol.* 2005;41(9):484-488, [PMID: 16194510]
Exclusion code: 6

Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. *J. Natl. Cancer Inst.* 2008;100(20):1432-1438, [PMID: 18840817]
Exclusion code: 2

Petersen RH, Hansen HJ, Dirksen A, Pedersen JH. Lung cancer screening and video-assisted thoracic surgery. *J Thorac Oncol.* 2012;7(6):1026-1031, [PMID: 22588154]
Exclusion code: 7

Petkova E, Grudeva V, Hadzhidekova V. Low doses of ionizing radiation - Medical application and possible effects. *General Medicine.* 2011;13(2):37-40, [PMID:

Exclusion code: 5

Peto R, Lopez AD, Boreham J, Thun M, Heath CJ. *Mortality from Smoking in Developed Countries 1950-2000. Indirect Estimates from National Vital Statistics.* New York: Oxford University Press; 1994
Exclusion code: 8

Petrov D, Vlasov V, Stanoev V, Kostadinov M, Danon S, Kirova G. [Results of the operative treatment of primary pulmonary sarcomas]. *Khirurgiia (Sofia).* 2008(1-2):13-17, [PMID: 18983003]
Exclusion code: 6

Petty TL. The early identification of lung carcinoma by sputum cytology. *Cancer.* 2000;89(11 Suppl):2461-2464, [PMID: 11147627]
Exclusion code: 2

Petty TL. The early diagnosis of lung cancer. *Dis. Mon.* 2001;47(6):204-264, [PMID: 11473242]
Exclusion code: 5

Petty TL. Lung cancer detection: a new challenge for Irish medicine. *Ir. Med. J.* 2001;94(2):36-37, [PMID: 11321167]
Exclusion code: 5

Petty TL. Sputum cytology for the detection of early lung cancer. *Curr. Opin. Pulm. Med.* 2003;9(4):309-312, [PMID: 12806245]
Exclusion code: 5

Petty TL. Screening for lung cancer. *Ann. Intern. Med.* 2004;141(8):649-650, [PMID: 15492350]
Exclusion code: 5

Pfannschmidt J, Muley T, Bulzebruck H, Hoffmann H, Dienemann H. Prognostic

Appendix A6. List of Excluded Full-Text Papers

assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. *Lung Cancer*. 2007;55(3):371-377, [PMID: 17123661]
Exclusion code: 7

Pfannschmidt J, Muley T, Hoffmann H, Bulzebruck H, Dienemann H. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification]. *Dtsch. Med. Wochenschr*. 2006;131(47):2643-2648, [PMID: 17109272]
Exclusion code: 6

Phelps RM, Smith DK, Heilig CM, et al. Cancer incidence in women with or at risk for HIV. *Int. J. Cancer*. 2001;94(5):753-757, [PMID: 11745473]
Exclusion code: 5

Phillips M, Altorki N, Austin JHM, et al. Prediction of lung cancer using volatile biomarkers in breath. *Cancer Biomark*. 2007;3(2):95-109, [PMID: 17522431]
Exclusion code: 2

Picozzi G, Paci E, Lopez Pegna A, et al. Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial "Italung-CT". *Radiol. Med. (Torino)*. 2005;109(1-2):17-26, [PMID: 15729183]
Exclusion code: 3

Pierce DA, Sharp GB, Mabuchi K. Joint effects of radiation and smoking on lung cancer risk among Atomic bomb survivors. *Radiat. Res*. 2005;163(6):694-695, [PMID: 16044494]
Exclusion code: 3

Pigula FA, Keenan R, J, , Ferson PF, Landreneau RJ. Unsuspected lung cancer found in work-up for lung reduction operation *Ann. Thorac. Surg*.

1996;61(1):174-176, [PMID: 8561548]
Exclusion code: 4

Pilgram TK, Quirk JD, Bierhals AJ, et al. Accuracy of emphysema quantification performed with reduced numbers of CT sections. *AJR. Am. J. Roentgenol*. 2010;194(3):585-591, [PMID: 20173132]
Exclusion code: 7

Pinsky PF, Freedman M, Kvale P, Oken M, Caporaso N, Gohagan J. Abnormalities on chest radiograph reported in subjects in a cancer screening trial. *Chest*. 2006;130(3):688-693, [PMID: 16963664]
Exclusion code: 2

Pistelli F, Aquilini F, Tavanti L, et al. Smoking cessation over the first year of follow up in a lung cancer screening with spiral chest CT scan (Italung CT study) [Abstract]. *Eur. Respir. J*. 2007;30(Suppl 51):503s
Exclusion code: 5

Pizzocaro G, Schiavo M, Solima S, Vitellaro M, BIASONI N, Nicolai N. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003]. *Urologia*. 2010;77 Suppl 17:50-56, [PMID: 21308676]
Exclusion code: 6

Plickova K, Spidlen V, Pesek M, Mukensnabl P. [Patient survival analysis in surgery of bronchogenic carcinoma from 1986 to 1997]. *Rozhl. Chir*. 2003;82(6):293-299, [PMID: 12898778]
Exclusion code: 6

Ploeg AJ, Kappetein AP, van Tongeren RB, Pahlplatz PV, Kastelein GW, Breslau PJ. Factors associated with perioperative complications and long-term results after

Appendix A6. List of Excluded Full-Text Papers

pulmonary resection for primary carcinoma of the lung. *Eur. J. Cardiothorac. Surg.* 2003;23(1):26-29, [PMID: 12493499]
Exclusion code: 3

Poghosyan H, Kennedy Sheldon L, Cooley ME. The impact of computed tomography screening for lung cancer on smoking behaviors: A teachable moment? *Cancer Nurs.* 2011, [PMID: 22209869]
Exclusion code: 2

Popescu I. [Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention]. *Pneumologia.* 2008;57(4):201-208, [PMID: 19186682]
Exclusion code: 6

Porrello C, Alifano M, Forti Parri SN, et al. Surgical treatment of stage I lung cancer. Results and prognostic factors. *J. Cardiovasc. Surg. (Torino).* 2002;43(5):723-727, [PMID: 12386592]
Exclusion code: 10

Port JL, Kent M, Altorki NK. Early lung cancer detection and treatment strategies. *Surg. Oncol.* 2002;11(4):191-199, [PMID: 12450555]
Exclusion code: 5

Portalone L. Low dose spiral computed tomography. *Monaldi Archives for Chest Disease.* 2002;57(5-6):291-292, [PMID: 12814044]
Exclusion code: 5

Porter JC, Spiro SG. Detection of early lung cancer. *Thorax.* 2000;55 Suppl 1:S56-62, [PMID: 10943641]
Exclusion code: 5

Postmus PE. Screening and early diagnosis in lung cancer. *Expert Rev Anticancer Ther.* 2008;8(10):1529-1531, [PMID: 18925844]
Exclusion code: 5

Postmus PE. Screening for lung cancer, an ongoing debate. *Ann. Oncol.* 2008;19 Suppl 7:vii25-27, [PMID: 18790961]
Exclusion code: 5

Prasse A, Waller C, Passlick B, Muller-Quernheim J. [Lung cancer from the perspective of internal medicine and surgery]. *Radiologe.* 2010;50(8):662-668, [PMID: 20652215]
Exclusion code: 6

Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control. Clin. Trials.* 2000;21(6 Suppl):273S-309S, [PMID: 11189684]
Exclusion code: 8

Pu Q, Liu L-X, Che G-W, et al. [The learning curve of single-direction complete video-assisted thoracoscopic surgery for lung cancer]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery].* 2010;48(15):1161-1165, [PMID: 21055011]
Exclusion code: 6

Pyenson BS, Sander MS, Jiang Y, Khan H, Mulshine JL. An Actuarial Analysis Shows That Offering Lung Cancer Screening As An Insurance Benefit Would Save Lives At Relatively Low Cost *Health Aff. (Millwood).* 2012;31(4):770-779, [PMID: 22492894]
Exclusion code: 2

Qiao M, Pardee AB. Biomarkers, regeons, and pathways to lethal cancer. *J. Cell. Biochem.* 2007;102(5):1076-1086, [PMID: 17957698]
Exclusion code: 5

Qin M, Fu Y, Yu D, Xu S, Han M, Wang Z. [Diagnosis and treatment of tracheal or bronchotracheal adenoid cystic

Appendix A6. List of Excluded Full-Text Papers

carcinoma]. *Zhongguo Fei Ai Za Zhi*. 2010;13(6):628-631, [PMID: 20681452]
Exclusion code: 6

Qiu Q, Todd NW, Li R, et al. Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. *Cancer*. 2008;114(4):275-283, [PMID: 18484646]
Exclusion code: 2

Quekel LG, Kessels AG, Goei R, Van Engelshoven JM. Miss rate of lung cancer on the chest radiograph in clinical practice. *Chest*. 1999;115(3):720-724, [PMID: 10084482]
Exclusion code: 5

Raji OY, Duffy SW, Agbaje OF, et al. Predictive Accuracy of the Liverpool Lung Project Risk Model for Stratifying Patients for Computed Tomography Screening for Lung Cancer A Case-Control and Cohort Validation Study. *Ann. Intern. Med*. 2012;157(4):242-250, [PMID: 22910935]
Exclusion code: 2

Ram SF, RodriguezRoisin R, GranadosNavarrete A, GarciaAymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease [Systematic Review]: Cochrane Database of Systematic Reviews; 2011
Exclusion code: 4

Ravenel JG, Costello P, Silvestri GA. Screening for lung cancer. *AJR. Am. J. Roentgenol*. 2008;190(3):755-761, [PMID: 18287449]
Exclusion code: 2

Raynaud C, Le Caer H, Borget I, et al. [Comprehensive geriatric assessment and complications after resection for lung cancer]. *Rev. Mal. Respir*. 2010;27(5):483-488, [PMID: 20569881]

Exclusion code: 6

Read C, Janes S, George J, Spiro S. Early lung cancer: screening and detection. *Prim*. 2006;15(6):332-336, [PMID: 17088104]
Exclusion code: 5

Reed MF, Molloy M, Dalton EL, Howington JA. Survival after resection for lung cancer is the outcome that matters. *Am. J. Surg*. 2004;188(5):598-602, [PMID: 15546578]
Exclusion code: 10

Reich J. Hazards of lung cancer screening: three vignettes and a critique. *Chest*. 2001;119(2):659-660, [PMID: 11171757]
Exclusion code: 5

Reich JM. Improved survival and higher mortality: the conundrum of lung cancer screening. *Chest*. 2002;122(1):329-337, [PMID: 12114377]
Exclusion code: 5

Reich JM. Lung-cancer screening. *N. Engl. J. Med*. 2005;353(20):2194-2195; author reply 2194-2195, [PMID: 16291993]
Exclusion code: 5

Reich JM. Estimated impact of LDCT-identified stage IA non-small-cell lung cancer on screening efficacy. *Lung Cancer*. 2006;52(3):265-271, [PMID: 16616394]
Exclusion code: 5

Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. *Thorax*. 2008;63(4):377-383, [PMID: 18364449]
Exclusion code: 2

Reich JM. Lung cancer screening outcomes. *Radiology*. 2009;253(1):277, [PMID: 19789261]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 5

Reich JM, Kim JS. Lung cancer growth dynamics. *Eur. J. Radiol.* 2011;80(3):e458-e461, [PMID: 20810232]

Exclusion code: 5

Resnick EM, Keitt SK, Marts SA. A report from the Society for Women's Health Research. *Lung Cancer.* 2005;47(3):427-433, [PMID: 15782441]

Exclusion code: 2

Retico A, Delogu P, Fantacci ME, Gori I, Preite Martinez A. Lung nodule detection in low-dose and thin-slice computed tomography. *Comput. Biol. Med.* 2008;38(4):525-534, [PMID: 18342844]

Exclusion code: 2

Rice D, Kim H-W, Sabichi A, et al. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. *Ann. Thorac. Surg.* 2003;76(4):1001-1007; discussion 1007-1008, [PMID: 14529975]

Exclusion code: 4

Rino Y, Sekino Y, Yamada T, et al. [Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2007;34(7):1095-1098, [PMID: 17637547]

Exclusion code: 6

Riquet M, Le Pimpec Barthes F, Scotte F, et al. [Relevance of surgery in small cell lung cancer]. *Rev. Pneumol. Clin.* 2009;65(3):129-135, [PMID: 19524800]

Exclusion code: 6

Risch A, Plass C. Lung cancer epigenetics and genetics. *Int. J. Cancer.* 2008;123(1):1-7, [PMID: 18425819]

Exclusion code: 2

Rivera C, Dahan M, Bernard A, Falcoz P-E, Thomas P. Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. *Eur. J. Cardiothorac. Surg.* 2011;39(6):981-986, [PMID: 21030267]

Exclusion code: 3

Rivera C, Falcoz P-E, Bernard A, Thomas PA, Dahan M. Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: a nested case-control study. *Chest.* 2011;140(4):874-880, [PMID: 21436251]

Exclusion code: 3

Rivera MP, Stover DE. Gender and lung cancer. *Clin. Chest Med.* 2004;25(2):391-400, [PMID: 15099898]

Exclusion code: 2

Rizvi N, Hayes DF. A "breathalyser" for lung cancer? [comment]. *Lancet.* 1999;353(9168):1897-1898, [PMID: 10371562]

Exclusion code: 5

Roberts HC, Patsios D, Paul NS, et al. Lung cancer screening with low-dose computed tomography: Canadian experience. *Can. Assoc. Radiol. J.* 2007;58(4):225-235, [PMID: 18186434]

Exclusion code: 5

Roberts HC, Patsios DA, Paul NS, et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. *J Thorac Oncol.* 2009;4(5):620-628, [PMID: 19357540]

Exclusion code: 2

Rodondi N, Cornuz J. Potential pitfalls in reading medical articles for primary care

Appendix A6. List of Excluded Full-Text Papers

physicians. *Lecture d'articles médicaux: Quelques pièges à éviter*. 2007;3(135):2718-2723, [PMID: 18214225]

Exclusion code: 5

Rodríguez Lajusticia L. Epidemiology of lung cancer. *Revisión en Cancer*. 2009;23(4):125-130, [PMID: Exclusion code: 6]

Rosell R, Wei J, Taron M. Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2009;10(1):8-9, [PMID: 19289365]

Exclusion code: 2

Rosenbaum DH, Bhojani RA, Dikmen E, et al. Routine computed tomography screening of the chest in high-risk cardiac transplant recipients may improve survival. *J. Heart Lung Transplant*. 2005;24(12):2043-2047, [PMID: 16364847]

Exclusion code: 3

Rotunno M, Hu N, Su H, et al. A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma. *Cancer Prev Res (Phila Pa)*. 2011;4(10):1599-1608, [PMID: 21742797]

Exclusion code: 2

Roviaro G, Varoli F, Vergani C, Nucca O, Maciocco M, Grignani F. Long-term survival after videothoroscopic lobectomy for stage I lung cancer. *Chest*. 2004;126(3):725-732, [PMID: 15364748]

Exclusion code: 10

Rozenstein A, White CS, Austin JHM. Incidental lung carcinoma detected at CT in patients selected for lung volume reduction surgery to treat severe pulmonary

emphysema. *Radiology*. 1998;207:487-490, [PMID: 9577499]

Exclusion code: 3

Rubin RN. Asymptomatic smoker who requests lung cancer screening. *Consultant*. 2007;47(6):575-576

Exclusion code: 5

Rubin RN. A 69-year-old former smoker with cough. *Consultant*. 2010;50(10)

Exclusion code: 5

Rueth NM, Andrade RS. Is VATS lobectomy better: perioperatively, biologically and oncologically? *Ann. Thorac. Surg*. 2010;89(6):S2107-2111, [PMID: 20493991]

Exclusion code: 2

Rueth NM, Parsons HM, Habermann EB, et al. The long-term impact of surgical complications after resection of stage I nonsmall cell lung cancer: a population-based survival analysis. *Ann. Surg*. 2011;254(2):368-374, [PMID: 21617585]

Exclusion code: 3

Rueth NM, Parsons HM, Habermann EB, et al. Surgical treatment of lung cancer: predicting postoperative morbidity in the elderly population. *J. Thorac. Cardiovasc. Surg*. 2012;143(6):1314-1323, [PMID: 22341420]

Exclusion code: 2

Ruiz M. Early lung cancer detection in HIV: the role of CT screening in high risk cases. *HIV Clinician*. 2010;22(1):1-5, [PMID: 20333820]

Exclusion code: 5

Russo P, Paleari L, Granone P, Cesario A, Pastorino U. Computed tomography screening for lung cancer in a high-risk population: update on current status. *J.*

Appendix A6. List of Excluded Full-Text Papers

Natl. Cancer Inst. 2008;100(14):1043-1044, [PMID: 18612133]
Exclusion code: 2

Rzechonek A, Kołodziej J, Kołodziej M. Multirow computed X-ray tomography in surgical treatment of lung tumors. *Family Medicine and Primary Care Review.* 2008;10(3):1052-1060
Exclusion code: 6

Sadovnikov AA, Panchenko KI. [Infiltrative tuberculosis and lung cancer]. *Probl.* 2007(1):55-60, [PMID: 17338357]
Exclusion code: 6

Sagawa M, Nakayama T, Tsukada H, et al. The efficacy of lung cancer screening conducted in 1990s: four case-control studies in Japan. . *Lung Cancer.* 2003;41(1):29-36, [PMID: 12826309]
Exclusion code: 5

Sagawa M, Saito Y, Sato M, et al. The efficacy of sputum cytology in mass screening program for early detection of lung cancer. *Anticancer Res.* 2003;23(1B):597-600, [PMID: 12680153]
Exclusion code: 2

Saghir Z, Ashraf H, Dirksen A, Brodersen J, Pedersen JH. Contamination during 4 years of annual CT screening in the Danish Lung Cancer Screening Trial (DLCST). *Lung Cancer.* 2011;71(3):323-327, [PMID: 20619924]
Exclusion code: 2

Saito G, Takasuna K, Yoshida K, Nishimura H. [Acute pulmonary embolism following lung resection: report of two cases]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2007;60(10):946-949, [PMID: 17877019]
Exclusion code: 6

Saito M, Miura T, Furukawa K, Kato H. [Reevaluation of the surgical indications for lung cancer based on the N factor]. *Nippon Geka Gakkai Zasshi.* 2001;102(7):511-516, [PMID: 11505502]
Exclusion code: 6

Sakamoto S, Homma S, Kawabata M, et al. [Fatal acute exacerbation of idiopathic pulmonary fibrosis/usual interstitial pneumonia initially in the right lung after surgery lobectomy for left lung cancer]. *Nihon Kokyuki Gakkai Zasshi.* 2004;42(8):760-766, [PMID: 15455951]
Exclusion code: 6

Sakhelashvili MI, Soldatenko OI, Pritula EI, Lutsyshin TV. [Diagnostic features of tuberculosis and cancer of the lung detected in patients during planned screening]. *Probl. Tuberk.* 2002(5):27-29, [PMID: 12164115]
Exclusion code: 6

Sakurai H, Asamura H, Goya T, et al. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study. *J Thorac Oncol.* 2010;5(10):1594-1601, [PMID: 20736855]
Exclusion code: 5

Sakurai H, Dobashi Y, Mizutani E, et al. [Prognosis of resected stage I bronchioloalveolar carcinoma of the lung]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2004;57(6):440-443, [PMID: 15202261]
Exclusion code: 6

Salomaa ER. Does the early detection of lung carcinoma improve prognosis? The Turku Study. *Cancer.* 2000;89(11 Suppl):2387-2391, [PMID: 11147616]
Exclusion code: 8

Appendix A6. List of Excluded Full-Text Papers

Samet JM, Crowell RE, Estepar RSJ, et al. Providing Guidance for Lung Cancer Screening: The American Lung Association Interim Report on Lung Cancer Screening. 2012

Exclusion code: 2

Samet JM, Thun MJ, De Gonzalez AB. Models of smoking and lung cancer risk: A means to an end. *Epidemiology*.

2007;18(5):649-651, [PMID: 17700254]

Exclusion code: 5

Sánchez De Cos Escuín J. Lung Cancer in Spain. Current Epidemiology, Survival, and Treatment. *Arch. Bronconeumol*.

2009;45(7):341-348, [PMID: 19324488]

Exclusion code: 6

Sanderson DR, Fontana R. Results of Mayo Lung Project: an interim report. *Recent Results Cancer Res*.

1982;82:179-186,

[PMID: 6287546]

Exclusion code: 5

Sandler DP, Weinberg CR, Shore DL, et al. Indoor radon and lung cancer risk in connecticut and utah. *J Toxicol Environ Health A*.

2006;69(7):633-654, [PMID:

16608830]

Exclusion code: 2

Sano I, Hara S, Matsumoto K, Hatachi G, Nakamura A, Minami H. [Clinical analysis of resected pulmonary pleomorphic carcinoma]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*.

2009;62(3):187-191, [PMID: 19280947]

Exclusion code: 6

Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R.

EUROCare-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. *Eur. J. Cancer*.

2009;45(6):931-991, [PMID: 19171476]

Exclusion code: 5

Santo A, Genestreti G, Fiorio E, et al.

[Non-small cell lung cancer (NSCLC): the evolution of neo-adjuvant chemotherapy in the last 15 years]. *Recenti Prog. Med*.

2006;97(4):211-218, [PMID: 16729492]

Exclusion code: 6

Sasaki Y, Abe K, Tabei M, Katsuragawa S, Kurosaki A, Matsuoka S. Clinical

usefulness of temporal subtraction method in screening digital chest radiography with a mobile computed radiography system.

Radiol Phys Technol. 2011;4(1):84-90,

[PMID: 21170689]

Exclusion code: 4

Sato A, Sueoka-Aragane N, Saitoh J, et al.

Establishment of a new method,

transcription-reverse transcription

concerted reaction, for detection of plasma

hnRNP B1 mRNA, a biomarker of lung

cancer. *J. Cancer Res. Clin. Oncol*.

2008;134(11):1191-1197, [PMID:

18461365]

Exclusion code: 7

Sato M, Saito Y, Endo C, et al. The natural history of radiographically occult

bronchogenic squamous cell carcinoma: a

retrospective study of overdiagnosis bias.

Chest. 2004;126(1):108-113, [PMID:

15249450]

Exclusion code: 3

Sato M, Sakurada A, Sagawa M, et al.

Diagnostic results before and after

introduction of autofluorescence

bronchoscopy in patients suspected of

having lung cancer detected by sputum

cytology in lung cancer mass screening.

Lung Cancer. 2001;32(3):247-253, [PMID:

11390006]

Exclusion code: 7

Appendix A6. List of Excluded Full-Text Papers

Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. *J Thorac Oncol.* 2007;2(4):327-343, [PMID: 17409807]

Exclusion code: 7

Sawada S, Komori E, Yamashita M, et al. Comparison in prognosis after VATS lobectomy and open lobectomy for stage I lung cancer: retrospective analysis focused on a histological subgroup. *Surg. Endosc.* 2007;21(9):1607-1611, [PMID: 17762957]

Exclusion code: 10

Schaberg FJ, Jr., Prinz RA, Chen EL, et al. Incidental findings at surgery-part 2. *Curr. Probl. Surg.* 2008;45(6):388-439, [PMID: 18452760]

Exclusion code: 5

Schachter EN, Neuman T. Targeted therapies for the prevention of lung cancer. *Drugs of Today.* 2007;43(12):897-936, [PMID: 18174975]

Exclusion code: 5

Schaefer-Prokop C, Prokop M. New imaging techniques in the treatment guidelines for lung cancer. *European Respiratory Journal - Supplement.* 2002;35:71s-83s, [PMID: 12064683]

Exclusion code: 5

Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. *N. Engl. J. Med.* 2002;346(14):1047-1053, [PMID: 11932471]

Exclusion code: 3

Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. *J. Nucl. Med.* 2001;42(12):1800-1804, [PMID: 11752076]

Exclusion code: 7

Schmidt B, Liebers U, Witt C. [Screening for bronchial carcinoma -- pro]. *Dtsch. Med. Wochenschr.* 2005;130(9):466, [PMID: 15731960]

Exclusion code: 6

Schneider J. Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels. *Cancer Biomark.* 2010;6(3-4):149-162, [PMID: 20660961]

Exclusion code: 5

Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. *Cancer Detect. Prev.* 2000;24(6):531-535, [PMID: 11198266]

Exclusion code: 4

Schneider J, Presek P, Braun A, Loffler S, Woitowitz HJ. Serum ras (p21) as a marker for occupationally derived lung cancer? *Clin. Chem. Lab. Med.* 2000;38(4):301-305, [PMID: 10928648]

Exclusion code: 4

Schnipper LE. Update in oncology. *Ann. Intern. Med.* 2007;147(11):775-782, [PMID: 18056661]

Exclusion code: 5

Schnoll RA, Bradley P, Miller SM, Unger M, Babb J, Cornfeld M. Psychological issues related to the use of spiral CT for lung cancer early detection. *Lung Cancer.* 2003;39(3):315-325, [PMID: 12609570]

Exclusion code: 2

Schnoll RA, Miller SM, Unger M, McAleer C, Halbherr T, Bradley P. Characteristics of female smokers attending a lung cancer

Appendix A6. List of Excluded Full-Text Papers

screening program: a pilot study with implications for program development. *Lung Cancer*. 2002;37(3):257-265, [PMID: 12234693]
Exclusion code: 10

Schnoll RA, Wileyto EP, Hornik R, Schiller J, Lerman C. Spiral computed tomography and lung cancer: Science, the media, and public opinion. *J. Clin. Oncol*. 2007;25(36):5695-5697, [PMID: 18089863]
Exclusion code: 5

Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N. Engl. J. Med*. 2012;366(25):2345-2357, [PMID: 22612596]
Exclusion code: 2

Schoepf UJ, Becker CR, Obuchowski NA, et al. Multi-slice computed tomography as a screening tool for colon cancer, lung cancer and coronary artery disease. *Eur. Radiol*. 2001;11(10):1975-1985, [PMID: 11702131]
Exclusion code: 5

Schrieber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer. Summary of published evidence. *Chest*. 2003;123 (Supplement):115s-128s, [PMID: 12527571]
Exclusion code: 5

Schultz EM, Silvestri GA, Gould MK. Variation in experts' beliefs about lung cancer growth, progression, and prognosis. *J Thorac Onc*. 2008;3(4):422-426, [PMID: 18379363]
Exclusion code: 2

Schwartz AM, Henson DE, American College of Chest P. Diagnostic surgical

pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. 2007;132(3 Suppl):78S-93S, [PMID: 17873162]
Exclusion code: 7

Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. *J. Thorac. Cardiovasc. Surg*. 2010;139(4):976-981; discussion 981-973, [PMID: 20172539]
Exclusion code: 3

Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. 2007;132(3 SUPPL.):234S-242S, [PMID: 17873171]
Exclusion code: 2

Sedjo RL, Byers T, Barrera Jr E, et al. A midpoint assessment of the American Cancer Society challenge goal to decrease cancer incidence by 25% between 1992 and 2015. *CA Cancer Journal for Clinicians*. 2007;57(6):326-340, [PMID: 17989128]
Exclusion code: 5

Seijo LM, Montuenga LM, Zulueta JJ. Re: Inconsistencies in findings from the early lung cancer action project studies of lung cancer screening. *J. Natl. Cancer Inst*. 2012;104(3):254, [PMID: 22275407]
Exclusion code: 5

Seki N, Eguchi K, Kaneko M, et al. The adenocarcinoma-specific stage shift in the Anti-lung Cancer Association project: significance of repeated screening for lung cancer for more than 5 years with low-dose helical computed tomography in a high-risk

Appendix A6. List of Excluded Full-Text Papers

cohort. *Lung Cancer*. 2010;67(3):318-324, [PMID: 19481832]

Exclusion code: 2

Sekine Y, Fujisawa T. [Prognostic factors on surgical treatment for lung cancer].

Kyobu Geka - Japanese Journal of Thoracic Surgery. 2003;56(8 Suppl):722-727, [PMID: 12910959]

Exclusion code: 6

Sekine Y, Yamada Y, Chiyo M, et al. Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection. *Ann. Thorac. Surg*. 2007;84(3):946-950, [PMID: 17720404]

Exclusion code: 7

Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case control study of screening sigmoidoscopy and mortality from colorectal cancer. *N Eng J Med*. 1992;326(10):653-657, [PMID: 1736103]

Exclusion code: 5

Selva A, Puig T, López Alcalde J, Bonfill X. Efficacy of screening for lung cancer. Systematic review. *Revisión sistemática sobre la eficacia del cribado del cáncer de pulmón*. 2011;137(12):565-571, [PMID: 21316716]

Exclusion code: 5

Sen S, Guleria R, Singh N. Screening for lung cancer in India. *Natl. Med. J. India*. 2002;15(4):210-212, [PMID: 12296476]

Exclusion code: 5

Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. *J Thorac Oncol*. 2009;4(3):281-283, [PMID: 19247082]

Exclusion code: 2

Serke M, Kollmeier J. [Multimodal therapy of small cell and non-small cell lung carcinoma]. *Dtsch. Med. Wochenschr*. 2007;132(22):1221-1224, [PMID: 17520508]

Exclusion code: 6

Serke M, Schonfeld N. [Diagnosis and staging of lung cancer]. *Dtsch. Med. Wochenschr*. 2007;132(21):1165-1169, [PMID: 17506012]

Exclusion code: 6

Sestini P. Reduced lung-cancer mortality with CT screening. *N. Engl. J. Med*. 2011;365(21):2037; author reply 2037-2038, [PMID: 22111732]

Exclusion code: 5

Shah SI, Applebaum EL. Lung cancer after head and neck cancer: role of chest radiography. *Laryngoscope*. 2000;110(12):2033-2036, [PMID: 11129015]

Exclusion code: 3

Shaham D, Goitein O, Yankelevitz DF, Vazquez M, Reeves AP, Henschke C. Screening for lung cancer using low-radiation dose computed tomography. *Imaging Decisions MRI*. 2002;6(4):4-13. [PMID: 12111732]

Exclusion code: 5

Shaikh U, Lewis-Jones H. Commercial CT scans: VOMIT victim of medical investigative technology. *BMJ*. 2008;336(7634):8, [PMID: 18174573]

Exclusion code: 5

Shao F, Yang R, Xu D, et al. [Bronchial sleeve lobectomy and carinal resection in the treatment of central lung cancer: a report of 92 cases]. *Zhongguo Fei Ai Za Zhi*. 2010;13(11):1056-1058, [PMID: 21081048]

Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Shaw AS, Williams MV. The cancer reform strategy. *Clin. Radiol.* 2008;63(12):1292-1296, [PMID: 18996258]
Exclusion code: 5

Shen L, Li Z-m, Lu S. [Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2011;33(6):442-446, [PMID: 21875485]
Exclusion code: 6

Shepherd FA. A targeted approach to reducing lung cancer mortality. *J. Clin. Oncol.* 2005;23(14):3173-3174, [PMID: 15886303]
Exclusion code: 5

Shevchenko VE, Arnotskaya NE, Zaridze DG. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. *European Journal of Mass Spectrometry.* 2010;16(4):539-549, [PMID: 20625202]
Exclusion code: 2

Shimizu T, Shigemasa Y, Kajiwarra K, et al. [A case of radiation therapy successfully treated liver and lung tumors arising from postoperative cecum cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2009;36(12):2149-2151, [PMID: 20037352]
Exclusion code: 6

Shinohara H, Tsuchida M, Hashimoto T, Hayashi J. [Surgical treatment for metachronous lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2010;63(11):952-955, [PMID: 20954349]
Exclusion code: 6

Shiraishi T, Yoshinaga Y, Yoneda S, et al. [Clinical evaluation of VATS lobectomy for lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2000;53(1):4-7, [PMID: 10639784]
Exclusion code: 6

Shirakusa T. [Lung cancer in elderly patients: clinicopathological features]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2005;58(8 Suppl):734-738, [PMID: 16097628]
Exclusion code: 6

Shundo Y, Takahashi T, Itaya T, et al. [Clinical study of forty-two patients who underwent resection for pulmonary adenosquamous carcinoma]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2011;64(10):871-876; discussion 876-879, [PMID: 21899122]
Exclusion code: 6

Shuryak I, Sachs RK, Brenner DJ. Cancer risks after radiation exposure in middle age. *J. Natl. Cancer Inst.* 2010;102(21):1628-1636, [PMID: 20975037]
Exclusion code: 5

Siddiq S, Pamphilon D, Brunskill S, Doree C, Hyde C, Stanworth S. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. *Cochrane Database of Systematic Reviews.* 2009(1), [PMID: 19160282]
Exclusion code: 4

Sieren JC, Ohno Y, Koyama H, Sugimura K, McLennan G. Recent technological and application developments in computed tomography and magnetic resonance imaging for improved pulmonary nodule detection and lung cancer staging. *J. Magn. Reson. Imaging.* 2010;32(6):1353-1369, [PMID: 21105140]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 2

Sigel K, Bonomi M, Packer S, Wisnivesky J. Effect of age on survival of clinical stage I non-small-cell lung cancer. *Ann. Surg. Oncol.* 2009;16(7):1912-1917, [PMID: 19408051]

Exclusion code: 3

Sigurdardottir JM, Isaksson HJ, Johannsson KB, Jonsson S, Gudbjartsson T. [Histology does not accurately predict the clinical behaviour of bronchopulmonary carcinoids - results from an Icelandic population-based study]. *Laeknabladid.* 2008;94(2):125-130, [PMID: 18310777]

Exclusion code: 6

Sigurdson AJ, Jones IM, Wei Q, et al. Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Carcinogenesis.* 2011;32(1):69-73, [PMID: 20929901]

Exclusion code: 2

Sikora K. Cancer screening. *Medicine (Baltimore).* 2008;36(1):45-49, [PMID: 18310777]

Exclusion code: 5

Sikora K. Cancer screening. *Medicine (Baltimore).* 2012;40(1):24-28, [PMID: 22411111]

Exclusion code: 5

Silvestri GA. CT screening for lung cancer. *N. Engl. J. Med.* 2007;356(7):745; author reply 746-747, [PMID: 17310518]

Exclusion code: 2

Silvestri GA. Deaths among patients with screen-detected lung cancer. *Clin. Cancer Res.* 2008;14(8):2511; author reply 2511-2512, [PMID: 18413845]

Exclusion code: 2

Silvestri GA, Nietert PJ, Zoller J, Carter C, Bradford D. Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. *Thorax.* 2007;62(2):126-130, [PMID: 17101739]

Exclusion code: 7

Silvestri GA, Tanoue LT. Lung cancer: evolving concepts. *Semin.* 2008;29(3):221-222, [PMID: 18506659]

Exclusion code: 5

Simpson NK, Johnson CC, Ogden SL, et al. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. *Control. Clin. Trials.* 2000;21(6 Suppl):356S-378S, [PMID: 11189688]

Exclusion code: 5

Singh S, Pinsky P, Fineberg NS, et al. Evaluation of reader variability in the interpretation of follow-up CT scans at lung cancer screening. *Radiology.* 2011;259(1):263-270, [PMID: 21248232]

Exclusion code: 2

Sirbu H, Schreiner W, Dalichau H, Busch T. Surgery for non-small cell carcinoma in geriatric patients: 15-year experience. *Asian Cardiovasc Thorac Ann.* 2005;13(4):330-336, [PMID: 16304220]

Exclusion code: 3

Skillrud D, Offord K, Miller R. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. *Ann. Intern. Med.* 1986;105(4):503-507, [PMID: 3752756]

Exclusion code: 2

Skuladottir R, Oskarsdottir GN, Isaksson HJ, Jonsson S, Thorsteinsson H, Gudbjartsson T. [Postoperative complications following lobectomy for lung cancer in Iceland during 1999-2008].

Appendix A6. List of Excluded Full-Text Papers

Laeknabladid. 2010;96(4):243-249,
[PMID: 20339163]

Exclusion code: 6

Slatore CG, Au DH, Gould MK. An official American Thoracic Society systematic review: Insurance status and disparities in lung cancer practices and outcomes. *Am. J. Respir. Crit. Care Med*. 2010;182(9):1195-1205, [PMID: 21041563]

Exclusion code: 2

Slatore CG, Gould MK, Au DH, Deffebach ME, White E. Lung cancer stage at diagnosis: Individual associations in the prospective VITamins and lifestyle (VITAL) cohort. *BMC Cancer*. 2011;11:228, [PMID: 21649915]

Exclusion code: 7

Slatore CG, Littman AJ, Au DH, Satia JA, White E. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. *Am. J. Respir. Crit. Care Med*. 2008;177(5):524-530, [PMID: 17989343]

Exclusion code: 5

Smith D, Spanel P, Sule-Suso J. Advantages of breath testing for the early diagnosis of lung cancer. *Expert Review of Molecular Diagnostics*. 2010;10(3):255-257, [PMID: 20370582]

Exclusion code: 2

Smith JJ, Berg CD. Lung cancer screening: promise and pitfalls. *Semin. Oncol. Nurs*. 2008;24(1):9-15, [PMID: 18222147]

Exclusion code: 5

Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. *CA. Cancer J. Clin*. 2009;59(1):27-41, [PMID: 19147867]

Exclusion code: 5

Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. *CA. Cancer J. Clin*. 2007;57(2):90-104, [PMID: 17392386]

Exclusion code: 5

Smith RA, Cokkinides V, Eyre HJ, American Cancer Society. American Cancer Society guidelines for the early detection of cancer, 2006. *CA. Cancer J. Clin*. 2006;56(1):11-25, [PMID: 16449183]

Exclusion code: 5

Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. *CA. Cancer J. Clin*. 2002;52(1):8-22, [PMID: 11814067]

Exclusion code: 5

Smith RA, Field JK, Duffy SW. A global approach to cancer-screening trials. *Lancet Oncol*. 2008;9(10):908-909, [PMID: 18805732]

Exclusion code: 2

Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection.[Erratum appears in *CA Cancer J Clin* 2001 May-Jun;51(3):150]. *CA. Cancer J. Clin*. 2001;51(1):38-75; quiz 77-80, [PMID: 11577479]

Exclusion code: 5

Smith-Bindman R. Is Computed Tomography Safe? *N. Engl. J. Med*. 2010;363(1):1-4, [PMID: 20573919]

Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Smith-Bindman R. Environmental causes of breast cancer and radiation from medical imaging: Findings from the Institute of Medicine report. *Arch. Intern. Med.* 2012;172(13):1023-1027, [PMID: 22688684]
Exclusion code: 5

Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common coputed tomography examinations and the associated lifetime attributable risk of cancer. *Arch. Intern. Med.* 2009;169(22):2078-2086, [PMID: 20008690]
Exclusion code: 2

Smith-Bindman R, Miglioretti DL. CTDI vol, DLP, and effective dose are excellent measures for use in CT quality improvement. *Radiology.* 2011;261(3):999, [PMID: 22096003]
Exclusion code: 5

Smith-Bindman R, Miglioretti DL, Johnson E, et al. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. *JAMA - Journal of the American Medical Association.* 2012;307(22):2400-2409, [PMID: 22692172]
Exclusion code: 5

Smythe WR, American College of Chest P. Treatment of stage I non-small cell lung carcinoma. *Chest.* 2003;123(1 Suppl):181S-187S, [PMID: 12527578]
Exclusion code: 2

Sobue T. A case-control study for evaluating lung cancer screening in Japan. *Cancer.* 2000;89(11 Suppl):2392-2396, [PMID: 11147617]
Exclusion code: 5

Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. *J. Clin. Oncol.* 2002;20(4):911-920, [PMID: 11844811]
Exclusion code: 3

Sobue T, Suzuki T, Matsuda M, Kuroishi T, Ikeda S, Naruke T. Survival for clinical stage I lung cancer not surgically treated. Comparison between screen-detected and symptom-detected cases. The Japanese Lung Cancer Screening Research Group. *Cancer.* 1992;69(3):685-692, [PMID: 1730119]
Exclusion code: 2

Sone S, Li F, Yang ZG, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. *Br. J. Cancer.* 2001;84(1):25-32, [PMID: 11139308]
Exclusion code: 5

Sone S, Li F, Yang ZG, et al. Characteristics of small lung cancers invisible on conventional chest radiography and detected by population based screening using spiral CT. *Br. J. Radiol.* 2000;73(866):137-145, [PMID: 10884725]
Exclusion code: 2

Sone S, Matsumoto T, Honda T, et al. HRCT features of small peripheral lung carcinomas detected in a low-dose CT screening program. *Acad. Radiol.* 2010;17(1):75-83, [PMID: 19879779]
Exclusion code: 4

Sone S, Nakayama T, Honda T, et al. CT findings of early-stage small cell lung cancer in a low-dose CT screening programme. *Lung Cancer.* 2007;56(1):207-215, [PMID: 17258349]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Sone S, Nakayama T, Honda T, et al. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. *Lung Cancer*. 2007;58(3):329-341, [PMID: 17675180]
Exclusion code: 4

Song Y, Yang L, Ma J-h, Liu X-f, Wang J-w. [Long-term outcome of testicular seminoma in 294 patients]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2008;30(8):626-629, [PMID: 19102945]
Exclusion code: 6

Sortini D, Maravegias K, Sortini A. Difficulty of early diagnosis in patients with solitary pulmonary nodule. *J. Thorac. Cardiovasc. Surg*. 2005;129(5):1196; author reply 1196-1197, [PMID: 15867812]
Exclusion code: 2

Souquet P-J, Geriniere L. [Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer]. *Bull. Cancer (Paris)*. 2002;89 Spec No:S80-84, [PMID: 12449035]
Exclusion code: 6

Sox HC. Screening for Lung Cancer With Chest Radiographs. *JAMA - Journal of the American Medical Association*. 2011;306(17):1916-1918, [PMID: 22031727]
Exclusion code: 2

Sox HC. Better evidence about screening for lung cancer. *N. Engl. J. Med*. 2011;365(5):455-457, [PMID: 21714644]
Exclusion code: 2

Sozzi G, Roz L, Conte D, et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year

results of a prospective study. *Am. J. Respir. Crit. Care Med*. 2009;179(1):69-74, [PMID: 18787214]
Exclusion code: 2

Spaggiari L, Veronesi G, Bellomi M, Maisonneuve P. Computed tomography screening for lung cancer. *JAMA*. 2007;298(5):514; author reply 515-516, [PMID: 17666670]
Exclusion code: 5

Spigno F, Gentile R, Valente T, Capannelli G. [Diagnosis in related pathologic asbestosis, clinical case of a suspected occupational neoplasm]. *G. Ital. Med. Lav. Ergon*. 2008;30(4):324-328, [PMID: 19344083]
Exclusion code: 6

Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. *Nat. Med*. 2007;13(3):361-366, [PMID: 17334370]
Exclusion code: 4

Spiro SG. Screening for lung cancer: yet another problem. *Thorax*. 2007;62(2):105-106, [PMID: 17287303]
Exclusion code: 5

Spiro SG, Navani N. Screening for lung cancer: Is this the way forward? *Respirology*. 2012;17(2):237-246, [PMID: 22142440]
Exclusion code: 5

Spiro SG, Tanner NT, Silvestri GA, et al. Lung cancer: progress in diagnosis, staging and therapy. *Respirology*. 2010;15(1):44-50, [PMID: 20199634]
Exclusion code: 2

Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. *J.*

Appendix A6. List of Excluded Full-Text Papers

Natl. Cancer Inst. 2007;99(9):715-726, [PMID: 17470739]

Exclusion code: 5

Sreseli RT, Binder H, Kuhn M, et al. Identification of a 17-protein signature in the serum of lung cancer patients. *Oncol. Rep.* 2010;24(1):263-270, [PMID: 20514471]

Exclusion code: 3

Sriram KB, Larsen JE, Yang IA, Bowman RV, Fong KM. Genomic medicine in non-small cell lung cancer: Paving the path to personalized care. *Respirology.* 2011;16(2):257-263, [PMID: 21044232]

Exclusion code: 5

Stabile LP, Siegfried JM. Sex and gender differences in lung cancer. *Journal of Gender-Specific Medicine.* 2003;6(1):37-48, [PMID: 12661176]

Exclusion code: 2

Stanbrook MB, Flegel K. A pause for thought on lung cancer screening. *CMAJ Canadian Medical Association Journal.* 2009;180(8):793, [PMID: 19364781]

Exclusion code: 5

Stanley RJ. Inherent dangers in radiologic screening. *AJR. Am. J. Roentgenol.* 2001;177(5):989-992, [PMID: 11641152]

Exclusion code: 5

Stanzel F. Fluorescent bronchoscopy: contribution for lung cancer screening? *Lung Cancer.* 2004;45 Suppl 2:S29-37, [PMID: 15552779]

Exclusion code: 5

Staring M, Pluim JPW, de Hoop B, et al. Image subtraction facilitates assessment of volume and density change in ground-glass opacities in chest CT. *Invest. Radiol.* 2009;44(2):61-66, [PMID: 19104438]

Exclusion code: 3

Starnes SL, Reed MF, Meyer CA, et al. Can lung cancer screening by computed tomography be effective in areas with endemic histoplasmosis? *J. Thorac. Cardiovasc. Surg.* 2011;141(3):688-693, [PMID: 20933243]

Exclusion code: 2

Stearman RS, Dwyer-Nield L, Grady MC, Malkinson AM, Geraci MW. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. *Cancer Res.* 2008;68(1):34-43, [PMID: 18172294]

Exclusion code: 5

Steeghs MML, Cristescu SM, Munnik P, Zanen P, Harren FJM. An off-line breath sampling and analysis method suitable for large screening studies. *Physiol. Meas.* 2007;28(5):503-514, [PMID: 17470984]

Exclusion code: 4

Stellman SD, Takezaki T, Wang L, et al. Smoking and lung cancer risk in American and Japanese men: An international case-control study. *Cancer Epidemiology Biomarkers and Prevention.* 2001;10(11):1193-1199, [PMID: 11700268]

Exclusion code: 2

Stempfer R, Syed P, Vierlinger K, et al. Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens. *BMC Cancer.* 2010;10:627, [PMID: 21078204]

Exclusion code: 4

Stengel JW, Webb EM, Poder L, Yeh BM, Smith-Bindman R, Coakley FV. Acute appendicitis: Clinical outcome in patients with an initial false-positive CT diagnosis.

Appendix A6. List of Excluded Full-Text Papers

Radiology. 2010;256(1):119-126, [PMID: 20505066]

Exclusion code: 5

Stephan F, Boucheseiche S, Hollande J, et al. Pulmonary complications following lung resection: A comprehensive analysis of incidence and possible risk factors. *Chest*. 2000;118(5):1263-1270, [PMID: 11083673]

Exclusion code: 8

Stephenson SM, Mech KF, Sardi A. Lung cancer screening with low-dose spiral computed tomography. *Am. Surg.* 2005;71(12):1015-1017, [PMID: 16447470]

Exclusion code: 3

Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance--United States, 1990-2000. *Morbidity & Mortality Weekly Report. Surveillance Summaries*. 2004;53(3):1-108, [PMID: 15179359]

Exclusion code: 2

Stiles BM, Altorki NK. Screening for Lung Cancer: Challenges for the Thoracic Surgeon. *Surg. Oncol. Clin. N. Am.* 2011;20(4):619-635, [PMID: 21986261]

Exclusion code: 5

Stoelben E, Sauerbrei W, Ludwig C, Hasse J. Tumor stage and early mortality for surgical resections in lung cancer. *Langenbecks Arch. Surg.* 2003;388(2):116-121, [PMID: 12712342]

Exclusion code: 3

Strauss G, Gleason R, Sugarbaker D. Screening for lung cancer (LC) re-examined: a reinterpretation of the Mayo Lung Project (MLP) randomized trial for screening for the early detection of lung cancer [abstract]. Paper presented at:

Proceedings of the American Society of Clinical Oncology, 1992.

Exclusion code: 5

Strauss GM. Screening for lung cancer: An evidence-based synthesis. *Surg. Oncol. Clin. N. Am.* 1999;8(4):747-774, viii, [PMID: 10452939]

Exclusion code: 2

Strauss GM. Randomized population trials and screening for lung cancer: breaking the cure barrier. *Cancer*. 2000;89(11 Suppl):2399-2421, [PMID: 11147619]

Exclusion code: 2

Strauss GM. The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality. *J. Clin. Oncol.* 2002;20(8):1973-1983, [PMID: 11956255]

Exclusion code: 5

Su X, Wang X, Long H, et al. Mediastinal lymph node dissection affects survival in patients with stage I non-small cell lung cancer. *Thorac. Cardiovasc. Surg.* 2008;56(4):226-230, [PMID: 18481243]

Exclusion code: 5

Su X-D, Huang Z-F, Rong T-H, Yang M-T. [Combined surgical treatment for limited small cell lung cancer: clinical analysis of 51 cases]. *Ai Zheng*. 2003;22(10):1099-1101, [PMID: 14558961]

Exclusion code: 6

Su X-D, Long H, Wang X, et al. [Impact of visceral pleural invasion on the prognosis of stage Ib non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2008;30(5):368-371, [PMID: 18953838]

Exclusion code: 6

Su X-d, Wang X, Rong T-h, et al. [Prognostic effect of mediastinal lymph

Appendix A6. List of Excluded Full-Text Papers

node dissection in patients with stage I non-small cell lung cancer]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 2007;45(22):1543-1545, [PMID: 18282391]
Exclusion code: 6

Suemitsu R, Yamaguchi M, Takeo S, et al. Favorable surgical results for patients with nonsmall cell lung cancer over 80 years old: a multicenter survey. *Ann. Thorac. Cardiovasc. Surg.* 2008;14(3):154-160, [PMID: 18577893]
Exclusion code: 3

Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T, Machara Y. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. *Surg. Today*. 2004;34(11):896-901, [PMID: 15526122]
Exclusion code: 2

Sugarbaker DJ. Lung cancer. 6: The case for limited surgical resection in non-small cell lung cancer. *Thorax*. 2003;58(7):639-641, [PMID: 12832686]
Exclusion code: 5

Sugi K, Kobayashi S, Sudou M, et al. [Video-assisted thoracic surgery (VATS) for clinical stage I lung cancer in consideration of the diameters and characteristics of each tumor and the technical limitations of VATS]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2009;62(4):277-280, [PMID: 19348210]
Exclusion code: 6

Sugio K, Sugaya M, Hanagiri T, Yasumoto K. [Tumor marker in primary lung cancer]. *J Uoeh*. 2004;26(4):473-479, [PMID: 15624359]
Exclusion code: 6

Sugiura Y, Takeuchi K, Kakizaki T, Kaseda S. [Complete response by S-1 with multiple pulmonary metastases 4 years after lung resection-a case report]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2009;36(13):2611-2614, [PMID: 20009464]
Exclusion code: 6

Sullivan DC. Congressional update: Report from the biomedical imaging program of the National Cancer Institute. Research recommendations from a lung cancer screening workshop. *Acad. Radiol*. 2001;8(9):942-943, [PMID: 11724050]
Exclusion code: 5

Sumitani M, Takifuji N, Nanjyo S, et al. Clinical relevance of sputum cytology and chest X-ray in patients with suspected lung tumors. *Intern. Med.* 2008;47(13):1199-1205, [PMID: 18591840]
Exclusion code: 2

Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. *Am. J. Clin. Oncol*. 2000;23(3):241-243, [PMID: 10857885]
Exclusion code: 7

Sun SS, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. *Nat Rev Cancer*. 2007;7:778-790, [PMID: 17882278]
Exclusion code: 2

Sutedja G. New techniques for early detection of lung cancer. *European Respiratory Journal - Supplement*. 2003;39:57s-66s, [PMID: 12572703]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Sutedja TG, Venmans BJ, Smit EF, Postmus PE. Fluorescence bronchoscopy for early detection of lung cancer: a clinical perspective. *Lung Cancer*. 2001;34(2):157-168, [PMID: 11679174]
Exclusion code: 5

Suzuki T, Horio H, Sakaguchi K, Yamamoto M. [Lobectomy for local recurrence of lung cancer after 3-dimensional-conformal radiotherapy]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2007;60(9):830-833, [PMID: 17703623]
Exclusion code: 6

Sverzellati N, Cademartiri F, Bravi F, et al. Relationship and prognostic value of modified coronary artery calcium score, FEV 1, and emphysema in lung cancer screening population: The MILD trial. *Radiology*. 2012;262(2):460-467, [PMID: 22114241]
Exclusion code: 7

Sverzellati N, Guerri L, Randi G, et al. Interstitial lung diseases in a lung cancer screening trial. *Eur. Respir. J.* 2011;38(2):392-400, [PMID: 21233262]
Exclusion code: 5

Sverzellati N, Ingegnoli A, Calabrò E, et al. Bronchial diverticula in smokers on thin-section CT. *Eur. Radiol.* 2010;20(1):88-94, [PMID: 19597819]
Exclusion code: 5

Swellam M, Ragab HM, Abdalla NA, El-Asmar A-BH. Soluble cytokeratin-19 and E-selectin biomarkers: their relevance for lung cancer detection when tested independently or in combinations. *Cancer Biomark*. 2008;4(1):43-54, [PMID: 18334733]
Exclusion code: 7

Swensen SJ. CT screening for lung cancer. *AJR. Am. J. Roentgenol.* 2002;179(4):833-836, [PMID: 12239020]
Exclusion code: 2

Swensen SJ. Screening for cancer with computed tomography. *BMJ*. 2003;326(7395):894-895, [PMID: 12714453]
Exclusion code: 2

Swensen SJ, Jett JR, Hartmen TE, et al. Lung Cancer Screening with CT: Mayo Clinic Experience. *Radiology*. 2003;226(3):756-761, [PMID: 12601181]
Exclusion code: 5

Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung cancer with low dose spiral computed tomography. *Am. J. Respir. Crit. Care Med.* 2002;165(4):508-513, [PMID: 11850344]
Exclusion code: 5

Takahashi I, Matsuzaka M, Umeda T, et al. Differences in the influence of tobacco smoking on lung cancer between Japan and the USA: possible explanations for the 'smoking paradox' in Japan. *Public Health*. 2008;122(9):891-896, [PMID: 18420238]
Exclusion code: 2

Takahashi K, Matsumoto H, Nakano D, et al. [Is it necessary to carry out hepatic resection and pulmonary resection to obtain a cure for liver and lung metastases from colorectal cancer?]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2011;38(2):187-192, [PMID: 21368482]
Exclusion code: 6

Takao M, Inoue K, Watanabe F, et al. [A rational approach of limited resection for small peripheral lung adenocarcinoma with curative intent; analyses of multiple

Appendix A6. List of Excluded Full-Text Papers

primary adenocarcinomas]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2004;57(1):9-13, [PMID: 14733092]
Exclusion code: 6

Takashima S, Sone S, Li F, Maruyama Y, Hasegawa M, Kadoya M. Indeterminate solitary pulmonary nodules revealed at population-based CT screening of the lung: using first follow-up diagnostic CT to differentiate benign and malignant lesions. *AJR. Am. J. Roentgenol*. 2003;180(5):1255-1263, [PMID: 12704034]
Exclusion code: 2

Takashima S, Sone S, Li F, et al. Small solitary pulmonary nodules (≤ 1 cm) detected at population-based CT screening for lung cancer: Reliable high-resolution CT features of benign lesions. *AJR. Am. J. Roentgenol*. 2003;180(4):955-964, [PMID: 12646435]
Exclusion code: 2

Takizawa M, Sone S, Hanamura K, Asakura K. Telemedicine system using computed tomography van of high-speed telecommunication vehicle. *IEEE Transactions on Information Technology in Biomedicine*. 2001;5(1):2-9, [PMID: 11300213]
Exclusion code: 4

Tammemagi MC, Freedman MT, Pinsky PF, et al. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study. *J Thorac Oncol*. 2009;4(6):710-721, [PMID: 19404219]
Exclusion code: 2

Tan C, Chen H, Xia C. Early prediction of lung cancer based on the combination of trace element analysis in urine and an Adaboost algorithm. *J. Pharm. Biomed.*

Anal. 2009;49(3):746-752, [PMID: 19150588]
Exclusion code: 4

Tan S, Yu F, Hu W, Tang J, Wang X, Zou M. [Clinical application of completed video-assisted thoracic surgery lobectomy (with 186 cases report)]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. 2011;36(1):80-83, [PMID: 21311144]
Exclusion code: 6

Tang X-J, Zhou Q-H, Zhang S-F, Liu L-X. [Expressions of Nm23, E-cadherin, and beta-catenin in non-small cell lung cancer and their correlations with metastasis and prognosis]. *Ai Zheng*. 2005;24(5):616-621, [PMID: 15890109]
Exclusion code: 6

Tanino M, Nishimura M, Betsuyaku T, et al. [A comparative study of computed tomographic techniques for the detection of emphysema in middle-aged and older patient populations]. *Nihon Kokyuki Gakkai Zasshi*. 2000;38(5):368-372, [PMID: 10921283]
Exclusion code: 6

Tanner NT, Mehta H, Silvestri GA. New testing for lung cancer screening. *Oncology*. 2012;26(2):1-12, [PMID: 22489353]
Exclusion code: 5

Tanner NT, Silvestri GA. An up to date look at lung cancer screening. *Cell Adhesion & Migration*. 2010;4(1):96-99, [PMID: 20139695]
Exclusion code: 5

Tanoue LT, Gettinger S. Treatment of Lung Cancer in Older Patients. *Clin. Chest Med*. 2007;28(4):735-749, [PMID: 17967291]
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Tao C, Gierada DS, Zhu F, Pilgram TK, Wang JH, Bae KT. Automated matching of pulmonary nodules: evaluation in serial screening chest CT. *AJR. Am. J. Roentgenol.* 2009;192(3):624-628, [PMID: 19234256]

Exclusion code: 4

Tarro G, Perna A, Esposito C. Early diagnosis of lung cancer by detection of tumor liberated protein. *J. Cell. Physiol.* 2005;203(1):1-5, [PMID: 15389637]

Exclusion code: 2

Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. *J. Natl. Cancer Inst.* 2004;96(14):1083-1094, [PMID: 15265970]

Exclusion code: 3

Taylor WF, Fontana RS. Biometric design of the Mayo Lung project for early detection and localization of bronchogenic carcinoma. *Cancer.* 1972;30(5):1344-1347, [PMID: 5083070]

Exclusion code: 5

Taylor WF, Fontana RS, Uhlenhopp MA, Davis CS. Some results of screening for early lung cancer. *Cancer.* 1981;47:1114-1120, [PMID: 6263442]

Exclusion code: 5

Teschner M, Starp F, Lullig H. [Resection of bronchial carcinoma combined with lung volume reduction]. *Pneumologie.* 2003;57(7):367-372, [PMID: 12861492]

Exclusion code: 6

The Canadian Coordinating Office for Health Technology Assessment. Multi-slice/Helical Computed Tomography for Lung Cancer Screening. *Health Technol.*

Assess. 2003(43).

http://www.cadth.ca/media/pdf/213_ct_ceta_p_e.pdf Accessed 30 Jan 2013

Exclusion code: 5

The Group for the Study on the Accuracy Management and Accurate Evaluation in Lung Cancer Mass Screening. *The Manual of Clinic-based Lung Cancer Screening Program* 1992

Exclusion code: 8

The Japan Lung Cancer Society. *The Manual of Mass Screening for Lung Cancer*: Kanehara & Co., Ltd.; 1987

Exclusion code: 8

The National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Baseline characteristics of participants in the randomized national lung screening trial. *J. Natl. Cancer Inst.*

2010;102(23):1771-1779, [PMID: 21119104]

Exclusion code: 2

Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: Effect on the incidence of colorectal cancer: Telemark Polyp Study I. *Scand. J. Gastroenterol.* 1999;34(4):414-420, [PMID: 10365903]

Exclusion code: 8

Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. *Chest.* 2005;128(1):370-381, [PMID: 16002959]

Exclusion code: 2

Thomas P, Doddoli C, Thirion X, et al. Stage I non-small cell lung cancer: a pragmatic approach to prognosis after complete resection. *Ann. Thorac. Surg.* 2002;73(4):1065-1070, [PMID: 11996242]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 10

Thorsteinsson H, Jonsson S, Alfredsson H, Isaksson HJ, Gudbjartsson T. [Results of pneumonectomy for non-small cell lung cancer in Iceland]. *Laeknabladid*. 2009;95(12):823-829, [PMID: 19996469]
Exclusion code: 6

Thunnissen FB, Kerr KM, Brambilla E, et al. EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer. *Eur. Respir. J.* 2006;28(6):1186-1189, [PMID: 16899486]
Exclusion code: 7

Thunnissen FBJM. Sputum examination for early detection of lung cancer. *J. Clin. Pathol.* 2003;56(11):805-810, [PMID: 14600122]
Exclusion code: 5

Tieu B, Schipper P. Specialty Matters in the Treatment of Lung Cancer. *Semin Thoracic Surg.* 2012;24:99-105, [PMID: 22920525]
Exclusion code: 2

Tiitola M, Kivisaari L, Huuskonen MS, et al. Computed tomography screening for lung cancer in asbestos-exposed workers. *Lung Cancer.* 2002;35(1):17-22, [PMID: 11750708]
Exclusion code: 2

Tino G. Clinical year in review I: Lung cancer, interventional pulmonology, pediatric pulmonary disease, and pulmonary vascular disease. *Proc.* 2007;4(6):478-481, [PMID: 17761962]
Exclusion code: 5

Tino G, Ware LB, Moss M. Clinical year in review IV: Chronic obstructive pulmonary disease, nonpulmonary critical care,

diagnostic imaging, and mycobacterial disease. *Proc.* 2007;4(6):494-498, [PMID: 17761965]
Exclusion code: 5

Tockman MS. Advances in sputum analysis for screening and early detection of lung cancer. *Cancer Control.* 2000;7(1):19-24, [PMID: 10740657]
Exclusion code: 5

Tockman MS. Lung cancer: chemoprevention and intermediate effect markers. *IARC Sci. Publ.* 2001;154:257-270, [PMID: 11220665]
Exclusion code: 5

Tockman MS. Improbable estimate of lung cancer mortality from screening trials. *J. Clin. Oncol.* 2005;23(9):2106-2107; author reply 2107-2108, [PMID: 15774802]
Exclusion code: 2

Tockman MS, Hazelton T, Coppage L. Lung cancer screening with helical CT: Evidence for a stage shift. Paper presented at: 10th International Congress on Lung Cancer 2003.
Exclusion code: 5

Togashi K, Hirahara H, Sugawara M, Miyamura H, Sato Y. [Surgery for synchronous primary lung cancers and intrapulmonary metastases]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2002;55(1):30-33, [PMID: 11797405]
Exclusion code: 6

Togashi K, Hirahara H, Sugawara M, Miyamura H, Satoh Y. [Surgery for intrathoracic recurrence and second primary tumors in resected lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2002;55(5):383-387, [PMID: 11995320]
Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Togashi K, Hosaka Y, Okada A, Sato S. [Iterative surgical resections for second primary and local recurrent lung cancer; comparison of lobectomy and limited resection]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2010;63(11):963-968, [PMID: 20954351]
Exclusion code: 6

Togashi K, Koike T, Emura I, Usuda H. [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2008;61(7):519-522; discussion 522-514, [PMID: 18616092]
Exclusion code: 6

Togashi K-i, Koike T. [Surgical treatment for patients aged 80 years or older with primary lung cancer and differences in outcomes according to sex]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2008;61(5):347-351; discussion 351-344, [PMID: 18464476]
Exclusion code: 6

Togashi K-i, Saito M, Asami F, Sato H, Niyoshi S, Tanba H. [Long-term results after recurrence of completely resected primary lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2006;59(13):1137-1140; discussion 1140-1133, [PMID: 17163204]
Exclusion code: 6

Tokarskaya ZB, Scott BR, Zhuntova GV, et al. Interaction of radiation and smoking in lung cancer induction among workers at the Mayak nuclear enterprise. *Health Phys*. 2002;83(6):833-846, [PMID: 12467291]
Exclusion code: 3

Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers.

Cancer. 1996;78(5):1004-1010, [PMID: 8780538]
Exclusion code: 2

Torok S, Hegedus B, Laszlo V, et al. Lung cancer in never smokers. *Future Oncology*. 2011;7(10):1195-1211, [PMID: 21992731]
Exclusion code: 2

Touboul E, Deniaud-Alexandre E, Pereira R, Deluen F. [Postoperative radiotherapy after complete resection of stage II (N1) non-small-cell lung cancer: reasons for not proposing it]. *Rev. Pneumol. Clin*. 2000;56(5):287-292, [PMID: 11139758]
Exclusion code: 6

Travis K. Lung cancer screening for all? Not yet, panel says. *J. Natl. Cancer Inst*. 2004;96(12):900-901, [PMID: 15199105]
Exclusion code: 5

Travis K. Cancer in Europe: new report, recent efforts take continent-wide perspective. *J. Natl. Cancer Inst*. 2008;100(18):1274-1275, [PMID: 18780856]
Exclusion code: 5

Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. *J Thorac Oncol*. 2011;6(2):244-285, [PMID: 21847068]
Exclusion code: 2

Trejos AL, Lin AW, Mohan S, et al. MIRA V: An integrated system for minimally invasive robot-assisted lung brachytherapy, Conference proceedings, 2008
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

Trejos AL, Mohan S, Bassan H, et al. An experimental test-bed for robot-assisted image-guided minimally invasive lung braehytherapy, Conference proceedings 2007.

Exclusion code: 5

Trichopoulos D, Mollo F, Tomatis L, Agapitos E, Delsedime L, Zavitsanos X. Active and passive smoking and pathological indicators of lung cancer risk in an autopsy study. *JAMA*. 1992;268(13):1697-1701, [PMID: 1527879]

Exclusion code: 5

Truong MT, Munden RF. Lung cancer screening. *Curr Oncol Rep*. 2003;5(4):309-312, [PMID: 12781073]

Exclusion code: 5

Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. *Molecular Cancer*. 2007;6:70, [PMID: 17967182]

Exclusion code: 4

Tsuboi M, Ikeda N, Kato H. Experience with surgical intervention for screening-detected lung cancer. *Chest*. 2004;125(5 Suppl):167S, [PMID: 15136491]

Exclusion code: 2

Tsuchiya R. Surgery for stage I NSCLC in Japan. *J Thorac Oncol*. 2007;2(7 Suppl 3):S113-114, [PMID: 17603305]

Exclusion code: 5

Tsuchiya Y, Kodera Y, Tanaka R, Sanada S. Quantitative kinetic analysis of lung nodules using the temporal subtraction technique in dynamic chest radiographies performed with a flat panel detector. *J. Digit. Imaging*. 2009;22(2):126-135, [PMID: 18415648]

Exclusion code: 4

Tsunezuka Y, Oda M, Moriyama H. [A case of a second cancer of metachronous multiple primary non-small cell lung cancer successfully treated with TS-1 and CDDP chemotherapy]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2006;33(5):651-653, [PMID: 16685165]

Exclusion code: 6

Tsushima Y, Tateishi U, Uno H, et al. Diagnostic performance of PET/CT in differentiation of malignant and benign non-solid solitary pulmonary nodules. *Ann. Nucl. Med*. 2008;22(7):571-577, [PMID: 18756359]

Exclusion code: 3

Tunn PU, Schlag PM. [Giant cell tumor of bone. An evaluation of 87 patients]. *Z. Orthop. Ihre Grenzgeb*. 2003;141(6):690-698, [PMID: 14679436]

Exclusion code: 6

Turetz ML, O'Connor TP, Tilley AE, et al. Trachea epithelium as a "Canary" for cigarette smoking-induced biologic phenotype of the small airway epithelium. *Clinical and Translational Science*. 2009;2(4):260-272, [PMID: 20443905]

Exclusion code: 5

Twombly R. Full-body CT screening: preventing or producing cancer? *J. Natl. Cancer Inst*. 2004;96(22):1650-1651, [PMID: 15547173]

Exclusion code: 5

Twombly R. Lung cancer screening debate continues despite international CT study results. *J. Natl. Cancer Inst*. 2007;99(3):190-195, [PMID: 17284710]

Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

U. S. Preventive Services Task Force. Lung cancer screening: recommendation statement. *Ann. Intern. Med.* 2004;140(9):738-739, [PMID: 15126258]
Exclusion code: 2

U.S. Cancer Statistics Working Group. *United States Cancer Statistics: 1999-2007 Incidence and Mortality Web-based Report*. Atlanta: U.S. Department of Health and Human Services, Center for Disease Control and Prevention and National Cancer Institute 2010.
Exclusion code: 2

Uchikov A, Batashki I, Paskalev G, et al. [Postoperative and remote outcome of non small cell pulmonary carcinoma in patients over 70 years old]. *Khirurgiia (Sofia)*. 2006(1):35-37, [PMID: 18771135]
Exclusion code: 6

Uchikov A, Dimitrov I, Hadjiev B, et al. [Extent of resection as a prognostic factor in patients with non-small cell lung cancer]. *Khirurgiia (Sofia)*. 2010(2-3):15-18, [PMID: 21972689]
Exclusion code: 6

Uematsu M. [Stereotactic radiation therapy for non small cell lung cancer]. *Nippon Geka Gakkai Zasshi*. 2002;103(2):256-257, [PMID: 11904990]
Exclusion code: 6

Ueno K, Kusunoki Y, Imamura F, et al. Clinical experience with autofluorescence imaging system in patients with lung cancers and precancerous lesions. *Respiration*. 2007;74(3):304-308, [PMID: 16679756]
Exclusion code: 4

Ullrich RT, Zander T, Neumaier B, et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-

fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). *PLoS ONE*. 2008;3(12):e3908, [PMID: 19079597]
Exclusion code: 4

Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R, Nakamura Y. UHRF1 is a novel diagnostic marker of lung cancer. *Br. J. Cancer*. 2010;103(2):217-222, [PMID: 20517312]
Exclusion code: 3

Utsumi T, Inoue M, Kadota Y, et al. [Outcomes of bronchoplasty procedures for lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2008;61(11):945-949, [PMID: 18939430]
Exclusion code: 6

van de Wiel JCM, Wang Y, Xu DM, et al. Neglectable benefit of searching for incidental findings in the Dutch-Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT. *Eur. Radiol.* 2007;17(6):1474-1482, [PMID: 17206426]
Exclusion code: 2

van den Bergh KAM, Essink-Bot ML, van Klaveren R, de Koning HJ. Informed decision making does not affect health-related quality of life in lung cancer screening (NELSON trial). *Eur. J. Cancer*. 2010;46(18):3300-3306, [PMID: 20580546]
Exclusion code: 7

van den Bergh KAM, Essink-Bot M-L, Bunge EM, et al. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). *Cancer*. 2008;113(2):396-404, [PMID: 18484588]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

van der Aalst CM, de Koning HJ, van den Bergh KAM, Willemsen MC, van Klaveren RJ. The effectiveness of a computer-tailored smoking cessation intervention for participants in lung cancer screening: A randomised controlled trial. *Lung Cancer*. 2012;76(2):204-210, [PMID: 22054915]
Exclusion code: 2

van der Aalst CM, van Iersel CA, van Klaveren RJ, et al. Generalisability of the results of the Dutch-Belgian randomised controlled lung cancer CT screening trial (NELSON): does self-selection play a role? *Lung Cancer*. 2012;77(1):51-57, [PMID: 22459203]
Exclusion code: 2

van der Aalst CM, van Klaveren RJ, de Koning HJ. Does participation to screening unintentionally influence lifestyle behaviour and thus lifestyle-related morbidity? *Best Practice & Research in Clinical Gastroenterology*. 2010;24(4):465-478, [PMID: 20833350]
Exclusion code: 2

van Geel AN, van der Pol C, Notenboom A, et al. [Long-term results of the multidisciplinary surgical treatment of non-small-cell bronchial carcinoma in the superior sulcus (Pancoast tumour): a retrospective study]. *Ned. Tijdschr. Geneesk*. 2007;151(25):1406-1411, [PMID: 17668607]
Exclusion code: 6

van Ginneken B, Armato SG, 3rd, de Hoop B, et al. Comparing and combining algorithms for computer-aided detection of pulmonary nodules in computed tomography scans: The ANODE09 study. *Med. Image Anal*. 2010;14(6):707-722, [PMID: 20573538]
Exclusion code: 7

van Klaveren RJ. Lung cancer screening. *Eur. J. Cancer*. 2011;47 (Suppl 3):S147-155, [PMID: 21943968]
Exclusion code: 5

van Klaveren RJ, Habbema JD, de Koning HJ, Oudkerk M, Damhuis RA, Hoogsteden HC. [Screening for lung cancer in the Netherlands: the role of spiral CT scan]. *Ned. Tijdschr. Geneesk*. 2001;145(11):521-526, [PMID: 11284285]
Exclusion code: 6

van Klaveren RJ, Habbema JDF, Pedersen JH, de Koning HJ, Oudkerk M, Hoogsteden HC. Lung cancer screening by low-dose spiral computed tomography. *Eur. Respir. J*. 2001;18(5):857-866, [PMID: 11757637]
Exclusion code: 2

Van Klaveren RJ, Oudkerk M, Mali WPTM, De Koning HJ. Multi-detector CT screening for lung cancer is still to be discouraged for the time being. *Nederlands Tijdschrift voor Geneeskunde*. 2008;152(3):125-128, [PMID: 18271456]
Exclusion code: 5

van Klaveren RJ, van't Westeinde SC, de Hoop B-J, Hoogsteden HC. Stem cells and the natural history of lung cancer: implications for lung cancer screening. *Clin. Cancer Res*. 2009;15(7):2215-2218, [PMID: 19293258]
Exclusion code: 2

van Klaveren RV, Oudkerk M, Mali W, et al. Baseline and second round results from the population based Dutch-Belgian randomized lung cancer screening trial (NELSON) [abstract no. 1508]. *Journal of Clinical Oncology: ASCO annual meeting proceedings*. 2008;26(15S part I):78, [PMID: 17131307]
Exclusion code: 5

Appendix A6. List of Excluded Full-Text Papers

van Loon J, Grutters J, Wanders R, et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. *Eur. J. Cancer*. 2009;45(4):588-595, [PMID: 19046631]
Exclusion code: 3

van Meerbeeck JP, Tournoy KG. Screening and diagnosis of NSCLC. *Ann. Oncol*. 2004;15 Suppl 4:iv65-70, [PMID: 15477337]
Exclusion code: 5

van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. *Chest*. 2000;117(2):374-379, [PMID: 10669677]
Exclusion code: 8

van Rikxoort EM, de Hoop B, van de Vorst S, Prokop M, van Ginneken B. Automatic segmentation of pulmonary segments from volumetric chest CT scans. *IEEE Trans. Med. Imaging*. 2009;28(4):621-630, [PMID: 19211346]
Exclusion code: 4

Van Schil PE, Hendriks JM, Hertoghs M, Lauwers P, Choong C. Current surgical treatment of non-small-cell lung cancer. *Expert Rev Anticancer Ther*. 2011;11(10):1577-1585, [PMID: 21999131]
Exclusion code: 5

Vansteenkiste JF. Imaging in lung cancer: positron emission tomography scan. *European Respiratory Journal - Supplement*. 2002;35:49s-60s, [PMID: 12064681]

Exclusion code: 4

Vansteenkiste JF, Stroobants SS. PET scan in lung cancer: current recommendations and innovation. *J Thorac Oncol*. 2006;1(1):71-73, [PMID: 17409830]
Exclusion code: 4

Van't Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer. *Cancer J*. 2011;17(1):3-10, [PMID: 21263260]
Exclusion code: 2

Varella-Garcia M, Schulte AP, Wolf HJ, et al. The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. *Cancer Prev Res (Phila Pa)*. 2010;3(4):447-453, [PMID: 20332298]
Exclusion code: 2

Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer A-M, DeCamp MM. Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis. *J. Thorac. Cardiovasc. Surg*. 2011;142(3):538-546, [PMID: 21684554]
Exclusion code: 3

Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. *Cancer*. 2009;115(4):851-858, [PMID: 19140203]
Exclusion code: 3

Vassallo F, Imperatori A, Rovera F, Pericelli A, Antonini C, Dominioni L. The PRE.DI.CA. project for radiographic lung cancer screening in cigarette smokers. *Rays*. 2004;29(4):383-385, [PMID: 15852724]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 4

Vastag B. Lung screening study to test popular CT scans. *JAMA*.

2002;288(14):1705-1706, [PMID: 12365935]

Exclusion code: 5

Vazquez M, Carter D, Brambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. *Lung Cancer*. 2009;64(2):148-154, [PMID: 18951650]

Exclusion code: 2

Vazquez M, Flieder D, Travis W, et al. Early lung cancer action project pathology protocol. *Lung Cancer*. 2003;39(2):231-232, [PMID: 12581579]

Exclusion code: 2

Vazquez MF, Flieder DB. Small peripheral glandular lesions detected by screening CT for lung cancer. A diagnostic dilemma for the pathologist. *Radiol. Clin. North Am*. 2000;38(3):579-589, [PMID: 10855263]

Exclusion code: 7

Vazquez MF, Koizumi JH, Henschke CI, Yankelevitz DF. Reliability of cytologic diagnosis of early lung cancer. *Cancer*. 2007;111(4):252-258, [PMID: 17614298]

Exclusion code: 2

Vegi SR, Boovanahalli SK, Patro B, Mukkanti K. SPF32629A and SPF32629B: Enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. *Eur J Med Chem*. 2011;46(5):1803-1812, [PMID: 21397370]

Exclusion code: 5

Veglia F, Vineis P, Overvad K, et al. Occupational exposures, environmental tobacco smoke, and lung cancer.

Epidemiology. 2007;18(6):769-775, [PMID: 18062064]

Exclusion code: 2

Vehmas T. Factors influencing the prevalence of pulmonary nodules in lung cancer screening trials: re-evaluation of a CT study. *Ups. J. Med. Sci*.

2008;113(3):279-286, [PMID: 18991240]

Exclusion code: 2

Veronesi G, Bellomi M, Spaggiari L. The rate of incidental findings in lung cancer screening trials is not negligible. *Eur. Radiol*. 2008;18(3):529, [PMID: 17994239]

Exclusion code: 5

Veronesi G, Bellomi M, Spaggiari L, et al. Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. *J. Clin. Oncol*.

2006;24(18s):7029

Exclusion code: 5

Veronesi G, Bellomi M, Veronesi U, et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. *Ann. Thorac. Surg*. 2007;84(3):959-965; discussion 965-956, [PMID: 17720408]

Exclusion code: 3

Veronesi G, Maisonneuve P, De Pas TM, Bellomi M. Does lung cancer screening with low-dose CT remain promising despite disappointing DANTE results? *Am. J. Respir. Crit. Care Med*.

2010;182(5):720-721; author reply 721, [PMID: 20802172]

Exclusion code: 5

Veronesi G, Maisonneuve P, Spaggiari L, et al. Long-term outcomes of a pilot CT screening for lung cancer.

Appendix A6. List of Excluded Full-Text Papers

ecancermedicalscience. 2010;4(1), [PMID: 22276037]

Exclusion code: 5

Veronesi G, Szabo E, Decensi A, et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. *Cancer Prev Res (Phila Pa)*. 2011;4(1):34-42, [PMID: 21163939]
Exclusion code: 2

Vidal Serrano S, Méndez AL. CT screening for lung cancer; sistematic review. *Cribado de cáncer de pulmón con TC de tórax: Revisión sistemática*. 2007;129(15):582-587, [PMID: 17988617]
Exclusion code: 5

Vierikko T, Jarvenpaa R, Autti T. Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings. *Eur. Respir. J*. 2007;29(1):78-84, [PMID: 17050560]
Exclusion code: 5

Vierikko T, Kivisto S, Jarvenpaa R, et al. Psychological impact of computed tomography screening for lung cancer and occupational pulmonary disease among asbestos-exposed workers. *Eur. J. Cancer Prev*. 2009;18(3):203-206, [PMID: 19728402]
Exclusion code: 3

Viñes JJ. Effectiveness of early detection of diseases. *La efectividad de la detección precoz de las enfermedades*. 2007;30(1):11-27, [PMID: 17491604]
Exclusion code: 5

Vollset S, Tverdal A, Gjessing H. Smoking and Deaths between 40 and 70 years of age in women and men. *Ann. Intern. Med*. 2006;144:381-389, [PMID: 16549850]
Exclusion code: 2

Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC, American College of Chest P. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. 2007;132(3 Suppl):94S-107S, [PMID: 17873163]
Exclusion code: 5

Wakelee HA, Gomez SL, Chang ET. Sex differences in lung-cancer susceptibility: a smoke screen? *Lancet Oncol*. 2008;9(7):609-610, [PMID: 18598927]
Exclusion code: 2

Waldman MJ, Neher JO, Harper A, Huber T. Does screening reduce lung cancer mortality? *J. Fam. Pract*. 2008;57(1):49-50, [PMID: 18171571]
Exclusion code: 5

Waldman MJ, Neher JO, Harper A, Huber TE. Clinical inquiries. Does screening reduce lung cancer mortality? *J. Fam. Pract*. 2008;57(1):49-50, [PMID: 18171571]
Exclusion code: 5

Wallace GMF, Winter JH, Winter JE, Taylor A, Taylor TW, Cameron RC. Chest X-rays in COPD screening: are they worthwhile? *Respir. Med*. 2009;103(12):1862-1865, [PMID: 19631518]
Exclusion code: 3

Wang B, Li L, Yao L, Liu L, Zhu Y. Detection of p53 gene mutations in sputum samples and their implications in the early diagnosis of lung cancer in suspicious patients. *Chin. Med. J. (Engl)*. 2001;114(7):694-697, [PMID: 11780329]
Exclusion code: 3

Appendix A6. List of Excluded Full-Text Papers

Wang BY, Hung JJ, Jeng WJ, et al. Surgical Outcomes in Resected Non-small Cell Lung Cancer ≤ 1 cm in Diameter. *Journal of the Chinese Medical Association*. 2010;73(6):308-313, [PMID: 20603088]
Exclusion code: 10

Wang D-F, Zeng C-G, Lin Y-B, Hou J-H, Zhu Z-H. [Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer]. *Ai Zheng*. 2006;25(3):359-362, [PMID: 16536995]
Exclusion code: 6

Wang H, Guo X-H, Jia Z-W, et al. Multilevel binomial logistic prediction model for malignant pulmonary nodules based on texture features of CT image. *Eur. J. Radiol*. 2010;74(1):124-129, [PMID: 19261415]
Exclusion code: 7

Wang H-J, Sun K-L, Zhang X-R, Sun Y, Shi Y-K. [Combined modality therapy for small cell lung cancer patient with limited stage disease]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2007;29(9):701-703, [PMID: 18246803]
Exclusion code: 6

Wang H-w, Zhang Y-q, Luo J, Yan X, Lu H-y. [Percutaneous lung cancer cryotherapy guided by computer tomography]. *Chung-Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis & Respiratory Diseases*. 2004;27(5):311-314, [PMID: 15196339]
Exclusion code: 6

Wang J, Wu N, Zheng Q-f, Feng Y, Yan S, Yang Y. [Application of the 2007 lung cancer staging system by International Association for the Study of Lung Cancer]. *Beijing Da Xue Xue Bao*. 2009;41(4):442-

446, [PMID: 19727235]
Exclusion code: 6

Wang JC, Sone S, Feng L, et al. Rapidly growing small peripheral lung cancers detected by screening CT: correlation between radiological appearance and pathological features. *Br. J. Radiol*. 2000;73(873):930-937, [PMID: 11064644]
Exclusion code: 2

Wang J-w, Yang L, Wang J-y, et al. [Long-term results of multimodality therapy of testicular germ cell tumor]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2003;25(4):382-385, [PMID: 12921572]
Exclusion code: 6

Wang Q, Takashima S, Wang JC, Zheng LM, Sone S. Prevalence of emphysema in individuals who underwent screening CT for lung cancer in Nagano prefecture of Japan. *Respiration*. 2001;68(4):352-356, [PMID: 11464080]
Exclusion code: 7

Wang Q, Wang S, Wang H, Li P, Ma Z. MicroRNAs: Novel biomarkers for lung cancer diagnosis, prediction and treatment. *Exp. Biol. Med*. 2012;237(3):227-235, [PMID: 22345301]
Exclusion code: 4

Wang S-Y, Zhu Z-Z, Peng D-F, et al. [Efficacy of modified radical operation of preserving nipple-areolar complex on early stage breast cancer]. *Ai Zheng*. 2009;28(4):408-411, [PMID: 19622302]
Exclusion code: 6

Wang X, Chorley BN, Pittman GS, et al. Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung

Appendix A6. List of Excluded Full-Text Papers

cancer. *PLoS ONE*. 2010;5(8):e11934, [PMID: 20689807]
Exclusion code: 3

Wang Y, Chen J. [Bronchogenic carcinoma after lung transplantation: a case report and literature review]. *Zhongguo Fei Ai Za Zhi*. 2011;14(1):75-78, [PMID: 21219838]
Exclusion code: 6

Wang Y, Zhang X-r, Fu J, Tan W, Zhang W. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2004;26(6):369-372, [PMID: 15312350]
Exclusion code: 6

Wang Y-Z, Boudreaux JP, Dowling A, Woltering EA. Percutaneous localisation of pulmonary nodules prior to video-assisted thoroscopic surgery using methylene blue and TC-99. *Eur. J. Cardiothorac. Surg*. 2010;37(1):237-238, [PMID: 19700335]
Exclusion code: 4

Wardwell NR, Massion PP. Novel strategies for the early detection and prevention of lung cancer. *Semin. Oncol*. 2005;32(3):259-268, [PMID: 15988680]
Exclusion code: 5

Warner E, Jotkowitz A, Maimon N. Lung cancer screening--are we there yet? *European Journal of Internal Medicine*. 2010;21(1):6-11, [PMID: 20122605]
Exclusion code: 5

Warner EE, Mulshine JL. Lung cancer screening with spiral CT: toward a working strategy. *Oncology (Williston)*. 2004;18(5):564-575, discussion 578, 583-564, 587, [PMID: 15209187]
Exclusion code: 5

Watanabe A, Koyanagi T, Osawa H, et al. [Lung cancer in patients with idiopathic interstitial pneumonia]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2005;58(1):9-14, [PMID: 15678959]
Exclusion code: 6

Watanabe A, Tabata A, Ingu A, et al. [The validity and problems of a new staging system for lung cancer from the point of view of surgical results]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2000;53(11):929-932, [PMID: 11048444]
Exclusion code: 6

Watanabe S, Shimokawa S, Sakasegawa K, et al. [Simultaneous operation for lung tumor and cardiovascular disease]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2000;53(5):353-357; discussion 357-359, [PMID: 10808281]
Exclusion code: 6

Watanabe T, Motosono N, Hirono T. [Surgical results for second primary lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2010;63(11):940-943, [PMID: 20954347]
Exclusion code: 6

Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK, Boylan AM. CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. *Am. J. Respir. Cell Mol. Biol*. 2008;38(6):671-678, [PMID: 18218995]
Exclusion code: 5

Weber M. Screening for lung cancer with computed tomography: an examination of the evidence. *Jaapa*. 2004;17(8):14-18, [PMID: 15357166]
Exclusion code: 2

Weder W, Hillinger S. [Tumor surveillance after resection of lung cancer]. *Ther*.

Appendix A6. List of Excluded Full-Text Papers

Umsch. 2008;65(6):315-318, [PMID: 18622953]

Exclusion code: 6

Wei L, Chen M-Y, Chen Z, Wu S, Jia J-Z. [Clinical study of lymphadenectomy of lung cancer by video-assisted thoracic small incision surgery]. *Chung Hua I Hsueh Tsa Chih.* 2009;89(33):2346-2348, [PMID: 20095358]

Exclusion code: 6

Wei W-D, Wen Z-S, Su X-D, Lin P, Rong T-H, Chen L-K. [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection]. *Ai Zheng.* 2007;26(11):1231-1236, [PMID: 17991324]

Exclusion code: 6

Weissfeld JL, Fagerstrom RM, O'Brien B, Prostate LC, Ovarian Cancer Screening Trial Project T. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control. Clin. Trials.* 2000;21(6 Suppl):390S-399S, [PMID: 11189690]

Exclusion code: 5

Welch HG, Black WC. Overdiagnosis in cancer. *J. Natl. Cancer Inst.*

2010;102(9):605-613, [PMID: 20413742]

Exclusion code: 2

Welch HG, Woloshin S, Schwartz LM, et al. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. *Arch. Intern. Med.* 2007;167(21):2289-2295, [PMID: 18039986]

Exclusion code: 2

Wender R, Fontham ETH, Barrera E, et al. American Cancer Society Lung cancer Screening guidelines. *CA. Cancer J. Clin.*

2013 [PMID: 23315954]

Exclusion code: 2

Wender RC, Smith R, Harper D. Cancer screening. *Prim. Care.* 2002;29(3):697-725, [PMID: 12529905]

Exclusion code: 2

Wex P, Utta E, Haas V. [What can thoracic surgery accomplish in recurrent/second carcinoma of non-small-cell bronchial carcinoma?]. *Kongressbd Dtsch Ges Chir Kongr.* 2002;119:785-791, [PMID: 12704929]

Exclusion code: 6

White CS. National Lung Screening Trial: a breakthrough in lung cancer screening? *J. Thorac. Imaging.* 2011;26(2):86-87, [PMID: 21508730]

Exclusion code: 5

Whitson BA, D'Cunha J. The National Lung Cancer Screening Trial: the ripple effect begins? *Semin. Thorac. Cardiovasc. Surg.* 2010;22(4):274-275, [PMID: 21549266]

Exclusion code: 5

Whitson BA, Groth SS, Andrade RS, Maddaus MA, Habermann EB, D'Cunha J. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. *Ann. Thorac. Surg.* 2011;92(6):1943-1950, [PMID: 21962268]

Exclusion code: 5

Whitson BA, Groth SS, Andrade RS, Mitiek MO, Maddaus MA, D'Cunha J. Invasive adenocarcinoma with bronchoalveolar features: a population-based evaluation of the extent of resection in bronchoalveolar cell carcinoma. *J. Thorac. Cardiovasc. Surg.*

Appendix A6. List of Excluded Full-Text Papers

2012;143(3):591-600.e591, [PMID: 22177098]

Exclusion code: 3

Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. "What do you mean, a spot?": A qualitative analysis of patients' reactions to discussions with their doctors about pulmonary nodules. *Chest*. 2012;doi: 10.1378/chest.12-1095. [Epub ahead of print], [PMID: 22814873]

Exclusion code: 2

Wilck EJ. Computed tomography screening for lung cancer. *Ann. Thorac. Surg*. 2008;85(2):S699-700, [PMID: 18222199]

Exclusion code: 5

Wilde JA. A 10 year follow up of semiannual screening for early detection of lung cancer in the Erfurt country, GDR. *Eur. Respir. J*. 1989;2:656-662, [PMID: 2776873]

Exclusion code: 5

Wilkinson NW, Loewen GM, Klippenstein DL, Litwin AM, Anderson TM. The evolution of lung cancer screening. *J. Surg. Oncol*. 2003;84(4):234-238, [PMID: 14756435]

Exclusion code: 5

Williams DE, Pairolero PC, Davis CS, et al. Survival of patients surgically treated for stage I lung cancer. *J. Thorac. Cardiovasc. Surg*. 1981;82(1):70-76, [PMID: 7242135]

Exclusion code: 5

Willmore-Payne C, Holden JA, Wittwer CT, Layfield LJ. The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer. *Journal of Biomolecular Techniques: JBT*. 2008;19(3):217-224, [PMID: 19137110]

Exclusion code: 3

Wilson DO, Leader JK, Fuhrman CR, Reilly JJ, Sciurba FC, Weissfeld JL. Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the pittsburgh lung screening study. *J Thorac Oncol*. 2011;6(7):1200-1205, [PMID: 21610523]

Exclusion code: 7

Wilson DO, Ryan A, Fuhrman CR, et al. Doubling times and CT screen-detected lung cancers in the Pittsburgh Lung Screening Study. *Am. J. Respir. Crit. Care Med*. 2012;185(1):85-89, [PMID: 21997335]

Exclusion code: 2

Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. *Am. J. Respir. Crit. Care Med*. 2008;178(7):738-744, [PMID: 18565949]

Exclusion code: 2

Winawer SJ, Zauber AG, May Nah H, et al. Prevention of colorectal cancer by colonoscopic polypectomy. *N. Engl. J. Med*. 1993;329(27):1977-1981, [PMID: 8247072]

Exclusion code: 8

Winer E, Gralow J, Diller L, et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.[Erratum appears in J Clin Oncol. 2009 Jun 20;27(18):3070-1]. *J. Clin. Oncol*. 2009;27(5):812-826, [PMID: 19103723]

Exclusion code: 5

Winkler V, Ng N, Tesfaye F, Becher H. Predicting lung cancer deaths from

Appendix A6. List of Excluded Full-Text Papers

smoking prevalence data. *Lung Cancer*. 2011;74:170-177, [PMID: 21420756]
Exclusion code: 2

Wisnivesky JP, Henschke CI, Swanson S, et al. Limited resection for the treatment of patients with stage IA lung cancer. *Ann. Surg.* 2010;251(3):550-554, [PMID: 20160639]
Exclusion code: 10

Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. *Chest*. 2003;124(2):614-621, [PMID: 12907551]
Exclusion code: 7

Wisnivesky JP, Szwarcberg JB, McGinn TG. Lung cancer. Screening, counseling, and treating long-term smokers. *Geriatrics*. 2002;57(11):28-32, [PMID: 12442566]
Exclusion code: 5

Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns--getting past uninformative persuasion. *N. Engl. J. Med.* 2012;367(18):1677-1679, [PMID: 23113476]
Exclusion code: 2

Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening: Clinical practice guidelines in oncology. *JNCCN Journal of the National Comprehensive Cancer Network*. 2012;10(2):240-265, [PMID: 22308518]
Exclusion code: 2

Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. *N. Engl. J. Med.* 2002;346(14):1041-1046, [PMID: 11932470]
Exclusion code: 3

Woolner LB, Fontana RS, Sanderson DR, Miller WE, Muhm JR, Taylor WF. Mayo Lung Project: evaluation of lung cancer screening through December 1979. *Mayo Clin. Proc.* 1981;56(9):544-555, [PMID: 6267386]
Exclusion code: 5

Wormanns D, Fiebich M, Saidi M, Diederich S, Heindel W. Automatic detection of pulmonary nodules at spiral CT: clinical application of a computer-aided diagnosis system. *Eur. Radiol.* 2002;12(5):1052-1057, [PMID: 11976846]
Exclusion code: 7

Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. *Thorax*. 2006;61(7):597-603, [PMID: 16449262]
Exclusion code: 5

Wu G-P, Wang E-H, Li J-H, Fu Z-M, Han S. Clinical application of the liquid-based cytological test in cytological screening of sputum for the diagnosis of lung cancer. *Respirology*. 2009;14(1):124-128, [PMID: 19144056]
Exclusion code: 5

Wu MH, Gotway MB, Lee TJ, et al. Features of non-small cell lung carcinomas overlooked at digital chest radiography. *Clin. Radiol.* 2008;63(5):518-528, [PMID: 18374715]
Exclusion code: 3

Wu M-T, Yang P, Huang Y-L, et al. Coronary arterial calcification on low-dose ungated MDCT for lung cancer screening: concordance study with dedicated cardiac CT. *AJR. Am. J. Roentgenol.* 2008;190(4):923-928, [PMID: 18356438]
Exclusion code: 7

Appendix A6. List of Excluded Full-Text Papers

Wu Y, Wang S, Huang Z. [Extent of lymphadenectomy in stage I-IIIa non-small cell lung cancer: a randomized clinical trial]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2001;23(1):43-45, [PMID: 11783068]
Exclusion code: 6

Wu Yl, Huang Z-f, Wang S-y, Yang X-n, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. *Lung Cancer*. 2002;36(1):1-6, [PMID: 11891025]
Exclusion code: 3

Wu Z, Zhou Q. Molecular diagnostics and molecular staging of lung cancer. *Zhongguo Fei Ai Za Zhi*. 2008;11(1):34-39, [PMID: 20727263]
Exclusion code: 4

Xie G-s, Hou A-r, Li L-y, Gao Y-n, Cheng S-j. Quantification of plasma DNA as a screening tool for lung cancer. *Chin. Med. J. (Engl)*. 2004;117(10):1485-1488, [PMID: 15498370]
Exclusion code: 3

Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. *Mod. Pathol*. 2010;23(8):1157-1164, [PMID: 20526284]
Exclusion code: 4

Xing S, Khanavkar B, Nakhosteen JA, et al. Predictive value of image cytometry for diagnosis of lung cancer in heavy smokers. *Eur. Respir. J*. 2005;25(6):956-963, [PMID: 15929948]
Exclusion code: 2

Xing T, Brattstrom D, Bergqvist M, Isaksson U, Wagenius G, Brodin O. Radiation responsiveness of human lung cancer cell lines measured with a short term

semiautomatic assay. *Anticancer Res*. 2001;21(6A):3925-3928, [PMID: 11911271]
Exclusion code: 4

Xiong T, Richardson M, Woodroffe R, Halligan S, Morton D, Lilford RJ. Incidental lesions found on CT colonography: their nature and frequency. *Br. J. Radiol*. 2005;78(925):22-29, [PMID: 15673525]
Exclusion code: 4

Xu DM, van der Zaag-Loonen HJ, Oudkerk M, et al. Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow-up. *Radiol*. 2009;250(1):264-272, [PMID: 18984780]
Exclusion code: 2

Xu DM, van Klaveren RJ, de Bock GH, et al. Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. *Eur. J. Radiol*. 2008;68(2):347-352, [PMID: 17920800]
Exclusion code: 2

Xu DM, van Klaveren RJ, de Bock GH, et al. Role of baseline nodule density and changes in density and nodule features in the discrimination between benign and malignant solid indeterminate pulmonary nodules. *Eur. J. Radiol*. 2009;70(3):492-498, [PMID: 18417311]
Exclusion code: 2

Xue Z, Wong K, Wong S. Joint registration and segmentation of serial lung CT images in microendoscopy molecular image-guided therapy. *Comput. Med. Imaging Graph*. 2008;34(1):55-60, [PMID: 19709855]
Exclusion code: 4

Appendix A6. List of Excluded Full-Text Papers

Xue Z, Wong K, Wong STC. Joint registration and segmentation of serial lung CT images for image-guided lung cancer diagnosis and therapy. *Comput. Med. Imaging Graph.* 2010;34(1):55-60, [PMID: 19709855]

Exclusion code: 4

Yamaguchi M, Bessho Y, Inoue T, Asai Y, Matsumoto T, Murase K. Investigation of optimal viewing size for detecting nodular ground-glass opacity on high-resolution computed tomography with cine-mode display. *Radiol Phys Technol.*

2011;4(1):13-18, [PMID: 20820964]

Exclusion code: 2

Yamakawa Y, Saitou Y, Kiriya M, et al. [Surgery for multiple primary lung cancers]. *Kyobu Geka - Japanese Journal of Thoracic Surgery.* 2002;55(1):10-14, [PMID: 11797401]

Exclusion code: 6

Yamamoto K, Ohsumi A, Kojima F, et al. Long-term survival after video-assisted thoracic surgery lobectomy for primary lung cancer. *Ann. Thorac. Surg.*

2010;89(2):353-359, [PMID: 20103297]

Exclusion code: 10

Yamamoto K, Padilla Alarcon J, Calvo Medina V, et al. Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients. *Eur. J. Cardiothorac. Surg.* 2003;23(1):21-25, [PMID: 12493498]

Exclusion code: 10

Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. *J. Clin. Oncol.* 2009;27(15):2553-2562, [PMID:

19289625]

Exclusion code: 10

Yang J, Yang S-Y, Hu X-Y, et al. Serum peptidome profiling in patients with lung cancer. *Anatomical Record (Hoboken, N.J.):* 2007. 2010;293(12):2027-2033, [PMID: 21082738]

Exclusion code: 3

Yang SY. The status quo, confusion and prospect of early diagnosis for lung cancer. *Journal of Xi'an Jiaotong University (Medical Sciences).* 2011;32(1):1-5

Exclusion code: 6

Yang S-y, Xiao X-y, Zhang W-g, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. *BMC Cancer.* 2005;5:83, [PMID: 16029516]

Exclusion code: 4

Yang ZG, Sone S, Li F, et al. Visibility of small peripheral lung cancers on chest radiographs: influence of densitometric parameters, CT values and tumour type. *Br. J. Radiol.* 2001;74(877):32-41, [PMID: 11227774]

Exclusion code: 2

Yang ZG, Sone S, Takashima S, et al. High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. *AJR. Am. J. Roentgenol.* 2001;176(6):1399-1407, [PMID: 11373200]

Exclusion code: 7

Yangui I, Msaad S, Fouzi S, Ayoub A. [Toward optimization of small cell lung cancer management]. *Tunis. Med.* 2007;85(12):1050-1057, [PMID: 19170386]

Exclusion code: 6

Appendix A6. List of Excluded Full-Text Papers

Yankelevitz D. CT screening for lung cancer. *AJR. Am. J. Roentgenol.* 2003;180(6):1736-1737; author reply 1737, [PMID: 12760953]
Exclusion code: 5

Yankelevitz D, Henschke CI. State-of-the-art screening for lung cancer: (part 2): CT scanning. *Thorac Surg Clin.* 2004;14(1):53-59, [PMID: 15382308]
Exclusion code: 5

Yankelevitz DF. Randomized controlled trials and cancer screening. *Radiology.* 2003;229(2):603; author reply 603-604, [PMID: 14595156]
Exclusion code: 5

Yankelevitz DF. Perhaps it is time for a change in policy on lung cancer screening. *Cleve. Clin. J. Med.* 2007;74(6):438-440, [PMID: 17569201]
Exclusion code: 2

Yankelevitz DF. CT screening for lung cancer: editorials can be deceiving. *J.* 2007;4(6):429-430; author reply 430, [PMID: 17544148]
Exclusion code: 5

Yankelevitz DF. Screening for a cancer: acting on social responsibility. *AJR. Am. J. Roentgenol.* 2007;188(5):1171-1172, [PMID: 17449753]
Exclusion code: 2

Yankelevitz DF. In reply [4]. *Cleve. Clin. J. Med.* 2007;74(11):770
Exclusion code: 5

Yankelevitz DF. Will the national lung screening trial be able to demonstrate a mortality reduction? *Radiology.* 2008;246(2):653; author reply 653-654, [PMID: 18227565]
Exclusion code: 2

Yankelevitz DF. Quantifying "overdiagnosis" in lung cancer screening. *Radiology.* 2008;246(1):332-333; author reply 332-333, [PMID: 18096549]
Exclusion code: 2

Yankelevitz DF, Kostis WJ, Henschke CI, et al. Overdiagnosis in chest radiographic screening for lung carcinoma: frequency. *Cancer.* 2003;97(5):1271-1275, [PMID: 12599235]
Exclusion code: 5

Yankelevitz DF, Reeves AP, Kostis WJ, Zhao B, Henschke CI. Small pulmonary nodules: Volumetrically determined growth rates based on CT evaluation. *Radiology.* 2000;217(1):251-256, [PMID: 11012453]
Exclusion code: 8

Yasufuku K. Early diagnosis of lung cancer. *Clin. Chest Med.* 2010;31(1):39-47, Table of Contents, [PMID: 20172431]
Exclusion code: 2

Yau G, Lock M, Rodrigues G. Systematic review of baseline low-dose CT lung cancer screening. *Lung Cancer.* 2007;58(2):161-170, [PMID: 17723250]
Exclusion code: 2

Yee AJ, Lynch TJ. CT screening for lung cancer. *N. Engl. J. Med.* 2007;356(7):744-745; author reply 746-747, [PMID: 17310519]
Exclusion code: 2

Yee J, Sadar MD, Sin DD, et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. *J. Clin. Oncol.* 2009;27(17):2787-2792, [PMID: 19414677]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Yi S-Z, Zhang D-C, Wang Y-G, Sun K-L. [Clinical features and prognosis of multiple primary tumors of lung combined with other organs--report of 281 cases]. *Ai Zheng*. 2006;25(6):731-735, [PMID: 16764770]

Exclusion code: 6

Yilmaz HH, Yazihan N, Tunca D, et al. Cancer trends and incidence and mortality patterns in Turkey. *Jpn. J. Clin. Oncol*. 2011;41(1):10-16, [PMID: 20558464]

Exclusion code: 5

Yokoi K, Matsuguma H, Nakahara R. [Extrapleural pneumonectomy for thoracic malignancies]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2004;57(11):1000-1004, [PMID: 15510811]

Exclusion code: 6

Yoneda S, Okabayashi K, Kawahara K, et al. [Result of surgical treatment to early stage peripheral non-small cell lung cancer]. *Kyobu Geka - Japanese Journal of Thoracic Surgery*. 2001;54(11):932-937, [PMID: 11593730]

Exclusion code: 6

Yoo DS, Wong TZ, Brizel DM. The role of adaptive and functional imaging modalities in radiation therapy: Approach and application from a radiation oncology perspective. *Seminars in Ultrasound, CT and MRI*. 2010;31(6):444-461, [PMID: 21147372]

Exclusion code: 4

Yoshida M, Kondo K, Tada T. The relation between the cancer screening rate and the cancer mortality rate in Japan. *J. Med. Invest*. 2010;57(3-4):251-259, [PMID: 20847525]

Exclusion code: 3

Yoshimoto A, Tsuji H, Takazakura E, et al. Reasons for the delays in the definitive diagnosis of lung cancer for more than one year from the recognition of abnormal chest shadows. *Intern. Med*. 2002;41(2):95-102, [PMID: 11868615]

Exclusion code: 3

Yoshino I, Yamaguchi M, Yamazaki K, Shoji F, Hamatake M, Maehara Y. Surgical outcome of an anatomical resection of clinical stage IA non-small cell lung cancer assisted with a video-thoracoscopy. *Surg. Today*. 2010;40(8):719-724, [PMID: 20676854]

Exclusion code: 10

Younes RN, Deutsch F, Badra C, Gross J, Haddad F, Deheinzeln D. Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution. *Rev. Hosp. Clin. Fac. Med. Sao Paulo*. 2004;59(3):119-127, [PMID: 15286831]

Exclusion code: 3

Yu C-h, Wang Y-x, Chu X-y, Sun Y-e, Wang T. [Long-term outcome of bronchoplastic procedures in the treatment of lung cancer]. *Chung Hua I Hsueh Tsa Chih*. 2003;83(19):1668-1670, [PMID: 14642100]

Exclusion code: 6

Yuan R, Vos PM, Cooperberg PL. Computer-aided detection in screening CT for pulmonary nodules. *AJR. Am. J. Roentgenol*. 2006;186(5):1280-1287, [PMID: 16632719]

Exclusion code: 2

Yuan Z-y, Wang S-s, Zhu M-q, et al. [Clinical characteristics and prognosis of different subtypes of breast cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2008;30(6):456-461, [PMID: 19024523]

Appendix A6. List of Excluded Full-Text Papers

Exclusion code: 6

Yung RC, Zeng MY, Stoddard GJ, Garff M, Callahan K. Transcutaneous computed bioconductance measurement in lung cancer: A treatment enabling technology useful for adjunctive risk stratification in the evaluation of suspicious pulmonary lesions. *Journal of Thoracic Oncology*. 2012;7(4):681-689, [PMID: 22425917]
Exclusion code: 4

Zeng H, Fawzy YS, Short MA, et al. Combining field imaging endoscopy with point analysis spectroscopy for improving early lung cancer detection. *Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine & Biology Society*. 2008;2008:1849-1850, [PMID: 19163043]
Exclusion code: 4

Zhang J, Chen C, Zheng H, Chen G. [Clinicopathologic analysis of 57 cases of primary pulmonary mucinous adenocarcinoma]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2009;31(1):66-68, [PMID: 19538874]
Exclusion code: 6

Zhang J, Fu Y, Mei Y, Jiang F, Lakowicz JR. Fluorescent metal nanoshell probe to detect single miRNA in lung cancer cell. *Anal. Chem*. 2010;82(11):4464-4471, [PMID: 20433154]
Exclusion code: 4

Zhang L-b, Sun Y-e, Yu C-h, Liu Y. [Clinical diagnosis and surgical treatment of primary pulmonary lymphoma]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 2006;44(2):97-99, [PMID: 16620666]
Exclusion code: 6

Zhang P, Xu B-h, Ma F, Li Q. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2010;32(2):128-131, [PMID: 20403244]
Exclusion code: 6

Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. *Lung Cancer*. 2010;69(2):225-231, [PMID: 20004997]
Exclusion code: 4

Zhang Z, Liu D, Guo Y, et al. [The common causes of conversion of VATS during operation for 248 non-small cell lung cancers]. *Zhongguo Fei Ai Za Zhi*. 2011;14(6):523-528, [PMID: 21645457]
Exclusion code: 6

Zhang Z, Wang Y. [Clinical experiences of bronchopleural fistula-related fatal hemoptysis after the resection of lung cancer: a report of 7 cases]. *Zhongguo Fei Ai Za Zhi*. 2012;15(1):39-43, [PMID: 22237123]
Exclusion code: 6

Zhao Z-L, Song N, Huang Q-Y, Liu Y-P, Zhao H-R. [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma--a report of 17 cases]. *Ai Zheng*. 2007;26(2):183-188, [PMID: 17298750]
Exclusion code: 6

Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. *Int J Clin Exp Pathol*. 2011;4(6):575-586, [PMID: 21904633]
Exclusion code: 2

Appendix A6. List of Excluded Full-Text Papers

Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer. *Am. J. Respir. Crit. Care Med.* 2005;172(10):1308-1314, [PMID: 16109979]
Exclusion code: 3

Zhong X-J, Li D-T, Li X-L, Mu D-B, Zhang X-G, Luo J-Y. [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. *Ai Zheng.* 2007;26(7):785-789, [PMID: 17626761]
Exclusion code: 6

Zhou S-J, Xu S-F, Zhang H-Q, Liu Z-D. [Expression of HDGF and its implication in stage I non-small cell lung cancer]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]*. 2007;29(12):927-930, [PMID: 18478933]
Exclusion code: 6

Zhu M, Fu XN, Chen X. Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer. *Frontiers of Medicine in China.* 2011;5(1):53-60, [PMID: 21681675]
Exclusion code: 5

Zochbauer-Muller S, Minna JD. The biology of lung cancer including potential clinical applications. *Chest Surg. Clin. N. Am.* 2000;10(4):691-708, [PMID: 11091920]
Exclusion code: 5

Zompatori M, Battista G, Sciascia N, Di Scioscio V, Canini R. [Screening for bronchogenic carcinoma using computed tomography. More questions than answers]. *Radiol. Med. (Torino).* 2001;101(5):313-320, [PMID: 11438781]

Exclusion code: 6

Zona A, Bruno C. Health surveillance for subjects with past exposure to asbestos: From international experience and Italian regional practices to a proposed operational model. *Annali dell'Istituto Superiore di Sanita.* 2009;45(2):147-161, [PMID: 19636166]
Exclusion code: 4

Zorn GL, 3rd, Nesbitt JC. Surgical management of early stage lung cancer. *Semin. Surg. Oncol.* 2000;18(2):124-136, [PMID: 10657914]
Exclusion code: 5

Zudaire I, Lozano MD, Vazquez MF, et al. Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. *Histol. Histopathol.* 2008;23(1):33-40, [PMID: 17952855]
Exclusion code: 7

Zullig LL, Jackson GL, Dorn RA, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. *Mil. Med.* 2012;177(6):693-701, [PMID: 22730846]
Exclusion code: 7

Zulueta J, Montuenga LM. [Early detection of lung cancer: the right time]. *Med. Clin. (Barc).* 2002;118(12):460-462, [PMID: 11958764]
Exclusion code: 6

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Population	Risk group	Screening comparison (In vs. Co)	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
National Lung Screening Trial (NLST)					
National Lung Screening Trial Research Team et al, 2011 ⁵⁴ <i>Reduced lung-cancer mortality with low-dose computed tomographic screening</i>	Ages 55 to 74 years	Current or former (quit ≤ 15 years ago) smoker with ≥ 30 pack-year smoking history	CT vs. CXR: CT: Low-dose (1.5 mSv), multidetector, ≥ 4 channels CXR: 1 view, PA with deep inspiration	Certified radiologists and technicians by appropriate boards Radiologists trained in image quality and standardized image acquisition NCN ≥ 4 mm were classified positive, suspicious for lung cancer Adenopathy, effusion could be positive, suspicious Other abnormal findings suggesting clinically important, nonlung cancer diagnosis reported Stability on year 2 scan could be classified as minor rather than positive	Results and recommendations from radiologist to subject's community provider
Lung Screening Study (LSS)					
Gohagan et al, 2004 ⁵⁵ <i>Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs. chest radiograph: the Lung Screening Study of the National Cancer Institute</i>	Ages 55 to 74 years	Former or current smokers ≥ 30 pack-years who quit < 10 years prior	LDCT vs. single PA CXR examination	Encouraged via study to be evaluated Diagnostic evaluation assessed by record review	Positive = any nodule ≥ 4 mm (although varied with time)
Gohagan et al, 2005 ⁷⁴ <i>Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest x-ray screening for lung cancer</i>	Ages 55 to 74 years	Former or current smokers ≥ 30 pack-years who quit < 10 years prior	LDCT vs. single PA CXR examination	Encouraged via study to be evaluated Diagnostic evaluation assessed by record review	Positive = any nodule ≥ 4 mm (although varied with time)
Pinsky et al, 2005 ⁷⁵ <i>Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen</i>	Ages 55 to 74 years	Former or current smokers ≥ 30 pack-years who quit < 10 years prior	LDCT vs. single PA CXR examination	Encouraged via study to be evaluated Diagnostic evaluation assessed by record review	Positive = any nodule ≥ 4 mm (although varied with time)
Croswell et al, 2010 ⁷³ <i>Cumulative incidence of false-positive test results in lung cancer screening</i>	Ages 55 to 74 years	Former or current smokers ≥ 30 pack-years who quit < 10 years prior	LDCT vs. single PA CXR examination	Encouraged via study to be evaluated Diagnostic evaluation assessed by record review	Positive = any nodule ≥ 4 mm (although varied with time)

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Population	Risk group	Screening comparison (In vs. Co)	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays (DANTE)					
Infante et al, 2009 ⁵¹ <i>A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial</i>	Screening vs. none Mean age: 64.3 vs. 64.6 years Current smoker: 56% vs. 57% Mean pack-years: 47.3 vs. 47.2 Prior cancer (considered cured): 1.0% vs. 0.6% Respiratory comorbidity: 35% vs. 31% (p=0.04)	Asymptomatic male current or former smokers with ≥20 pack-years Ages 60 to 74 years	CT vs. annual clinical review	Per study protocol: Case-by-case basis for nonsmooth ≥6 but ≤10 mm lesion that has not regressed after antibiotics on repeat imaging. PET positive nonsmooth ≥10 but ≤20 mm lesion that has not regressed with antibiotics PET positive nonsmooth lesion ≥20 mm Case-by-case for focal ground glass opacities that have not responded to antibiotics or regressed on repeat imaging	Pursued within the study via established diagnostic protocol
Danish Lung Cancer Screening Study (DLCST)					
Pedersen et al, 2009 ⁶ <i>The Danish Randomized Lung Cancer CT Screening Trial—overall design and results of the prevalence round</i>	CT vs. control Mean age: 57.9 vs. 57.8 Mean pack-years: 36.4 vs. 35.9 Current/former smokers: 1545/507 vs. 1579/473	Healthy volunteer men and women ages 50 to 70 years Current and former smokers (<10 years and >4 weeks since smoking cessation) with ≥20 pack-years smoking history	LDCT vs. usual care	Imaging assessed and followup imaging within study	Screen-detected findings, single center affiliated with study Control group outside study, but mostly with same specialists
Saghir et al, 2012 ⁵² <i>CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT</i>	CT vs. control Mean age: 57.9 vs. 57.8 Mean pack-years: 36.4 vs. 35.9 Current/former smokers: 1545/507 vs. 1579/473	Healthy volunteer men and women ages 50 to 70 years Current and former smokers (<10 years and >4 weeks since smoking cessation) with ≥20 pack-years smoking history	LDCT vs. usual care	All CT scans reviewed by 2 study radiologists, within study protocol	Referred to chest physicians for diagnostic evaluation at 2 lung cancer centers when HRCT, PET-CT, bronchoscopy, and/or biopsy performed In control group, lung cancer diagnosed and treated by the usual clinical practice, which mostly involved the same centers/strategies

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Population	Risk group	Screening comparison (In vs. Co)	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
Ashraf et al, 2008 ⁵² <i>Smoking habits are unaffected by CT screening at 1-year follow-up in the Danish Lung Cancer Screening Trial</i>	CT vs. control Mean age: 57.9 vs. 57.8 Mean pack-years: 36.4 vs. 35.9 Current/former smokers: 1545/507 vs. 1579/473	Healthy volunteer men and women ages 50 to 70 years Current and former smokers (<10 years and >4 weeks since smoking cessation) with ≥20 pack-years smoking history	LDCT vs. usual care	Imaging assessed and followup imaging within study	Screen-detected findings, single center affiliated with study Control group outside study, but mostly with same specialists
ITALUNG					
Lopes Pegna et al, 2009 ⁵⁷ <i>Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT</i>	Mean age: 64 years (range: 55 to 69)	≥20 pack-years since the last 10 years (former smokers who quit >10 years ago excluded)	CT vs. usual care	5 SCT scanners (1 single row, 4 multirow detectors) Subsequent management per ELCAP study 3 radiologists read first reading, 15 read second	Negative study = no focal findings, <5 mm solid NCN, or <10 mm nonsolid nodule
Mascalchi et al, 2011 ⁵² <i>Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT</i>	Mean age: 64 years (range: 55 to 69)	≥20 pack-years since the last 10 years (former smokers who quit >10 years ago excluded)	CT vs. usual care	8 SCT scanners Subsequent management per ELCAP study 3 radiologists read first reading, 15 read second	Negative study = no focal findings, <5 mm solid NCN, or <10 mm nonsolid nodule
Mascalchi et al, 2006 ⁸¹ <i>Risk–benefit analysis of x-ray exposure associated with lung cancer screening in the ITALUNG-CT trial</i>	Mean age: 64 years (range: 55 to 69)	≥20 pack-years since the last 10 years (former smokers who quit >10 years ago excluded)	CT vs. usual care	Followed in study per ELCAP criteria	Negative study = no focal findings, <5 mm solid NCN, or <10 mm non-solid nodule
Multi-centric Italian Lung Detection (MILD)					
Pastorino et al, 2012 ⁵³ <i>Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial</i>	Age ≥49 years 63% to 68% male 10% former smokers Mean pack-years: 38 to 39	Smokers with a smoking history >20 pack-years or quit <10 years ago	LDCT (annual vs. biennial) vs. usual care	Volumetrics used: <60 mm ³ (4.8 mm) continue 1–2 year schedule 60–250 mm ³ (5 to 8 mm) repeat in 3 months, if <25% increase in volume, resume 1 or 2 year schedule >250 mm ³ (>8 mm) referred for evaluation, generally with PET	Volumetric followup of intermediate nodules PET scan for nodules >250 mm ³ No further description

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Population	Risk group	Screening comparison (In vs. Co)	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
Nederlands-Leuven Longkanker Screenings Onderzoek (NELSON)					
<p>van Iersel et al, 2006⁷⁹ <i>Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON)</i></p> <p>Xu et al, 2006⁶⁴ <i>Nodule management protocol of the NELSON randomised lung cancer screening trial</i></p> <p>van den Bergh et al, 2009⁷⁸ <i>Informed participation in a randomised controlled trial of computed tomography screening for lung cancer</i></p> <p>van Klaveren et al, 2009⁵⁶ <i>Management of lung nodules detected by volume CT scanning</i></p>	Median age: 59 years (SD 6) 16% female	Asymptomatic current or former smokers with 15 cigarettes/day for >25 years or >10 cigarettes/day for >30 years smoking history, and if former smoker, quit ≤10 years ago Could have prior lung cancer if >5 years prior and not being treated	CT vs. no screening	Imaging assessment and followup dictated by the study using volumetric indices	Positive test: solid nodule, >500 mm ³ were referred to pulmonologist Positive test: solid, between 50 to 500 mm ³ ; solid, pleural-based between 5 to 10 mm in diameter, partially solid with nonsolid component >7 mm; partially solid with solid component between 50 to 500 mm ³ ; or nonsolid, >7 mm diameter: referred for repeat CT scan in 3 to 4 months
van den Bergh et al, 2010 ⁷⁷ <i>Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON)</i>	Median age: 59 years (SD 6) 16% female	Asymptomatic current or former smokers with 15 cigarettes/day for >25 years or >10 cigarettes/day for >30 years smoking history, and if former smoker, quit ≤10 years ago Could have prior lung cancer if >5 years prior and not being treated	CT vs. no screening	Imaging assessment and followup dictated by the study using volumetric indices	Positive test: solid nodule, >500 mm ³ were referred to pulmonologist Positive test: solid, between 50 to 500 mm ³ ; solid, pleural-based between 5 to 10 mm in diameter, partially solid with nonsolid component >7 mm; partially solid with solid component between 50 to 500 mm ³ ; or nonsolid, >7 mm diameter: referred for repeat CT scan in 3 to 4 months

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Population	Risk group	Screening comparison (In vs. Co)	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
van den Bergh et al, 2011 ⁶⁹ <i>Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial</i>	Median age: 59 years (SD 6) 16% female	Asymptomatic current or former smokers with 15 cigarettes/day for >25 years or >10 cigarettes/day for >30 years smoking history, and if former smoker, quit ≤10 years ago Could have prior lung cancer if >5 years prior and not being treated	CT vs. no screening	Imaging assessment and followup dictated by the study using volumetric indices	Positive test: solid nodule, >500 mm ³ were referred to pulmonologist Positive test: solid, between 50 to 500 mm ³ ; solid, pleural-based between 5 to 10 mm in diameter, partially solid with nonsolid component >7 mm; partially solid with solid component between 50 to 500 mm ³ ; or nonsolid, >7 mm diameter: referred for repeat CT scan in 3 to 4 months
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial					
Croswell et al, 2009 ⁷³ <i>Cumulative incidence of false-positive results in repeated, multimodal cancer screening</i>	CXR vs. usual care Men: 50% vs. 50% White: 86% vs. 85% Current smokers: 10% vs. 10% Former smokers: 42% vs. 42% Never smokers: 45% vs. 44% NLST eligible: 20% vs. 21% Family history: 11% vs. 11%	Those with ≥30 pack-year smoking history; current smokers or quit <15 years ago	CXR vs. usual care	Advised to seek diagnostic evaluation which was decided outside of study; study obtained their records Participants/ health care providers notified of results and evaluation determined by patient with provider	Positive result = nodule, mass, infiltrate, or other abnormality suspicious for lung cancer
Hocking et al, 2010 ⁸⁴ <i>Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial</i>	CXR vs. usual care Men: 50% vs. 50% White: 86% vs. 85% Current smokers: 10% vs. 10% Former smokers: 42% vs. 42% Never smokers: 45% vs. 44% NLST eligible: 20% vs. 21% Family history: 11% vs. 11%	Those with ≥30 pack-year smoking history; current smokers or quit <15 years ago	CXR vs. usual care	Advised to seek diagnostic evaluation which was decided outside of study; study obtained their records Participants/ health care providers notified of results and evaluation determined by patient with provider	Positive result = nodule, mass, infiltrate, or other abnormality suspicious for lung cancer

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
National Lung Screening Trial (NLST)					
National Lung Screening Trial Research Team et al, 2011 ⁵⁴ <i>Reduced lung-cancer mortality with low-dose computed tomographic screening</i>	Asymptomatic men and women ages 55 to 74 years with ≥30 pack-year smoking history and if former smoker quit ≤15 years ago	Hemoptysis or unexplained >15 lb weight loss in preceding year, chest CT within 18 months	Number approached: NR Number eligible: NR Number enrolled: 53,454 (26,722 vs. 26,732)	United States Multicenter (10 LSS centers and 23 ACRIN centers)	NCI
Lung Screening Study (LSS)					
Gohagan et al, 2004 ⁵⁵ <i>Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs. chest radiograph: the Lung Screening Study of the National Cancer Institute</i>	Men and women ages 55 to 74 years with ≥30 pack-year smoking history and quit during <10 years	Prior lung cancer, prior lung surgery, prior chest CT ≤2 years, current treatment for any cancer (other than nonmelanoma skin cancer), participation in another lung cancer screening trial	Number approached: 653,417 Number eligible: 4828 Number enrolled: 3318 (1660 vs. 1658)	6 centers in United States	NCI
Gohagan et al, 2005 ⁷⁴ <i>Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest x-ray screening for lung cancer</i>	Men and women ages 55 to 74 years with ≥30 pack-year smoking history and quit during <10 years	Prior lung cancer, prior lung surgery, prior chest CT ≤2 years, current treatment for any cancer (other than nonmelanoma skin cancer), participation in another lung cancer screening trial	Number approached: 653,417 Number eligible: 4828 Number enrolled: 3318 (1660 vs. 1658) Number at 1 year: 2715 (1398 vs. 1317)	6 centers in United States	NCI
Pinsky et al, 2005 ⁷⁵ <i>Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen</i>	Men and women ages 55 to 74 years with ≥30 pack-year smoking history and quit during <10 years	Prior lung cancer, prior lung surgery, prior chest CT ≤2 years, current treatment for any cancer (other than nonmelanoma skin cancer), participation in another lung cancer screening trial	Number approached: 653,417 Number eligible: 4828 Number enrolled: 3318 (1660 vs. 1658) Number at 1 year: 2715 (1398 vs. 1317)	6 centers in United States	NCI

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
Croswell et al, 2010 ⁷³ <i>Cumulative incidence of false-positive test results in lung cancer screening</i>	Men and women ages 55 to 74 years with ≥ 30 pack-year smoking history and quit during < 10 years	Prior lung cancer, prior lung surgery, prior chest CT ≤ 2 years, current treatment for any cancer (other than nonmelanoma skin cancer), participation in another lung cancer screening trial	Number approached: 653,417 Number eligible: 4828 Number enrolled: 3318 (1660 vs. 1658) Number analyzed: 3190 (1610 vs. 1580)	6 centers in United States	NCI
Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays (DANTE)					
Infante et al, 2009 ⁵¹ <i>A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial</i>	Male current or former smokers with a history of ≥ 20 pack-years and ages 60 to 74 years	Comorbid conditions carrying a life expectancy of < 5 years, a history of previous malignancy treated within 10 years before accrual (exceptions allowed for early laryngeal cancer and nonmelanoma skin cancer if 5-year disease free interval met), or if unable to comply with the followup protocol for any reason	Number approached: 2811 (1403 vs. 1408) Number enrolled: 2472 patients (1276 vs. 196)	Italy, 3 hospitals from same hospital network	Italian Association for the Fight Against Cancer (donations from benefactors and charities directed at financing the study)
Danish Lung Cancer Screening Study (DLCST)					
Pedersen et al, 2009 ¹⁶ <i>The Danish Randomized Lung Cancer CT Screening Trial—overall design and results of the prevalence round</i>	Current or former smokers with history of ≥ 20 pack-years, ages 50 to 70 years Former smokers who quit smoking after age 50 years and < 10 years ago, able to climb 2 flights of stairs without pausing, PFT baseline forced expiratory volume-1 was $\geq 30\%$ of predicted normal	Body weight > 130 kg; previous treatment for lung cancer, breast cancer, malignant melanoma, or hypernephroma; history of any other cancer within previous 5 years; tuberculosis within 2 years; any other serious illness that would shorten life expectancy to < 10 years	Number approached: 5861 Number eligible: NR Number enrolled: 4104 (2052 vs. 2052)	Denmark, single site University Hospital, enrolled from October 2004 to March 2006	Danish Ministry of Interior and Health
Saghir et al, 2012 ⁵² <i>CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT</i>	Current or former smokers with history of ≥ 20 pack-years, ages 50 to 70 years Former smokers who quit smoking after age 50 years and < 10 years ago, able to climb 2 flights of stairs without pausing, PFT baseline forced expiratory volume-1 was $\geq 30\%$ of predicted normal	Body weight > 130 kg; previous treatment for lung cancer, breast cancer, malignant melanoma, or hypernephroma; history of any other cancer within previous 5 years; tuberculosis within 2 years; any other serious illness that would shorten life expectancy to < 10 years	Number approached: 5861 Number eligible: NR Number enrolled: 4104 (2052 vs. 2052)	Denmark, single site University Hospital, enrolled from October 2004 to March 2006	Danish Ministry of Interior and Health

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
Ashraf et al, 2008 ⁶² <i>Smoking habits are unaffected by CT screening at 1-year follow-up in the Danish Lung Cancer Screening Trial</i>	Current or former smokers with history of ≥ 20 pack-years, ages 50 to 70 years Former smokers who quit smoking after age 50 years and < 10 years ago, able to climb 2 flights of stairs without pausing, PFT baseline forced expiratory volume-1 was $\geq 30\%$ of predicted normal	Body weight > 130 kg; previous treatment for lung cancer, breast cancer, malignant melanoma, or hypernephroma; history of any other cancer within previous 5 years; tuberculosis within 2 years; any other serious illness that would shorten life expectancy to < 10 years	Number approached: 5861 Number eligible: NR Number enrolled: 4104 (2052 vs. 2052)	Denmark, single site University Hospital, enrolled from October 2004 to March 2006	Government grant
ITALUNG					
Lopes Pegna et al, 2009 ⁵⁷ <i>Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT</i>	≥ 20 pack-years since the last 10 years	History of cancer and inability to tolerate lung cancer resection surgery, former smokers who quit > 10 years ago	Number approached: 71,232 Number eligible: NR Number enrolled: 1613 (1406 vs. 1593)	Italy, general population	Regional Health Public Authority
Mascalchi et al, 2011 ⁸² <i>Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT</i>	≥ 20 pack-years since the last 10 years	History of cancer and inability to tolerate lung cancer resection surgery, former smokers who quit > 10 years ago	Number approached: 71,232 Number eligible: NR Number enrolled: 1613 (1406 vs. 1593)	Italy, general population	Regional Health Public Authority
Mascalchi et al, 2006 ⁸¹ <i>Risk-benefit analysis of x-ray exposure associated with lung cancer screening in the ITALUNG-CT trial</i>	≥ 20 pack-years since the last 10 years	History of cancer and inability to tolerate lung cancer resection surgery, former smokers who quit > 10 years ago	Number approached: NR Number eligible: NR Number analyzed: 60 (210 CT scans)	Italy, general population	Health Department of the Region of Tuscany, Italian League Against Tumors, and the Ministry of Education, Universities, and Research
Multi-centric Italian Lung Detection (MILD)					
Pastorino et al, 2012 ⁵³ <i>Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial</i>	Smokers ages ≥ 49 years with ≥ 20 pack-year smoking history or if former smoker quit < 10 years ago	History of cancer in past 5 years	Number approached: NR Number eligible: NR Number enrolled: 4099 (1190 vs. 1186 vs. 1723)	Single institution, Milan	Foundations and Ministry of Health

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON)					
van Iersel et al, 2006 ⁷⁹ <i>Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON)</i> Xu et al, 2006 ⁶⁴ <i>Nodule management protocol of the NELSON randomised lung cancer screening trial</i> van den Bergh et al, 2009 ⁷⁸ <i>Informed participation in a randomised controlled trial of computed tomography screening for lung cancer</i> van Klaveren et al, 2009 ⁵⁶ <i>Management of lung nodules detected by volume CT scanning</i>	Men born between 1928 and 1956 who smoked >15 cigarettes/day during >25 years or smoked >10 cigarettes/day during >30 years, current or former smokers who quit smoking ≤10 years ago	Moderate or bad self-reported health who were unable to climb 2 flights of stairs; body weight ≥140 kg; current or past renal cancer, melanoma, or breast cancer; lung cancer diagnosed <5 years ago or ≥5 years ago but still under treatment; chest CT examination <1 year before starting study	Number approached: 548,489 Number eligible: NR Number enrolled: 15,822 (7907 vs. 7915)	Belgium, the Netherlands, Denmark	Netherlands Organisation of Health Research and Development, Dutch Cancer Society, Health Insurance Innovation Foundation, Siemens Germany, Roche Diagnostics, G. Ph. Verhagen Stichting, Rotterdam Oncologic Thoracic Study Group, Erasmus Trust Fund, Stichting tegen Kanker, Vlaamse Liga tegen Kanker, and LOGO Leuven
van den Bergh et al, 2010 ⁷⁷ <i>Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON)</i>	Men born between 1928 and 1956 who smoked >15 cigarettes/day during >25 years or smoked >10 cigarettes/day during >30 years, current or former smokers who quit smoking ≤10 years ago Consecutive sample of 733 patients in CT group sent surveys on health related quality of life	Moderate or bad self-reported health who were unable to climb 2 flights of stairs; body weight ≥140 kg; current or past renal cancer, melanoma, or breast cancer; lung cancer diagnosed <5 years ago or ≥5 years ago but still under treatment; chest CT examination <1 year before starting study	Number approached: 692 sent 1st survey, 685 sent 2nd survey, 667 sent 3rd survey, 684 sent 4th survey Number eligible: NR Number analyzed: 630 returned 1st survey, 641 returned 2nd survey, 620 returned 3rd survey, 600 returned 4th survey	The Netherlands/ Belgium	Netherlands Organisation of Health Research and Development, Dutch Cancer Society, Health Insurance Innovation Foundation, Siemens Germany, Roche Diagnostics, G. Ph. Verhagen Stichting, Rotterdam Oncologic Thoracic Study Group, Erasmus Trust Fund, Stichting tegen Kanker, Vlaamse Liga tegen Kanker, and

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
van den Bergh et al, 2011 ⁶⁹ <i>Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial</i>	Men born between 1928 and 1956 who smoked >15 cigarettes/day during >25 years or smoked >10 cigarettes/day during >30 years, current or former smokers who quit smoking ≤10 years ago Consecutive sample of 733 patients in CT group sent surveys on health related quality of life	Moderate or bad self-reported health who were unable to climb 2 flights of stairs; body weight ≥140 kg; current or past renal cancer, melanoma, or breast cancer; lung cancer diagnosed <5 years ago or ≥5 years ago but still under treatment; chest CT examination <1 year before starting study	Number approached: 1466 sent 1st survey, 684 sent 2nd survey, 1180 sent 3rd survey, 684 sent 4th survey Number eligible: NR Number analyzed: 1288 returned 1st survey (90% vs. 86%), 600 returned 2nd survey, 931 returned 3rd survey (89% vs. 65%), 600 returned 4th survey	The Netherlands/ Belgium	LOGO Leuven Netherlands Organisation of Health Research and Development, Dutch Cancer Society, Health Insurance Innovation Foundation, Siemens Germany, Roche Diagnostics, G. Ph. Verhagen Stichting, Rotterdam Oncologic Thoracic Study Group, Erasmus Trust Fund, Stichting tegen Kanker, Vlaamse Liga tegen Kanker, and LOGO Leuven
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial					
Croswell et al, 2009 ⁷³ <i>Cumulative incidence of false-positive results in repeated, multimodal cancer screening</i>	Men and women ages 55 to 74 years, eligible for NLST	History of a PLCO cancer, prior pneumonectomy, current cancer treatment	Number approached: NR Number eligible: NR Number enrolled: 154,901 (77,445 vs. 77,456) Number with false-positives in intervention: 11,851 (6320 men and 5531 women)	10 centers	NCI

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
Hocking et al, 2010 ⁵⁴ <i>Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial</i>	Men and women ages 55 to 74 years, eligible for NLST	History of a PLCO cancer, prior pneumonectomy, current cancer treatment	Number approached: NR Number eligible: NR Number enrolled: 154,901 (77,445 vs. 77,456) Number with false-positives in intervention: 11,851 (6320 men and 5531 women)	10 centers	NCI

Author, year, title	Results		Sensitivity
	Intervention	Control	
National Lung Screening Trial (NLST)			
National Lung Screening Trial Research Team et al, 2011 ⁵⁴ <i>Reduced lung-cancer mortality with low-dose computed tomographic screening</i>	Lung cancer mortality: 356 (247/100,000 py); RR, 20% (95% CI, 6.8 to 27%) Overall mortality: 1877; RR, 6.7% (95% CI, 1.2 to 14%) Adherence to screening: 95% Positive screen (T0, T1, T2, total patients): 27%, 28%, 17%, 39% Incidence: 1060 (645/100,000 py)	Lung cancer mortality: 443 (309/100,000 py) Overall mortality: 1998 Adherence to screening: 93% Positive screen (T0, T1, T2, total patients): 9.2%, 6.2%, 5.0%, 16% Incidence: 941 (572/100,000 py)	NR
Lung Screening Study (LSS)			
Gohagan et al, 2004 ⁵⁵ <i>Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs. chest radiograph: the Lung Screening Study of the National Cancer Institute</i>	Positive: 325/1586 Any procedure: 309 Clinical evaluation: 244 Comparison with prior: 155 Chest CT: 232 CXR: 92 PFT: 73 Any invasive procedure: 53 Lung cancer: 30 Lung cancer incidence: 1.9% Stage I: 16 (53%) Stage IV: 3 (10%) Adenocarcinoma: 19 (63%)	Positive: 152/1550 Any procedure: 140 Clinical evaluation: 71 Comparison with prior: 71 Chest CT: 76 CXR: 68 PFT: 20 Any invasive procedure: 15 Lung cancer: 7 Lung cancer incidence: 0.5% Stage I: 6 (86%) Stage IV: 0 Adenocarcinoma: 3 (43%)	<u>Baseline:</u> PPV CXR or CT: 9.2% CT: 30 lung cancers and 325 positive exams CXR: 7 lung cancers and 152 positive exams Sensitivity: NR at baseline

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Results		Sensitivity
	Intervention	Control	
Gohagan et al, 2005 ⁷⁴ <i>Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest x-ray screening for lung cancer</i>	Year 1 results: Positive: 360 Followup status known: 351 Any procedure: 332 Comparison with prior imaging: 231 CXR: 64 Chest CT: 140 PFT: 70 Bronchoscopy: 14 Biopsy/resection: 18 Lung cancer: 8 (0.6%) Cumulative results: Positive: 35% Screen-detected lung cancer: 38/40 (2 interval cancer) Stage I: 48%	Year 1 results: Positive: 115 Followup status known: 111 Any procedure: 101 Comparison with prior imaging: 57 CXR: 45 Chest CT: 55 PFT: 14 Bronchoscopy: 8 Biopsy/resection: 10 Lung cancer: 9 (0.7%) Cumulative results: Positive: 16% Screen-detected lung cancer: 16/20 (4 interval cancer) Stage I: 40%	NR
Pinsky et al, 2005 ⁷⁵ <i>Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen</i>	After 1st positive screen (n=522) <u>Highest level procedure</u> Biopsy/resection: 63 (12%) Invasive procedure without resection: 5 (1%) Chest CT: 287 (55%) Other (PET/MRI): 10 (2%) PFT/sputum cytology: 31 (6%) CXR: 26 (5%) Comparison with other imaging: 63 (12%) Clinical exam: 21 (4%) No evaluation: 16 (3%) <u>Findings</u> Lung cancer: 37 Other lung diseases: 114 COPD/emphysema: 59 Pulmonary fibrosis: 31 Renal cancer: 1	NR	NR
Croswell et al, 2010 ⁷³ <i>Cumulative incidence of false-positive test results in lung cancer screening</i>	Received ≥1 false-positive: 506 (31%) Baseline risk false-positive: 21% 1st incident screen false-positive: 33%	Received ≥1 false-positive: 216 (14%) Baseline risk false-positive: 9% 1st incident screen false-positive: 15% Baseline false-negative: 4	NR

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Results		Sensitivity
	Intervention	Control	
Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays (DANTE)			
Infante et al, 2009 ⁵¹ <i>A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial</i>	All-cause mortality: 46 (3.6%) Lung cancer mortality: 20 (1.6%) Other mortality causes: 26 (2.0%) Patients with lung cancers: 60 (4.7%) Total number of lung cancers: 63 (4.9%) Stage IA: 20 (1.6%) All stage I: 33 (2.6%) Stage II: 4 (0.3%) Stage IIIA: 7 (0.6%) Stage IIIB: 6 (0.5%) Stage IV: 11 (0.9%) Any abnormality on CT or CXR: 351 (28%) Additional CT: 199 (16%) Diagnostic PET: 57 (4.5%) Any investigation: 226 (18%) Any invasive procedure: 96 (7.5%) Histology: 6 (0.5%) Small cell: 57 (4.4%)	All-cause mortality: 45 (3.8%) p=0.83 Lung cancer mortality: 20 (1.7%) p=0.84 Other mortality causes: 25 (2.1%) p=0.93 Patients with lung cancers: 34 (2.8%) p=0.02 Total number of lung cancers: 36 (3.0%) Stage IA: 4 (0.3%) All stage I: 12 (1.0%) p=0.004 Stage II: 2 (0.2%) Stage IIIA: 4 (0.3%) Stage IIIB: 3 (0.3%) Stage IV: 14 (1.2%) Any abnormality on CT or CXR: 22 (1.8%) Additional CT: 4 (0.3%) Diagnostic PET: 153 (13%) p=0.001 Any investigation: 36 (3.0%) p<0.0001 Any invasive procedure: 2 (0.2%) Histology: 34 (2.8%) Small cell: NR	NR
Danish Lung Cancer Screening Study (DLCST)			
Pedersen et al, 2009 ⁷⁶ <i>The Danish Randomized Lung Cancer CT Screening Trial—overall design and results of the prevalence round</i>	Prevalence round LDCT	NR	NR in study 189/2052 (9.2%) with study requiring followup 17 cases of lung cancer detected 7.9% false-positive
Saghir et al, 2012 ⁵² <i>CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT</i>	Overall 69 lung cancers 3 small cell 66 NSCLC 44 stage I or II 21 stage III or IV 53 pathologically identified within 1 year of CT first seen on 1 interval cancer Deaths: 61 (3.0%) Lung cancer death: 15 (0.7%) All 5 rounds 1029 nodules 560 baseline 469 incidence 611 individuals with nodules/5 years 198 (of 9800 scans) referred for diagnostic evaluation 7 VATS benign Baseline false-positive rate: 7.9%	24 lung cancers 6 extensive SCLC 17 NSCLC 8 stage I or II 16 stage III or IV Deaths: 42 (2.1%); p=0.059 Lung cancer death: 11 (0.5%); p=0.42	NR 1 interval cancer diagnosed after 3rd incidence screen

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Results		Sensitivity
	Intervention	Control	
	Annual false-positive rate range: 1.6% to 2.0%		
Ashraf et al, 2008 ⁶² <i>Smoking habits are unaffected by CT screening at 1-year follow-up in the Danish Lung Cancer Screening Trial</i>	Quit rate: 174/1545 Relapse rate: 85/507	Quit rate: 165/1579 Relapse rate: 98/473	NR
ITALUNG			
Lopes Pegna et al, 2009 ⁵⁷ <i>Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT</i>	639 nodules in 426 subjects 366 followup CT, 4/5 with increased nodule size had PET 59 had PET, bronchus in 18 16 FNA biopsy in 15 subjects 12 FNA biopsy positive for lung cancer, 2 indeterminate (later lung cancer), 1 benign 20 with lung cancer, 1 with 2 primary NSCLC: 86%; 10 stage I, 8 stage IA 17 cancer in 16 subjects surgically resected; 1 resection for a benign lesion 16 had cancer after baseline screen 5 had cancer after 1 year followup	NR	NR
Mascalchi et al, 2011 ⁶² <i>Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT</i>	1406 baseline CT 3924 annual screen CT 990 followup CT for 6320 total 879 of 6320 scans on single-detector 95 PETs for 90 patients 59 suspicious nodules at baseline, 36 during annual screen 38 CT-guided biopsies in 34 patients Mean collective effective dose: 8.75 Sv to 9.36 Sv Mean effective dose per patient over 4 years: 6.2 mSv to 6.8 mSv Mean number of radiation-induced cancers: 0.12 to 0.33 per 1000 patients (0.12 to 0.13 per 1000 men; 0.31 to 0.33 per 1000 women)	NR	NR
Mascalchi et al, 2006 ⁸¹ <i>Risk-benefit analysis of x-ray exposure associated with lung cancer screening in the ITALUNG-CT trial</i>	Actual radiation dose: Multidetector CT: 0.49 mSv/year Single-slice CT: 1.9 mSv/year Projected radiation dose in full ITALUNG (assumed 10% of subjects would have indeterminate nodules): Multidetector CT: 0.83 mSv/year Single-slice CT: 1.78 mSv/year Lung cancer risk from radiation: Multidetector CT: 11.7/100,000 Single-slice CT: 24.9/100,000	NR	NA

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Results		Sensitivity
	Intervention	Control	
Multi-centric Italian Lung Detection (MILD)			
Pastorino et al, 2012 ⁵³ <i>Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial</i>	Positive baseline CT: 177 vs. 158 Recall rates: 14% vs. 15% Lung cancer incidence: 34 (662/100,000 py) vs. 25 (457/100,000 py) Stage IA lung cancer: 59% vs. 55% Stage IV lung cancer: 17% vs. 15%	Lung cancer incidence: 20 (216/100,000 py) Stage IA lung cancer: NR Stage IV lung cancer: NR	NR
Nederlands-Leuven Longkanker Screenings Onderzoek (NELSON)			
van Iersel et al, 2006 ⁷⁹ <i>Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON)</i> Xu et al, 2006 ⁶⁴ <i>Nodule management protocol of the NELSON randomised lung cancer screening trial</i> van den Bergh et al, 2009 ⁷⁸ <i>Informed participation in a randomised controlled trial of computed tomography screening for lung cancer</i> van Klaveren et al, 2009 ⁵⁶ <i>Management of lung nodules detected by volume CT scanning</i>	Overall 127 (1.6%) diagnosed with lung cancer 3 with interval diagnosis between round 1 and 2 <u>Round 1</u> Negative scan: 5987 (79%) Indeterminate scan: 1451 (19%) Positive scan: 119 (1.6%) Total positive after followup imaging: 196 (2.6%) 70 (35%) with diagnosis of lung cancer <u>Round 2</u> Negative scan: 6719 (92%) Indeterminate scan: 480 (6.6%) Positive scan: 90 (1.2%) Total positive after followup imaging: 128 (1.8%) 54 (42%) with diagnosis of lung cancer <u>Combining both rounds</u> Positive scan: 209 (2.7 %)	NR	For diagnosis of lung cancer Round 1: 95% (95% CI, 87 to 98) Round 2: 96% (95% CI, 87 to 99)
van den Bergh et al, 2010 ⁷⁷ <i>Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON)</i>	Mean scores (total, negative result, indeterminate) <u>HRQOL: SF-12 T0 vs. T3</u> SF-12 PCS: 49.5 vs. 50.0 Neg: 49.7 vs. 50.3 Ind: 48.5 vs. 48.9 SF-12 MCS: 51.9 vs. 51.6 Neg: 51.9 vs. 51.6 Ind: 51.8 vs. 51.9 <u>EuroQOL (EQ)-5D T0 vs. T1 vs. T2 vs. T3</u> EQ-5D: 79.3 vs. 78.3 vs. 79.1 vs. 78.4 Neg: 79.4 vs. 78.7 vs. 79.4 vs. 79.2 Ind: 79.1 vs. 76.8 vs. 78.3 vs. 75.0 <u>STAI-6</u> STAI-6: 33.2 vs. 34.6 vs. 32.7 vs. 33.0	NR	NR

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Results		Sensitivity
	Intervention	Control	
	Neg: 33.1 vs. 34.4 vs. 32.5 vs. 32.6 Ind: 33.6 vs. 35.2 vs. 33.5 vs. 34.8 <u>IES</u> IES-D: 4.2 vs. 5.9 vs. 4.5 vs. 3.6 Neg: 4.1 vs. 5.8 vs. 4.5 vs. 2.4 Ind: 4.5 vs. 6.3 vs. 4.9 vs. 8.3		
van den Bergh et al, 2011 ⁶⁹ <i>Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial</i>	At T0 and T2 no significant differences in HRQOL scores over time between groups or between the indeterminate or negative 2nd-round screening. There was a temporary increase in IES scores after an indeterminate baseline result: T0: mean 4.0 (95% CI, 2.8 to 5.3) T1: mean 7.8 (95% CI, 6.5 to 9.0) T2: mean 4.5 (95% CI, 3.3 to 5.8) At 2-year followup, the HRQOL of screened subjects was similar to that of control subjects, the unfavorable short-term effects of an indeterminate baseline screening result had resolved, and an indeterminate result at the 2nd screening round had no impact on HRQOL	NR	NR
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial			
Croswell et al, 2009 ⁷³ <i>Cumulative incidence of false-positive results in repeated, multimodal cancer screening</i>	<u>Cumulative incidence-false positive (men vs. women)</u> Underwent repeated screening: 3216 vs. 2907 Underwent other imaging: 1466 vs. 1498 Underwent minimally invasive procedure: 52 vs. 56 Underwent moderately invasive procedure: 77 vs. 93 Underwent major surgical procedure: 35 vs. 40 Cumulative risk false-positive after 4 screens: 22% vs. 22%	NR	NR
Hocking et al, 2010 ⁸⁴ <i>Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial</i>	Positive scans: 7.5% Lung cancer diagnosis: 306 (284 NSCLC) 147 interval 62 among nonscreened PPV: 1.7%	NR	Calculated: 66% for NSCLC

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

Author, year, title	Results		Sensitivity
	Intervention	Control	
National Lung Screening Trial Research Team et al, 2011 ⁵⁴ <i>Reduced lung-cancer mortality with low-dose computed tomographic screening</i>	Positive CXRs: Baseline: 8.9% Round 1: 7.1% Round 2: 6.6% Round 3: 7.0% Cumulative lung cancer: 7.5% Lung cancer incidence: 20.1/10,000 py Screening period # lung cancer: 505 (307 screen-detected) Interval: 198 (39%) Lung cancer never screened: 193 (during screening period) 13 years followup: 1696 cancers (307 screen-detected) Lung cancers diagnosed after screening ended: 998 Stage I: 32% Stage III or IV: 373/1696 (22%) Cumulative death: 1213 Cumulative incidence: 14/100,000 py Lung cancer mortality: RR, 0.99 (95% CI, 0.87 to 1.22) Lung cancer mortality women: RR, 0.92 (95% CI, 0.81 to 1.06) Lung cancer mortality men: RR, 1.02 (95% CI, 0.92 to 1.13) RR late-stage lung cancer after 6 years: 0.88 (95% CI, 0.78 to 0.99) RR late-stage lung cancer after 7 years: 0.94 (95% CI, 0.84 to 1.05) Other deaths: 12% <u>Among the NLST eligible group</u> RR lung cancer: 1.0 (95% CI, 0.89 to 1.13) RR lung cancer death: 0.94 (95% CI, 0.81 to 1.10) <u>Restricting analysis to lung cancer diagnosis within 6 years of screening</u> Lung cancer mortality: RR, 0.89 (95% CI, 0.80 to 1.00) Lung cancer: 518 Lung cancer deaths: 316 Cumulative incidence lung cancer: 606/100,000 py Cumulative lung cancer mortality: 361/100,000 py	Lung cancer incidence: 19.2/10,000 py Stage I: 27% Stage III or IV: 895/1620 (55%) Cumulative death: 1230 Cumulative lung cancer mortality: 14.2/100,000 py Other deaths: 12% Lung cancer: 520 Lung cancer deaths: 334 Cumulative incidence lung cancer: 608/100,000 py Cumulative lung cancer mortality: 383/100,000 py	307/505 during screening period

Abbreviations: ACRIN = American College of Radiology Imaging Network; ARDS = acute respiratory distress syndrome; CI = confidence interval; Co = control group; COPD = chronic obstructive pulmonary disease; CT = computed tomography; CXR = chest x-ray; DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; DVT = deep venous thrombosis; EBUS = endobronchial ultrasound; ELCAP = Early Lung Cancer Action Program; EUS = endoscopic ultrasound; FNA = fine needle aspiration; HRCT = high-resolution computed tomography; HRQOL = health-related quality of life; IES = Impact of Event Scale; In = intervention; LDCT = low-dose computed tomography; LSS = Lung Screening Study; MCS = Mental Health Composite Score; MILD = Multi-centric Italian Lung Detection; MRI = magnetic resonance imaging; NA = not applicable; NCI = National Cancer Institute; NCN = noncalcified nodule; NELSON = Nederlands-Leuven Longkanker Screenings Onderzoek; NLST = National Lung Screening Trial; NSCLC = non-small cell lung cancer; NR = not reported; PA = posteranterior; PCS = Physical Health Composite Scores;

Appendix B1. Evidence Table of Included Randomized, Controlled Trials

PET = positron emission tomography; PFT = pulmonary function testing; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; PPV = positive predictive value; py = person-years; RR = relative risk; SCLC = small-cell lung cancer; SCT = spiral computed tomography; SD = standard deviation; SF-12 = 12-item Health Survey; STAI = Spielberger State-Trait Anxiety Inventory; sV = short volume; VATS = video-assisted thoracic surgery

Appendix B2. Quality Rating Table of Included Studies

Study	Randomization adequate?	Allocation concealment adequate?	Groups similar at baseline?	Maintain Comparable Groups?	Eligibility criteria specified?	Outcome assessors masked?	Care provider masked?
NLST ⁵⁴	Yes	Yes	Yes	Yes	Yes	Mortality outcome: Yes Incidence outcome: No	NR
DANTE ⁵¹	Yes	Unclear, allocation concealment reported but participants randomized during phone interview	No, 35% with pulmonary problems in LDCT and 31% in controls	No, nearly twice the dropout rate in the controls vs. LDCT (166 vs. 91)	Yes	Unclear	NR
DLCST ^{76, 52}	Yes	Unclear	Yes	Yes	Yes	Unclear	NR
MILD ⁵³	Probably not	Yes	No; more obstructive pulmonary disease among LDCT compared with controls (81% vs. 72%), more current smokers in the control groups (90% vs. 68%), fewer former smokers in the LDCT group compared with controls (31% vs. 10%)	Not comparable	Yes	Mortality outcome: Yes Incidence outcome: No	NR
PLCO ⁵⁹	Yes	Unclear	Yes	Unclear	Yes	Mortality outcome: Yes Incidence outcome: Unclear	No
Mayo ⁸⁷	Yes	Unclear	Unclear	Unclear	Yes	No	No

Study	Patient masked?	Reporting of attrition, crossovers, adherence, and contamination	Loss to followup: differential/high	Intention-to-screen analysis	Post-randomization exclusions	Outcomes prespecified	Funding source	External validity	Quality Rating
NLST ⁵⁴	No	Yes	No	Yes	Yes	Yes	NIH	Good	Good
DANTE ⁵¹	No	Yes	Less followup in controls (31.5 months in controls vs. 35.7 months in LDCT group)	Yes	No	Yes	Italian Association for the Fight Against Cancer	Fair (only men)	Fair
DLCST ^{76, 52}	No	Yes	Study reports less complete followup among controls	Yes	No	Yes	Government grant	Good	Fair
MILD ⁵³	No	Yes	Significant differences in followup time (44.9 months in controls vs. 56 months in LDCT group)	Yes	No	Yes	Italian Association for Cancer Research; Italian Ministry of Health, the Lombardy Region; and the Cariplo Foundation	Good	Poor
PLCO ⁵⁹	No	Yes	No	Yes	Yes	Yes	NCI	Good	Good
Mayo ⁸⁷	No	Yes	No	Yes	No	Yes	NCI and Mayo Clinic	Good	Fair

Abbreviations: DANTE = Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST = Danish Lung Cancer Screening Trial; LDCT = low-dose computed tomography; LSS = Lung Screening Study; MILD = Multi-centric Italian Lung Detection; NCI = National Cancer Institute; NIH = National Institutes of Health; NLST = National Lung Screening Trial; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Population	Risk Group	Screening intervention	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
Continuing Observation of Smoking Subjects (COSMOS)					
Veronesi et al, 2008 ⁹⁶ <i>Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program</i>	Median pack-years: 44 Mean age: 57.7 years 64% men 80% current smokers	Smoking history ≥20 pack-years, if former smoker quit <10 years ago	LDCT High speed multirow detector or 16 slice	Within the study	Within the study: Nodules ≥5 mm repeat CT 1 year Nodules ≥5 to 8 mm repeat CT 3 to 6 months Nodules ≥8 mm or growing CT-PET Nodules growing or CT-PET positive biopsy
Veronesi et al, 2008 ⁹⁷ <i>Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules</i>	Median pack-years: 44 Mean age: 57.7 years 64% men 80% current smokers	Smoking history ≥20 pack-years, if former smoker quit <10 years ago	LDCT High speed multirow detector or 16 slice	Within the study	Within the study: Nodules ≥5 mm repeat CT 1 year Nodules ≥5 to 8 mm repeat CT 3 to 6 months Nodules ≥8 mm or growing CT-PET Nodules growing or CT-PET positive biopsy
Japan Studies					
Toyoda et al, 2008 ⁸⁹ <i>Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography</i>	NR	Cohort includes anyone with ≥1 LDCT	LDCT vs. CXR	Individuals with positive studies asked to followup at Osaka Medical Center	Participants with positive studies asked to undergo further evaluation at Osaka Medical Center and all patients with positive CXR were asked to undergo CT
Tsushima et al, 2008 ⁹⁰ <i>Radiological diagnosis of small pulmonary nodules detected on low-dose screening computed tomography</i>	Mean age: 51 years 39% female	High-risk men (70% ever smokers) and medium-risk women (11% ever smokers)	LDCT multislice	Within study	Within study
International Early Lung Cancer Action Program (I-ELCAP)					
Henschke et al, 2004 ⁸⁸ <i>CT screening for lung cancer: assessing a regimen's diagnostic performance</i>	ELCAP 1: 46% women ELCAP 2: Median age: 59 years 52% women Median pack-years: 32	ELCAP 1 ≥10 pack-years high-risk ELCAP 2 ≥1 pack-year	CXR in ELCAP 1	Most in screening center	Most in screening center
Henschke et al, 2006 ³¹ <i>I-ELCAP Investigators Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer</i>	Median age: 67 years Median pack-years: 47	Asymptomatic current or former smokers, not otherwise described	Baseline and repeat LDCT	Protocol specified a diagnostic approach Indications for biopsy: Tumor growth Positive PET Nodules ≥15 mm Antibiotics 1 month out No response to CT	ELCAP protocol: specified a common regimen of screening. The definition of positive and the diagnostic evaluation differed for the baseline and annual screening. Evaluations conducted in each study center and recommendations for diagnostic workup were made to the participant and the referring physician.

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Population	Risk Group	Screening intervention	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
Henschke et al, 2006 ¹⁶⁷ I-ELCAP Investigators <i>Survival of patients with stage I lung cancer detected on CT screening</i>	Median age: 61 years Median pack-years: 30	History of smoking or occupational exposure with increased risk or secondhand smoke	Baseline plus annual LDCT	Recommendations made to community physicians	For baseline screen: a positive result defined as identifying ≥1 solid or partially solid nodule ≥5 mm; ≥1 nonsolid NCN ≥8 mm or solid endobronchial nodule For annual screens: positive result was any new NCN
Shemesh et al, 2006 ¹⁶⁸ <i>Frequency of coronary artery calcification on low-dose computed tomography screening for lung cancer</i>	ELCAP population, otherwise not described	High risk smokers	CXR	Most in screening center	Most in screening center
Menezes et al, 2010 ⁸⁶ <i>Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience</i> Wagnetz et al, 2012 ⁹⁴ <i>Screening for lung cancer: implication of lung biopsy recommendations</i>	Median age: 60 years (range: 50 to 83) Median pack-years: 30 54% female	High-risk smokers with ≥10 pack-years smoking history	CT Variable row detector configuration (4 to 64)	Recommendations within protocol to community providers	Positive: NCN ≥5 mm or 1 nonsolid nodule ≥8 mm Nodules or nodules <5 mm considered of unlikely clinical significance Biopsy recommended for nodules >15 mm immediately or after 1 month of antibiotics
Liu et al, 2011 ⁹⁵ <i>The outcome differences of CT screening for lung cancer pre and post following an algorithm in Zhuhai, China</i>	Zhuhai city 1994 to 2002: 70% nonsmokers 2003 to 2009: 71% nonsmokers	Moderate	1994 to 2002: single slice CT 2003 to 2009: 16 MDCT	Up to 2002, image interpretation based on morphology and growth Semiautomatic volumetric software used after 2003	1994–2002 high suspicion: recommended surgery moderate suspicion: PET 2003–2009 ELCAP protocol
Lung Cancer Screening Intervention trial (LUSI)					
Becker et al, 2012 ⁹⁸ <i>Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round</i>	46% ages 50–54 years 28% ages 60–69 years 2622 men; 1430 women 62% current smokers	Current or former (quit <10 years ago) smokers with ≥25 years smoking of ≥15 cigarettes/day or ≥30 years smoking of ≥10 cigarettes/day	LDCT (multidetector, 4 annual) vs. no screening	Nodules <5 mm evaluate annually Nodules 5–7 mm evaluate every 6 months Nodules 8–10 mm evaluate every 3 months Immediate recall for >10 mm nodules	Contact physician of choice
Mayo Clinic					
Swensen et al, 2005 ⁸⁷ <i>CT Screening for lung cancer: five-year prospective experience</i>	788 men; 732 women 61% current smokers Median pack-years: 45 (range: 20 to 230)	Current or former (quit <10 years ago) smokers with ≥20 pack-years	CT (4-detector row helical CT, at low-dose)	Mayo Clinic	Mayo Clinic

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Population	Risk Group	Screening intervention	Imaging evaluation strategy	Suspicious abnormality finding evaluation strategy
Marcus et al, 2006 ⁵⁸ <i>Extended lung cancer incidence follow-up in the Mayo Lung Project and over-diagnosis</i>	NR	High risk	CXR with sputum cytology either every 4 months vs. usual care	SCT at Mayo Clinic	Mayo Clinic
Sincirope et al, 2010 ¹⁰¹ <i>Perceptions of lung cancer risk and beliefs in screening accuracy of spiral computed tomography among high-risk lung cancer family members</i>	NR	1 st -degree relative with lung cancer and ≥3 blood relatives with lung cancer	SCT	SCT at Mayo Clinic	Mayo Clinic
Pittsburgh Lung Screening Study (PLUSS)					
Wilson et al, 2008 ⁹⁷ <i>The Pittsburgh Lung Screening Study</i>	Mean age: 59 years 51% men, 49% women Mean pack-years: 47 60% current smokers	Current or former (quit <10 years ago) smokers with ≥half a pack/day history for 25 years	CT	Screening study results reported to patient and personal physician described as low, moderate, or high risk of being malignant. Study physicians an option. Only imaging within study is initial and 1 year LDCT.	Followup evaluation in the community
Byrne et al, 2008 ¹⁰⁰ <i>Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening</i>	Mean age: 59 years 51% men, 49% women Mean pack-years: 47 60% current smokers	Current or former (quit <10 years ago) smokers with ≥half a pack/day history for 25 years	CT	Screening study results reported to patient and personal physician described as low, moderate, or high risk of being malignant. Study physicians an option. Only imaging within study is initial and 1 year LDCT.	Followup evaluation in the community

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
Continuing Observation of Smoking Subjects (COSMOS)					
Veronesi et al, 2008 ⁹⁶ <i>Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program</i>	Asymptomatic men and women ages >50 years with a ≥20 pack-year history; current or prior smokers who quit <10 years ago	Prior malignant disease (except nonmelanoma skin cancer)	Number approached: NR Number eligible: NR Number enrolled: 5200	Italy	NR

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
Veronesi et al, 2008 ⁹¹ <i>Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules</i>	Asymptomatic men and women ages >50 years with a ≥20 pack-year history; current or prior smokers who quit <10 years ago	Prior malignant disease (except nonmelanoma skin cancer)	Number approached: NR Number eligible: NR Number enrolled: 5200	Italy	NR
Japan Studies					
Toyoda et al, 2008 ⁸⁹ <i>Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography</i>	All residents from Osaka between 1998 and 2000, smokers recommended to undergo LDCT and sputum cytology	Past or suspected lung cancer	Number approached: NR Number eligible: NR Number enrolled: 18,070 (4689 vs. 13,381)	Japan	Ministry of Health, Labor, and Welfare Japan
Tsushima et al, 2008 ⁹⁰ <i>Radiological diagnosis of small pulmonary nodules detected on low-dose screening computed tomography</i>	All population, NR	NR	Number approached: NR Number eligible: NR Number enrolled: 2486	Japan	NR
International Early Lung Cancer Action Program (I-ELCAP)					
Henschke et al, 2004 ⁸⁸ <i>CT screening for lung cancer: assessing a regimen's diagnostic performance</i>	ELCAP 1 Ages ≥60 years with a smoking history of ≥10 pack-years ELCAP 2 Ages ≥40 years with a smoking history of ≥1 pack-years	CT scan <3 years prior	Number approached: NR Number eligible: NR Number analyzed: 1000 (ELCAP 1) and 1968 (ELCAP 2)	United States	NCI
Henschke et al, 2006 ³¹ <i>I-ELCAP Investigators Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer</i>	Asymptomatic past or current smokers ages ≥40 years fit for surgery	History of cancer	Number approached: NR Number eligible: NR Number enrolled: 14,435 (6296 women vs. 8139 men)	International study involving many countries, including the United States	NIH, many supporting institutions
Henschke et al, 2006 ¹⁶⁷ <i>I-ELCAP Investigators Survival of patients with stage I lung cancer detected on CT screening</i>	Asymptomatic adults ages >40 years with a history of smoking or occupational exposure with increased risk or secondhand smoke	NR	Number approached: NR Number eligible: NR Number enrolled: 31,567	International: Europe, United States, Japan, China, Israel	NIH, DOE, New York City
Shemesh et al, 2006 ¹⁶⁸ <i>Frequency of coronary artery calcification on low-dose computed tomography screening</i>	ELCAP 1 Ages ≥60 years with a smoking history of ≥10 pack-years ELCAP 2 Ages ≥40 years with a smoking	CT scan <3 years prior	Number approached: NR Number eligible: NR Number enrolled: 4250	United States	NCI

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
<i>for lung cancer</i>	history of ≥ 1 pack-year				
Menezes et al, 2010 ⁸⁶ <i>Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience</i>	Asymptomatic, ages ≥ 50 years, and ≥ 10 pack-year smoking history	Prior cancer (except nonmelanoma skin cancer) and poor health	Number approached: NR Number eligible: NR Number enrolled: 3352	Canada	Princess Margaret Foundation
Wagnetz et al, 2012 ⁹⁴ <i>Screening for lung cancer: implication of lung biopsy recommendations</i>					
Liu et al, 2011 ⁹⁵ <i>The outcome differences of CT screening for lung cancer pre and post following an algorithm in Zhuhai, China</i>	Government workers age ≥ 40 years	NR	Number approached: NR Number eligible: NR Number analyzed: 3348 (1994 to 2002) and 3582 (2003 to 2009)	Zhuhai City, China	NR
Lung Cancer Screening Intervention trial (LUSI)					
Becker et al, 2012 ⁹⁸ <i>Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round</i>	Current or former (quit < 10 years ago) male and female smokers with ≥ 25 years smoking of ≥ 15 cigarettes/day or ≥ 30 years smoking of ≥ 10 cigarettes/day, ages 50 to 69 years	Cancer diagnosis within the past 5 years, medical circumstances preventing surgical treatment in case of a lung cancer diagnosis in screening, serious illness shortening life expectancy below 10 years	Number approached: 292,440 Number eligible: 4913 Number enrolled: 4052 Number analyzed: 2029	Germany	German Research Foundation and Dietmar-Hopp-Stiftung, members of the German Center for Lung Research by the German Research Ministry
Mayo Clinic					
Swensen et al, 2005 ⁸⁷ <i>CT Screening for lung cancer: five-year prospective experience</i>	Current or former (quit < 10 years ago) smokers with ≥ 20 pack-years history, age > 50 years	On supplemental O ₂ , history of cancer within 5 years, mentally incompetent, unable to undergo lung resection surgery, and < 5 -year life expectancy	Number approached: NR Number eligible: NR Number enrolled: 1520	United States, single site at Mayo Clinic	NCI and Mayo Clinic
Marcus et al, 2006 ⁵⁸ <i>Extended lung cancer Incidence follow-up in the Mayo Lung Project and over-diagnosis</i>	Male smokers who had tested negative for lung cancer with CXR and/or sputum cytology at baseline judged to have life expectancy of ≥ 5 years and sufficient respiratory reserve to undergo lobectomy if needed	Tested positive for lung cancer on CXR	Number approached: NR Number eligible: NR Number enrolled: 9121 (4618 vs. 4503)	Mayo Clinic	NCI

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Inclusion criteria	Exclusion criteria	Number of subjects	Country and setting	Sponsor
Sincrope et al, 2010 ¹⁰¹ <i>Perceptions of lung cancer risk and beliefs in screening accuracy of spiral computed tomography among high-risk lung cancer family members</i>	Ages >30 years, 1 st -degree relative with lung cancer and ≥3 blood relatives with lung cancer and current medical insurance	Personal history of lung cancer	Number approached: NR Number eligible: 371 Number enrolled: 60	United States, single site at Mayo Clinic	NCI
Pittsburgh Lung Screening Study (PLuSS)					
Wilson et al, 2008 ⁹⁷ <i>The Pittsburgh Lung Screening Study</i>	Current or former (quit <10 years ago) smoker with ≥half a pack/day history for 25 years, and symptoms were allowed	Prior history of lung cancer, chest CT within past year, weight >400 lbs, and other lung cancer screening	Number approached: 9386 Number eligible: 5034 Number enrolled: 3642	United States, single site in Pittsburgh	University of Pittsburgh Cancer Institute via NCI
Byrne et al, 2008 ¹⁰⁰ <i>Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening</i>	Current or former (quit <10 years ago) smoker with ≥half a pack/day history for 25 years, and symptoms were allowed	Prior history of lung cancer, chest CT within past year, weight >400 lbs, and other lung cancer screening	Number approached: 9386 Number eligible: 5034 Number enrolled: 3642 Number analyzed: 341	United States, single site in Pittsburgh	University of Pittsburgh Cancer Institute via NCI

Author, year, title	Results	Sensitivity	Specificity
Continuing Observation of Smoking Subjects (COSMOS)			
Veronesi et al, 2008 ⁹⁶ <i>Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program</i>	43% NCN 106 invasive procedures: 15 for benign disease 91 lung cancers, of which 71% stage I (89 screen-detected) 79/91 curative surgery 24-month survival (85%) Interval cancer: NR *This paper defines false-negative as any cancer beyond stage I at diagnosis	91%	100%
Veronesi et al, 2008 ⁹¹ <i>Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules</i>	2198 at baseline had ≥1 NCN ≤5 mm 354 (6.8%) had ≥1 NCN 5.1 to 8 mm 206 had nodules >8 mm 504/5201 had ≥1 indeterminate nodule recalled for ≥1 additional evaluations 55 cancers diagnosed at baseline 36 cancers diagnosed at year 1 1 interval cancer after 1st incidence screening Among 36 cancers diagnosed at 2nd screen, 24 had prevalent nodule 1st year prior, 12 had new malignancy Baseline cancers: 79 Incidence: 13 Stage I: 66%	91% 1 interval cancer after incidence screen 36 cancers detected on incidence screen, of which 24 on baseline	100%

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Results	Sensitivity	Specificity
Japan Studies			
Toyoda et al, 2008 ⁸⁹ <i>Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography</i>	40 cancers 5 interval cancer LDCT	Overall: 89% Smokers: 84% Nonsmokers: 100% Adenocarcinoma LDCT: 100% Nonadenocarcinoma: 62% Women: 85% Men: 91%	LDCT: 93% CXR: 97% LDCT baseline: 91% LDCT annual: 96% Men LDCT: 92% Women: 94% Smokers: 92% Nonsmokers: 94%
Tsushima et al, 2008 ⁹⁰ <i>Radiological diagnosis of small pulmonary nodules detected on low-dose screening computed tomography</i>	2486 scans Negative: 2132 Seminegative: 140/354 (14%) patients with nodules Semipositive: 111 Positive: 103 HRCT: 1837 cancers 3/7 cancers in nonsmoking women	100%	97% PPV LDCT: 9.9%
International Early Lung Cancer Action Program (I-ELCAP)			
Henschke et al, 2004 ⁸⁸ <i>CT screening for lung cancer: assessing a regimen's diagnostic performance</i>	Baseline (positive result: ≥ 1 solid/part solid nodule ≥ 5 mm; semi positive: < 5 mm NCN): 368 nodules 79 lung cancer 2 interval 77 screen-detected 75 stage I 65 adenocarcinoma <u>Repeat screen (any new or growing nodule; interval cancer = lung cancer diagnosis within 1 year of prior CT): N=4538</u> 254 nodules (6%) 29 lung cancer 1 interval 27 stage I 17 adenocarcinoma	Baseline: 77/79 (97%)* Annual: 28/29 (97%)*	Baseline: 2889/3178 (91%) 11 screen 254 abnormal 29 false-positive: 225 TN: 286/3085 Annual: 2860/3085 (93%) 4538 screens 254 abnormal 29 lung cancer False-positive: 225 TN: 4509
Henschke et al, 2006 ³¹ I-ELCAP Investigators <i>Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer</i>	Lung cancer: 156 Stage I: 139 Resection: 125 Lung cancer deaths: NR Carcinoid: 8 Adenocarcinoma: 114 Squamous: 22 Large cell: 5 Small cell: 4 Other NSCLC, not specified: 3	NR	NR

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Results	Sensitivity	Specificity
Henschke et al, 2006 ¹⁶⁷ I-ELCAP Investigators <i>Survival of patients with stage I lung cancer detected on CT screening</i>	Baseline (n=31,567) 4186 with concerning nodule (13%) 405 lung cancer (prevalence 1.3%) 5 interval cancers among 27,381 without nodule Annual (n=484 diagnosed cancers) 1460 new nodules (5%) 74 lung cancer (prevalence 0.3%) Interval cancers (n=484 diagnosed cancers) 411 resected, 57 radiation therapy, chemoprevention or both 16 no treatment Operative mortality: 0.5% (2/411) 412 stage I 39 died 75/484 with lung cancer died, including 2 who died ≤4 weeks before surgery	Baseline: 4186/4191 (99%) Annual: 100%	NR
Shemesh et al, 2006 ¹⁶⁸ <i>Frequency of coronary artery calcification on low-dose computed tomography screening for lung cancer</i>	CAC score 2: 1544 (36%) Positive CAC: 2706 (64%) Frequency of positive CAC: 66% in former vs. 62% in current smokers CAC increased with age and was higher in men	NA	NA
Menezes et al, 2010 ⁸⁶ <i>Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience</i> Wagnetz et al, 2012 ⁹⁴ <i>Screening for lung cancer: implication of lung biopsy recommendations</i>	Nodules: Positive: 600/3352 (18%) CT with contrast: 12 1-month followup: 44 3-month followup: 521 6-month followup: 3 Biopsy (within 6 months): 57 Lung cancer: 44 (13% previous) ≥1 repeat CT: 2686 (range: 1 to 5) 65 total cancers 3 interval (false-negative) 48/65 women 56/65 prevalent 6/65 incident 3/65 interval Stage Stage I: 42/65 Stage II: 4 Stage III/IV: 10 Pathology Adenocarcinoma: 44 Squamous: 9 Small cell: 4 Unknown: 1 Carcinoid: 1	1 year: 88% For NSCLC: 89%	99%

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Results	Sensitivity	Specificity
Liu et al, 2011 ⁹⁵ <i>The outcome differences of CT screening for lung cancer pre and post following an algorithm in Zhuhai, China</i>	<u>1994 to 2002 cohort</u> 36 screen-detected cancers with 1 interval cancer 6.2% had nodules ≥ 5 mm 67% stage I 35 contrast CT scans 9 PET scans Cumulative incidence: 0.9% <u>2003 to 2009 cohort</u> 34 cancers with no interval cancers 9.8% had nodule ≥ 5 mm 91% stage I 89 contrast CT scans Lung cancer diagnosis: 0.9%	NR	NR
Lung Cancer Screening Intervention trial (LUSI)			
Becker et al, 2012 ⁹⁸ <i>Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round</i>	<u>2029 initial screens</u> 1488 (73%) negative 540 (27%) suspicious -31% solitary -35% 2–4 nodules -27% 5–9 nodules -7% >10 nodules 393 (19%) 5–7 mm nodules -72 “cleared” and back to normal 78 (5%) 8–10 mm nodules -7 “cleared” and back to normal 69 (5%) >10 mm nodules -11 “cleared” and back to normal 22 lung cancers diagnosed in first round -4 in 5–7 mm nodules -1 in 8–10 mm nodules -17 in >10 mm nodules 1 interval cancer from round 1 to 2, stage IV adenocarcinoma	NR	NR
Mayo Clinic			
Swensen et al, 2005 ⁸⁷ <i>CT Screening for lung cancer: five-year prospective experience</i>	2038 nodules <4 mm; 1034 (4 to 7 mm); 268 (8 to 20 mm); 16 (>20 mm) Subjects with prevalence nodules: 780 False-positive rate: 92% to 96%; 69% with ≥ 1 Prevalent lung cancer stage: N=31; IA: 20, IB: 2, IIA: 4, IIIA: 2, IV: 1, SCLC: 2 Incident/interval lung cancer stage: N=35; IA: 16, IB: 1, IIA: 2, IIB: 2, IIIA: 4, IIIB: 2, IV: 0, unknown: 2, SCLC: 6 Mortality: overall: 48; lung cancer: 9 (of 5481.5 py) Volume doubling time: of 48 cancers with info, mean VDT: 518 days (SD, 1094); 13 tumors with VDT more than 400 days (11/13 in women)	3 interval cancers 63/66: 95%	NR
Marcus et al, 2006 ⁵⁸ <i>Extended lung cancer Incidence follow-up in the Mayo Lung Project and over-diagnosis</i>	At the end of the study (1983) 206 lung cancers diagnosed in intervention, after followup (1999) 379 more lung cancers diagnosed in intervention group	NR	NA

Appendix B3. Evidence Table of Included Cohort Studies

Author, year, title	Results	Sensitivity	Specificity
Sincirope et al, 2010 ¹⁰¹ <i>Perceptions of lung cancer risk and beliefs in screening accuracy of spiral computed tomography among high-risk lung cancer family members</i>	Baseline vs. 1 month negative vs. 1 month nonnegative vs. 6 month negative vs. 6 month nonnegative Cancer thoughts (some): 65% vs. 54% vs. 87% vs. 59% vs. 69% Mood affected by results (some): 34% vs. 29% vs. 27% vs. 21% vs. 31% Daily activity affected (some): 8% vs. 3% vs. 0% vs. 6% vs. 6% Cancer concern (concern): 94% vs. 89% vs. 100% vs. 91% vs. 94% Perceived comparative cancer risk (higher): 76% vs. 74% vs. 69% vs. 57% vs. 81% Perceived absolute cancer risk (likely): 64% vs. 63% vs. 75% vs. 66% vs. 75%	NR	NR
Pittsburgh Lung Screening Study (PLUSS)			
Wilson et al, 2008 ⁹⁷ <i>The Pittsburgh Lung Screening Study</i>	80 cases of lung cancer (2.2% cumulative incidence [95% CI, 1.7 to 2.2]) 11 small cell (45% limited stage) 69 NSCLC Stage I: 58% Stage II: 17% Stage III: 30% Stage IV: 7% Initial LDCT: 1477 (41%) with abnormality and referred for further evaluation (40 [1.1%] high, 182 [5%] moderate, 1255 [85%] low); 1070 imaging studies in 821 subjects in year after initial LDCT; 82 subjects with significant incidental finding	NR	NR
Byrne et al, 2008 ¹⁰⁰ <i>Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening</i>	Negative vs. indeterminate vs. suspicious State anxiety Initial: 35.9 vs. 34.4 vs. 32.6 Post: 35.9 vs. 37.7 vs. 38.3 6 months: 34.4 vs. 37.3 vs. 32.6 12 months: 35.1 vs. 35.3 vs. 35.1 Trait anxiety Initial: 37.0 vs. 36.7 vs. 33.9 Post: 36.6 vs. 37.5 vs. 36.6 6 months: 35.7 vs. 36.7 vs. 35.4 12 months: 35.8 vs. 36.3 vs. 35.0 Cancer fear Initial: 7.0 vs. 7.2 vs. 6.4 Post: 7.0 vs. 7.5 vs. 8.5 6 months: 6.5 vs. 7.1 vs. 7.4 12 months: 6.7 vs. 7.1 vs. 7.1 Perceived risk (%) Objective: <1 vs. 1 to 5 vs. 15 to 20 Initial: 17 vs. 19 vs. 19 Post: 11 vs. 20 vs. 35 6 months: 13 vs. 15 vs. 30 12 months: 13 vs. 19 vs. 31	NR	NR

*Calculated.

Appendix B3. Evidence Table of Included Cohort Studies

Abbreviations: CAC = coronary artery calcification; CI = confidence interval; COSMOS = Continuing Observation of Smoking Subjects; CT = computed tomography; CXR = chest x-ray; DOE = Department of Education; ELCAP = Early Lung Cancer Action Program; HRCT = high-resolution computed tomography; I-ELCAP = International Early Lung Cancer Action Program; FNA = fine needle aspiration; LDCT = low-dose computed tomography; LUSI = Lung Cancer Screening Intervention; MDCT = multidetector row computed tomography; NA = not applicable; NCI = National Cancer Institute; NCN = noncalcified nodule; NIH = National Institutes of Health; NR = not reported; NSCLC = non-small cell lung cancer; py = person years; PET = positron emission tomography; PLoSS = Pittsburgh Lung Screening Study; PPV = positive predictive value; SCLC = small cell lung cancer; SCT = spiral computed tomography; SD = standard deviation; TN = true negative; VATS = video-assisted thoracic surgery; VDT = volume doubling time